cn, concept, rep_cuis, excluded_cuis, status, proposed_name,
-10,%,,,inprogress,discard pile here
-10,a,,,inprogress,discard pile here
-10,a a ( $nmbr$ ( % ),,,inprogress,discard pile here
-10,aapo $nmbr$ at rest mm hg,C2700280,,completed,
-10,abbreviations : ace angiotensin - converting enzyme bmi body mass index ( calculated as weight in kilograms divided by height in meters squared ) dm diabetes mellitus hba $nmbr$ c hemoglobin a $nmbr$ c hmg - coa $nmbr$ - hydroxy - $nmbr$ - methylglutaryl coenzyme a . asome subjects took more than $nmbr$ oral anti - dm drug in addition to metformin and thus the total number of concomitant oral anti - dm drugs in the columns exceed the “ n ” values in the colesevelam hydrochloride and placebo group headings . bsulfonylureas include chlorpropamide glibenclamide glimepiride glipizide and tolazamide . cthiazolidinediones include pioglitazone pioglitazone hydrochloride rosiglitazone and rosiglitazone maleate . d - glucosidase inhibitors include acarbose or miglitol .,C0032042,,inprogress,
-10,abbreviations : chd coronary heart disease cl confidence interval ml myocardial infarction rr relative risk . ^ defined as a composite end point comprising the first of any of these events : nonfatal ml nonfatal stroke or cardiovascular death . tp value for interaction < . $nmbr$ for major cardiovascular event . no other interactions are significant . ^ calculated as weight in kilograms divided by the square of height in meters . § hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg a diastolic blood pressure > $nmbr$ mm hg or physician - diagnosed hypertension . | | hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl_ ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . ^ diabetes defined by self - report . # calculated using the framingham risk score among $nmbr$ $nmbr$ women who provided a blood sample at baseline .,C0008377,,completed,
-10,a / c,,,inprogress,discard pile here
-10,acd,C0972395,,completed,
-10,ace = angiotensin - converting enzyme cabg = coronary artery bypass graft ccsc = canadian cardiovascular society classification mi = myocardial infarction pci = percutaneous coronary,C0010055,,completed,
-10,aceis angiotensin - converting enzyme inhibitors c candesartan des drug - eluting stent egfr estimated glomerular filtration rate hdl high - density lipoprotein ldl low - density lipoprotein nc non - candesartan .,,,completed,
-10,acenocoumaroi,C0149793,,completed,
-10,afcaps /,C0002454,,completed,
-10,agea,C0005902;C1879646,,completed,
-10,agi,C1299007,,completed,
-10,alvef ( per $nmbr$ % ),C0018801;C0428772,,completed,
-10,anakinra,C2718773,,completed,
-10,angiogenesis,C0521942,,completed,
-10,angiotensin -,C0521942,,completed,
-10,aniagonisi,C1518422;C0679199;C0006684,,completed,
-10,a $nmbr$,,,inprogress,discard pile here
-10,a $nmbr$ c,,,inprogress,discard pile here
-10,a $nmbr$ c %,,,inprogress,discard pile here
-10,a $nmbr$ c ( % ),,,inprogress,discard pile here
-10,a $nmbr$ c < $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,a $nmbr$ c > $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,a $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,a $nmbr$ c > s . $nmbr$ - s . $nmbr$ %,,,inprogress,discard pile here
-10,a $nmbr$ . $nmbr$ ± $nmbr$ a . $nmbr$,,,inprogress,discard pile here
-10,anti - anaemics,C1321567,,completed,
-10,anti - p $nmbr$,C4318437,,completed,
-10,any acuity bleeding,,,inprogress,discard pile here
-10,apo apolipoprotein dm diabetes mellitus hdl - c high - density lipoprotein cholesterol ldl - c low - density lipoprotein cholesterol tc total cholesterol,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
-10,aqc < $nmbr$,C1828181,,completed,
-10,aqe i $nmbr$,C1828181,,completed,
-10,aqe ^ $nmbr$,C1828181,,completed,
-10,aqe < $nmbr$,C1828181,,completed,
-10,areas,C0005902;C1879646,,completed,
-10,arthritis mutilans,C0003862,,completed,
-10,atonic,C0392707,,completed,
-10,attack ( % ),C0455536,,completed,
-10,attain,C0455536,,completed,
-10,atypical absence,,,inprogress,discard pile here
-10,b,,,inprogress,discard pile here
-10,b + a ( n = $nmbr$ ),,,inprogress,discard pile here
-10,basal,C0650607,,completed,
-10,bid,C1739768;C0004057,,completed,
-10,bisphosphonates,,,inprogress,discard pile here
-10,blockers,C0086440,,completed,
-10,^ - blockers,C0086440,,completed,
-10,bmi body mass index hrt hormone replacement therapy lvh left ventricular hypertrophy nsaids nonsteroidal anti - inflammatory drugs pvd peripheral vascular disease tia transient ischemic attack . ahistory of and / or currently taking lipid - lowering or antidiabetic medications . bp < $nmbr$ . $nmbr$ for verapamil sustained - release ( sr ) vs . atenolol . chistory of or currently have elevated serum creatinine but less than $nmbr$ mg / dl . dblood pressure control defined as < $nmbr$ / $nmbr$ or < $nmbr$ / $nmbr$ in patients with diabetes or a history of renal insufficiency .,C0004147,,completed,
-10,bp : blood pressure ci : confidence interval esrd : end - stage renal disease hr hazard ratio . all patients ( except patients with other race ) were included with missing covariates imputed . event : no . of patients with esrd rate : event rate per $nmbr$ years of follow - up pre - specified : a cox model with treatment group and region as covariates and baseline proteinuria level ( o or x $nmbr$ g / g ) as strata adjusted : a multivariate cox model with treatment group time - varying systolic and diastolic bp as covariates . pre - specified analysis and adjusted for time - varying bp,C2985465,,inprogress,
-10,breakfastb,C0231832,,completed,
-10,bursitis,C1282952,,completed,
-10,c,,,inprogress,discard pile here
-10,calcitonin,C1533591,,completed,
-10,caribbean,,,inprogress,discard pile here
-10,centrally acting sympathomimetics,,,inprogress,discard pile here
-10,= cerebrospinal fluid .,,,inprogress,discard pile here
-10,chest discomfort,,,inprogress,discard pile here
-10,colesevelam ( n = $nmbr$ ),,,inprogress,discard pile here
-10,computed tomographic angiography,,,inprogress,discard pile here
-10,concern,C1527249,,completed,
-10,coronary risk factors — no . ( % ),C1261316,,completed,
-10,currentd,C3241966,,completed,
-10,cutoffs,,,inprogress,discard pile here
-10,cystitis,;C0035455,,completed,
-10,czech repumc,,,inprogress,discard pile here
-10,data are expressed as n / total ( % ) unless otherwise speci ﬁ ed . systeme international unit conversion : to convert creatinine clearance to ml / s multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation † at discharge . ace angiotensin - converting enzyme cabg coronary artery bypass graft ccsc canadian cardiovascular society classi ﬁ cation mi myocardial infarction pci percutaneous coronary intervention .,C0010055,,completed,
-10,data are expressed as n / total ( % ) unless otherwise specified . systeme international unit conversion : to convert creatinine clearance to ml / s multiply by $nmbr$ . $nmbr$ . * estimated with cockroft - gault equation,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
-10,* data are given as percentage of subjects unless otherwise specified . ptca indicates percutaneous transluminal coronary angioplasty cabg coronary artery bypass graft ace angiotensin - converting enzyme bmi body mass index ( calculated as weight in kilograms divided by square of height in meters ) hdl - c high - density lipoprotein cholesterol ldl - c low - density lipoprotein cholesterol fpg fasting plasma glucose and fpi fasting plasma insulin . tto convert cholesterol values to micromoles per liter multiply by $nmbr$ . $nmbr$ . to convert triglycerides to micromoles per liter multiply by $nmbr$ . $nmbr$ . to convert fpg to micromoles per liter multiply by $nmbr$ . $nmbr$ . to convert fpi to picomoles per liter multiply by $nmbr$ . $nmbr$ .,C0023824,,completed,
-10,data are mean ( sd ) or n ( % ) . ace = angiotensin - converting enzyme arb = angiotensin - receptor blocker . chf = congestive heart failure . * any use in $nmbr$ h before surgery except for aspirin which only required any use in the $nmbr$ days before surgery .,C0018801,;C0168634;C1524003,completed,
-10,data are number of patients ( % ) or hazard ratio ( $nmbr$ % cl ) p values are forthe test of heterogeneity . cad = coronary artery disease . bmi = body - mass index which is weight in kg divided by the square of height in metres . ldl = low - density lipoprotein . hdl = high - density lipoprotein . there is a deficit of clinical data in some patients with the events .,C0005910,,completed,
-10,data are presented as mean sd . * n $nmbr$ for ldl cholesterol . † n $nmbr$ for ldl cholesterol . ‡ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance ) p $nmbr$ . $nmbr$ . § signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance ) p $nmbr$ . $nmbr$ . ¶ signi ﬁ cantly different from baseline values by repeated measures ( analysis of variance ) p $nmbr$ . $nmbr$ .,C0023824,,completed,
-10,dd,C0028873,,completed,
-10,dd ( n = $nmbr$ ),C0028873,,completed,
-10,decreased appetite,,,inprogress,discard pile here
-10,dizziness,,,inprogress,discard pile here
-10,e,,,inprogress,discard pile here
-10,e $nmbr$ + a $nmbr$,,,inprogress,discard pile here
-10,e $nmbr$ + a $nmbr$ -,,,inprogress,discard pile here
-10,e $nmbr$ ( n = $nmbr$ ),,,inprogress,discard pile here
-10,e $nmbr$ / s $nmbr$ ( n = $nmbr$ ),,,inprogress,discard pile here
-10,entocort ec ( n = $nmbr$ ),,,inprogress,discard pile here
-10,environmental stimuli,,,inprogress,discard pile here
-10,e - rs total scoreb,C0035970;C0017452,,completed,
-10,erysipelas,,,inprogress,discard pile here
-10,estonia,C0032285,,completed,
-10,evidence or thombus n ( % ),C0042373,,completed,
-10,exercise category ( % ),,,inprogress,discard pile here
-10,extenswe,C0205231,,completed,
-10,extracranial,C0151699,,completed,
-10,extreme tortuosity,C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
-10,fas,;C0020162,,completed,
-10,( fxs ),,,inprogress,discard pile here
-10,gm geometric mean gmr geometric mean ratio over baseline uacr urinary albumimcreatinine ratio . % reduction : $nmbr$ x ( $nmbr$ — ratio of gmr for losartan versus gmr for placebo ) . amean of change with change calculated as difference between time indicated and baseline as measured for each participant difference of changes between treatment groups . cp - values compare differences from no change .,,,inprogress,
-10,golden - $nmbr$,C1527249,,completed,
-10,golden - $nmbr$ and - $nmbr$,C1527249,,completed,
-10,goncomitant treatment with age inhibitors / angiotensin,C0001779,,completed,
-10,has - bledo,,,inprogress,discard pile here
-10,hdl cholesterol < $nmbr$ ( men ) or < $nmbr$ mg / dl ( women ),C0043210,;C3541888;C1720467,completed,
-10,history of gestational diabetes mellitus — no . ( % of women ),C0043210,;C3541888;C1720467,completed,
-10,hub,,,inprogress,discard pile here
-10,* hypercholesterolemia was defined as a low - density lipoprotein cholesterol level at enrollment of more than $nmbr$ mg per deciliter ( $nmbr$ . $nmbr$ mmol per liter ) after an overnight fast . † nonsustained ventricular tachycardia was defined as $nmbr$ or more consecutive ventricular beats at a heart rate of more than $nmbr$ beats per minute . ‡ to convert weight to kilograms divide by $nmbr$ . $nmbr$ . § to convert values for creatinine to micromoles per liter multiply by $nmbr$ . $nmbr$ . ¶ data for follow - up medication were available for $nmbr$ patients ( amiodarone $nmbr$ placebo $nmbr$ and icd $nmbr$ ) . ace de - notes angiotensin - converting enzyme and arb angiotensin ii – receptor blocker . ¿ p < $nmbr$ . $nmbr$ for the comparison among the groups,,,completed,
-10,hypovolaemia,C4553966;C0020621,;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637,completed,
-10,idegasp bid,C1739768;C0004057,,completed,
-10,idr,C0011065,,completed,
-10,improved,C0027396,,completed,
-10,imt ( $nmbr$ ),,,completed,carotid intima medial thickness
-10,im - uniti,C1282952,,completed,
-10,inguinal hernia repair,,,inprogress,discard pile here
-10,inter .,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
-10,intracranial,C0151699,,completed,
-10,inversion,C0520887,,completed,
-10,jejunum,,,inprogress,discard pile here
-10,j $nmbr$ - blocker,C0001645,,completed,
-10,large / very large,,,inprogress,discard pile here
-10,leflunomide,,,inprogress,discard pile here
-10,legend,C0429029,,completed,
-10,leukotriene modifier,,,inprogress,discard pile here
-10,lm $nmbr$ bid ( n = $nmbr$ ),C1261082,,completed,
-10,lm $nmbr$ $nmbr$,C1261082,,completed,
-10,lymphadenopathy,,,inprogress,discard pile here
-10,mean ( sd ) values are presented for all variables except medical history race or ethnic group and sex ( n % ) and urinary albumin / creatinine ratio ( median ( range ) ) . abody mass index is the weight in kilograms divided by the square of the height in meters . bto convert values to micromoles per liter multiply by $nmbr$ . $nmbr$ . estimated using the modified equation from the modification of diet in renal disease study . dto convert values to millimoles per liter multiply by $nmbr$ . $nmbr$ . eto convert values to millimoles per liter multiply by $nmbr$ . $nmbr$ . ^ to convert values to millimoles per liter multiply by $nmbr$ . $nmbr$ .,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
-10,m / f,,,inprogress,discard pile here
-10,mfns ( n = $nmbr$ ),C0080179,,completed,
-10,nap,,,inprogress,discard pile here
-10,ne,C0004238,,completed,
-10,( ne ne ),C0004238,,completed,
-10,nilvadipine,,,completed,
-10,^ $nmbr$,,,inprogress,discard pile here
-10,< = $nmbr$,,,inprogress,discard pile here
-10,< = $nmbr$ %,,,inprogress,discard pile here
-10,< $nmbr$,,,inprogress,discard pile here
-10,< $nmbr$ ( % ),,,inprogress,discard pile here
-10,< $nmbr$ { % ),,,inprogress,discard pile here
-10,< $nmbr$ %,,,inprogress,discard pile here
-10,≤ $nmbr$,,,inprogress,discard pile here
-10,≤ $nmbr$ %,,,inprogress,discard pile here
-10,= $nmbr$,,,inprogress,discard pile here
-10,= $nmbr$ ’ ),,,inprogress,discard pile here
-10,≥ $nmbr$,,,inprogress,discard pile here
-10,≥ $nmbr$ %,,,inprogress,discard pile here
-10,> = $nmbr$,,,inprogress,discard pile here
-10,> = $nmbr$ ( % ),,,inprogress,discard pile here
-10,> = $nmbr$ * ( % ),,,inprogress,discard pile here
-10,> $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ ( % ),,,inprogress,discard pile here
-10,> $nmbr$ %,,,inprogress,discard pile here
-10,. $nmbr$,,,inprogress,discard pile here
-10,« = $nmbr$,,,inprogress,discard pile here
-10,$ $nmbr$,,,inprogress,discard pile here
-10,$ $nmbr$ %,,,inprogress,discard pile here
-10,$nmbr$,,,inprogress,discard pile here
-10,$nmbr$ §,,,inprogress,discard pile here
-10,$nmbr$ +,,,inprogress,discard pile here
-10,£ $nmbr$,,,inprogress,discard pile here
-10,£ $nmbr$ %,,,inprogress,discard pile here
-10,\ $nmbr$,,,inprogress,discard pile here
-10,\ $nmbr$ %,,,inprogress,discard pile here
-10,( $nmbr$ blocker,C0001645,,completed,
-10,$nmbr$ - blocker,C0001645,,completed,
-10,/ $nmbr$ - blockers,C0001645,,completed,
-10,< $nmbr$ cells / pl,C0014467;C0007584,,completed,
-10,> $nmbr$ cells / pl,C0014467;C0007584,,completed,
-10,$nmbr$ % c . i .,,,inprogress,discard pile here
-10,$nmbr$ c . t,,,inprogress,discard pile here
-10,$nmbr$ e < $nmbr$ %,,,inprogress,discard pile here
-10,$nmbr$ e $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ e < $nmbr$ % n ( % ),,,inprogress,discard pile here
-10,^ $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,< = $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,< - $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,< $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,< $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,< $nmbr$ . $nmbr$ ( % ),,,inprogress,discard pile here
-10,< $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,≤ $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,> = $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,> - $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ < $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ < = $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ < $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ - < $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ . $nmbr$ ( % ),,,inprogress,discard pile here
-10,> $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,> $nmbr$ $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ % $nmbr$,,,inprogress,discard pile here
-10,« $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,( % ) ( $nmbr$ - $nmbr$ ),,,inprogress,discard pile here
-10,( % ) ( $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,( % ) $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ < - $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ - < $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ - < $nmbr$ ( % ),,,inprogress,discard pile here
-10,$nmbr$ - < $nmbr$ %,,,inprogress,discard pile here
-10,$nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ / $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,$nmbr$ ( < $nmbr$ % ),,,inprogress,discard pile here
-10,$nmbr$ ( > $nmbr$ % ),,,inprogress,discard pile here
-10,$nmbr$ ( $nmbr$ % ),,,inprogress,discard pile here
-10,$nmbr$ $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ % - $nmbr$ %,,,inprogress,discard pile here
-10,$nmbr$ % $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ — < $nmbr$,,,inprogress,discard pile here
-10,£ $nmbr$ . $nmbr$ % * *,,,inprogress,discard pile here
-10,% $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ ± b . b,,,inprogress,discard pile here
-10,$nmbr$ ( $nmbr$ e < $nmbr$ % ),,,inprogress,discard pile here
-10,$nmbr$ ( $nmbr$ j ) z $nmbr$ ( $nmbr$ . e,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ ( ne ne ),C0004238,,completed,
-10,> $nmbr$ - $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ - < $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ - $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ / $nmbr$ ( $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ - < $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ % ( $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ ( $nmbr$ $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ ( $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ ( $nmbr$ . $nmbr$ % ),,,inprogress,discard pile here
-10,> $nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,> $nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ $nmbr$ - < $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ - $nmbr$ - $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ - < $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ % - $nmbr$ . $nmbr$ %,,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ + $nmbr$ . $nmbr$,,,inprogress,discard pile here
-10,$nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,- $nmbr$ . $nmbr$ ( - $nmbr$ . $nmbr$ - c ) . $nmbr$ r,,,inprogress,discard pile here
-10,$nmbr$ / $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ ( $nmbr$ $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ $nmbr$ / $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ . $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ % t,C0016018,,completed,
-10,$nmbr$ - $nmbr$ ( s $nmbr$ - $nmbr$ ) t,,,inprogress,discard pile here
-10,$nmbr$ . ' ^ / $nmbr$ t $nmbr$ c } u,C0016018,,completed,
-10,$nmbr$ . $nmbr$ % vs . $nmbr$ . $nmbr$ %,C0086582;C0086287,,inprogress,
-10,< $nmbr$ » < $nmbr$ y,,,inprogress,discard pile here
-10,$nmbr$ - < $nmbr$ y,,,inprogress,discard pile here
-10,$nmbr$ - $nmbr$ y n ( % ),,,inprogress,discard pile here
-10,< $nmbr$ no . ( % ),C0004238,,completed,
-10,$nmbr$ q $nmbr$ w ( n = $nmbr$ ),,,inprogress,discard pile here
-10,$nmbr$ to < $nmbr$ hr,C3494202,,completed,
-10,* $nmbr$ to < $nmbr$ y,C0205682,,completed,
-10,> $nmbr$   vs .   ≤   $nmbr$,C0086582;C0086287,,inprogress,
-10,< $nmbr$ y,,,inprogress,discard pile here
-10,> = $nmbr$ y,,,inprogress,discard pile here
-10,> $nmbr$ y,,,inprogress,discard pile here
-10,» $nmbr$ y,,,inprogress,discard pile here
-10,$nmbr$ y,,,inprogress,discard pile here
-10,^ $nmbr$ y n ( % ),,,inprogress,discard pile here
-10,< $nmbr$ y n ( % ),,,inprogress,discard pile here
-10,> $nmbr$ y n ( % ),,,inprogress,discard pile here
-10,> $nmbr$ y . n ( % ),,,inprogress,discard pile here
-10,< $nmbr$ y ( n = $nmbr$ ),,,inprogress,discard pile here
-10,> $nmbr$ y ( n = $nmbr$ ),,,inprogress,discard pile here
-10,< $nmbr$ y ( n = $nmbr$ $nmbr$ . $nmbr$ % ),,,inprogress,discard pile here
-10,> $nmbr$ y ( n = $nmbr$ $nmbr$ . $nmbr$ % ),,,inprogress,discard pile here
-10,$nmbr$ μ g bid ( n = $nmbr$ ),C1739768;C0004057,,completed,
-10,noirecerving,C3251812,,completed,
-10,noliecervrig,C3251812,,completed,
-10,no ocs use no nasal polyps pre - bd fvc s $nmbr$ % of predicted and age at diagnosis < $nmbr$ years,C1828181,,completed,
-10,ocn,C0013384,,completed,
-10,olaemia n ( % ),C4553966;C0020621,;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637,completed,
-10,orthopaedic,C0085619,,completed,
-10,osteitis,;C0035455,,completed,
-10,otherb,C0920424,,completed,
-10,other $nmbr$,C0456525,,completed,
-10,oxcarbazepine,,,inprogress,discard pile here
-10,oxidative stress,,,inprogress,discard pile here
-10,pao $nmbr$ at rest mm hg,C2700280,,completed,
-10,pci = percutaneous coronary intervention . cabg = coronary - artery bypass graft . for hope > $nmbr$ mg / l for europa > $nmbr$ mg / l or on a lipid - lowering treatment for peace data are mean ( sd ) . data are mean ( sd ) unless otherwise indicated .,C0010055,,completed,
-10,personal relationships,,,inprogress,discard pile here
-10,phenobarbital,,,inprogress,discard pile here
-10,philippines,,,inprogress,discard pile here
-10,pin /,C0004604,,completed,
-10,= placebo eze = ezetimibe erol apo = apolipoprotein metabolic syndrome patients were eans and percentage changes are,C0003591,,completed,
-10,/ pl $nmbr$ $nmbr$,C0014467;C0007584,,completed,
-10,* p < $nmbr$ . $nmbr$ for eze / simva ( pooled across doses ) vs . simva ( pooled across doses ) for the entire cohort data are presented as least squares mean ± standard error ( † median ± se for tg ) for the entire cohort and also for each selected subgroup simva = simvastatin eze = ezetimibe tc = total cholesterol tg = triglycerides hdl - c = high - density lipoprotein - cholesterol non - hdl - c = non - high - density lipoprotein cholesterol apo = apolipoprotein,C0041004,,completed,
-10,poba n ( % ),C1553379,,completed,
-10,poland,C0027978,;C0324547,completed,
-10,polyarticular arthritis no rheumatoid nodules,C0003862,,completed,
-10,potential predictor,,,inprogress,discard pile here
-10,primary and secondary prevention subgroups adjusted for age gender hypertension diabetes mellitus and smoking . hr indicates hazard ratio $nmbr$ % cl $nmbr$ % confidence interval tia transient ischemic attack .,C2985465,,inprogress,
-10,probenecid,C0006560,,completed,
-10,proctosigmoiditis,,,inprogress,discard pile here
-10,prothrombin mutation ( % ),C0449238;C0872146,,completed,
-10,puerperium,,,inprogress,discard pile here
-10,puerto rican,,,inprogress,discard pile here
-10,p value ( men versus women ),C0043210,;C3541888;C1720467,completed,
-10,p value * placebo group p value * hyponatremia normonatremic group tolvaptan vs hyponatremic vs placebo,C4553967,,completed,
-10,qids - sr $nmbr$,,,inprogress,discard pile here
-10,qmaxi rn l / s,,,inprogress,discard pile here
-10,q $nmbr$ ( n   = $nmbr$ ),,,inprogress,discard pile here
-10,q $nmbr$ - q $nmbr$,,,inprogress,discard pile here
-10,q $nmbr$ w ( n = $nmbr$ ),,,inprogress,discard pile here
-10,q $nmbr$ w ( n $nmbr$ $nmbr$ ),,,inprogress,discard pile here
-10,q ( q $nmbr$ \,,,inprogress,discard pile here
-10,radial,C0589360;C0442038,,completed,
-10,radionuclide ventriculography,,,inprogress,discard pile here
-10,“ relative risk of outcome in acei group iw control group . bbaseline variables for models included : logarithm of age reciprocal of serum creatinine sbp up excretion treatment assignment and terms for studies $nmbr$ $nmbr$ $nmbr$ and $nmbr$ ( see footnotes of table $nmbr$ ) . other baseline variables considered for analysis ( p < $nmbr$ . $nmbr$ in univariate analysis ) included dp mean arterial pressure type of antihypertensive regimen in the control group planned duration of follow - up whether or not the investigators were blinded whether or not dietary advice was given and the year of publication .,;C0003364,,completed,
-10,rs - breathlessnessb,C0035970;C0017452,,completed,
-10,rs - chest symptomsd,C0035970;C0017452,,completed,
-10,rs $nmbr$,C0035970;C0017452,,completed,
-10,rs $nmbr$ ( aa ) & rs $nmbr$,C0035970;C0017452,,completed,
-10,rs $nmbr$ ( ac ) & rs $nmbr$,C0035970;C0017452,,completed,
-10,rs $nmbr$ & rs $nmbr$,C0035970;C0017452,,completed,
-10,rs - totala,C0035970;C0017452,,completed,
-10,sa,C0036243,,completed,
-10,sa acs,C0036243,,completed,
-10,sack,C1277691,,completed,
-10,so,C3529352,,completed,
-10,soc,C3529352,,completed,
-10,so $nmbr$ %,C3529352,,completed,
-10,southern europe,,,completed,
-10,streptokinase,,,inprogress,discard pile here
-10,* subgroups were defined on the basis of variables assessed before randomization . the lipid levels represent the averages of the values measured four weeks before randomization and those measured at randomization . to convert values for cholesterol to millimoles per liter multiply by $nmbr$ . $nmbr$ to convert values for triglycerides to millimoles per liter multiply by $nmbr$ . $nmbr$ . ci denotes confidence interval ldl low - density lipoprotein and hdl high - density lipoprotein . tests for heterogeneity of treatment effect were undertaken across each of the subgroups . in addition we performed tests for interaction between treatment and the following continuous base - line variables : age total ldl and hdl cholesterol and triglyceride levels . there was no evidence of significant heterogeneity of treat - ment effect in any prespecified subgroup ( p » $nmbr$ . $nmbr$ ) . † data were missing for three patients two in the placebo group and one in the pravastatin group .,C1705492,,completed,
-10,t,C0016018,,completed,
-10,ta,C0439092,,completed,
-10,tah ( n = $nmbr$ ),C0439092,,completed,
-10,ta ( n = $nmbr$ ),C0439092,,completed,
-10,tendonitis,C0868908,,completed,
-10,texcaps,C0002454,,completed,
-10,* the $nmbr$ substrata with baseline ( bl ) ldl cholesterol $nmbr$ to $nmbr$ mg / dl and $nmbr$ to $nmbr$ mg / dl were combined to make $nmbr$ group with bl ldl cholesterol $nmbr$ to $nmbr$ mg / dl because of small numbers of patients included in the substrata with $nmbr$ to $nmbr$ mg / dl . † bl hdl cholesterol cutoffs were $nmbr$ or $nmbr$ mg / dl for men and $nmbr$ or $nmbr$ mg / dl for women . bars indicate se . bmi body mass index e ezetimibe $nmbr$ mg hdl - c hdl cholesterol ldl - c ldl cholesterol tg triglycerides,C0023824,,completed,
-10,the test for heterogeneity ( interaction ) indicates whether the treatment effect varied significantly among the sub - groups . the hochberg method was applied to each of the two comparisons of the treatment groups . bmi denotes body - mass index ( the weight in kilograms divided by the square of the height in meters ) .,C1305855,,completed,
-10,thyroid hormone,C0019930,,completed,
-10,tio,C2985465,,inprogress,
-10,tio ( n $nmbr$ $nmbr$ ),C2985465,,inprogress,
-10,t - jj ( $nmbr$ - $nmbr$ ),C0016018,,completed,
-10,t $nmbr$ d,C0016018,,completed,
-10,t ( n = $nmbr$ $nmbr$ ),,,inprogress,discard pile here
-10,trait,;C0041912,,completed,
-10,transradial,C0151699,,completed,
-10,ttf - fv,,,inprogress,discard pile here
-10,two - dimensional echocardiography,,,inprogress,discard pile here
-10,ucr,C0011065,,completed,
-10,undeterminedc,C0478157,,completed,
-10,unhappy,,,inprogress,discard pile here
-10,uniti - $nmbr$,C1282952,,completed,
-10,uniti - $nmbr$ and uniti - $nmbr$ im - uniti,C1282952,,completed,
-10,upcr n ( % ),C0011065,,completed,
-10,uvb,,,inprogress,discard pile here
-10,uveitis,C1282952,,completed,
-10,values are mean ± sd median [ quartile range ] or % . ace indicates angiotensin - converting enzyme arb angiotensin receptor blocker bnp b - type natriuretic peptide bp blood pressure bun blood urea nitrogen lvef left ventricular ejection fraction and nt - probnp n - terminal pro - b - type natriuretic peptide .,C0018801;C0428772,,completed,
-10,values are presented as mean sd unless stated otherwise . data shown are for the randomized population . * body mass index values were missing from $nmbr$ patients in the aliskiren group and $nmbr$ patients in the hydrochlorothiazide group . † obesity was defined as body mass index $nmbr$ kg / m $nmbr$ . ‡ metabolic syndrome was defined according to the third report of the national cholesterol education program expert panel on detection evaluation and treatment of high blood cholesterol in adults ( adult treatment panel iii ) criteria $nmbr$ as any $nmbr$ of the following : waist circumference $nmbr$ cm for men or $nmbr$ cm for women triglycerides $nmbr$ mg / dl high - density lipoprotein cholesterol $nmbr$ mg / dl for men or $nmbr$ mg / dl for women mssbp $nmbr$ mm hg or msdbp $nmbr$ mm hg fasting glucose $nmbr$ mg / dl . § by medical history . aliskiren n $nmbr$ hydrochlorothiazide n $nmbr$ .,;C1305855,,completed,BMI
-10,values expressed as mean sd or number ( percent ) . * two patients were missing values for body mass index . † other forms of atherosclerosis are peripheral arterial disease abdom - inal aortic aneurysm symptomatic carotid artery disease transient isch - emic attack and stroke . ‡ family history of premature chd de ﬁ ned as chd in male ﬁ rst - degree relative aged $nmbr$ years or female ﬁ rst - degree relative $nmbr$ years . § blood pressure $nmbr$ / $nmbr$ mm hg on antihypertensive medication or diagnosis of hypertension based on medical history . n number of randomly assigned patients ncep atp national cholesterol education program adult treatment panel .,C0085096,,completed,
-10,very good or excellent,,,inprogress,discard pile here
-10,v $nmbr$ ( n = $nmbr$,,,inprogress,discard pile here
-10,v ( n = $nmbr$ ),,,inprogress,discard pile here
-10,voluntary,C0010068;C1956346,;C0026410;C1710701,completed,
-10,vora,C0016536,,completed,
-10,w,,,inprogress,discard pile here
-10,whitea,C1533021,,completed,
-10,wssng,C4684714,,completed,
-10,x ? = l - $nmbr$ p = $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,x / n,,,inprogress,discard pile here
-10,x / n *,,,inprogress,discard pile here
-10,x ? = $nmbr$ - l p = $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,x $nmbr$ n ( % ),,,inprogress,discard pile here
-10,x $nmbr$ = $nmbr$ - l p = $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,x $nmbr$ = $nmbr$ - $nmbr$ p = $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,x ? = $nmbr$ - $nmbr$ p = $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,x $nmbr$ = $nmbr$ p = $nmbr$ - $nmbr$,,,inprogress,discard pile here
-10,yearl,C1277691,,completed,
-10,y $nmbr$,,,inprogress,discard pile here
-10,之 $nmbr$,,,inprogress,discard pile here
1,weeks_measured,;C0444706;C3541902,;C2699239;C0439230,inprogress,weeks_measured
3,leisure,,,unhelpful,
3,outcome measure,,,unhelpful,
4,prasugrel,C1620287,,completed,
4,prasugrel or ticagrelor,C1620287,,completed,
5,pvalue,;C1709380,C0242960,completed,p value
5,pvalue ∗,;C1709380,C0242960,completed,p value
5,p value for heterogeneity,;C1709380,C0242960,completed,p value
5,pvalue for heterogeneity,;C1709380,C0242960,completed,p value
5,p value for heterogeneity （ rosiglitazone versus metformin ）,;C1709380,C0242960,completed,p value
8,cabg or valve,C0374711;C0184252,;C1704414;C3888056;C0035139;C0043240;C4553149;C1720467,completed,
8,valve repair / replacement only,C0374711;C0184252,;C1704414;C3888056;C0035139;C0043240;C4553149;C1720467,completed,
8,valve repair / replacement with or without cabg,C0374711;C0184252,;C1704414;C3888056;C0035139;C0043240;C4553149;C1720467,completed,
8,valve replacement / repair with or without cabg,C0374711;C0184252,;C1704414;C3888056;C0035139;C0043240;C4553149;C1720467,completed,
10,energy / fatigue,C0015672,;C4050243;C3542016;C0424589;C0542479;C1442080;C4330907;C0444504;C4553152,completed,
10,facit - fatigue . mean $nmbr$ sd ( range $nmbr$ - $nmbr$ ),C0015672,;C4050243;C3542016;C0424589;C0542479;C1442080;C4330907;C0444504;C4553152,completed,
10,fatigue,C0015672,;C4050243;C3542016;C0424589;C0542479;C1442080;C4330907;C0444504;C4553152,completed,
10,fatigue ( range $nmbr$ - $nmbr$ ),C0015672,;C4050243;C3542016;C0424589;C0542479;C1442080;C4330907;C0444504;C4553152,completed,
10,question $nmbr$ ( fatigue / tiredness ),C0015672,;C4050243;C3542016;C0424589;C0542479;C1442080;C4330907;C0444504;C4553152,completed,
12,baseline heart failure severity amongthose with priorheartfailure %,C0018801,;C0168634;C1524003,completed,
12,cardiac failure,C0018801,;C0168634;C1524003,completed,
12,cardiac failure §,C0018801,;C0168634;C1524003,completed,
12,cardiac failure *,C0018801,;C0168634;C1524003,completed,
12,cardiac failure —,C0018801,;C0168634;C1524003,completed,
12,cardiac failure n ( % ),C0018801,;C0168634;C1524003,completed,
12,cardiovascular death / hospitalization for heart failure,C3898876,;C0026544,completed,
12,cause of heart failure,C0018801,;C0168634;C1524003,completed,
12,cause of heart failure — no . ( % ),C0018801,;C0168634;C1524003,completed,
12,chronic heart failure,C0018801,;C0168634;C1524003,completed,
12,chronic heart failure class ii - iii,C0018801,;C0168634;C1524003,completed,
12,combined cardiac failure cardiomyopathy or other cardiac disorder n ( % ) luts severity n ( % ),C0018801,;C0168634;C1524003,completed,
12,congestive heart failure,C0018801,;C0168634;C1524003,completed,
12,congestive heart failure §,C0018801,;C0168634;C1524003,completed,
12,congestive heart failure †,C0018801,;C0168634;C1524003,completed,
12,congestive heart failure — %,C0018801,;C0168634;C1524003,completed,
12,congestive heart failure at randomisation,C0018801,;C0168634;C1524003,completed,
12,congestive heart failure ( chf ) ( in past $nmbr$ weeks ),C0018801,;C0168634;C1524003,completed,
12,congestive heart failure ( definite ),C0018801,;C0168634;C1524003,completed,
12,congestive heart failure n ( % ),C0018801,;C0168634;C1524003,completed,
12,congestive heart failure ( < $nmbr$ wk ),C0018801,;C0168634;C1524003,completed,
12,congestive heart failure — no . ( % ),C0018801,;C0168634;C1524003,completed,
12,congestive heart failure — no . ( % ) |,C0018801,;C0168634;C1524003,completed,
12,congestive heart failure — no . ( % ) | |,C0018801,;C0168634;C1524003,completed,
12,fatal & nonfatal hospitalized heart failure,C0018801,;C0168634;C1524003,completed,
12,heart failure,C0018801,;C0168634;C1524003,completed,
12,heart failure *,C0018801,;C0168634;C1524003,completed,
12,heart failure ‡,C0018801,;C0168634;C1524003,completed,
12,heart failure at entry no . ( % ),C0018801,;C0168634;C1524003,completed,
12,heart failure cause,C0018801,;C0168634;C1524003,completed,
12,heart failure criteria met,C0018801,;C0168634;C1524003,completed,
12,heart failure history,C0018801,;C0168634;C1524003,completed,
12,heart failure hospitalizations,C3898876,;C0026544,completed,
12,heart failure hospitalized or fatal,C0018801,;C0168634;C1524003,completed,
12,heart failure n ( % ),C0018801,;C0168634;C1524003,completed,
12,heart failure — no . ( % ),C0018801,;C0168634;C1524003,completed,
12,heart failure no . / total no . ( % ),C0018801,;C0168634;C1524003,completed,
12,heart failure — no . / total no . ( % ),C0018801,;C0168634;C1524003,completed,
12,heart failure ( treated / hospitalized / fatal ),C0018801,;C0168634;C1524003,completed,
12,histor y of congestive heart failure — no . ( % ),C0018801,;C0168634;C1524003,completed,
12,histor y of heart failure,C0018801,;C0168634;C1524003,completed,
12,hospital admission for heart failure,C0018801,;C0168634;C1524003,completed,
12,hospitalisation for heart failure,C3898876,;C0026544,completed,
12,hospitalization for heart failure,C3898876,;C0026544,completed,
12,hospitalization for heart failure n ( % ),C3898876,;C0026544,completed,
12,hospitalization for heart failure within $nmbr$ mo,C3898876,;C0026544,completed,
12,hospitalized / fatal heart failure,C0018801,;C0168634;C1524003,completed,
12,hospitalized for heart failure during that time period,C0018801,;C0168634;C1524003,completed,
12,hospitalized heart failure,C0018801,;C0168634;C1524003,completed,
12,medical history of cv disease or heart failure n ( % ),C0018801,;C0168634;C1524003,completed,
12,mortality shock or congestive heart failure within $nmbr$ days,C0018801,;C0168634;C1524003,completed,
12,no heart failure,C0018801,;C0168634;C1524003,completed,
12,no prior heart failure,C0018801,;C0168634;C1524003,completed,
12,no prior heart failure ( n = $nmbr$ $nmbr$ ),C0018801,;C0168634;C1524003,completed,
12,not hospitalized for heart failure in the year prior to study enrollment,C0018801,;C0168634;C1524003,completed,
12,participants with heart failure,C0018801,;C0168634;C1524003,completed,
12,participants without heart failure,C0018801,;C0168634;C1524003,completed,
12,previous hospital admission for heart failure,C0018801,;C0168634;C1524003,completed,
12,prior heart failure,C0018801,;C0168634;C1524003,completed,
12,prior heart failure %,C0018801,;C0168634;C1524003,completed,
12,priorheartfailure %,C0018801,;C0168634;C1524003,completed,
12,prior heart failure n ( % ),C0018801,;C0168634;C1524003,completed,
12,prior heart failure n / n ( % ),C0018801,;C0168634;C1524003,completed,
12,prior heart failure ( n = $nmbr$ $nmbr$ ),C0018801,;C0168634;C1524003,completed,
12,prior heart failure — no . { % ),C0018801,;C0168634;C1524003,completed,
12,prior heart failure yes,C0018801,;C0168634;C1524003,completed,
12,recurrent heart failure,C0018801,;C0168634;C1524003,completed,
12,required hospitalization,C3898876,;C0026544,completed,
12,score on the minnesota living with heart failure scaled,C0018801,;C0168634;C1524003,completed,
12,time since diagnosis of heart failure,C0018801,;C0168634;C1524003,completed,
12,worsening heart failure,C0018801,;C0168634;C1524003,completed,
15,arterial blood pressure mm hg,C0005823,,completed,
15,blood pressure,C0005823,,completed,
15,blood pressure ( % ),C0005823,,completed,
15,blood pressure at entry ( mm   hg ),C0005823,,completed,
15,blood pressure at target level ( % ) §,C0005823,,completed,
15,blood pressure eontrolt,C0005823,,completed,
15,blood pressure - lowering treatment,C0005823,,completed,
15,blood pressure mm,C0005823,,completed,
15,blood pressure mmhg,C0005823,,completed,
15,blood pressure mm hg,C0005823,,completed,
15,blood pressure ( mm hg ),C0005823,,completed,
15,blood pressure ( mm hg ) *,C0005823,,completed,
15,blood pressure ( mmhg ),C0005823,,completed,
15,blood pressure — mmhg,C0005823,,completed,
15,blood pressure — mm hg,C0005823,,completed,
15,blood pressure mmhg systolic,C0005823,,completed,
15,blood pressure < $nmbr$ mm hg,C0005823,,completed,
15,blood pressure > $nmbr$ mm hg,C0005823,,completed,
15,blood pressure < $nmbr$ / $nmbr$ mmhg n ( % ),C0005823,,completed,
15,blood pressure while seated — mm hg,C0005823,,completed,
15,body - mass index : ! : blood pressure — mm hg,C0005823,,completed,
15,lvh by ecgt blood pressure mm hg,C0005823,,completed,
15,preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria,C0005823,,completed,
15,treatment with any blood - pressure -,C0005823,,completed,
15,weight kg blood pressure mm hg,C0005823,,completed,
20,both impaired glucose tolerance and impaired fasting glucose tolerance — no .,C1272092,,inprogress,
20,impaired fasting glucose,C1272092,,inprogress,
20,impaired fasting glucose §,C1272092,,inprogress,
20,impaired fasting glucose level ( n = $nmbr$ ),C1272092,,inprogress,
20,impaired glucose tolerance or impaired fasting glucose,C1272092,,inprogress,
20,impaired glucose tolerance or impaired fasting glucose — no . ( % ),C1272092,,inprogress,
20,who / idf impaired fasting glucose,C1272092,,inprogress,
21,baseline fasting plasma glucose,C0455280;C0015663,;C0168634,completed,
21,casual plasma glucose ( mg / dl ),C0455280;C0015663,;C0168634,completed,
21,fascng plasma glucose a medan,C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose,C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose *,C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose categories n ( % ),C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose mg / dl,C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose ( mg / dl ),C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose — mg / dl,C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose mg / dl mean ( sd ),C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose mg / dl mean ( sd ) b,C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose ( mg / dl ) $nmbr$,C0455280;C0015663,;C0168634,completed,
21,fasting plasma glucose $nmbr$ medan,C0455280;C0015663,;C0168634,completed,
21,$nmbr$ - hr plasma glucose — mg / dl,C0455280;C0015663,;C0168634,completed,
27,exposed,C0332157,;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607,completed,
27,exposed ( n = $nmbr$ ),C0332157,;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607,completed,
27,exposure,C0332157,;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607,completed,
27,ltg - exposed,C0332157,;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607,completed,
27,previous tnf antagonist exposure n ( % ),C0332157,;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607,completed,
27,tnf antagonist - exposed,C0332157,;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607,completed,
27,tnfi exposed,C0332157,;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607,completed,
27,tnfi - exposed †,C0332157,;C0274281;C0231491;C1420817;C4521367;C4521846;C1552607,completed,
28,absolute difference estimate vs placebo ( $nmbr$ % ci ),C0032042,,inprogress,
28,absolutedifferenceestimate vs placebo ( $nmbr$ % ci ),C0032042,,inprogress,
28,active vs placebo,C0032042,,inprogress,
28,active   versus   placebo,C0032042,,inprogress,
28,ambulatory sbp difference vs placebo ( $nmbr$ % cl ),C0032042,,inprogress,
28,a $nmbr$ vs placebo,C0032042,,inprogress,
28,any placebo,C0032042,,inprogress,
28,assigned to placebo,C0032042,,inprogress,
28,baseline to eom placebo ( n = $nmbr$ ),C0032042,,inprogress,
28,b digit symbol substitution omega - $nmbr$ fatty acids vs placebo,C0032042,,inprogress,
28,chf on placebo ( % ),C0032042,,inprogress,
28,comparison with placebo,C0032042,,inprogress,
28,comparison with placebo ( mean,C0032042,,inprogress,
28,copd - placebo ( $nmbr$ pt ) n . ( % ),C0032042,,inprogress,
28,copd - placebo ( n = $nmbr$ ),C0032042,,inprogress,
28,dapagliflozin placebo no . of events / no . of patients,C0032042,,inprogress,
28,difference ( a ) vs placebo ( $nmbr$ % cl ),C0032042,,inprogress,
28,difference from placebo,C0032042,,inprogress,
28,difference from placebo ¥,C0032042,,inprogress,
28,difference from placebo ( $nmbr$ % ci ),C0032042,,inprogress,
28,difference from placebo * ( $nmbr$ % ci ),C0032042,,inprogress,
28,difference from placebo ( $nmbr$ % cl ),C0032042,,inprogress,
28,difference ( n - $nmbr$ fa - placebo ) lsm ± se ( mm / year ),C0032042,,inprogress,
28,differences between indacaterol + tiotropium versus tiotropium + placebo,C0032042,,inprogress,
28,difference vs placebo,C0032042,,inprogress,
28,difference vs . placebo,C0032042,,inprogress,
28,difference vs placebo ',C0032042,,inprogress,
28,difference vs placebo * *,C0032042,,inprogress,
28,difference vs placebo ( $nmbr$ % ci ),C0032042,,inprogress,
28,difference vs . placebo % ( $nmbr$ % cl ),C0032042,,inprogress,
28,difference vs placebo % [ $nmbr$ % cl ] p,C0032042,,inprogress,
28,dm - ( aliskiren vs . placebo ),C0032042,,inprogress,
28,dm + ( aliskiren vs . placebo ),C0032042,,inprogress,
28,duration from clopidogrel / placebo to pci min ( median iqr ),C0032042,,inprogress,
28,esrd on placebo ( % ),C0032042,,inprogress,
28,favors ffa / i favors placebo,C0032042,,inprogress,
28,feno,C0032042,,inprogress,
28,feno placebo ( lsm ),C0032042,,inprogress,
28,figure $nmbr$ least squares ( ls ) mean differences between ro ﬂ umilast and placebo in ( a ) pre - and ( b ) postbronchodilator fev $nmbr$ in the itt population and subpopulations . copd chronic obstructive pulmonary disease fev $nmbr$ forced expiratory volume in $nmbr$ s ics inhaled corticosteroid itt intent to treat laba long - acting b $nmbr$ - agonist .,C0032042,,inprogress,
28,f $nmbr$ vs placebo,C0032042,,inprogress,
28,hba $nmbr$ c difference vs placebo ( $nmbr$ % cl ),C0032042,,inprogress,
28,ics ( tiotropium n = $nmbr$ placebo n = $nmbr$ ),C0032042,,inprogress,
28,[ } ifrerence vs . placebo % ( $nmbr$ % cl ),C0032042,,inprogress,
28,i placebo,C0032042,,inprogress,
28,i placebo ( n = $nmbr$ ),C0032042,,inprogress,
28,laba ( tiotropium n = $nmbr$ placebo n = $nmbr$ ),C0032042,,inprogress,
28,ls mean difference ( se ) vs placebo,C0032042,,inprogress,
28,ls mean difference vs placebo ( $nmbr$ % ci ),C0032042,,inprogress,
28,ls mean [ $nmbr$ % ci ] treatment difference vs placebo,C0032042,,inprogress,
28,mtx plus placebo,C0032042,,inprogress,
28,n ( indacaterol $nmbr$ ug / indacaterol $nmbr$ ug / placebo ),C0032042,,inprogress,
28,$nmbr$ mg / day - placebo,C0032042,,inprogress,
28,- $nmbr$ placebo,C0032042,,inprogress,
28,$nmbr$ placebo,C0032042,,inprogress,
28,$nmbr$ placebo n = $nmbr$,C0032042,,inprogress,
28,$nmbr$ placebo ( n = $nmbr$ $nmbr$ ),C0032042,,inprogress,
28,$nmbr$ - year rates in placebo groups,C0032042,,inprogress,
28,no laba no ics ( tiotropium n = $nmbr$ placebo n = $nmbr$ ),C0032042,,inprogress,
28,nominal p vs placebo,C0032042,,inprogress,
28,no . of patients ( indacaterol / placebo ),C0032042,,inprogress,
28,omega - $nmbr$ fatty acid vs placebo least - squares mean ( $nmbr$ % cl ),C0032042,,inprogress,
28,or placebo treatment,C0032042,,inprogress,
28,patients in the placebo group nt - probnp values were reported for $nmbr$ patients,C0032042,,inprogress,
28,placebo,C0032042,,inprogress,
28,placebo |,C0032042,,inprogress,
28,placebo /,C0032042,,inprogress,
28,placebo ( % ),C0032042,,inprogress,
28,placebo §,C0032042,,inprogress,
28,placebo %,C0032042,,inprogress,
28,placebo allocation,C0032042,,inprogress,
28,placebo analysed ( % ),C0032042,,inprogress,
28,placebo arm,C0032042,,inprogress,
28,placebo - carisbamate $nmbr$ mg - carisbamate $nmbr$ mg,C0032042,,inprogress,
28,placebo croup n / n ( % ),C0032042,,inprogress,
28,placebo - dexlansoprazole,C0032042,,inprogress,
28,placebo diabetes n = $nmbr$,C0032042,,inprogress,
28,placebo ( dm - vs . dm + ),C0032042,,inprogress,
28,placebo dn = $nmbr$ ),C0032042,,inprogress,
28,placebo dr = $nmbr$ ),C0032042,,inprogress,
28,placebo event rate ( n = $nmbr$ ) %,C0032042,,inprogress,
28,placebo ( events / n ( % ) ),C0032042,,inprogress,
28,placebo events / n ( % ),C0032042,,inprogress,
28,placebo events / patients ( % ),C0032042,,inprogress,
28,placebo events / patients (,C0032042,,inprogress,
28,placebo events / patients ( % ),C0032042,,inprogress,
28,placebo every $nmbr$ weeks ( n = $nmbr$ ),C0032042,,inprogress,
28,= placebo eze : tes ( fc j > $nmbr$ rr $nmbr$ definition ) .,C0032042,,inprogress,
28,placebo group,C0032042,,inprogress,
28,placebo group ( n = $nmbr$ ),C0032042,,inprogress,
28,placebo group ( n = $nmbr$ ) f,C0032042,,inprogress,
28,placebo group ( n = $nmbr$ ) ’ j ',C0032042,,inprogress,
28,placebo group ( n = $nmbr$ $nmbr$ ) ( $nmbr$ $nmbr$ person years ),C0032042,,inprogress,
28,placebo km %,C0032042,,inprogress,
28,placebo ( lsm ),C0032042,,inprogress,
28,placebo ls means ( n ),C0032042,,inprogress,
28,placebo mdi,C0032042,,inprogress,
28,placebo mean,C0032042,,inprogress,
28,placebo mean change ( sd ),C0032042,,inprogress,
28,placebo mean ( n ),C0032042,,inprogress,
28,placebo mortality rate events per $nmbr$ person - y,C0032042,,inprogress,
28,placebo + mtx,C0032042,,inprogress,
28,placebo + mtx ( n = $nmbr$ ),C0032042,,inprogress,
28,placebo n,C0032042,,inprogress,
28,placebo n,C0032042,,inprogress,
28,placebo n ( % ),C0032042,,inprogress,
28,placebo n *,C0032042,,inprogress,
28,placebo n ( % ),C0032042,,inprogress,
28,placebo n = i $nmbr$,C0032042,,inprogress,
28,placebo n = l $nmbr$,C0032042,,inprogress,
28,placebo ( n = l $nmbr$ ),C0032042,,inprogress,
28,placebo ( « = $nmbr$ ),C0032042,,inprogress,
28,placebo ( » = $nmbr$ ),C0032042,,inprogress,
28,placebo $nmbr$,C0032042,,inprogress,
28,placebo ( $nmbr$ = $nmbr$ ),C0032042,,inprogress,
28,placebo $nmbr$ $nmbr$,C0032042,,inprogress,
28,placebo $nmbr$ / $nmbr$,C0032042,,inprogress,
28,placebo $nmbr$ . $nmbr$,C0032042,,inprogress,
28,placebo ( $nmbr$ $nmbr$ . $nmbr$ % ),C0032042,,inprogress,
28,placebo $nmbr$ . $nmbr$ pt yrs,C0032042,,inprogress,
28,placebo $nmbr$ o $nmbr$,C0032042,,inprogress,
28,placebo $nmbr$ year km ( % ),C0032042,,inprogress,
28,placebo $nmbr$ yr km %,C0032042,,inprogress,
28,placebo % > ( n / n ),C0032042,,inprogress,
28,placebo % ( n / n ),C0032042,,inprogress,
28,placebo n / n ( % ),C0032042,,inprogress,
28,placebo n / n,C0032042,,inprogress,
28,placebo n / n ( % ),C0032042,,inprogress,
28,placebo ( n = $nmbr$ ),C0032042,,inprogress,
28,placebo n = $nmbr$,C0032042,,inprogress,
28,placebo n   =   $nmbr$,C0032042,,inprogress,
28,placebo ( n = $nmbr$,C0032042,,inprogress,
28,placebo ( n = $nmbr$ ),C0032042,,inprogress,
28,placebo ( n = $nmbr$ ) ',C0032042,,inprogress,
28,placebo ( n = $nmbr$ ) †,C0032042,,inprogress,
28,placebo ( n = $nmbr$ * ),C0032042,,inprogress,
28,placebo ( n - $nmbr$ ),C0032042,,inprogress,
28,placebo ( n : $nmbr$ ),C0032042,,inprogress,
28,placebo ( n [ $nmbr$ ),C0032042,,inprogress,
28,placebo ( n $nmbr$ ),C0032042,,inprogress,
28,placebo ( n   =   $nmbr$ ),C0032042,,inprogress,
28,placebo ( n — $nmbr$ ),C0032042,,inprogress,
28,placebo [ n = $nmbr$ |,C0032042,,inprogress,
28,placebo [ n = $nmbr$ ],C0032042,,inprogress,
28,placebo n = $nmbr$,C0032042,,inprogress,
28,placebo n [ $nmbr$,C0032042,,inprogress,
28,placebo ( n   =   $nmbr$ ) a,C0032042,,inprogress,
28,placebo ( n   =   $nmbr$ ) b,C0032042,,inprogress,
28,placebo ( n = $nmbr$ ) i -,C0032042,,inprogress,
28,placebo ( n = $nmbr$ i $nmbr$ ),C0032042,,inprogress,
28,placebo ( n = $nmbr$ l ),C0032042,,inprogress,
28,placebo ( n = $nmbr$ ) n ( % ),C0032042,,inprogress,
28,placebo ( n = $nmbr$ ) n ( % ),C0032042,,inprogress,
28,placebo n = $nmbr$ n ( % ),C0032042,,inprogress,
28,placebo ( n = $nmbr$ $nmbr$ ),C0032042,,inprogress,
28,placebo ( n = $nmbr$ $nmbr$ ),C0032042,,inprogress,
28,placebo ( n - $nmbr$ . $nmbr$ ),C0032042,,inprogress,
28,placebo ( n $nmbr$ $nmbr$ ),C0032042,,inprogress,
28,placebo ( n $nmbr$ $nmbr$ $nmbr$ ),C0032042,,inprogress,
28,placebo ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0032042,,inprogress,
28,placebo ( n = $nmbr$ o ),C0032042,,inprogress,
28,placebo n = $nmbr$ subjects,C0032042,,inprogress,
28,placebo no diabetes n = $nmbr$,C0032042,,inprogress,
28,placebo no . ( $nmbr$ - y km % ),C0032042,,inprogress,
28,placebo no . of events / no .,C0032042,,inprogress,
28,placebo no . of events / total no . ( % ),C0032042,,inprogress,
28,placebo no . / total ( % ),C0032042,,inprogress,
28,placebo no . / total no .,C0032042,,inprogress,
28,placebo n ( rate ),C0032042,,inprogress,
28,placebo n ( rate ) *,C0032042,,inprogress,
28,placebo n ( rate ) $nmbr$,C0032042,,inprogress,
28,placebo ( n z $nmbr$ ),C0032042,,inprogress,
28,placebo [ n z $nmbr$ ],C0032042,,inprogress,
28,placebo ( n   = $nmbr$ ),C0032042,,inprogress,
28,placebo ( n   = $nmbr$ $nmbr$ ),C0032042,,inprogress,
28,placebo ( n   =   $nmbr$ ),C0032042,,inprogress,
28,placebo ( n   =   $nmbr$ $nmbr$ ),C0032042,,inprogress,
28,placebo patients / events n,C0032042,,inprogress,
28,placebo patients with events,C0032042,,inprogress,
28,placebo patients with events / total,C0032042,,inprogress,
28,placebo + pioglitazone ( n = $nmbr$ ),C0032042,,inprogress,
28,placebo plus aspirin,C0032042,,inprogress,
28,placebo plus statin ( n = $nmbr$ ),C0032042,,inprogress,
28,placebo r %,C0032042,,inprogress,
28,placebo secukinumab pooled,C0032042,,inprogress,
28,placebo / simva,C0032042,,inprogress,
28,placebo slope lsm ± se ( mm / year ),C0032042,,inprogress,
28,placebo + statin,C0032042,,inprogress,
28,placebo + statin ( n = $nmbr$ $nmbr$ ),C0032042,,inprogress,
28,placebo tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0032042,,inprogress,
28,placebo to ustekinumab $nmbr$ mgt,C0032042,,inprogress,
28,placebo - vonoprazan $nmbr$,C0032042,,inprogress,
28,placebo - vonoprazan $nmbr$ - vonoprazan $nmbr$,C0032042,,inprogress,
28,placebo ( w = $nmbr$ ),C0032042,,inprogress,
28,plaeebo,C0032042,,inprogress,
28,p $nmbr$ vs placebo,C0032042,,inprogress,
28,pooled placebo,C0032042,,inprogress,
28,proportion ( % ) of individuals a alirocumab • placebo,C0032042,,inprogress,
28,p value versus placebo,C0032042,,inprogress,
28,p vs placebo,C0032042,,inprogress,
28,p   vs . placebo,C0032042,,inprogress,
28,ranolazine ( n = $nmbr$ ) placebo ( n = $nmbr$ ),C0032042,,inprogress,
28,ranolazine vs . placebo km failure rate,C0032042,,inprogress,
28,rate ratio vs placebo ( $nmbr$ % ci ),C0032042,,inprogress,
28,rerandomization to placebo ( n = $nmbr$ ) f,C0032042,,inprogress,
28,sbp difference vs placebo ( $nmbr$ % cl ),C0032042,,inprogress,
28,serum uric acid difference vs placebo ( $nmbr$ % cl ),C0032042,,inprogress,
28,s $nmbr$ - $nmbr$ vs placebo,C0032042,,inprogress,
28,s $nmbr$ vs placebo,C0032042,,inprogress,
28,statin + placebo ( n = $nmbr$ ),C0032042,,inprogress,
28,therapy ( asa $nmbr$ $nmbr$ / placebo $nmbr$ ),C0032042,,inprogress,
28,therapy ( asa $nmbr$ / placebo $nmbr$ ),C0032042,,inprogress,
28,( tiotropium n = $nmbr$ placebo n,C0032042,,inprogress,
28,( tiotropium n = $nmbr$ placebo n =,C0032042,,inprogress,
28,tiotropium + placebo ( n [ $nmbr$ ),C0032042,,inprogress,
28,vorapaxar placebo $nmbr$ - yr . km %,C0032042,,inprogress,
28,vs . placebo,C0032042,,inprogress,
28,we recorded no significant interactions for any subgroup analysis . nyha = new york heart association . lvef = left ventricular ejection fraction . ' $nmbr$ % cl was calculated by cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ rosuvastatin $nmbr$ placebo ) .,C0032042,,inprogress,
28,we recorded no significant interactions for any subgroup analysis . pufa = polyunsaturated fatty acids . nyha = new york heart association . lvef = left ventricular ejection fraction . * $nmbr$ % cl was calculated with a cox proportional hazards model . tmedian value . data for total cholesterol were available for $nmbr$ patients ( $nmbr$ n - $nmbr$ pufa $nmbr$ placebo ) .,C0032042,,inprogress,
28,with placebo,C0032042,,inprogress,
28,with placebo ( n $nmbr$ $nmbr$ ),C0032042,,inprogress,
29,hyperlipidaemia,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidaemia ( % ),C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidaemia n ( % ) yes,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia ^,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia | |,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia %,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia ( % ),C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia ( % ) §,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia §,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia n ( % ),C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia n / n ( % ),C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia — no . ( % ),C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia — no . / total no . ( % ),C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia | | yes,C0020473;C4555212,;C0439810;C1710701,completed,
29,hyperlipidemia § yes,C0020473;C4555212,;C0439810;C1710701,completed,
30,hyperkalaemia,C0020461;C4552983,;C0439375;C0700287;C0684224;C0035173,completed,
30,hyperkalaemia ( investigator reported ),C0020461;C4552983,;C0439375;C0700287;C0684224;C0035173,completed,
30,hyperkalemia * ’,C0020461;C4552983,;C0439375;C0700287;C0684224;C0035173,completed,
30,hyperkalemiab,C0020461;C4552983,;C0439375;C0700287;C0684224;C0035173,completed,
30,hyperkalemia n ( % ),C0020461;C4552983,;C0439375;C0700287;C0684224;C0035173,completed,
30,hyperkalemia ( > $nmbr$ . $nmbr$ meq / l ),C0020461;C4552983,;C0439375;C0700287;C0684224;C0035173,completed,
31,hyponatremia,C4553967,,completed,
32,hvookalemia,C4553966;C0020621,;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637,completed,
32,hypokalaemia,C4553966;C0020621,;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637,completed,
32,hypokalemia,C4553966;C0020621,;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637,completed,
32,hypokalemia ‡   ( potassium < $nmbr$ . $nmbr$ mmol / l ),C4553966;C0020621,;C0032821;C0202194;C0304475;C0597277;C1532563;C3714637,completed,
33,antihyperglycemic,C0020616,;C0013227;C3244316;C4284232;C0450442;C1254351;C1515187;C1521826;C2826257,completed,
33,antihyperglycemic medication usage,C0020616,;C0013227;C3244316;C4284232;C0450442;C1254351;C1515187;C1521826;C2826257,completed,
33,antihyperglycemictherapies %,C0020616,;C0013227;C3244316;C4284232;C0450442;C1254351;C1515187;C1521826;C2826257,completed,
33,any new anti - hyperglycemic rx,;C0040223,,completed,time to treatment
33,hypoglycaemic agents,C0020616,;C0013227;C3244316;C4284232;C0450442;C1254351;C1515187;C1521826;C2826257,completed,
33,hypoglycemic agent,C0020616,;C0013227;C3244316;C4284232;C0450442;C1254351;C1515187;C1521826;C2826257,completed,
33,other hypoglycemic agent n ( % ),C0020616,;C0013227;C3244316;C4284232;C0450442;C1254351;C1515187;C1521826;C2826257,completed,
33,took prior antihyperglycemic agent ( any ),C0020616,;C0013227;C3244316;C4284232;C0450442;C1254351;C1515187;C1521826;C2826257,completed,
35,b nonsevere hypoglycemia,C0020615,,completed,
35,hosji fcrhypoglycemia,C0020615,,completed,
35,hypoglycemia,C0020615,,completed,
35,hypoglycemia ^,C0020615,,completed,
35,hypoglycemiat,C0020615,,completed,
35,investigator - reported hypoglycaemia,C0020615,,completed,
35,investigator - reported hypoglycaemia *,C0020615,,completed,
35,major hypoglycemia,C0020615,,completed,
35,no nonsevere hypoglycemia,C0020615,,completed,
35,nonsevere hypoglycemia,C0020615,,completed,
47,adverse event,C0877248;C0016976,,completed,
47,adverse eventy,C1320716,,completed,
47,any adverse event ( ae ),C0877248,,completed,
47,any ae,C0877248,,completed,
47,any ae n ( % ) ‡,C0877248,,completed,
47,any clinical ae,C0877248,,completed,
47,any drug - related ae n ( % ),C0877248,,completed,
47,any early adverse event,C0877248;C0016976,,completed,
47,because of ae,C0877248,,completed,
47,clinical ae n ( % },C0877248,,completed,
47,drug - related ae *,C0877248,,completed,
47,laboratory ae n ( % },C0877248,,completed,
47,≥ $nmbr$ ae,C0877248,,completed,
47,unacceptable adverse events,C0877248;C0016976,,completed,
47,unacceptable side effects,C0877248;C0016976,,completed,
65,angina,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina .,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina n ( % ),C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina or acute mi,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina pectoris,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina pectoris ( % ),C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina pectoris *,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina pectorisf,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina pectoris — no . ( % ),C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina pectoris 本,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,angina symptoms ^,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,due worsening angina,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,hospitaiization for angina,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,myocardial infarction or angina,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,no prior angina ( n = $nmbr$ $nmbr$ ),C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,no rest angina,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,previous angina n ( % ),C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,previous angina pectoris,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,prior angina,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,prior angina n / n ( % ),C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,prior angina ( n = $nmbr$ $nmbr$ ),C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,prior angina pectoris,C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,prior angina pectoris — no . / total no . ( % ),C0002962,;C1552607;C0428953;C2926063;C3810814;C1424025;C2606415;C1883468,completed,
65,rec . ischemia due worsening angina,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,rest angina,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,rest angina but not past $nmbr$ h,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,rest angina past $nmbr$ h,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,unstable angina,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,unstable angina ( n = $nmbr$ $nmbr$ ),C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,unstable angina — no . ( % ),C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,unstable but no rest angina,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
65,worsening angina,C0002965,;C0152172;C0033727;C0369286;C0441932;C0564385;C4284302;C4528284;C1424025;C2606415;C4321499;C1883468,completed,
66,theophylline compound,C0039771,,completed,
66,theophyllines,C0039771,,completed,
67,rolofylline,C0166128,;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1114758;C1425688;C1521941;C2709207,completed,
67,rolofylline dose,C0166128,;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1114758;C1425688;C1521941;C2709207,completed,
67,rolofylline n,C0166128,;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1114758;C1425688;C1521941;C2709207,completed,
67,rolofylline $nmbr$ mg ( n = $nmbr$ ),C0166128,;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1114758;C1425688;C1521941;C2709207,completed,
67,rolofylline ( n = $nmbr$ ),C0166128,;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1114758;C1425688;C1521941;C2709207,completed,
67,rolofylline ( n = $nmbr$ $nmbr$ ),C0166128,;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1114758;C1425688;C1521941;C2709207,completed,
67,rolofylline rx,C0166128,;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1114758;C1425688;C1521941;C2709207,completed,
68,ivabradine,C0257190,;C0687744;C1257890;C1519504;C1705428;C1705429;C0441848,completed,
68,ivabradine group,C0257190,;C0687744;C1257890;C1519504;C1705428;C1705429;C0441848,completed,
68,ivabradine group ( n = $nmbr$ ),C0257190,;C0687744;C1257890;C1519504;C1705428;C1705429;C0441848,completed,
68,ivabradine ( n = $nmbr$ ),C0257190,;C0687744;C1257890;C1519504;C1705428;C1705429;C0441848,completed,
69,giargine,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,glargine,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,glargine allocation,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,glargine $nmbr$,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,iglar ( insulin glargine l $nmbr$ u ),C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,iglar ( n   =   $nmbr$ ),C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insuiin giargine ± oad,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine allocation,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine + insulin lispro ( award - $nmbr$ n = $nmbr$ ),C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine ( n = $nmbr$ ),C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine n ( x ),C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine   ±   oad,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine   ±   oad   +   > bd prandial,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine   ±   oad   +   bd prandial,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,insulin glargine   ±   oad   +   od prandial,C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
69,placebo + insulin glargine ( award - $nmbr$ n = $nmbr$ ),C0907402,;C1998602;C0004446;C0005126;C2344255;C4050145;C0229089;C0439164;C1512019;C3273373;C3665488,completed,
70,amlodipine / chlorthalidone,C0008294,,completed,
70,amlodipine / lisinopril / chlorthalidone comparison,C0008294,,completed,
70,amlodipine vs chlorthalidone normal,C0008294,,completed,
70,amlodipione - chlorthalidone,C0008294,,completed,
70,chlorthalidone,C0008294,,completed,
70,chlorthalidone group,C0008294,,completed,
70,chlorthalidone $nmbr$,C0008294,,completed,
70,chlorthalidone ( n = $nmbr$ ),C0008294,,completed,
70,chlorthalidone vs doxazosin,C0008294,,completed,
70,favors amlodipine favors chlorthalidone,C0008294,,completed,
70,favors favors amlodipine chlorthalidone,C0008294,,completed,
70,favors favors lisinopril chlorthalidone,C0008294,,completed,
70,favors lisinopril favors chlorthalidone,C0008294,,completed,
70,lisinopril - chlorthalidone,C0008294,,completed,
70,lisinopril / chlorthalidone,C0008294,,completed,
70,lisinopril vs chlorthalidone,C0008294,,completed,
70,lisinopril vs chlorthalidone normal,C0008294,,completed,
70,$nmbr$ amlodipine - chlorthalidone,C0008294,,completed,
70,$nmbr$ chlorthalidone,C0008294,,completed,
70,$nmbr$ chlorthalidone amlodipine,C0008294,,completed,
70,$nmbr$ chlorthalidone ( n = $nmbr$ ),C0008294,,completed,
70,$nmbr$ lisinopril - chlorthalidone,C0008294,,completed,
72,any thiazolidinedione,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinedione,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinedioneb,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinedione based,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinedione ( includes pioglitazone ),C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinedione no,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinediones,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinediones *,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinedionesc,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinedione use at baseline,C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
72,thiazolidinedione 一 no . ( % ),C1257987,;C0289779;C1527178;C1705938;C1552866;C2700399;C0168634,completed,
73,aspirin and thienopyridine therapy,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,aspirin + thienopyridine,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,no thienopyridine,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,planned thienopyridine at enrollment,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,prior thienopyridine ( - ),C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,prior thienopyridine ( + ),C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,thienopyridine,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,- thienopyridine,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,+ thienopyridine,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,thienopyridine + dipyridamole,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,thienopyridine ( n = $nmbr$ ),C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,thienopyridine n = $nmbr$,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,thienopyridine type,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
73,thienopyridine use,C1120149,;C0039798;C0087111;C1363945;C1709561;C1947944,completed,
74,famotidine $nmbr$ - famotidine $nmbr$,C0015620,,completed,
74,placebo - famotidine $nmbr$,C0015620,,completed,
74,placebo - famotidine $nmbr$ - famotidine $nmbr$,C0015620,,completed,
75,lamotrigine,C0064636,;C0524166;C0274281,completed,
75,prior exposure to lamotrigine,C0064636,;C0524166;C0274281,completed,
77,corticosteroid - azathioprine / $nmbr$ - mercaptopurine,C0000618,,completed,
77,mercaptopurine,C0000618,,completed,
77,$nmbr$ - mercaptopurine,C0000618,,completed,
77,$nmbr$ - mercaptopurine / azathioprine,C0000618,,completed,
78,amlodipine,,,completed,
78,! amlodipine,,,completed,
78,amlodipine - amlodipine / valsartan,,,completed,
78,amlodipine / lisinopril $nmbr$,,,completed,
78,amlodipine ( n = $nmbr$ ),,,completed,
78,amlodipine / vaisartan ( n = $nmbr$ ),,,completed,
78,amlodipine vs chlorthalidone obese,,,completed,
78,amlodipine vs chlorthalidone overweight,,,completed,
78,amlodipine / wlsartan i $nmbr$ / $nmbr$ mg,,,completed,
78,benazepril / hydrochlorothiazide - benazepril / amlodipine,,,completed,
78,chlorthalidone - amlodipine - lisinopril,,,completed,
78,chlorthalidone vs amlodipine,,,completed,
79,creatinine ciearance,C0010294,;C0205173;C0549183,completed,
79,creatinine clearance,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance an   ( % ),C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance at randomization,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance at randomization ( ixrs ),C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearanceb ml / min,C0010294,;C0205173;C0549183,completed,
79,creatinine clearance category [ ml / min ],C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance category ml / min no . ( % ) b,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance n ( % ),C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance ， : : $nmbr$ ml / min %,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance < $nmbr$ ml / min no . / total ( % ),C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance < $nmbr$ ml / min — no . ( % ) weight < $nmbr$ kg — no . ( % ),C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance no . ( % ),C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,creatinine clearance — no . ( % ),C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,estimated creatinine clearance !,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,estimated creatinine clearance < $nmbr$ ml / mint,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,estimated * creatinine clearance < $nmbr$ mlvmin %,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,estimated creatinine clearance < $nmbr$ rmb ' mint,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
79,estimated creatinine clearancet,C0010294,;C0205173;C0549183,completed,
79,renal fmclicn : creatntoe clearance,C0812399,;C3889287;C0452249;C0522467;C1337213;C1576800;C3890003;C0005910;C0022718;C1305866;C1705104;C1705224;C3887665,completed,
80,albumin creatinine ratio,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,albumin / creatinine ratio n ( % ),C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,albumin - to - creatinine ratio,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,albumin - to - creatinine ratio ( acr ),C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,baseline albumin / creatinine ratio in $nmbr$ classes,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,median albumin - to - creatinine ratio ( interquartile range ),C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,ratio of urinary albumin ( mg ) to creatinine ( g ),C0010294,;C0205173;C0549183,completed,
80,ratio of urinary albumin ( mg ) to creatinine ( g ) median,C0010294,;C0205173;C0549183,completed,
80,urinary albumimcreatinine ratio,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urinary albumin : creatinine ratio ^,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urinary albumin : creatinine ratio *,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urinary albumin : creatinine ratioa ( mg / g ),C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urinary albumin : creatinine ratio ( mg / g ),C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urinary albumin - to - creatinine ratio ^,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urinary albumin - to - creatinine ratio §,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urinary albumin - to - creatinine ratio — no . ( % ) §,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urinary protein - to - creatinine ratio | |,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urine albumin / creatinine ( mg / mmol ),C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urine albumin / creatinine ratio ( mg / g ),C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urine albumin / creatinine ratio mg / mmol,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urine albumin - to - creatinine ratio,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urine albumin - to - creatinine ratio - no . ( % ) § §,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
80,urine albumin - to - ereatinine ratio,C0455271,;C2348885;C1412134;C1515941;C0168634;C1705943;C4019422;C0549183;C0876920;C2362049,completed,
81,colchicine ( n = $nmbr$ ),C0009262,,completed,
81,no colchicine ( n = $nmbr$ ),C0009262,,completed,
90,atrial fibrillation duration — no . ( % ),C0004238,,completed,
90,duration of qualifying atrial fibrillation » $nmbr$ days — no . ( % ),C0004238,,completed,
90,lone atrial fibrillation — no . ( % ) §,C0004238,,completed,
90,new - onset atrial fibrillation,C0004238,,completed,
96,cigarettesmoking %,C0677453,;C3890423,completed,
96,cigarette users,C0677453,;C3890423,completed,
99,erosive reflux disease,C0017168,,completed,
99,gastroesophageal reflux disease,C0017168,,completed,
99,gastrooesophageal reflux disease,C0017168,,completed,
99,type of reflux disease,C0017168,,completed,
101,clinical disease activity index,C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,clinical disease activity index score ( $nmbr$ - $nmbr$ ),C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,disease activity,C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,disease activity ],C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,disease activity ( n ( % ) ),C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,high disease activity : > $nmbr$ . $nmbr$ n ( % ),C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,ptga of disease activity ( $nmbr$ ‒ $nmbr$ mm ) mean ( sd ) †,C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,simplified disease activity index,C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,simplified disease activity index score,C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
101,simplified disease activity index score ( $nmbr$ - $nmbr$ ),C1292728,;C4050231;C1299351;C2700149;C3887512;C3889660;C4321237;C4522209,completed,
103,cardiac valvular disease,C0018824,,completed,
103,mitral valve disease ( n = $nmbr$ $nmbr$ ),C0018824,,completed,
103,valvular disease,C0018824,,completed,
103,valvular disease ( % ),C0018824,,completed,
103,valvular disease mitral,C0018824,,completed,
103,valvular heart disease,C0018824,,completed,
103,valvular heart disease n ( % ),C0018824,,completed,
103,valvular heart disease — no . ( % ),C0018824,,completed,
104,chronic kidney diseased,C0022658,,completed,
104,diabetic kidney disease,C0022658,,completed,
104,duration of chronic kidney disease * ( years ),C0022658,,completed,
104,kidney disease ( usrds ),C0022658,,completed,
107,active inflammatory bowel disease,C0021390,,completed,
107,chronic inflammatory disease,C0021390,,completed,
107,inflammatory bowel disease,C0021390,,completed,
107,inflammatory disease,C0021390,,completed,
108,associated with connective tissue disease,C0009782,,completed,null
108,assoc with connective tissue disease,C0009782,,completed,null
108,connective - tissue disease,C0009782,,completed,null
108,connective tissue disease,C0009782,,completed,null
111,edoxaban higher dose vs warfarin,C0444956,,completed,
111,high dose,C0444956,,completed,
111,high - dose arb ( n = $nmbr$ ),C0444956,,completed,
111,high - dose edoxaban,C0444956,,completed,
111,high - dose edoxaban ( n = $nmbr$ ),C0444956,,completed,
111,high - dose edoxaban vs warfarin,C0444956,,completed,
111,high - dose statin,C0444956,,completed,
111,high dose statin ( n = $nmbr$ $nmbr$ ),C0444956,,completed,
111,high - dose statin use at screening *,C0444956,,completed,
111,high - dose statin use n ( % ) e,C0444956,,completed,
111,higher dose,C0444956,,completed,
111,higher - dose,C0444956,,completed,
111,higher - dose edoxaban ( n = $nmbr$ ) n ( % / y ),C0444956,,completed,
111,higher - dose edoxaban vs warfarin,C0444956,,completed,
112,edoxaban lower dose vs warfarin,C0445550,,completed,
112,fenofibric acid - i - low - dose statin,C0445550,,completed,
112,fenofibric acid + low - dose statin,C0445550,,completed,
112,fenofibric acid - $nmbr$ - low - dose statin,C0445550,,completed,
112,low dose,C0445550,,completed,
112,low dose combination therapy,C0445550,,completed,
112,low - dose statin,C0445550,,completed,
112,lower dose,C0445550,,completed,
112,lower - dose,C0445550,,completed,
120,baseline corticosteroid use ( mg ),C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,concomitant corticosteroid use,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,concomitant corticosteroid use n ( % ),C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,corticosteroid use,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,corticosteroid use %,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,corticosteroid use at baseline,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,corticosteroid use at baseline - no,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,corticosteroid use at randomization,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,corticosteroid use at randomization   n   ( % ),C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,corticosteroid use n ( % ),C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,corticosteroid use $nmbr$ n ( % ),C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,no steroid use at baseline ( ref ),C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,steroid use %,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,steroid use at baseline,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,steroid use at baseline n ( % ),C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
120,systemic corticosteroid use,C0239126,;C0168634;C0024671;C0026410;C0439269;C1960952;C2346927;C4321396;C4521761;C1425988;C1947944,completed,
123,enrolled in russia or georgia,C0035970;C0017452,,completed,
123,europe and russia,C0035970;C0017452,,completed,
123,russia,C0035970;C0017452,,completed,
123,russia and georgia,C0035970;C0017452,,completed,
123,russia / georgia,C0035970;C0017452,,completed,
123,russia / georgia ( n = $nmbr$ ),C0035970;C0017452,,completed,
124,baseline total ipss,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,erectile function ipss,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,= international prostate symptom score,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,ipss,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,ipss categories,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,ipss hrql,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,ipss “ / o,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,ipss - s,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,ipss total score,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,ipss ( unit ),C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,ipss - v,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,mild ( ipss < $nmbr$ ),C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,mild / moderate ( ipss < $nmbr$ ),C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,mild - to - moderate ( ipss < $nmbr$ ),C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,moderate ( ipss < $nmbr$ ) ( n = $nmbr$ ),C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,moderate ( $nmbr$ < ipss < $nmbr$ ),C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,( ngml ' ' ) total mean ipss score,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,severe ( ipss > $nmbr$ ),C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,severe ( ipss > $nmbr$ ) age group,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,severe ( ipss > $nmbr$ ) ( n = $nmbr$ ),C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
124,total ipss,C1998280,;C1019118;C3811063;C4050465;C4050466;C4049706;C0168634;C1705273;C1880519;C3853603,completed,
132,e $nmbr$ / s $nmbr$ vs e $nmbr$,,,unhelpful,
132,e $nmbr$ / s $nmbr$ vs s $nmbr$,,,unhelpful,
132,ith vs . without ),,,unhelpful,
132,> $nmbr$ and   ≤   $nmbr$   vs .   ≤   $nmbr$,,,unhelpful,
132,> $nmbr$ and   ≤   $nmbr$   vs   ≤   $nmbr$,,,unhelpful,
132,> $nmbr$ . $nmbr$   vs .   >   $nmbr$ . $nmbr$ and   ≤   $nmbr$ . $nmbr$,,,unhelpful,
132,> $nmbr$ to   ≤   $nmbr$   vs .   ≤   $nmbr$,,,unhelpful,
132,q $nmbr$ : $nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ kg ( n = $nmbr$ vs $nmbr$ ),,,unhelpful,
132,tp vs no tp,,,unhelpful,
154,combined infliximab,C0666743,,completed,
154,infliximab,C0666743,,completed,
154,infliximab combination therapy,C0870128,,completed,
154,infliximab - experienced ( n = $nmbr$ ),C0666743,,completed,
154,infliximab monotherapy,C0666743,,completed,
154,infliximab - naive ( n = $nmbr$ ),C0666743,,completed,
154,infliximab ( n = $nmbr$ ),C0666743,,completed,
154,inflix no,C0666743,,completed,
154,inflix yes,C0666743,,completed,
154,no previous treatment with infliximab,C0666743,,completed,
154,previous treatment with infliximab,C0666743,,completed,
169,nih stroke scale,C1697238,;C3484372;C0442734,inprogress,
169,$nmbr$ nil,C1697238,;C3484372;C0442734,inprogress,
170,coronary heart disease risk equivalents n ( % ) c,,,inprogress,
170,heart disease risk factors,,,inprogress,
170,$nmbr$ - yr risk of coronary heart disease ( % ) ^ |,,,inprogress,
170,rash,,,inprogress,
170,sk . $nmbr$,,,inprogress,
173,cardiac risk,C0035647,,completed,
173,cardio - renal risk,C0035647,,completed,
173,increased risk for falls,C0035647,,completed,
173,moderate risk ( > $nmbr$ - $nmbr$ ),C0035647,,completed,
173,ncep risk category at study entry n ( % ),C0035647,,completed,
173,> $nmbr$ ( moderate or high bleeding risk ) no . / total ( % ),C0035647,,completed,
173,no increased risk for falls,C0035647,,completed,
173,risk,C0035647,,completed,
173,risk *,C0035647,,completed,
173,risk at,C0035647,,completed,
173,risk categories,C0035647,,completed,
173,risk category ( points ),C0035647,,completed,
173,risk score category ( points ),C0035647,,completed,
173,risk stratum,C0035647,,completed,
173,shock risk indext,C0035647,,completed,
179,established,C0443211,,completed,
179,established disease,C0443211,,completed,
179,established maerovaseular disease and albuminuria,C0443211,,completed,
179,established ( n = $nmbr$ ),C0443211,,completed,
188,african,C0005680,;C1706779,completed,
188,african america,C0005680,;C1706779,completed,
188,african american,C0005680,;C1706779,completed,
188,african - american,C0005680,;C1706779,completed,
188,african - american / african heritage ( n = $nmbr$ ),C0005680,;C1706779,completed,
188,african american / black,C0005680,;C1706779,completed,
188,african american n ( % ),C0005680,;C1706779,completed,
188,african american n = $nmbr$,C0005680,;C1706779,completed,
188,african americans,C0005680,;C1706779,completed,
188,african - latin american,C0005680,;C1706779,completed,
188,a : worldwide black and non - black patients,C0005680,;C1706779,completed,
188,black,C0005680,;C1706779,completed,
188,black *,C0005680,;C1706779,completed,
188,black / african american,C0005680,;C1706779,completed,
188,black / african - american,C0005680,;C1706779,completed,
188,black / african american *,C0005680,;C1706779,completed,
188,black / african - american ( $nmbr$ . $nmbr$ % ),C0005680,;C1706779,completed,
188,black n ( % ),C0005680,;C1706779,completed,
188,black ( n — $nmbr$ ),C0005680,;C1706779,completed,
188,black no . ( % ),C0005680,;C1706779,completed,
188,black / non - black,C0005680,;C1706779,completed,
188,black non - hispanic,C0005680,;C1706779,completed,
188,black non - hispanic - n ( % ),C0005680,;C1706779,completed,
188,black ( n   = $nmbr$ ),C0005680,;C1706779,completed,
188,black or african,C0005680,;C1706779,completed,
188,black or african america,C0005680,;C1706779,completed,
188,black or african american,C0005680,;C1706779,completed,
188,black or african - american,C0005680,;C1706779,completed,
188,black or african ‐ american,C0005680,;C1706779,completed,
188,black or african heritage,C0005680,;C1706779,completed,
188,black participants,C0005680,;C1706779,completed,
188,black us,C0005680,;C1706779,completed,
188,black worldwide,C0005680,;C1706779,completed,
188,b : u . s . black and non - black patients,C0005680,;C1706779,completed,
188,hispanic black,C0005680,;C1706779,completed,
188,* non - black *,C0005680,;C1706779,completed,
188,non - black ( n = $nmbr$ ),C0005680,;C1706779,completed,
188,non - black participants,C0005680,;C1706779,completed,
188,non - black worldwide,C0005680,;C1706779,completed,
188,non - hispanic black,C0005680,;C1706779,completed,
188,non - hispanic black or african - american,C0005680,;C1706779,completed,
188,race black or african - american n ( % ),C0005680,;C1706779,completed,
188,u . s . non - black patients,C0005680,;C1706779,completed,
188,worldwide non - black patients,C0005680,;C1706779,completed,
189,austrafca and new zealand,C0027978,;C0324547,completed,
189,australia and new zealand,C0027978,;C0324547,completed,
189,new zealand,C0027978,;C0324547,completed,
189,north america ( plus australia and new zealand ),C0027978,;C0324547,completed,
189,north america plus australia and new zealand,C0027978,;C0324547,completed,
190,advanced,C0205179,,completed,
190,advanced n ( % ),C0205179,,completed,
190,locally advanced,C0205179,,completed,
191,ambulance,C0002422,;C4049621,completed,
191,ambulance ( % ),C0002422,;C4049621,completed,
191,ambulance n ( % ),C0002422,;C4049621,completed,
191,first medical contact in ambulance,C0002422,;C4049621,completed,
191,in ambulance,C0002422,;C4049621,completed,
191,in emergency department before ambulance transfer,C0002422,;C4049621,completed,
191,non - pci hospital / ambulance,C0002422,;C4049621,completed,
191,symptom onset to first medical contact : ambulance or emergency department,C0002422,;C4049621,completed,
193,about $nmbr$ mg / l,C0006560,,inprogress,
193,about $nmbr$ mg / l or more,C0006560,,inprogress,
193,baseline median mg / l,C0006560,,inprogress,
193,baseline serum mg < $nmbr$ . $nmbr$ mmol / l,C0006560,,inprogress,
193,baseline serum mg > = $nmbr$ . $nmbr$ mmol / l,C0006560,,inprogress,
193,cld $nmbr$ mg ( n = l $nmbr$ ),C0006560,,inprogress,
193,final median mg / l,C0006560,,inprogress,
193,< $nmbr$ mg / l,C0006560,,inprogress,
193,≤ $nmbr$ mg / l,C0006560,,inprogress,
193,> $nmbr$ mg / l,C0006560,,inprogress,
193,( < $nmbr$ mg / l ),C0006560,,inprogress,
193,( ≥ $nmbr$ mg / l ),C0006560,,inprogress,
193,< $nmbr$ mg / l ( n = $nmbr$ ),C0006560,,inprogress,
193,> $nmbr$ mg / l ( n = $nmbr$ ),C0006560,,inprogress,
193,< $nmbr$ . $nmbr$ mg / l,C0006560,,inprogress,
193,> $nmbr$ . $nmbr$ mg / l,C0006560,,inprogress,
193,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ mg / l,C0006560,,inprogress,
193,$nmbr$ to $nmbr$ mg / l ( n = $nmbr$ ),C0006560,,inprogress,
198,brv dosage mg / d,,,inprogress,
198,brv > $nmbr$ mg / day,,,inprogress,
198,brv $nmbr$ mg / day ( n =,,,inprogress,
198,brv $nmbr$ mg / day ( n = $nmbr$ ),,,inprogress,
198,brv $nmbr$   mg / day,,,inprogress,
198,dapagliflozin $nmbr$ mg / day ( n = $nmbr$ ),,,inprogress,
198,dietary epa - dha intake ( mg / day ) *,,,inprogress,
198,dose ( mg / day ),,,inprogress,
198,ind $nmbr$ mg q . d . n = $nmbr$,,,inprogress,
198,itca $nmbr$ $nmbr$ mg / day ( n = $nmbr$ ),,,inprogress,
198,mean dose ( sd ) ( mg / day ),,,inprogress,
198,mg / day,,,inprogress,
198,< $nmbr$ mg / day,,,inprogress,
198,> $nmbr$ mg / day,,,inprogress,
198,$nmbr$ mg / day,,,inprogress,
198,$nmbr$ mg / d ( n = $nmbr$ ),,,inprogress,
198,< $nmbr$ mg / d peq,,,inprogress,
198,> $nmbr$ mg / d peq,,,inprogress,
198,> $nmbr$ . $nmbr$ mg / day %,,,inprogress,
198,no . of $nmbr$ - mg acetaminophen tablets / day,,,inprogress,
198,placebo + $nmbr$ mg / d of simvastatin ( n = $nmbr$ ),,,inprogress,
198,rsg $nmbr$ mg / day,,,inprogress,
206,a $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,baseline bmi < $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,baseline bmi > $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,baseline bmi > $nmbr$ kg / m $nmbr$ n = $nmbr$,;C1305855,,completed,BMI
206,baseline bmi > $nmbr$ kg / m $nmbr$ n = $nmbr$ $nmbr$,;C1305855,,completed,BMI
206,baseline bmi > $nmbr$ kg / m $nmbr$ n = $nmbr$ $nmbr$ change from baseline to $nmbr$ weeks,;C1305855,,completed,BMI
206,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$ n = $nmbr$,;C1305855,,completed,BMI
206,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$ n = $nmbr$ change from baseline to $nmbr$ weeks,;C1305855,,completed,BMI
206,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$ n = $nmbr$ $nmbr$,;C1305855,,completed,BMI
206,baseline bmi $nmbr$ to < $nmbr$ kg / m $nmbr$ n = $nmbr$ $nmbr$ change from baseline to $nmbr$ weeks,;C1305855,,completed,BMI
206,bl bm $nmbr$ < $nmbr$ kg / m ^,;C1305855,,completed,BMI
206,bmi at baseline ( kg / m $nmbr$ ),;C1305855,,completed,BMI
206,bmi group ( kg / m ^ ),;C1305855,,completed,BMI
206,bmi kg / m ^,;C1305855,,completed,BMI
206,bmi kg / m ^ *,;C1305855,,completed,BMI
206,bmi # kg - m “ $nmbr$,;C1305855,,completed,BMI
206,bmi kg - m - $nmbr$,;C1305855,,completed,BMI
206,bmi kg / m $nmbr$ cholesterol mg / dl,;C1305855,,completed,BMI
206,bmi kg / m $nmbr$ mean,;C1305855,,completed,BMI
206,bmi kg / m $nmbr$ ( mean $nmbr$ sd ),;C1305855,,completed,BMI
206,bmi ( kg / m $nmbr$ ) median ( range ),;C1305855,,completed,BMI
206,bmi kg / m $nmbr$ n ( % ),;C1305855,,completed,BMI
206,bmi ( kg / m $nmbr$ ) < $nmbr$,;C1305855,,completed,BMI
206,bmi kg / m $nmbr$ ( sd ),;C1305855,,completed,BMI
206,bmi ( kg / m $nmbr$ ) ( sd ),;C1305855,,completed,BMI
206,bmi mean kg / m $nmbr$ ( ± sd ),;C1305855,,completed,BMI
206,bmi mean ( sd ) kg / m ^,;C1305855,,completed,BMI
206,bmi mean ( sd ) ( kg / m $nmbr$ ),;C1305855,,completed,BMI
206,bmi mean ( sd ) kg / m $nmbr$,;C1305855,,completed,BMI
206,bmi mean ± sd kg / m $nmbr$,;C1305855,,completed,BMI
206,bmi mean ± sd kg / m $nmbr$,;C1305855,,completed,BMI
206,bmi mean ( sd ) kg / m $nmbr$ c,;C1305855,,completed,BMI
206,bmi median ( iqr ) kg / m $nmbr$,;C1305855,,completed,BMI
206,bmi > $nmbr$ kg / m $nmbr$ ( % ),;C1305855,,completed,BMI
206,bmi > $nmbr$ kg / m $nmbr$ ( n = $nmbr$ / $nmbr$ ),;C1305855,,completed,BMI
206,bmi > = $nmbr$ kg / m $nmbr$ population ( n = $nmbr$ ),;C1305855,,completed,BMI
206,bmi > $nmbr$ kg / m * ( n = $nmbr$ / $nmbr$ ),;C1305855,,completed,BMI
206,bmi ( sd ) kg / m $nmbr$,;C1305855,,completed,BMI
206,bm $nmbr$ ( kg / m $nmbr$ ),;C1305855,,completed,BMI
206,bmp kg - m “ $nmbr$,;C1305855,,completed,BMI
206,body mass index group ( ≥ $nmbr$ kg / m $nmbr$ ) — no . ( % ),;C1305855,,completed,BMI
206,body - mass index ( kg / m - ) !,;C1305855,,completed,BMI
206,body - mass index ( kg / m ’ ),;C1305855,,completed,BMI
206,body mass index kg / m ^ ^,;C1305855,,completed,BMI
206,body mass index ( kg / m ^ ),;C1305855,,completed,BMI
206,body - mass index kg / m $nmbr$,;C1305855,,completed,BMI
206,body mass index ( kg / m $nmbr$ ) ∗,;C1305855,,completed,BMI
206,bodymass index ( kg / m $nmbr$ ),;C1305855,,completed,BMI
206,body mass index < $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,body mass index > $nmbr$ kg / m $nmbr$ *,;C1305855,,completed,BMI
206,body mass index > $nmbr$ kg / m $nmbr$ n ( % ),;C1305855,,completed,BMI
206,body mass index ( range ) ( kg / m $nmbr$ ),;C1305855,,completed,BMI
206,egfr ml / kg per $nmbr$ . $nmbr$ m $nmbr$,;C1305855,,completed,BMI
206,high ( i $nmbr$ kg / m $nmbr$ ) baseline bmi,;C1305855,,completed,BMI
206,high ( > $nmbr$ kg / m ^ ) baseline bmi,;C1305855,,completed,BMI
206,[ kg / m ^ ],;C1305855,,completed,BMI
206,kg / m $nmbr$,;C1305855,,completed,BMI
206,kg / m $nmbr$ ),;C1305855,,completed,BMI
206,lean ( < $nmbr$ kg / m $nmbr$ ),;C1305855,,completed,BMI
206,low ( < $nmbr$ kg / m ^ ) baseline bmi,;C1305855,,completed,BMI
206,low ( < $nmbr$ kg / m $nmbr$ ) baseline bmi,;C1305855,,completed,BMI
206,mean bmii 士 s . d . kg / m $nmbr$,;C1305855,,completed,BMI
206,mean bmi kg / m $nmbr$ ± sd,;C1305855,,completed,BMI
206,mean bmi ± s . d . kg / m ^,;C1305855,,completed,BMI
206,mean bmi ( sd ) kg / m $nmbr$,;C1305855,,completed,BMI
206,mean bmi ± s . d . kg / m $nmbr$,;C1305855,,completed,BMI
206,mean bmi ± sd ( kg / m $nmbr$ ),;C1305855,,completed,BMI
206,mean iief ef score mean iief domain score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),;C1305855,,completed,BMI
206,mean qmax score by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),;C1305855,,completed,BMI
206,mean ( sd ) bmi kg / m $nmbr$,;C1305855,,completed,BMI
206,mean total ipss mean ipss by bmi ( < $nmbr$ / < $nmbr$ to < $nmbr$ / < $nmbr$ kg / m $nmbr$ ),;C1305855,,completed,BMI
206,$nmbr$ bmi kg / m,;C1305855,,completed,BMI
206,< $nmbr$ kg / m ^,;C1305855,,completed,BMI
206,> $nmbr$ kg / m ^,;C1305855,,completed,BMI
206,> $nmbr$ kg / m ’,;C1305855,,completed,BMI
206,$nmbr$ kg / m ’,;C1305855,,completed,BMI
206,< $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,< $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,≥ $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,≥ $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,> = $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,> $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,$nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,£ $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,< $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),;C1305855,,completed,BMI
206,< $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),;C1305855,,completed,BMI
206,> $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),;C1305855,,completed,BMI
206,> $nmbr$ kg / m $nmbr$ ( n — $nmbr$ ),;C1305855,,completed,BMI
206,$nmbr$ kg / m $nmbr$ or more,;C1305855,,completed,BMI
206,> $nmbr$ kg / m ^ ( obesity ),;C1305855,,completed,BMI
206,> $nmbr$ - ^ $nmbr$ kg / m ’,;C1305855,,completed,BMI
206,< $nmbr$ . $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,> $nmbr$ . $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,$nmbr$ - < $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,$nmbr$ - $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,> $nmbr$ . $nmbr$ kg / m $nmbr$ hypertension :,;C1305855,,completed,BMI
206,> $nmbr$ - < $nmbr$ kg / m $nmbr$ ( n = $nmbr$ ),;C1305855,,completed,BMI
206,$nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,$nmbr$ $nmbr$ to < $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,> $nmbr$ - < s $nmbr$ kg / m ’,;C1305855,,completed,BMI
206,> $nmbr$ - s $nmbr$ kg / m ’,;C1305855,,completed,BMI
206,$nmbr$ to < $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
206,obese ( bmi > $nmbr$ kg / m $nmbr$ ),;C1305855,,completed,BMI
206,obese ( > $nmbr$ kg / m ^ $nmbr$ ),;C1305855,,completed,BMI
206,obesity ( bmi > $nmbr$ kg / m $nmbr$ ) %,;C1305855,,completed,BMI
206,obesity ( bmi £ $nmbr$ kg / m $nmbr$ ),;C1305855,,completed,BMI
206,obesity ( body mass index > $nmbr$ kg / m $nmbr$ ),;C1305855,,completed,BMI
206,patients with bw decrease of $ $nmbr$ % in patients with baseline bmi of $ $nmbr$ kg / m $nmbr$ +,;C1305855,,completed,BMI
206,s $nmbr$ kg / m ^,;C1305855,,completed,BMI
206,s $nmbr$ kg / m $nmbr$,;C1305855,,completed,BMI
209,baseline tg,C0041004,,completed,
209,baseline tg level ( n = $nmbr$ $nmbr$ ) < $nmbr$ . $nmbr$ mg / dl,C0041004,,completed,
209,baseline tg level ( n = $nmbr$ . $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0041004,,completed,
209,baseline tg level { n = $nmbr$ $nmbr$ ) > $nmbr$ . $nmbr$ mg / dl,C0041004,,completed,
209,baseline tg level ( n = $nmbr$ $nmbr$ ) s $nmbr$ . $nmbr$ mg / dl,C0041004,,completed,
209,baseline tg < $nmbr$ . $nmbr$ mmol / l,C0041004,,completed,
209,baseline tg > $nmbr$ . $nmbr$ mmol / l,C0041004,,completed,
209,change in tg,C0041004,,completed,
209,elevated tg,C0041004,,completed,
209,hdl - c   high - density lipoprotein cholesterol   ldl - c   low - density lipoprotein cholesterol   sestandard error   tg   triglycerides .,C0041004,,completed,
209,highest tg tertile,C0041004,,completed,
209,lowest tg tertile,C0041004,,completed,
209,median ( q $nmbr$ : q $nmbr$ ) tg - rich lipoprotein cholesterol,C0041004,,completed,
209,middle tg tertile,C0041004,,completed,
209,tg,C0041004,,completed,
209,tg ’,C0041004,,completed,
209,tg §,C0041004,,completed,
209,tg *,C0041004,,completed,
209,tg +,C0041004,,completed,
209,tg median ( min max ),C0041004,,completed,
209,tg ( mmol / l ),C0041004,,completed,
209,tg ( mmol / l ) c,C0041004,,completed,
209,tg < $nmbr$ hdl > $nmbr$ ( n = $nmbr$ ),C0041004,,completed,
209,tg < = $nmbr$ . $nmbr$,C0041004,,completed,
209,tg > $nmbr$ . $nmbr$,C0041004,,completed,
211,pooled,C1709595;C1524024,,completed,
211,pooled analysis,C1709595;C1524024,,completed,
211,pooled analysis of sustain $nmbr$ — $nmbr$ trials,C1709595;C1524024,,completed,
211,pooled analysis sample,C1709595;C1524024,,completed,
211,pooled itt,C1709595;C1524024,,completed,
211,tnt and ideal ( pooled ),C1709595;C1524024,,completed,
212,good,C0205170,,completed,
212,good / moderate response,C0205170,,completed,
213,gold a,C0024117;C0521117,,completed,
213,gold b,C0024117;C0521117,,completed,
213,gold c,C0024117;C0521117,,completed,
213,gold d,C0024117;C0521117,,completed,
213,gold group,C0024117;C0521117,,completed,
213,gold group b,C0024117;C0521117,,completed,
213,gold group d,C0024117;C0521117,,completed,
213,gold group d — no . ( % ) | |,C0024117;C0521117,,completed,
213,gold group n ( % ),C0024117;C0521117,,completed,
213,gold groups a - d using mmrcb,C0024117;C0521117,,completed,
213,gold ii,C0024117;C0521117,,completed,
213,gold n ( % ),C0024117;C0521117,,completed,
213,gold $nmbr$,C0024117;C0521117,,completed,
213,gold $nmbr$ groups,C0024117;C0521117,,completed,
213,gold $nmbr$ groups n ( % ),C0024117;C0521117,,completed,
213,gold $nmbr$ - $nmbr$,C0024117;C0521117,,completed,
213,gold $nmbr$ ( « = $nmbr$ ),C0024117;C0521117,,completed,
213,gold $nmbr$ - $nmbr$ ( « = $nmbr$ ),C0024117;C0521117,,completed,
213,gold $nmbr$ - $nmbr$ ( n = $nmbr$ ),C0024117;C0521117,,completed,
213,gold stage ( % ) : c,C0024117;C0521117,,completed,
213,moderate gold $nmbr$,C0024117;C0521117,,completed,
213,moderate ( gold $nmbr$ ),C0024117;C0521117,,completed,
213,severe gold $nmbr$,C0024117;C0521117,,completed,
213,severe ( gold $nmbr$ ),C0024117;C0521117,,completed,
213,severity of airflow limitation ( gold $nmbr$ ) n ( % ),C0024117;C0521117,,completed,
213,severity of airflow limitation ( gold $nmbr$ - $nmbr$ ) n ( % ),C0024117;C0521117,,completed,
213,severity ofcopd ( gold $nmbr$ ) n ( % ),C0024117;C0521117,,completed,
213,severity of copd n ( % ) ( gold $nmbr$ ) : moderate,C0024117;C0521117,,completed,
213,severity of the disease ( gold $nmbr$ ) n ( % ),C0024117;C0521117,,completed,
216,clopidogrel or ticlopidine,C0070166,,completed,
216,clopidogrel / ticlopidine,C0070166,,completed,
216,clopidogrel ticlopidine or prasugrel,C0070166,,completed,
216,loading dose of clopidogrel or ticlopidine,C0070166,,completed,
217,aspirin + clopidogrel ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0070166,;C0369286;C0033727;C4049621,completed,
217,aspirin i clopidogrel ( n = $nmbr$ $nmbr$ ),C0070166,;C0369286;C0033727;C4049621,completed,
217,aspirin $nmbr$ clopidogrel,C0070166,;C0369286;C0033727;C4049621,completed,
217,aspirin plus clopidogrel ( n = $nmbr$ ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel,C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel %,C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel %,C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel + aspirin ( n = $nmbr$ ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel given before procedure,C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel n / n ( % ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel n / n { % ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel ( n = $nmbr$ ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel ( n = $nmbr$ $nmbr$ ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel ( n = $nmbr$ $nmbr$ ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel ( n = $nmbr$ ) n / n ( % ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel no . of patients % ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel plus aspirin,C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel plus aspirin ( n = $nmbr$ ),C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel plus aspirin % / yr,C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel pretreatment duration,C0070166,;C0369286;C0033727;C4049621,completed,
217,clopidogrel / total no . of patients % %,C0070166,;C0369286;C0033727;C4049621,completed,
217,clopiodogrel,C0070166,;C0369286;C0033727;C4049621,completed,
217,duration of clopidogrel pretreatment 一 hr median,C0070166,;C0369286;C0033727;C4049621,completed,
217,interval clopidogrel to pci,C0070166,;C0369286;C0033727;C4049621,completed,
217,interval from clopidogrel loading h,C0070166,;C0369286;C0033727;C4049621,completed,
217,open - label clopidogrel after completion of study drug,C0070166,;C0369286;C0033727;C4049621,completed,
217,timing of clopidogrel loading dose,C0070166,;C0369286;C0033727;C4049621,completed,
217,use of clopidogrel,C0070166,;C0369286;C0033727;C4049621,completed,
218,cancer surgery,C0920424,,completed,
219,prior aortocoronary bypass surgery,C0010055,,completed,
219,prior aortocoronary bypass surgery — no . ( % ),C0010055,,completed,
219,prior aortocoronary bypass surgery 一 no . ( % ),C0010055,,completed,
219,prior cabg surgery,C0010055,,completed,
219,prior oabg surgery,C0010055,,completed,
220,cv death / mi / stroke / ucr,C0011065,,completed,
220,death mi idr st or gusto severe bleeding,C0011065,,completed,
220,death / q - mi / idr,C0011065,,completed,
220,death / udmi / idr,C0011065,,completed,
223,any coronary revascularization,C0877341,;C4049621;C1552607,completed,
223,coronary revascularisation,C0877341,;C4049621;C1552607,completed,
223,coronary revascularisation §,C0877341,;C4049621;C1552607,completed,
223,coronary revascularization,C0877341,;C4049621;C1552607,completed,
223,coronary revascularization procedure,C0877341,;C4049621;C1552607,completed,
223,history of coronary revascularization no . ( % ),C0877341,;C4049621;C1552607,completed,
223,history ol coronary revascularization *,C0877341,;C4049621;C1552607,completed,
223,previous coronary revascularisation,C0877341,;C4049621;C1552607,completed,
223,previous coronary revascularization,C0877341,;C4049621;C1552607,completed,
223,previous coronary revascularization — no . ( % ),C0877341,;C4049621;C1552607,completed,
223,prior coronary revascularization,C0877341,;C4049621;C1552607,completed,
223,prior coronary revascularization n ( % ),C0877341,;C4049621;C1552607,completed,
223,prior coronary revascularization n / n ( % ),C0877341,;C4049621;C1552607,completed,
223,prior coronary revascularization no . ( % ),C0877341,;C4049621;C1552607,completed,
223,prior coronary revascularization — no . { % ),C0877341,;C4049621;C1552607,completed,
223,prior coronary revascularization ( pci or cabg ),C0877341,;C4049621;C1552607,completed,
224,right coronary,C1261316,,completed,
224,right coronary artery,C1261316,,completed,
224,right coronary artery n ( % ),C1261316,,completed,
225,acute coronary event,C0948089,;C0026544,completed,
225,acute coronary syndrome,C0948089,;C0026544,completed,
225,acute coronary syndrome $nmbr$,C0948089,;C0026544,completed,
225,coronary events $nmbr$,C0948089,;C0026544,completed,
225,median time from index acute coronary syndrome to randomization ( iqr ) — mo,C0948089,;C0026544,completed,
225,time from acute coronary syndrome to randomization ( days ),C0948089,;C0026544,completed,
226,any coronary artery disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,any established coronary artery disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,* atherosclerotic coronary heart disease ischaemic stroke or peripheral arterial disease . † n / n = number of people in phase $nmbr$ studies only . ‡ high ‐ intensity statins were defined as atorvastatin $nmbr$ to $nmbr$ mg rosuvastatin $nmbr$ to $nmbr$ mg or simvastatin $nmbr$ mg daily .,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease ^,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease %,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease §,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease *,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease — %,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease history,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease n ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease ( n = $nmbr$ $nmbr$ ),C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease — no . ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease — no . ( % ) : ! :,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease — no . ( % ) : c,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease — no . / total no . ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary artery disease   n   ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary heart disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary heart disease ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary heart disease death,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary heart disease n ( % ) b,C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary heart disease — no . ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,coronary heart disease n ( % ) t,C0010068;C1956346,;C0026410;C1710701,completed,
226,• death from coronary heart disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,documented coronary artery disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,hope patients with coronary - artery disease ( n = $nmbr$ ),C0010068;C1956346,;C0026410;C1710701,completed,
226,multivessel coronary artery disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,multivessel coronary artery disease — no . / total no . ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,only coronary artery disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,previous coronary artery disease n ( % ),C0010068;C1956346,;C0026410;C1710701,completed,
226,previous coronary heart disease,C0010068;C1956346,;C0026410;C1710701,completed,
226,prior coronary artery disease yes,C0010068;C1956346,;C0026410;C1710701,completed,
226,stable coronary artery disease,C0010068;C1956346,;C0026410;C1710701,completed,
227,previous coronary artery bypass graft,C2144990,,completed,
227,previous coronary - artery bypass grafting,C2144990,,completed,
227,previous coronary artery bypass grafting,C2144990,,completed,
227,previous coronary artery bypass surgery no . ( % ),C2144990,,completed,
228,coronary artery,C0205042,,completed,
228,coronary artery osteochondrosis,C0205042,,completed,
228,coronary artery stenosis > $nmbr$ %,C0205042,,completed,
228,left main coronary artery bifurcation,C0205042,,completed,
228,native coronary - artery lesions,C0205042,,completed,
228,> $nmbr$ % coronary stenosis,C0205042,,completed,
230,nace ( primary endpoint ),C2986535,,completed,
230,primary cv endpoint,C2986535,,completed,
230,primary endpoint,C2986535,,completed,
230,primary end point,C2986535,,completed,
230,primary end - point,C2986535,,completed,
230,primary end point |,C2986535,,completed,
230,primary end point *,C2986535,,completed,
230,primary endpoint ^,C2986535,,completed,
230,primary endpoint :,C2986535,,completed,
230,primary endpoint ’,C2986535,,completed,
230,primary endpoint at $nmbr$ days,C2986535,,completed,
230,primary endpoint at $nmbr$ months,C2986535,,completed,
230,primary end point : death / mi / idr / st,C2986535,,completed,
230,primary endpoint death / mi / idr / st,C2986535,,completed,
230,primary end point kaplan - meier rate %,C2986535,,completed,
230,primary endpoint $nmbr$,C2986535,,completed,
230,primary indication,C2986535,,completed,
230,primary safety end point : severe / life - threatening,C2986535,,completed,
230,primary trial end point,C2986535,,completed,
231,concomitant conventional dmard use,C0242708,;C0026544,completed,
231,concomitant csdmards other than methotrexate n ( % ),C0025677,,completed,
231,concomitant use of conventional synthetic dmard up to $nmbr$ mo — no . { % ) methotrexate,C0242708,;C0026544,completed,
231,dmard | |,C0242708,;C0026544,completed,
231,dmard + ( n   =   $nmbr$ ),C0242708,;C0026544,completed,
231,dmard − ( n   =   $nmbr$ ),C0242708,;C0026544,completed,
231,nonbiologic disease - modifying drug other than methotrexate : :,C0025677,,completed,
231,non - mtx,C0025677,,completed,
231,non - mtx csdmards,C0025677,,completed,
231,other dmards,C0242708,;C0026544,completed,
231,other dmard use,C0242708,;C0026544,completed,
231,previously taken any other dmards n ( % ),C0242708,;C0026544,completed,
231,previously taken dmards other than methotrexate %,;C0039260,,completed,
234,fair or poor,C2700379,,completed,
234,fair / poor,C2700379,,completed,
234,poor,C2700379,,completed,
238,cuban,C1553379,,completed,
239,mra,,,inprogress,mra
239,mra ( % ),,,inprogress,mra
239,mra at baseline,,,inprogress,mra
239,mra regimen ( n - $nmbr$ ),,,inprogress,mra
239,mra use,,,inprogress,mra
239,no mra at baseline,,,inprogress,mra
241,baseline geometric mean ( $nmbr$ ® / l ),,,inprogress,
241,geometric mean,,,inprogress,
241,geometric mean ige on loge scale — u / ml,,,inprogress,
241,geometric mean of baseline,,,inprogress,
241,geometric mean uacr,,,inprogress,
241,ratio to baseline in total ige at week $nmbr$ geometric mean ( se on loge scale ) u / ml,,,inprogress,
243,mostly satisfied,C0242428,,completed,
244,post - mi,C0856742,,completed,
247,rest of the world,C2700280,,completed,
247,rest ofthe world,C2700280,,completed,
247,rest ofworld,C2700280,,completed,
247,rest of world,C2700280,,completed,
247,rest - of - world ( n = $nmbr$ ),C2700280,,completed,
247,rest of world n z $nmbr$,C2700280,,completed,
252,acute dvt study,C0149871,,completed,
252,concomitant dvt n ( % ),C0149871,,completed,
252,concomitant dvt — no . ( % ) baseline nt - probnp — no . ( % ),C0149871,,completed,
252,dvt,C0149871,,completed,
252,dvt only,C0149871,,completed,
252,kheeatne index dvt,C0149871,,completed,
252,locafon of index dvt,C0149871,,completed,
252,only dvt,C0149871,,completed,
252,treatment period index dvt : event,C0149871,,completed,
252,without dvt dvt alone,C0149871,,completed,
260,hospitalized,C0701159,,completed,
260,hospitalized !,C0701159,,completed,
260,hospitalized angina,C0701159,,completed,
260,hospitalized pneumonia events n,C0701159,,completed,
261,in - hospital,C0019994,;C4049621,completed,
261,in - hospital medication,C0019994,;C4049621,completed,
261,medications in the hospital after randomization — no . ( % ),C0019994,;C4049621,completed,
263,claudication,C0021775,,completed,
263,claudication ( fontaine class > $nmbr$ ),C0021775,,completed,
263,claudication only,C0021775,,completed,
263,intermittent claudication,C0021775,,completed,
264,calcification n ( % ),C1533591,,completed,
264,heavy calcification,C1533591,,completed,
266,ambition,C0870128,,completed,
267,cardiac catheterization,C0018795,;C4049621,completed,
267,diagnostic catheterization,C0018795,;C4049621,completed,
268,bronchitis,C0006277,,completed,
268,chronic bronchitis,C0006277,,completed,
268,chronic bronchitis !,C0006277,,completed,
268,chronic bronchitis ( % ),C0006277,,completed,
268,chronic bronchitis ( itt ) ( n = $nmbr$ ),C0006277,,completed,
268,chronic bronchitis ( n = $nmbr$ ),C0006277,,completed,
269,randomised patients with spondylitis at baseline n,C0038012,,completed,
269,spondylitis,C0038012,,completed,
270,extensive / pancolitis,C0868908,,completed,
270,pancolitis,C0868908,,completed,
271,enthesitis,C1282952,,completed,
271,enthesitis % §,C1282952,,completed,
271,enthesitis n ( % ),C1282952,,completed,
271,enthesitis score *,C1282952,,completed,
271,enthesitis score at baseline median ( iqr ) week $nmbr$,C1282952,,completed,
271,% improvement in enthesitis score at week $nmbr$ n,C1282952,,completed,
271,patients with enthesitis,C1282952,,completed,
271,patients with enthesitis at baseline no .,C1282952,,completed,
271,patients with enthesitis at week $nmbr$ n ( % ),C1282952,,completed,
271,patients with enthesitis n ( % ),C1282952,,completed,
271,patients with enthesitis no . ( % ),C1282952,,completed,
271,patients with $ $nmbr$ dactylitis digit at week $nmbr$ enthesitis,C1282952,,completed,
271,randomised patients with enthesitis at baselinet,C1282952,,completed,
272,allergic rhinitis,;C0035455,,completed,
272,allergic rhinitis duration mean ± sd y *,;C0035455,,completed,
272,allergic rhinitis — no . ( % ),;C0035455,,completed,
272,rhinitis,;C0035455,,completed,
273,nasopharyngitis,C0031350,,completed,
273,pharyngitis,C0031350,,completed,
274,arthritis,C0003864,,completed,
274,arthritis characteristics,C0003864,,completed,
274,arthritis type *,C0003864,,completed,
274,dip joint arthritis,C0003864,,completed,
277,albiglutide events / patients ( %,C2607479,,completed,
277,albiglutide ( n = $nmbr$ ),C2607479,,completed,
279,orthopnea,C0085619,,completed,
279,orthopnea ( % ),C0085619,,completed,
279,orthopnea frequent / continuous,C0085619,,completed,
280,estrogen - containing hormones,C0019932,,completed,
280,hormones,C0019932,,completed,
281,post - menopausal with hormone replacement,C0019930,,completed,
281,post - menopausal without hormone replacement,C0019930,,completed,
282,copd worsening,C0332271,;C1538440;C3273279;C1412502,completed,
282,hf symptom worsened,C0332271,;C1538440;C3273279;C1412502,completed,
282,incident or worsening nephropathy,C0332271,;C1538440;C3273279;C1412502,completed,
282,worsened,C0332271,;C1538440;C3273279;C1412502,completed,
284,asian / oriental,C0078988,,completed,
284,asian or oriental,C0078988,,completed,
284,oretal,C0078988,,completed,
284,oriental,C0078988,,completed,
285,protein in urine   ≥ $nmbr$ +,C0033687,,completed,
285,proteinuria $nmbr$ ( g / day ),C0033687,,completed,
285,proteinuria ( > $nmbr$ g / $nmbr$ h ) %,C0033687,,completed,
286,baseline crp category ( mg / l ),C0006560,,inprogress,
286,baseline crp levels < $nmbr$ mg / l,C0006560,,inprogress,
286,baseline crp levels ≥ $nmbr$ mg / l,C0006560,,inprogress,
286,batellna c - reective protein,C0006560,,completed,
286,% change median baseline crp > $nmbr$ mg / l,C0006560,,inprogress,
286,c - reactive protein,C0006560,,completed,
286,c - reactive proteinc,C0006560,,completed,
286,c - reactive protein concentration ( mg / l ),C0006560,,inprogress,
286,c - reactive protein ( mg / dl ),C0006560,,completed,
286,c - reactive protein ( mg / dl_ ),C0006560,,completed,
286,c - reactive protein * mg / l,C0006560,,inprogress,
286,c - reactive protein mg / l,C0006560,,inprogress,
286,c - reactive protein ( mg / l ),C0006560,,inprogress,
286,c - reactive protein — mg / literj,C0006560,,completed,
286,c - reactive protein u / l,C0006560,,completed,
286,crp mean mg / l ( sd ),C0006560,,inprogress,
286,crp mg / l,C0006560,,inprogress,
286,crp mg / l *,C0006560,,inprogress,
286,crp — mg / l,C0006560,,inprogress,
286,crp ( mg / l ) mean ( sd ),C0006560,,inprogress,
286,crp mg / l : median ( range ),C0006560,,inprogress,
286,crp ( mg / l ) median ± sd,C0006560,,inprogress,
286,crp ( mg / l ) n,C0006560,,inprogress,
286,crp ( mg / l ) : < $nmbr$,C0006560,,inprogress,
286,crp < $nmbr$ mg / l n,C0006560,,inprogress,
286,crp $ $nmbr$ mg / l n,C0006560,,inprogress,
286,das $nmbr$ ( c - reactive protein ),C0006560,,completed,
286,geometric mean crp concentration ( mg / l ),C0006560,,inprogress,
286,high - sensitivity c - reactive protein mg / l,C0006560,,inprogress,
286,high - sensitivity c - reactive protein ( mg / l ),C0006560,,inprogress,
286,high - sensitivityc - reactive protein mg / l,C0006560,,completed,
286,high sensitivity c - reactive protein ( mg / l ),C0006560,,inprogress,
286,high - sensitivity c - reactive protein — mg / liter |,C0006560,,completed,
286,high - sensitivity c - reactive protein mg / ltt,C0006560,,completed,
286,high - sensitivity c - reactive protein stratification,C0006560,,completed,
286,hscrp median ( iqr ) mg / l,C0006560,,inprogress,
286,hscrp mg / l,C0006560,,inprogress,
286,hscrp ( mg / l ),C0006560,,inprogress,
286,hscrp ( mg / l ) c,C0006560,,inprogress,
286,hscrp ( mg / l ) median ( first third quartiles ),C0006560,,inprogress,
286,hscrp ( mg / l ) median ( minimum ‒ maximum ),C0006560,,inprogress,
286,hscrp > $nmbr$ mg / l,C0006560,,inprogress,
286,hscrp < $nmbr$ . $nmbr$ mg / l,C0006560,,inprogress,
286,hscrp > $nmbr$ . $nmbr$ mg / l,C0006560,,inprogress,
286,hscrp > $nmbr$ to < $nmbr$ mg / l,C0006560,,inprogress,
286,mean crp level mg / l ( sd ),C0006560,,inprogress,
286,mean hscrp mg / l ( sd ),C0006560,,inprogress,
286,mean ( sd ) crp mg / l *,C0006560,,inprogress,
288,b postbronchodilator fevl ( % predicted ),C0024119,,completed,
288,diffusion capacity of the lung for carbon monoxide % predicted !,C0024119,,completed,
288,fevj % predicted ! t,C0024119,,completed,
288,fev $nmbr$ ( % predicted normal ),C0024119,,completed,
288,fev $nmbr$ % predicted normal,C0024119,,completed,
288,fev $nmbr$   % of predicted normal post - bronchodilator,C0024119,,completed,
288,mean ( sd ) % of predicted normal eevi,C0024119,,completed,
288,mean ( sd ) % of predicted normal fev $nmbr$,C0024119,,completed,
288,< $nmbr$ % predicted,C0024119,,completed,
288,> $nmbr$ % predicted,C0024119,,completed,
288,> $nmbr$ % predicted to < $nmbr$ % predicted,C0024119,,completed,
288,% of predicted,C0024119,,completed,
288,% of predicted normal value *,C0024119,,completed,
288,pef post - bronchodilator % predicted normal,C0024119,,completed,
288,postbronchodilator fevj ( % predicted ),C0024119,,completed,
288,prebronchodilator fev $nmbr$ ( % predicted normal ) t,C0024119,,completed,
288,% predicted,C0024119,,completed,
288,predicted normal ( % ),C0024119,,completed,
288,predicted normal ) t,C0024119,,completed,
288,% predicted value ( sd ),C0024119,,completed,
288,pulmonary function tests % of predicted,C0024119,,completed,
292,prostate biopsy,C0194804,,completed,
293,presence of erosions n ( % ),C1959609;C0150312,,completed,
295,predose fev - at randomization,C3714541;C0439565,,completed,
295,predose fev ^ at screening,C3714541;C0439565,,completed,
295,predose fev / fvc,C3714541;C0439565,,completed,
295,predose fev $nmbr$ ( l ) *,C3714541;C0439565,,completed,
295,predose fvc ( l ),C3714541;C0439565,,completed,
295,predose fvc ( l ) *,C3714541;C0439565,,completed,
296,fev $nmbr$ % pred,C3714541,,completed,
296,$nmbr$ ( fev $nmbr$ < $nmbr$ % pred ),C3714541,,completed,
296,post fev $nmbr$   % pred,C3714541,,completed,
296,% pred,C3714541,,completed,
296,pre fev $nmbr$   % pred,C3714541,,completed,
296,pre fvc % pred,C3714541,,completed,
298,erythrocyte sedimentation rate ( mm / h ),C1619634,,completed,
298,esr ( mm / h ),C1619634,,completed,
298,esr ( mm / h ) mean ( sd ),C1619634,,completed,
298,mean ( sd ) esr mm / h *,C1619634,,completed,
304,mmf ( n = $nmbr$ ),C0209368,,completed,
304,mycophenolate mofetil,C0209368,,completed,
304,mycophenolate mofetil - cyclophosphamide,C0209368,,completed,
304,recent treatment ( < $nmbr$ months mmf / ggs ),C0209368,,completed,
305,mean mmse score,C0451306,,completed,
305,mini - mental state examination,C0451306,,completed,
305,mini - mental state examination mean ( sd ) d,C0451306,,completed,
305,mmse = mini - mental state examination adas — cog = alzhei -,C0451306,,completed,
305,mmse < $nmbr$,C0451306,,completed,
305,mmse > $nmbr$,C0451306,,completed,
305,mmse $nmbr$ - $nmbr$,C0451306,,completed,
305,mmse ( points ),C0451306,,completed,
305,mmse score,C0451306,,completed,
305,mmse score *,C0451306,,completed,
305,> < $nmbr$ . $nmbr$ < $nmbr$ . $nmbr$ r < mmse = mini - mental,C0451306,,completed,
305,smmse,C0451306,,completed,
305,smmse < $nmbr$,C0451306,,completed,
306,gender   n   ( % men ),,,inprogress,
306,gmi ( men ),,,inprogress,
306,hdl < $nmbr$ / $nmbr$ mg / dl ( $nmbr$ . $nmbr$ / $nmbr$ . $nmbr$ mmol / l ) for men / women,,,inprogress,
306,hemoglobin ( < $nmbr$ men ， : : $nmbr$ women ),,,inprogress,
306,high hdl - c ( for men ≥ $nmbr$   mg / dl / for women ≥ $nmbr$   mg / dl ),,,inprogress,
306,low hdl - c ( for men < $nmbr$   mg / dl / for women < $nmbr$   mg / dl ),,,inprogress,
306,ment,,,inprogress,
306,$nmbr$ - $nmbr$ ( men ),,,inprogress,
306,( _ > $nmbr$ . $nmbr$ mmol / l ) hdl - c women : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ) men : < $nmbr$ mg / dl,,,inprogress,
306,no of events women men *,,,inprogress,
306,p $nmbr$ interaction women vs men,,,inprogress,
306,p ( women vs men ),,,inprogress,
306,ratio of women to men — %,,,inprogress,
306,sex men / women %,,,inprogress,
306,sex ( men / women ),,,inprogress,
306,sex ( women men ),,,inprogress,
306,women men,,,inprogress,
307,baseline ckd egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,baseline crcl ml / min,C3811844;C0017654,,inprogress,
307,baseline ecrq $nmbr$ $nmbr$ to < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,cgfrby ckd - epi ml / min / $nmbr$ . $nmbr$ m $nmbr$ median ( iqr ),C3811844;C0017654,,inprogress,
307,cgfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,chronic kidney disease stage : egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
307,crcl at baseline ml / min,C3811844;C0017654,,inprogress,
307,crcl at baseline < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,crcl at randomization ml / min,C3811844;C0017654,,inprogress,
307,crcl at randomization - ml / min,C3811844;C0017654,,inprogress,
307,crcl mean ml / min ( ± sd ),C3811844;C0017654,,inprogress,
307,crcl median ( iqr ) ml / min,C3811844;C0017654,,inprogress,
307,crcl ml / min,C3811844;C0017654,,inprogress,
307,crcl ( ml / min ),C3811844;C0017654,,inprogress,
307,crcl ( ml / min ) at randomization,C3811844;C0017654,,inprogress,
307,crcl ml / min mean ( sd ),C3811844;C0017654,,inprogress,
307,crcl < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,crcl > $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,crcl > $nmbr$ - < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,crcl of $nmbr$ - $nmbr$ ml min ' n ( % ),C3811844;C0017654,,inprogress,
307,crcl ( sd ) ml / min,C3811844;C0017654,,inprogress,
307,creat clearance < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,creat clearance > $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,creatine clearance ml / min,C3811844;C0017654,,inprogress,
307,creatinine clearance ml / min,C3811844;C0017654,,inprogress,
307,creatinine clearance ( ml / min ),C3811844;C0017654,,inprogress,
307,creatinine clearance — ml / min,C3811844;C0017654,,inprogress,
307,creatinine clearance ( ml / min ) mean ± sd,C3811844;C0017654,,inprogress,
307,creatinine clearance ml / min - $nmbr$ *,C3811844;C0017654,,inprogress,
307,creatinine clearance < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,creatinine clearance < $nmbr$ ml / min ( % ),C3811844;C0017654,,inprogress,
307,ecfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C3811844;C0017654,,inprogress,
307,ecfr ml / min per $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,ecrcl ml / min,C3811844;C0017654,,inprogress,
307,ecrcl < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,estimated creatinine clearance ( ml / min ),C3811844;C0017654,,inprogress,
307,estimated creatinine clearance — ml / min §,C3811844;C0017654,,inprogress,
307,estimated creatinine clearance — ml / min i,C3811844;C0017654,,inprogress,
307,estimated creatinine clearance < $nmbr$ ml / min *,C3811844;C0017654,,inprogress,
307,greater than or equal to $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,interquartile range — ml / min,C3811844;C0017654,,inprogress,
307,> l : $nmbr$ hrs : min ( n = $nmbr$ ),C3811844;C0017654,,inprogress,
307,mean ± sd egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,median crcl — ml / min,C3811844;C0017654,,inprogress,
307,median — ml / min,C3811844;C0017654,,inprogress,
307,median — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,mild decrease ( $nmbr$ - < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
307,mild dysfunction ( crcl > $nmbr$ - $nmbr$ ml / min n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C3811844;C0017654,,inprogress,
307,mildlydecreased baseline gfr ( $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
307,mild ( $nmbr$ – $nmbr$ ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$ ) n ( % ),C3811844;C0017654,,inprogress,
307,mild or no dysfunction ( crcl > $nmbr$ ml / min n = $nmbr$ $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C3811844;C0017654,,inprogress,
307,moderate or severe decrease in gfr ( < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
307,< $nmbr$ l / min,C3811844;C0017654,,inprogress,
307,> = $nmbr$ l / min,C3811844;C0017654,,inprogress,
307,> = $nmbr$ l_ / min,C3811844;C0017654,,inprogress,
307,^ $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,< = $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min — %,C3811844;C0017654,,inprogress,
307,≥ $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,> $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,$nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,£ $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,> $nmbr$ ml min ) $nmbr$,C3811844;C0017654,,inprogress,
307,> $nmbr$ ml / min / $nmbr$ . $nmbr$,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min / $nmbr$ $nmbr$ m ^,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,inprogress,
307,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min / $nmbr$ $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,> = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,> $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,> $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min ( n = $nmbr$ ),C3811844;C0017654,,inprogress,
307,> $nmbr$ ml / min ( n = $nmbr$ ),C3811844;C0017654,,inprogress,
307,> $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,> $nmbr$ ml / min per $nmbr$ - $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,( $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
307,( $ $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
307,< $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ n ( % ),C3811844;C0017654,,inprogress,
307,〉 $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ n ( % ),C3811844;C0017654,,inprogress,
307,$nmbr$ - < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,$nmbr$ - $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,$nmbr$ ( $ $nmbr$ ml / min ),C3811844;C0017654,,inprogress,
307,$nmbr$ – < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,$nmbr$ – ≤ $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,$nmbr$ - $nmbr$ ml min $nmbr$,C3811844;C0017654,,inprogress,
307,$nmbr$ - $nmbr$ ml min ) $nmbr$,C3811844;C0017654,,inprogress,
307,< $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,$nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,( $nmbr$ - $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
307,$nmbr$ - $nmbr$ ( < $nmbr$ ml / min ),C3811844;C0017654,,inprogress,
307,$nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,$nmbr$ ( $nmbr$ to < $nmbr$ ml / min ),C3811844;C0017654,,inprogress,
307,> $nmbr$ to < $nmbr$ egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C3811844;C0017654,,inprogress,
307,> $nmbr$ to < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,$nmbr$ to < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
307,$nmbr$ to < $nmbr$ ml / min / $nmbr$ - $nmbr$,C3811844;C0017654,,inprogress,
307,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,inprogress,
307,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,inprogress,
307,≥ $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,> $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,$nmbr$ to < $nmbr$ ml / min / $nmbr$ $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,$nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,$nmbr$ to < $nmbr$ ml min ’ $nmbr$ $nmbr$ . $nmbr$ m ' $nmbr$,C3811844;C0017654,,inprogress,
307,$nmbr$ to < $nmbr$ ml / min ( n = $nmbr$ $nmbr$ ),C3811844;C0017654,,inprogress,
307,$nmbr$ to < $nmbr$ ml / min per $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,inprogress,
307,$nmbr$ to $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ n ( % ),C3811844;C0017654,,inprogress,
307,$nmbr$ to o $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
307,normal function ( crcl > $nmbr$ ml / min n = $nmbr$ [ $nmbr$ . $nmbr$ % ] ),C3811844;C0017654,,inprogress,
307,• ? sd ml / min,C3811844;C0017654,,inprogress,
307,s $nmbr$ ml / min,C3811844;C0017654,,inprogress,
318,any vte or vte - related death — no . ( % ),C1861172,,completed,
318,any vte - related death,C1861172,,completed,
318,vte / vte - related deathsa n / n ( % ),C1861172,,completed,
318,vte / vte - related deathsb n / n ( % ),C1861172,,completed,
320,albuminuria and previous maerovaseular disease without established renal disease,C0022658,,completed,
320,contrast nephropathy risk score,C0022658,,completed,
320,established renal disease *,C0022658,,completed,
320,nephropathy,C0022658,,completed,
320,previous renal disease n ( % ),C0022658,,completed,
320,renal disease,C0022658,,completed,
320,renal disease ),C0022658,,completed,
323,time to first cv hospitalization or death from any cause,C0007465,,completed,
324,early death,C1836407,,completed,
326,health assessment questionnaire score,C2960025,,completed,
332,uncontrolled,C0205318,,completed,
332,uncontrolled on basal insulin,C0205318,,completed,
332,uncontrolled on oad ( s ),C0205318,,completed,
333,diet - controlled ( % ),C0743195,,completed,
333,diet controlled or no,C0743195,,completed,
336,cvd / stroke / see,C4554100,,completed,
336,ischemic stroke or see,C4554100,,completed,
336,old stroke *,C4554100,,completed,
336,stroke or see,C4554100,,completed,
336,stroke / see,C4554100,,completed,
336,stroke see or cv death,C4554100,,completed,
336,stroke see or death,C4554100,,completed,
337,east europe,C0015176,,completed,
337,e europe,C0015176,,completed,
337,e . europe,C0015176,,completed,
337,enrope + sonth afriea,C0015176,,completed,
337,europe,C0015176,,completed,
337,europe and australia,C0015176,,completed,
337,europe and canada,C0015176,,completed,
337,europe ( eu ),C0015176,,completed,
337,europe i,C0015176,,completed,
337,europe ( including south africa ),C0015176,,completed,
337,europe israel or australia,C0015176,,completed,
337,europe / lsrael,C0015176,,completed,
337,europe $nmbr$,C0015176,,completed,
337,europe $nmbr$ ¶,C0015176,,completed,
337,europe $nmbr$ +,C0015176,,completed,
337,europe $nmbr$ ( n = $nmbr$ ),C0015176,,completed,
337,europe $nmbr$ ( n = $nmbr$ $nmbr$ ),C0015176,,completed,
337,europe ( non - eu ),C0015176,,completed,
337,europe n z $nmbr$,C0015176,,completed,
337,europe ( plus south africa ),C0015176,,completed,
337,europe ( zone $nmbr$ ),C0015176,,completed,
337,geographic region - europe,C0015176,,completed,
337,non europe,C0015176,,completed,
337,region europe,C0015176,,completed,
337,western europe / australia,C0015176,,completed,
337,western europe / australia / israel,C0015176,,completed,
337,western europe israel australia or south africa,C0015176,,completed,
337,w est europe,C0015176,,completed,
337,w europe,C0015176,,completed,
337,w . europe,C0015176,,completed,
338,naproxen,C0027396,,completed,
340,estrogen,C0014939,,completed,
340,estrogen ( ' % ? ),C0014939,,completed,
340,estrogens,C0014939,,completed,
340,estrogen supplementation,C0014939,,completed,
340,estrogen supplementation -,C0014939,,completed,
340,no estrogen,C0014939,,completed,
340,women taking estrogen,C0014939,,completed,
341,gastroduodenal,C0450199,,completed,
341,gastroduodenum,C0450199,,completed,
342,composite of $nmbr$ % reduction in egfr end - stage kidney disease or death from renal causes,C0035078,,completed,
342,end - stage renal disease,C0035078,,completed,
342,erd * n ( % ),C0035078,,completed,
342,esrd,C0035078,,completed,
342,esrd ',C0035078,,completed,
342,esrd *,C0035078,,completed,
342,esrd on losartan ( % ),C0035078,,completed,
342,esrd or death,C0035078,,completed,
342,or esrd,C0035078,,completed,
342,sustained esrd death due to kidney failure or sustained decrease of > $nmbr$ % in egfr from baseline,C0035078,,completed,
343,lad,,,inprogress,
343,non - lad,,,inprogress,
343,scd ( % ),,,inprogress,
348,all bare metal stents,C2825200,,completed,
348,bare metal,C2825200,,completed,
348,bare - metal,C2825200,,completed,
348,bare - metal stent,C2825200,,completed,
348,bare metal stent,C2825200,,completed,
348,bare metal stent n ( % ),C2825200,,completed,
348,bare - metal stent — no . ( % ),C2825200,,completed,
353,either ocs use nasal polyps pre - bd fvc < $nmbr$ % of predicted or age at diagnosis sl $nmbr$ years,C0027430,,completed,
353,nasal polyposis or chronic rhinosinusitis — no . { % ),C0027430,,completed,
353,nasal polyps,C0027430,,completed,
353,nasal polyps at baseline : yes,C0027430,,completed,
353,nasal polyps n ( % ),C0027430,,completed,
353,no nasal polyps,C0027430,,completed,
354,basal insulin,C0650607,,completed,
354,basal insulin analogue dose * ( coefficient,C0650607,,completed,
354,basal insulin analogue : insulin,C0650607,,completed,
354,basal insulin dose at run - in ( u / day ),C0650607,,completed,
354,basal insulin doset,C0650607,,completed,
354,faster aspart   +   basal,C0650607,,completed,
354,placebo * ( add on to basal insulin ),C0650607,,completed,
356,radial access,C0589360;C0442038,,completed,
356,radial access — no . / total no . ( % ),C0589360;C0442038,,completed,
356,radial access site,C0589360;C0442038,,completed,
359,current xanthine derivative use,C0043318,,completed,
359,methylxanthines,C0043318,,completed,
359,xanthine,C0043318,,completed,
359,xanthines,C0043318,,completed,
359,xanthines b   n ( % ),C0043318,,completed,
359,xanthinesg,C0043318,,completed,
359,xanthines $nmbr$,C0043318,,completed,
360,anti - ccp antibodies *,C4318437,,completed,
360,anti - ccp antibody positive,C4318437,,completed,
360,anti - ccp antibody - positive n ( % ),C4318437,,completed,
360,anti - ccp antibody positive n ( % ),C4318437,,completed,
360,anti - ccp antibody ( u /,C4318437,,completed,
361,anti ‐ hyperglycaemic agent n ( % ),C1321567,,completed,
361,injectable anti ‐ hyperglycaemic n ( % ),C1321567,,completed,
362,number of previous anti - tnf treatments for psoriatic arthritis,C0747055,,completed,
362,previously taken tnfi %,;C0039260,,completed,
363,ethnicitya hispanic or latino,C0086528;C0086409;C0015031,,completed,
363,hispanic / latino,C0086528;C0086409;C0015031,,completed,
363,hispanic / latino ( n = $nmbr$ ),C0086528;C0086409;C0015031,,completed,
363,hispanic or latino,C0086528;C0086409;C0015031,,completed,
363,hispanic or latino ethnic group !,C0086528;C0086409;C0015031,,completed,
363,hispanic or latino ethnic group *,C0086528;C0086409;C0015031,,completed,
363,hispanic or latino ethnic groupb,C0086528;C0086409;C0015031,,completed,
363,hispanic or latino ethnic groupf,C0086528;C0086409;C0015031,,completed,
363,hispanic or latino ( n = $nmbr$ ),C0086528;C0086409;C0015031,,completed,
363,hispanic or latino ( n — $nmbr$ ),C0086528;C0086409;C0015031,,completed,
363,hispanie / latino,C0086528;C0086409;C0015031,,completed,
363,latino,C0086528;C0086409;C0015031,,completed,
363,not hispanie / latino,C0086528;C0086409;C0015031,,completed,
364,stent implanted,C0522776,,completed,
364,stent implanted — no . ( % ),C0522776,,completed,
364,stent placement,C0522776,,completed,
365,at least one drug - eluting stent,C1322815,,completed,
365,drug - eluting stent,C1322815,,completed,
365,drug eluting stent,C1322815,,completed,
365,drug - eluting stent implanted,C1322815,,completed,
365,drug - eluting stent implanted ( at least one ),C1322815,,completed,
365,drug - eluting stent implanted — no . ( % ),C1322815,,completed,
365,drug - eluting stent n ( % ),C1322815,,completed,
365,drug - eluting stent — no . ( % ),C1322815,,completed,
365,non - drug - eluting stent,C1322815,,completed,
365,received drug - eluting stent,C1322815,,completed,
365,type of drug - eluting stent n ( % ),C1322815,,completed,
368,baseline triglycerides < $nmbr$ mg / dl,C0041004,,completed,
368,baseline triglycerides > $nmbr$ mg / dl and,C0041004,,completed,
368,deviation tg triglyceride .,C0041004,,completed,
368,fasting triglycerides,C0041004,,completed,
368,fasting triglycerides mean ( sd ) mg / dl,C0041004,,completed,
368,fasting triglycerides mg / dl,C0041004,,completed,
368,fasting triglycerides — mg / dl,C0041004,,completed,
368,fasting triglycerides > $nmbr$ mg / dl *,C0041004,,completed,
368,median triglyceride ( mg / dl ),C0041004,,completed,
368,$nmbr$ . $nmbr$ mg / dl triglycerides ^,C0041004,,completed,
368,plasma triglyceride — mg / dl,C0023820,,completed,
368,pretreatment triglycerides,C0041004,,completed,
368,± standard deviation . triglyceride,C0041004,,completed,
368,tg triglycerides . * median values ( standard deviation for medians ) .,C0041004,,completed,
368,triglyceride,C0041004,,completed,
368,triglyceride a,C0041004,,completed,
368,triglyceride ( median : mg / dl ) a [ $nmbr$ - $nmbr$ percentile ],C0041004,,completed,
368,triglyceride ( median mg / dl ) - $nmbr$ [ $nmbr$ - $nmbr$ percentile |,C0041004,,completed,
368,triglyceride ( mg / dl ) d,C0041004,,completed,
368,triglyceride ( mg / dl ) $nmbr$,C0041004,,completed,
368,triglyceride mmol / l,C0041004,,completed,
368,triglyceride ( mmol / l ),C0041004,,completed,
368,triglyceride ( mmol / l ) * blood pressure,C0041004,,completed,
368,triglyceride ( mmol / l ) t,C0041004,,completed,
368,triglycerides,C0041004,,completed,
368,- triglycerides,C0041004,,completed,
368,triglycerides *,C0041004,,completed,
368,triglycerides * *,C0041004,,completed,
368,triglycerides median ( iqr ) mg / dl,C0041004,,completed,
368,triglycerides ( median iqr ) mg / dl,C0041004,,completed,
368,triglycerides median ( qi q $nmbr$ ) mmol / l,C0041004,,completed,
368,triglycerides median ( ql q $nmbr$ ) mmol / l,C0041004,,completed,
368,triglycerides mg / dl ^,C0041004,,completed,
368,triglycerides - mg / dl * *,C0041004,,completed,
368,triglycerides ( mg / dl ),C0041004,,completed,
368,triglycerides ( mg / dl ) * *,C0041004,,completed,
368,triglycerides * ( mg / dl ),C0041004,,completed,
368,triglycerides — mg / dl,C0041004,,completed,
368,triglycerides — mg / dl ^,C0041004,,completed,
368,triglycerides — mg / dl | |,C0041004,,completed,
368,triglycerides mg / dl median ( q $nmbr$ : q $nmbr$ ),C0041004,,completed,
368,triglycerides mg / l,C0041004,,completed,
368,triglycerides * mmol / l,C0041004,,completed,
368,triglycerides mmol / l,C0041004,,completed,
368,triglycerides mmol / l §,C0041004,,completed,
368,triglycerides mmol / l ®,C0041004,,completed,
368,triglycerides ( mmol / l ),C0041004,,completed,
368,triglycerides ( mmol / l ) :,C0041004,,completed,
368,triglycerides — mmol / l,C0041004,,completed,
368,triglycerides mmol / l mean ( sd ),C0041004,,completed,
368,triglycerides mmol / l mean ± sd,C0041004,,completed,
368,triglycerides ( mmol / l ) mean ( sd ),C0041004,,completed,
368,triglycerides ( mmol / l ) ( median iqr ),C0041004,,completed,
368,triglycerides $nmbr$ d third,C0041004,,completed,
368,triglycerides > $nmbr$ mg / dl,C0041004,,completed,
368,triglycerides > $nmbr$ mg / dl ( > $nmbr$ . $nmbr$ mmol / l ),C0041004,,completed,
368,triglycerides $ $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ),C0041004,,completed,
368,triglycerides $nmbr$ nd third,C0041004,,completed,
368,triglycerides < $nmbr$ - $nmbr$ mmol / l,C0041004,,completed,
368,triglycerides > $nmbr$ - $nmbr$ mmol / l,C0041004,,completed,
368,triglycerides ( week $nmbr$ ) a,C0041004,,completed,
369,geographical region,C0017446,,completed,
369,geographical region ( % ),C0017446,,completed,
369,geographical region n ( % ),C0017446,,completed,
369,geographic region ^,C0017446,,completed,
369,geographic region %,C0017446,,completed,
369,geographic region n ( % ),C0017446,,completed,
369,geographic region - other,C0017446,,completed,
369,grouped region,C0017446,,completed,
369,p treatment - by - region interaction,C0017446,,completed,
369,region,C0017446,,completed,
369,region %,C0017446,,completed,
369,region :,C0017446,,completed,
369,region ( % ),C0017446,,completed,
369,region *,C0017446,,completed,
369,region europe union,C0017446,,completed,
369,region latin america,C0017446,,completed,
369,region n ( % ),C0017446,,completed,
369,region - n ( % ),C0017446,,completed,
369,region n ( % ),C0017446,,completed,
369,region n ( % ) a,C0017446,,completed,
369,region of enrollment,C0017446,,completed,
369,region ofenrollment — %,C0017446,,completed,
369,region of enrollment n ( % ) +,C0017446,,completed,
369,region of enrollment no . ( % ),C0017446,,completed,
369,region of enrollment — no . ( % ),C0017446,,completed,
369,region of residence ( p = $nmbr$ $nmbr$ ),C0017446,,completed,
369,region of the world,C0017446,,completed,
369,region ofthe world,C0017446,,completed,
369,region of world — no . ( % ),C0017446,,completed,
369,region ( pooled ),C0017446,,completed,
369,regions n ( % ),C0017446,,completed,
369,regiont,C0017446,,completed,
369,region ( us ),C0017446,,completed,
369,region   n   ( % ),C0017446,,completed,
369,reqion,C0017446,,completed,
371,uistekinumab,C1608841,,completed,
371,usteki,C1608841,,completed,
371,ustekinu,C1608841,,completed,
371,ustekinumab,C1608841,,completed,
371,ustekinumab combined,C1608841,,completed,
371,ustekinumab $nmbr$ mg ( n = $nmbr$ ),C1608841,,completed,
371,ustekinumab ' ’ ( n = $nmbr$ ),C1608841,,completed,
371,ustekinumab ® ( n = $nmbr$ ),C1608841,,completed,
372,all canakinumab,C2718773,,completed,
372,canakinumab,C2718773,,completed,
372,canakinumab hscrp < $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0006560,,inprogress,
372,canakinumab hscrp > $nmbr$ - $nmbr$ mg / l at $nmbr$ months ( n = $nmbr$ ),C0006560,,inprogress,
372,canakinumab il - $nmbr$ lowest tertile,C2718773,,completed,
372,canakinumab il - $nmbr$ middle tertile,C2718773,,completed,
372,canakinumab il - $nmbr$ top tertilec,C2718773,,completed,
372,canakinumab $nmbr$ - month on - treatment il - $nmbr$ below the median value ( < $nmbr$ . $nmbr$ ng / l ) ( n   =   $nmbr$ ),C2718773,,completed,
373,lebrikizumab ( n = $nmbr$ ),C2981360,,completed,
373,rate difference ( lebrikizumab - placebo ),C2981360,,completed,
373,rate ratio ( lebrikizumab vs placebo $nmbr$ % cl ),C2981360,,completed,
374,abciximab,C0288672,,completed,
374,abciximab - facilitated pci,C0288672,,completed,
374,abciximab ( n = $nmbr$ ),C0288672,,completed,
374,abciximab no . / total ( % ),C0288672,,completed,
374,abciximab vs . primary,C0288672,,completed,
374,$nmbr$ abciximab ( n = $nmbr$ ),C0288672,,completed,
374,reteplase / abciximab - facilitated pci ( n = $nmbr$ ),C0288672,,completed,
375,albuminuria,C0001925,,completed,
375,albuminuria ( g / g ),C0001925,,completed,
375,albuminuria_p_interaction,C0001925,,completed,
375,albuminuria progression,C0001925,,completed,
375,any albuminuria,C0001925,,completed,
375,any albuminuria — no . ( % ),C0001925,,completed,
375,macro - albuminuria,C0001925,,completed,
375,micro - albuminuria,C0001925,,completed,
375,progression of albuminuria,C0001925,,completed,
376,and microalbuminuria or macroalbuminuria,C0033687,,completed,
376,macroalbuminuria ( uacr > $nmbr$ ),C0033687,,completed,
376,microalbuminuria,C0033687,,completed,
376,microalbuminuria n ( % ),C0033687,,completed,
376,microalbuminuria — no . ( % ),C0033687,,completed,
376,microalbuminuria — no . / total no . ( % ),C0033687,,completed,
376,microalbuminuria or macroalbuminuria,C0033687,,completed,
376,microalbuminuria or macroalbuminuria §,C0033687,,completed,
376,microalbuminuria or proteinuria,C0033687,,completed,
376,microalbuminuria ( uacr $nmbr$ – $nmbr$ ),C0033687,,completed,
376,normoalbuminuria or microalbuminuria,C0033687,,completed,
376,or no microalbuminuria or macroalbuminuria,C0033687,,completed,
376,patients with microalbuminuria at baseline,C0033687,,completed,
378,arthralgia,C0003862,,completed,
379,antiarrhythmic,C0003195,,completed,
379,anti arrhythmic,C0003195,,completed,
379,antiarrhythmic drug,C0003195,,completed,
379,antiarrhythmic drugs   n   ( % ),C0003195,,completed,
379,antiarrhythmics,C0003195,,completed,
379,antiarrhythmic therapy,C0003195,,completed,
379,any prerandomization failure of an antiarrhythmic drug — no . ( % ),C0003195,,completed,
379,other antiarrhythmics ^,C0003195,,completed,
379,previous use of antiarrhythmic drugs,C0003195,,completed,
380,arrhythmia,C0003811,,completed,
380,arrhythmia !,C0003811,,completed,
380,arrhythmias,C0003811,,completed,
380,cardiac arrhythmia,C0003811,,completed,
380,cardiac arrhythmia n ( % ),C0003811,,completed,
380,prior arrhythmias n ( % ),C0003811,,completed,
381,no . ( % ) of patients with atrial tachyarrhythmia,C0080203,,completed,
381,supraventricular tachyarrhythmias ( incl . atrial,C0080203,,completed,
381,tachyarrhythmias n ( % ),C0080203,,completed,
382,any antianginal drug !,C3537168,,completed,
382,intensification of antianginal therapy,C3537168,,completed,
382,new anti - anginal therapy,C3537168,,completed,
382,$nmbr$ antianginal drug,C3537168,,completed,
382,no antianginal drug,C3537168,,completed,
383,intraperitoneal,C0442120,,completed,
383,intrathoracic or intraperitoneal surgery,C0442120,,completed,
384,intracranial bleed,C0151699,,completed,
384,intracranial bleeding,C0151699,,completed,
384,intracranial hemorrhage,C0151699,,completed,
384,intracranial hemorrhage †,C0151699,,completed,
384,intracranial hemorrhage n ( % ),C0151699,,completed,
385,non - q wave,C1305738,,completed,
385,non - q - wave ml,C1305738,,completed,
385,non - q - wave myocardial infarction,C1305738,,completed,
385,q wave,C1305738,,completed,
389,cabg,C0010055,,completed,
389,cabg :,C0010055,,completed,
389,cabg ( % ),C0010055,,completed,
389,cabg n ( % ),C0010055,,completed,
389,cabg > $nmbr$ month ago,C0010055,,completed,
389,cabg — no . ( % ),C0010055,,completed,
389,cabg — no . { % ),C0010055,,completed,
389,cabg or pci,C0010055,,completed,
389,cabg surgery by no . of vessels $nmbr$,C0010055,,completed,
389,coronary artery bypass,C0010055,,completed,
389,coronary artery bypass graft,C0010055,,completed,
389,coronary artery bypass graft n ( % ),C0010055,,completed,
389,coronary artery bypass surgery,C0010055,,completed,
389,coronary bypass n ( % ),C0010055,,completed,
389,coronary bypass surgery,C0010055,,completed,
389,history of cabg surgery,C0010055,,completed,
389,history of cabg surgery n ( % ),C0010055,,completed,
389,no prior cabg,C0010055,,completed,
389,prior cabg,C0010055,,completed,
389,prior cabg %,C0010055,,completed,
389,prior cabg ( before index acs ),C0010055,,completed,
389,prior coronary artery bypass graft,C0010055,,completed,
389,prior coronary artery bypass grafting,C0010055,,completed,
389,prior coronary artery bypass graft surgery,C0010055,,completed,
389,prior coronary artery bypass surgery,C0010055,,completed,
389,prior coronary intervention or coronary artery bypass grafting,C0010055,,completed,
389,treated with cabg — no . / total no . ( % ),C0010055,,completed,
392,americas,C0002454,,completed,
392,americas * *,C0002454,,completed,
392,americas excluding us,C0002454,,completed,
392,americas ( n = $nmbr$ ),C0002454,,completed,
392,enrolled in the americas,C0002454,,completed,
398,alpha - glucosidase inhibitors,C1299007,,completed,
398,alpha glucosidase inhibitors,C1299007,,completed,
403,inadequate,C0205412,,completed,
403,inadequate response ( > $nmbr$ months mmf / ggs ),C0205412,,completed,
403,insufficient,C0205412,,completed,
406,ecg - lvh ( cornell ),C0232306,,completed,
406,ecg - lvh ( sokolow - lyon ),C0232306,,completed,
406,lvh by ecg,C0232306,,completed,
406,lvh by ecg / echo,C0232306,,completed,
406,lvh by ecg ( minnesota code ),C0232306,,completed,
406,lvh by ecg or echocardiographyd,C0232306,,completed,
406,lvh by ecg or echocardiography no ( % ),C0232306,,completed,
406,lvh by ecg or echo . n ( % ),C0232306,,completed,
406,lvh by echo or ecg,C0232306,,completed,
406,lvh on ecg,C0232306,,completed,
406,lv hypertrophy per ecg,C0232306,,completed,
413,recent,,,completed,
414,cardiovascular events,C1320716,,completed,
414,previous cardiovascular event ( % ),C1320716,,completed,
414,previous cardiovascular event at randomization,C1320716,,completed,
414,previous cardiovascular event — no . ( % ),C1320716,,completed,
414,previous cardiovascular events,C1320716,,completed,
414,recent cardiovascular eventf,,,completed,
417,symptom onset to start of reperfusion treatment : tenecteplase or arterial sheath insertion !,C0872913,,completed,
417,tenecteplase,C0872913,,completed,
420,currently smokes,C0037369,,completed,
420,never smoked,C0037369,,completed,
420,never smoked n ( % ),C0037369,,completed,
420,never smoked — no . ( % ),C0037369,,completed,
420,smoking,C0037369,,completed,
420,smoking %,C0037369,,completed,
420,smoking ' ! ',C0037369,,completed,
420,smoking ( % ),C0037369,,completed,
420,smoking *,C0037369,,completed,
420,smoking ( a ),C0037369,,completed,
420,smoking classification n ( % ),C0037369,,completed,
420,smoking in the past year,C0037369,,completed,
420,smoking ( % ) laboratory parameters,C0037369,,completed,
420,smoking n ( % ),C0037369,,completed,
420,smoking * ( > $nmbr$ pack - years ),C0037369,,completed,
420,smoking pack - years,C0037369,,completed,
420,smoking pack - yearsa,C0037369,,completed,
420,smoking pack - yearsb n ( % ),C0037369,,completed,
420,smoking pack year ( years ) ^,C0037369,,completed,
420,smoking pack year ( years ) fl,C0037369,,completed,
426,apob : apoa - i,C0003593,,completed,
426,apo b : apo a - i ratio,C0003593,,completed,
426,apob : apoa - i ratio,C0003593,,completed,
427,apo a $nmbr$ ( g / l ),C0003592,,completed,
427,apoa - $nmbr$ g / l,C0003592,,completed,
427,apo a $nmbr$ mean ( sd ),C0003592,,completed,
427,apo b / apo a - l,C0003592,,completed,
427,apob : apoa - l ratio,C0003592,,completed,
427,apo b / apo a - l ratio ( mean ),C0003592,,completed,
427,apob : apoa $nmbr$,C0003592,,completed,
427,apob : apoa - $nmbr$ ratio,C0003592,,completed,
427,apob : apoa $nmbr$ ratio,C0003592,,completed,
427,< $nmbr$ . $nmbr$ mmol / liter apob : apoa - l ratio,C0003592,,completed,
433,door - to - balloon time — hr,C3494202,,completed,
433,mean time to first subcutaneous injectiong h in relation to surgery hr,C3494202,,completed,
433,time to angiography — hr,C3494202,,completed,
433,time to treatment,C3494202,,completed,
433,time to treatment h,C3494202,,completed,
450,anticoagulant,C0003280,,completed,
450,anticoagulant group ( n = $nmbr$ ),C0085826,,completed,
450,anticoagulant — no . ( % ),C0085826,,completed,
450,anticoagulants,C0085826,,completed,
450,anti - coagulants,C0003280,,completed,
450,anti - coagulants - no . ( % ),C0003280,,completed,
450,concomitant anticoagulant antithrombotic or nsaid n ( % ),C0003280,,completed,
450,other anticoagulant,C0003280,,completed,
451,antiplatelet,C0085826,,completed,
451,antiplatelet agent or anticoagulant,C0085826,,completed,
451,antiplatelet or anticoagulant,C0085826,,completed,
451,antiplatelets,C0085826,,completed,
451,antiplatelets or anticoagulants,C0085826,,completed,
451,antithrombotic and anticoagulant medications,C0085826,,completed,
451,any anticoagulant,C0085826,,completed,
451,aspirin or other antiplatelet or anticoagulant agent,C0085826,,completed,
451,periprocedural anticoagulant,C0085826,,completed,
453,new york heart association class,C0018802;C1882083,,completed,
453,new york heart association congestive heart failure class,C0018802;C1882083,,completed,
453,nyha chf class,C0018802;C1882083,,completed,
453,nyha class,C0018802;C1882083,,completed,
453,nyha class ( % ),C0018802;C1882083,,completed,
453,nyha_class,C0018802;C1882083,,completed,
453,nyha class n ( % ),C0018802;C1882083,,completed,
453,nyha class n ( % ) i,C0018802;C1882083,,completed,
453,nyha class $nmbr$ - $nmbr$ : no { n = llll ),C0018802;C1882083,,completed,
453,nyha class $nmbr$ or higher,C0018802;C1882083,,completed,
453,nyha class — no . ( % ),C0018802;C1882083,,completed,
453,nyha class — no . ( % ) $,C0018802;C1882083,,completed,
453,nyha class not reported,C0018802;C1882083,,completed,
453,nyha class within past month — no . / total no . ( % ),C0018802;C1882083,,completed,
467,dyspepsia,C0013395,,completed,
467,history of dyspepsia,C0013395,,completed,
480,adolescents ( aged $nmbr$ - $nmbr$ y ) no . ( % ),C0001779,,completed,
480,adults ( aged   ≥ $nmbr$ y ) no . ( % ),C0001779,,completed,
480,age,C0001779,,completed,
480,age >,C0001779,,completed,
480,age :,C0001779,,completed,
480,age *,C0001779,,completed,
480,ageadj,C0001779,,completed,
480,age a $nmbr$,C0001779,,completed,
480,age at completion of highest level of,C0001779,,completed,
480,age at lipid randomization ( y ),C0001779,,completed,
480,age at randomisation,C0001779,,completed,
480,age at randomization,C0001779,,completed,
480,age at screening,C0001779,,completed,
480,age at time of first seizure,C0001779,,completed,
480,age b $nmbr$ y ( n = $nmbr$ ),C0001779,,completed,
480,aged $nmbr$ y or older n ( % ),C0001779,,completed,
480,age group n ( % ),C0001779,,completed,
480,age groups n ( % ),C0001779,,completed,
480,age group ( y ),C0001779,,completed,
480,age - interaction,C0001779,,completed,
480,age mean,C0001779,,completed,
480,age mean ( min - max ) ( yrs ),C0001779,,completed,
480,age mean ( sd ) [ range ] y,C0001779,,completed,
480,age mean ( sd ) y,C0001779,,completed,
480,age mean ± sd y,C0001779,,completed,
480,age mean ± sd ( year ),C0001779,,completed,
480,age mean ( sd ) yearsa,C0001779,,completed,
480,age mean ( sd ) yr,C0001779,,completed,
480,age mean ( sd ) yrs,C0001779,,completed,
480,age mean ( s . e . ),C0001779,,completed,
480,age mean yr,C0001779,,completed,
480,age mean yr ( sd ),C0001779,,completed,
480,age mean yrs ( sd ),C0001779,,completed,
480,age mean ( yrs ± sd ),C0001779,,completed,
480,age median ( interquartile range ) y,C0001779,,completed,
480,age n ( % ),C0001779,,completed,
480,age ^ $nmbr$,C0001779,,completed,
480,age < $nmbr$,C0001779,,completed,
480,age > = $nmbr$,C0001779,,completed,
480,age > : $nmbr$,C0001779,,completed,
480,age > $nmbr$,C0001779,,completed,
480,age > $nmbr$ %,C0001779,,completed,
480,age $nmbr$,C0001779,,completed,
480,age $nmbr$ +,C0001779,,completed,
480,age £ $nmbr$,C0001779,,completed,
480,age & $nmbr$,C0001779,,completed,
480,age $nmbr$ - $nmbr$,C0001779,,completed,
480,age $nmbr$ $nmbr$ y,C0001779,,completed,
480,age $nmbr$ - $nmbr$ y ( n = $nmbr$ ),C0001779,,completed,
480,age $nmbr$ * $nmbr$ yr,C0001779,,completed,
480,age $nmbr$ - $nmbr$ yr elevated biomarkers and previous vascular,C0001779,,completed,
480,age < $nmbr$ vears n = $nmbr$,C0001779,,completed,
480,age > $nmbr$ vears n = $nmbr$,C0001779,,completed,
480,age < $nmbr$ y,C0001779,,completed,
480,age > $nmbr$ y,C0001779,,completed,
480,age > $nmbr$ y,C0001779,,completed,
480,age > $nmbr$ y %,C0001779,,completed,
480,age > $nmbr$ y ( % ),C0001779,,completed,
480,age > $nmbr$ y *,C0001779,,completed,
480,age > $nmbr$ y * *,C0001779,,completed,
480,age $nmbr$ y,C0001779,,completed,
480,age $nmbr$ + y,C0001779,,completed,
480,age > $nmbr$ y n ( % ),C0001779,,completed,
480,age   ≥ $nmbr$   y n ( % ),C0001779,,completed,
480,age > $nmbr$ y n / n ( % ),C0001779,,completed,
480,age < $nmbr$ y ( n = $nmbr$ ),C0001779,,completed,
480,age > $nmbr$ y ( n = $nmbr$ ),C0001779,,completed,
480,age ' $nmbr$ y ( n $nmbr$ ),C0001779,,completed,
480,age < $nmbr$ yr,C0001779,,completed,
480,age > $nmbr$ yr,C0001779,,completed,
480,age > $nmbr$ yr ( % ),C0001779,,completed,
480,age > $nmbr$ yr and elevated biomarkers,C0001779,,completed,
480,age > $nmbr$ yr and st - segment changes,C0001779,,completed,
480,age > $nmbr$ yr elevated biomarkers and st - segment changes,C0001779,,completed,
480,age > $nmbr$ yr — no . ( % ),C0001779,,completed,
480,age < $nmbr$ yr or > $nmbr$ yr,C0001779,,completed,
480,age < $nmbr$ yrs,C0001779,,completed,
480,age > = $nmbr$ yrs,C0001779,,completed,
480,age > $nmbr$ yrs,C0001779,,completed,
480,age > $nmbr$ yrs %,C0001779,,completed,
480,age > $nmbr$ yrs *,C0001779,,completed,
480,age ' ^ $nmbr$ yrs,C0001779,,completed,
480,age $ $nmbr$ yrs,C0001779,,completed,
480,age # $nmbr$ yrs,C0001779,,completed,
480,age > $nmbr$ yr 十,C0001779,,completed,
480,age ( p = o - $nmbr$ ),C0001779,,completed,
480,age range,C0001779,,completed,
480,age range y,C0001779,,completed,
480,age ( sd ) y,C0001779,,completed,
480,age s $nmbr$,C0001779,,completed,
480,age s * $nmbr$ yr,C0001779,,completed,
480,age subgroups,C0001779,,completed,
480,age subgroup y,C0001779,,completed,
480,age x,C0001779,,completed,
480,age y,C0001779,,completed,
480,age . y,C0001779,,completed,
480,age ( y ),C0001779,,completed,
480,age ( y ) ∗,C0001779,,completed,
480,age — y £,C0001779,,completed,
480,age ya,C0001779,,completed,
480,age year,C0001779,,completed,
480,age ( year ),C0001779,,completed,
480,age ( year ) mean ± sd,C0001779,,completed,
480,age [ year ] mean ± sda,C0001779,,completed,
480,age year ( median ),C0001779,,completed,
480,age — year ( median ),C0001779,,completed,
480,age yf $nmbr$ - $nmbr$,C0001779,,completed,
480,age y gender n ( % ),C0001779,,completed,
480,age ( yij,C0001779,,completed,
480,age ( y ) mean ( range ),C0001779,,completed,
480,age y mean ± sd,C0001779,,completed,
480,age y ( mean ± s . d . ),C0001779,,completed,
480,age ( y ) mean ( sd ),C0001779,,completed,
480,age ( y ) [ mean - sd ],C0001779,,completed,
480,age — y meantsd,C0001779,,completed,
480,age ( y ) median ( iqr ),C0001779,,completed,
480,age ( y ) median ( min max ),C0001779,,completed,
480,age ( y ) median ( min max },C0001779,,completed,
480,age y median ( q $nmbr$ – q $nmbr$ ),C0001779,,completed,
480,age y median ( range ),C0001779,,completed,
480,age y < $nmbr$,C0001779,,completed,
480,age . . . . . . . . y ( n = $nmbr$ ),C0001779,,completed,
480,age y . o .,C0001779,,completed,
480,age yr,C0001779,,completed,
480,age ( yr ),C0001779,,completed,
480,age ( yr ) *,C0001779,,completed,
480,age — yr,C0001779,,completed,
480,age\\yr,C0001779,,completed,
480,age — yrf,C0001779,,completed,
480,age yr mean ( sd ),C0001779,,completed,
480,age ( yr ) mean ( sd ),C0001779,,completed,
480,age ( yr ) mean ( sd ) bmd t - score mean ( sd ),C0001779,,completed,
480,age yr n ( % ),C0001779,,completed,
480,age — yr race — no . ( % ) f,C0001779,,completed,
480,age yr range,C0001779,,completed,
480,age yrs,C0001779,,completed,
480,age yrs,C0001779,,completed,
480,age yrs *,C0001779,,completed,
480,age ( yrs ),C0001779,,completed,
480,age ( yrs ) mean *,C0001779,,completed,
480,age yrs mean ( sd ),C0001779,,completed,
480,age yrs ( mean ± sd ),C0001779,,completed,
480,age ( yrs ) mean ± sd,C0001779,,completed,
480,age y ( sd ),C0001779,,completed,
480,age y sex no . ( % ),C0001779,,completed,
480,age yt,C0001779,,completed,
480,average age ( year ),C0001779,,completed,
480,( b ) age subgroups,C0001779,,completed,
480,baseline age,C0001779,,completed,
480,cvd risk factors ( age > $nmbr$ ),C0001779,,completed,
480,cvd risk factors ( age > $nmbr$ ) ^ “ ^,C0001779,,completed,
480,established cvd ( age > $nmbr$ ),C0001779,,completed,
480,established cvd / chronic kidney disease ( age > $nmbr$ ) ^ * ’,C0001779,,completed,
480,family history of myocardial infarction prior to age $nmbr$ %,C0001779,,completed,
480,infarction before age $nmbr$ ( a ),C0001779,,completed,
480,low - trauma fracture since age $nmbr$ n ( % ),C0001779,,completed,
480,mean age ( range ) — yr,C0001779,,completed,
480,mean age ( sd ) y,C0001779,,completed,
480,mean age ± s . d . year,C0001779,,completed,
480,mean age ( sd ) yr,C0001779,,completed,
480,mean age y,C0001779,,completed,
480,mean age ( y ),C0001779,,completed,
480,mean age ( yr ),C0001779,,completed,
480,mean age — yr,C0001779,,completed,
480,mean age y : ( range ),C0001779,,completed,
480,mean age y ( range ),C0001779,,completed,
480,mean age — yr ( range ),C0001779,,completed,
480,mean age yrs,C0001779,,completed,
480,mean age ( yrs ),C0001779,,completed,
480,mean age 士 s . d . year,C0001779,,completed,
480,mean ( sd ) age y,C0001779,,completed,
480,mean ( sd ) age yr,C0001779,,completed,
480,mean ( sd ) age y race n ( % ) *,C0001779,,completed,
480,median age [ interquartile range ] — yr,C0001779,,completed,
480,median age ( $nmbr$ % $nmbr$ % ) y,C0001779,,completed,
480,median age — yr,C0001779,,completed,
480,median age — yr §,C0001779,,completed,
480,min - max age,C0001779,,completed,
480,< $nmbr$ yrs of age ( n = $nmbr$ $nmbr$ ),C0001779,,completed,
480,> $nmbr$ yrs of age ( n = $nmbr$ $nmbr$ ),C0001779,,completed,
480,patients aged > $nmbr$ y no ( ss ),C0001779,,completed,
480,p value for interaction ( age continuous ),C0001779,,completed,
480,unstable angina age,C0001779,,completed,
480,x cr $nmbr$ . $nmbr$ x age,C0001779,,completed,
481,age at baseline years,C1510829,,completed,
481,age at baseline ( years ),C1510829,,completed,
481,age at enrollment ( years ),C1510829,,completed,
481,age at enrolment years,C1510829,,completed,
481,age at entry ( years ),C1510829,,completed,
481,age at randomization ( years ),C1510829,,completed,
481,age categories,C1510829,,completed,
481,age categories n ( % ),C1510829,,completed,
481,age categories ( y ) n ( % ),C1510829,,completed,
481,age distribution,C1510829,,completed,
481,age distribution n ( % ),C1510829,,completed,
481,age distribution years n ( % ),C1510829,,completed,
481,age groiro : < $nmbr$ years,C1510829,,completed,
481,age group ( ≥ $nmbr$ years ) — no . ( % ),C1510829,,completed,
481,age in years,C1510829,,completed,
481,age in years mean,C1510829,,completed,
481,age in years mean ( sd ),C1510829,,completed,
481,age mean age years sex,C1510829,,completed,
481,age mean ( range ) years,C1510829,,completed,
481,age mean = sd years,C1510829,,completed,
481,age mean ( sd ) years,C1510829,,completed,
481,age mean ( sd ) years,C1510829,,completed,
481,age mean ( sd ) ( years ),C1510829,,completed,
481,age mean ± sd years,C1510829,,completed,
481,age - mean ( sd ) years,C1510829,,completed,
481,age mean ( sd ) years n ( % ),C1510829,,completed,
481,age mean years ( ± sd ),C1510829,,completed,
481,age mean years ( sd ),C1510829,,completed,
481,age median ( range ) ( years ),C1510829,,completed,
481,age median years,C1510829,,completed,
481,age ( median years ),C1510829,,completed,
481,age $nmbr$ - $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829,,completed,
481,age $nmbr$ - $nmbr$ years ( n = $nmbr$ ),C1510829,,completed,
481,age < $nmbr$ years,C1510829,,completed,
481,age ≥ $nmbr$ years,C1510829,,completed,
481,age > = $nmbr$ years,C1510829,,completed,
481,age > $nmbr$ years,C1510829,,completed,
481,age > $nmbr$ years %,C1510829,,completed,
481,age $nmbr$ years,C1510829,,completed,
481,age : < $nmbr$ years,C1510829,,completed,
481,age : > $nmbr$ years,C1510829,,completed,
481,age $ $nmbr$ years § *,C1510829,,completed,
481,age $nmbr$ years,C1510829,,completed,
481,age $nmbr$ + years,C1510829,,completed,
481,age < $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C1510829,,completed,
481,age < $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C1510829,,completed,
481,age ≥ $nmbr$ years and bmi < $nmbr$ kg / m $nmbr$,C1510829,,completed,
481,age ≥ $nmbr$ years and bmi ≥ $nmbr$ kg / m $nmbr$,C1510829,,completed,
481,age < $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829,,completed,
481,age > $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829,,completed,
481,age £ $nmbr$ years ( itt ) ( n = $nmbr$ ),C1510829,,completed,
481,age < $nmbr$ years ( median ),C1510829,,completed,
481,age > $nmbr$ years ( median ),C1510829,,completed,
481,age < $nmbr$ years n ( % ),C1510829,,completed,
481,age < $nmbr$ years ( n =,C1510829,,completed,
481,age ≥ $nmbr$ years n ( % ),C1510829,,completed,
481,age > $nmbr$ years n ( % ),C1510829,,completed,
481,age < $nmbr$ years $nmbr$,C1510829,,completed,
481,age > $nmbr$ years $nmbr$,C1510829,,completed,
481,age < $nmbr$ years ( n = $nmbr$ ),C1510829,,completed,
481,age > $nmbr$ years ( n = $nmbr$ ),C1510829,,completed,
481,age : < $nmbr$ years ( n = $nmbr$ ),C1510829,,completed,
481,age $nmbr$ years ( n = $nmbr$ ),C1510829,,completed,
481,age < $nmbr$ years ( n = $nmbr$ $nmbr$ ),C1510829,,completed,
481,age < $nmbr$ years — no . ( % ),C1510829,,completed,
481,age < $nmbr$ years old,C1510829,,completed,
481,age > = $nmbr$ years old,C1510829,,completed,
481,age $nmbr$ years or more,C1510829,,completed,
481,age > $nmbr$ ( years ) t,C1510829,,completed,
481,age ( per $nmbr$ years ),C1510829,,completed,
481,age ( range ) ( years ),C1510829,,completed,
481,age range years,C1510829,,completed,
481,age range ( years ),C1510829,,completed,
481,age s $nmbr$ years ( n = $nmbr$ $nmbr$ ),C1510829,,completed,
481,age years,C1510829,,completed,
481,age years,C1510829,,completed,
481,age ( years ),C1510829,,completed,
481,age years ^,C1510829,,completed,
481,age years “,C1510829,,completed,
481,age years *,C1510829,,completed,
481,age - years,C1510829,,completed,
481,age . years,C1510829,,completed,
481,age ( years ),C1510829,,completed,
481,age ( years ) :,C1510829,,completed,
481,age ( years ) *,C1510829,,completed,
481,age ( years ) +,C1510829,,completed,
481,age [ years ],C1510829,,completed,
481,age ( years ) a,C1510829,,completed,
481,age years geographical distribution of patients,C1510829,,completed,
481,age years geographic region,C1510829,,completed,
481,age [ years ] ( interaction : p = $nmbr$ . $nmbr$ ),C1510829,,completed,
481,age years ( mean $nmbr$ sd ),C1510829,,completed,
481,age years mean ( range ),C1510829,,completed,
481,age years mean ( sd ),C1510829,,completed,
481,age years mean ± sd,C1510829,,completed,
481,age years ( mean = sd ),C1510829,,completed,
481,age years ( mean ± sd ),C1510829,,completed,
481,age years mean ( s . d . ),C1510829,,completed,
481,age years mean ( sd ),C1510829,,completed,
481,age years mean ± sd,C1510829,,completed,
481,age ( years ) mean _ sd,C1510829,,completed,
481,age ( years ) mean ( s . d . ),C1510829,,completed,
481,age ( years ) mean ( sd ),C1510829,,completed,
481,age ( years ) mean ± sd,C1510829,,completed,
481,age ( years ) mean ± s . d .,C1510829,,completed,
481,age ( years ) mean   ±   sd,C1510829,,completed,
481,age ( years ) - mean ± sd,C1510829,,completed,
481,age ( years ) : mean ± sd,C1510829,,completed,
481,age ( years ) ( mean sd ),C1510829,,completed,
481,age ( years ) ( mean ± sd ),C1510829,,completed,
481,age years ( mean _ + sd ) sex n ( % ) :,C1510829,,completed,
481,age ( years ) [ median ( $nmbr$ th to $nmbr$ th percentile ) ],C1510829,,completed,
481,age ( years ) - < median ( n = $nmbr$ $nmbr$ ),C1510829,,completed,
481,age ( years ) - > = median ( n = $nmbr$ $nmbr$ ),C1510829,,completed,
481,age years : median ( range ),C1510829,,completed,
481,age ( years ) median ( range ),C1510829,,completed,
481,age [ years ] median ( range ),C1510829,,completed,
481,age years $nmbr$ ',C1510829,,completed,
481,age ( years ) : < $nmbr$,C1510829,,completed,
481,age ( years ) : > $nmbr$,C1510829,,completed,
481,age ( years ) : $nmbr$ - < $nmbr$,C1510829,,completed,
481,age years ( sd ),C1510829,,completed,
481,age ( years sd ),C1510829,,completed,
481,age ( years ( s . d . ) ),C1510829,,completed,
481,i $nmbr$ years of age,C1510829,,completed,
481,mean age ( sd ) years,C1510829,,completed,
481,mean age ± s . d . years,C1510829,,completed,
481,mean age ± sd ( years ),C1510829,,completed,
481,mean age years,C1510829,,completed,
481,mean age ( years ),C1510829,,completed,
481,mean age years ( $nmbr$ % ci ),C1510829,,completed,
481,mean age ( years ) race,C1510829,,completed,
481,mean age years ( range ),C1510829,,completed,
481,mean age years ± sd,C1510829,,completed,
481,mean age ( years sd ),C1510829,,completed,
481,mean age ( years ) ( s . d . ),C1510829,,completed,
481,mean ( s . d . ) age years,C1510829,,completed,
481,mean ± s . d . age years,C1510829,,completed,
481,median age years ( iqr ),C1510829,,completed,
481,< $nmbr$ years of age,C1510829,,completed,
481,> $nmbr$ years of age,C1510829,,completed,
481,> $nmbr$ years of age n ( % ),C1510829,,completed,
481,patients ' characteristics age ( years ) mean + sd,C1510829,,completed,
481,subjects $nmbr$ years of age n ( % ),C1510829,,completed,
481,subjects $ $nmbr$ years of age n ( % ),C1510829,,completed,
482,age groups,C0027362,,completed,
482,p between age groups,C0027362,,completed,
483,age at diagnosis < $nmbr$ years,C1828181,,completed,
483,age at diagnosis of ln years,C1828181,,completed,
483,age at diagnosis of sle years,C1828181,,completed,
483,age at diagnosis s $nmbr$ years,C1828181,,completed,
483,age at diagnosis y,C1828181,,completed,
492,dactylitis,C0239161,,completed,
492,dactylitis % #,C0239161,,completed,
492,dactylitis n ( % ),C0239161,,completed,
492,dactylitis score,C0239161,,completed,
492,dactylitis score ( $nmbr$ - $nmbr$ ),C0239161,,completed,
492,dactylitis score ( $nmbr$ - $nmbr$ ) mean ( sd ),C0239161,,completed,
492,dactylitis score ( $nmbr$ – $nmbr$ scale ),C0239161,,completed,
492,dactylitis severity score ) score > $nmbr$ — no . { % ),C0239161,,completed,
492,% improvement in dactylitis score at week $nmbr$ n,C0239161,,completed,
492,patients with dactylitis,C0239161,,completed,
492,patients with dactylitis at baseline no .,C0239161,,completed,
492,patients with dactylitis no . ( % ),C0239161,,completed,
492,randomised patients with dactylitis at baseline,C0239161,,completed,
504,european,C0239307,,completed,
504,european subcategories,C0239307,,completed,
504,european trial,C0239307,,completed,
504,non - european,C0239307,,completed,
504,non - european trial,C0239307,,completed,
504,white / european,C0239307,,completed,
578,grip strength > = median,C0429271,,completed,
578,grip strength < meidan,C0429271,,completed,
580,central america and south america,C0037713,,completed,
580,central and south america,C0037713,,completed,
580,central and south america and mexico,C0037713,,completed,
580,central or south america,C0037713,,completed,
580,central / south america,C0037713,,completed,
580,central / south america and mexico,C0037713,,completed,
580,latin america or south africa,C0037713,,completed,
580,south africa,C0037713,,completed,
580,south africa / south america,C0037713,,completed,
580,south america,C0037713,,completed,
580,south america ( % ),C0037713,,completed,
580,south american,C0037713,,completed,
580,south america ( n = $nmbr$ ),C0037713,,completed,
580,south asia,C0037713,,completed,
580,south asian,C0037713,,completed,
580,south ! central america,C0037713,,completed,
589,bacterial pneumonia,C0032285,,completed,
589,pneumonia,C0032285,,completed,
589,previous pneumonia,C0032285,,completed,
592,baseline ckd egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,baseline egfr,C3811844;C0017654,,completed,
592,baseline egfr ml / min / $nmbr$ . $nmbr$   m $nmbr$,C3811844;C0017654,,completed,
592,baseline egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,baseline egfr ( ml / min per $nmbr$ « $nmbr$ m ’ ),C3811844;C0017654,,completed,
592,baseline egfr < $nmbr$,C3811844;C0017654,,completed,
592,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,baseline egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,baseline egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ c,C3811844;C0017654,,inprogress,
592,baseline egfr ≥ $nmbr$ to < $nmbr$,C3811844;C0017654,,completed,
592,baseline gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n ( % ),C3811844;C0017654,,inprogress,
592,baseline gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ n ( % ),C3811844;C0017654,,inprogress,
592,bp = blood pressure egfr = estimated glomerular filtration rate ( men : $nmbr$ en : $nmbr$ x cr $nmbr$ . $nmbr$ x age $nmbr$ . $nmbr$ x $nmbr$ . $nmbr$ ) hdl = high - density lipoprotein .,C3811844;C0017654,,completed,
592,ckd ( egfr < $nmbr$ b ),C3811844;C0017654,,completed,
592,ckd ( egfr < $nmbr$ ) n ( % ),C3811844;C0017654,,completed,
592,egfr,C3811844;C0017654,,completed,
592,egfr -,C3811844;C0017654,,completed,
592,egfr and albuminuria,C3811844;C0017654,,completed,
592,egfr at baseline $nmbr$ ml / min ( % ) b,C3811844;C0017654,,inprogress,
592,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr by creatinine ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ geometric mean [ se ] ),C3811844;C0017654,,inprogress,
592,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ geometric mean [ se ] ),C3811844;C0017654,,inprogress,
592,egfr by cystatin c ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ mean [ se ] ),C3811844;C0017654,,inprogress,
592,egfr category,C3811844;C0017654,,completed,
592,egfr category ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) n ( % ),C3811844;C0017654,,completed,
592,egfr category n ( % ),C3811844;C0017654,,completed,
592,egfr ( ckd - epi cystatin c ) ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ( ckd - epi cystatinc ) ml / min / $nmbr$ . $nmbr$ m $nmbr$ n ( % ),C3811844;C0017654,,inprogress,
592,egfr crcl ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C3811844;C0017654,,inprogress,
592,egfr crcl < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr from the mdrd equation ( sd ) ml · min − $nmbr$ · $nmbr$ . $nmbr$ m − $nmbr$,C3811844;C0017654,,inprogress,
592,egfr in ml / min / $nmbr$ . $nmbr$ m ^ median ( iqr ),C3811844;C0017654,,inprogress,
592,egfr ( mdrd ) ml / min / $nmbr$ . $nmbr$ m * *,C3811844;C0017654,,inprogress,
592,egfr ( mdrd ) ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfrmdrd ml / min / $nmbr$ . $nmbr$ m $nmbr$ bsa,C3811844;C0017654,,inprogress,
592,egfrmdrd ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$,C3811844;C0017654,,inprogress,
592,egfrmdrd ， ml - min - $nmbr$ - $nmbr$ . $nmbr$ m_ $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ( mdrd ) ml min − $nmbr$ $nmbr$ . $nmbr$   m − $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ( mdrd ) n ( % ),C3811844;C0017654,,completed,
592,egfrmdrd < $nmbr$ ml - min - $nmbr$ - $nmbr$ . $nmbr$ m - $nmbr$ n ( % ),C3811844;C0017654,,inprogress,
592,egfr mean = sd ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr mean ( sd ) ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ( median iqr ) ml / min / $nmbr$ $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr median ( sd ) ml / min,C3811844;C0017654,,inprogress,
592,egfr ml / min,C3811844;C0017654,,inprogress,
592,egfr ( ml / min ),C3811844;C0017654,,inprogress,
592,egfr ml / min / bsa,C3811844;C0017654,,inprogress,
592,egfr ml / min ( mdrd ),C3811844;C0017654,,inprogress,
592,egfr ml / min / m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,completed,
592,egfr — ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,inprogress,
592,egfr — ml / min / $nmbr$ . $nmbr$ m * *,C3811844;C0017654,,inprogress,
592,egfr * ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ml / min / $nmbr$ . $nmbr$   m $nmbr$,C3811844;C0017654,,completed,
592,egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ ‡,C3811844;C0017654,,completed,
592,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) §,C3811844;C0017654,,inprogress,
592,egfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C3811844;C0017654,,inprogress,
592,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ [ mdrdequation ] ),C3811844;C0017654,,inprogress,
592,egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ) mean ( sd ),C3811844;C0017654,,inprogress,
592,egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ mean ( sd ),C3811844;C0017654,,inprogress,
592,egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ mean ± sd,C3811844;C0017654,,inprogress,
592,egfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) mean ( sd ),C3811844;C0017654,,inprogress,
592,egfr + ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mean ± sd ),C3811844;C0017654,,inprogress,
592,egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( sd ),C3811844;C0017654,,inprogress,
592,egfr ( ml / min / $nmbr$ - $nmbr$ mz ),C3811844;C0017654,,inprogress,
592,egfr ml min $nmbr$ $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr ( ml / min per $nmbr$ - $nmbr$ kg / m ^ ),C3811844;C0017654,,completed,
592,egfr ( ml / min per $nmbr$ ^ $nmbr$ m ' ),C3811844;C0017654,,completed,
592,egfr ( ml / min per $nmbr$ - $nmbr$ m ^ ),C3811844;C0017654,,completed,
592,egfr ( ml / min per $nmbr$ - $nmbr$ m ' ),C3811844;C0017654,,inprogress,
592,egfr ( ml / min per $nmbr$ - $nmbr$ m ’ ),C3811844;C0017654,,completed,
592,egfr ( ml / min per $nmbr$ + $nmbr$ m ”,C3811844;C0017654,,completed,
592,egfr ml / min per $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,egfr ml / min per $nmbr$ · $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,completed,
592,egfr ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C3811844;C0017654,,completed,
592,egfr ‡ ( ml / min per $nmbr$ · $nmbr$ m $nmbr$ ),C3811844;C0017654,,completed,
592,egfr ml / min per $nmbr$ . $nmbr$ m $nmbr$ mean ( sd ),C3811844;C0017654,,inprogress,
592,egfr ( ml / min per $nmbr$ - $nmbr$ m $nmbr$ ) t,C3811844;C0017654,,inprogress,
592,egfr ml • mn ' • $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,egfr ( mumin / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,completed,
592,egfr < $nmbr$,C3811844;C0017654,,completed,
592,egfr > $nmbr$,C3811844;C0017654,,completed,
592,egfr < $nmbr$ ml / min,C3811844;C0017654,,inprogress,
592,egfr > $nmbr$ ml / min,C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min n ( % ),C3811844;C0017654,,inprogress,
592,egfr > $nmbr$ ml / min n ( % ),C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$,C3811844;C0017654,,inprogress,
592,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$,C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,completed,
592,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,completed,
592,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,completed,
592,egfr < $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ §,C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ *,C3811844;C0017654,,inprogress,
592,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,egfr > $nmbr$ ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr > $nmbr$ ml / min / $nmbr$ - $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr £ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( mdrd ),C3811844;C0017654,,inprogress,
592,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n ( % ),C3811844;C0017654,,completed,
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C3811844;C0017654,,completed,
592,egfr ≥ $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C3811844;C0017654,,completed,
592,egfr $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr . $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr > = $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ % ),C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C3811844;C0017654,,inprogress,
592,egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ mz,C3811844;C0017654,,inprogress,
592,egfr < $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C3811844;C0017654,,completed,
592,egfr > $nmbr$ ml / min per $nmbr$ ^ $nmbr$ m ',C3811844;C0017654,,completed,
592,egfr < $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,egfr ≥ $nmbr$ ml / min per $nmbr$ · $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,egfr < $nmbr$ n ( % ),C3811844;C0017654,,completed,
592,egfr > $nmbr$ n ( % ),C3811844;C0017654,,completed,
592,egfr $nmbr$ - $nmbr$,C3811844;C0017654,,completed,
592,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr $nmbr$ – $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ ( $nmbr$ . $nmbr$ % ),C3811844;C0017654,,inprogress,
592,egfr $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n = $nmbr$ $nmbr$ ( $nmbr$ . $nmbr$ % ),C3811844;C0017654,,inprogress,
592,egfr $nmbr$ . $nmbr$ - $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C3811844;C0017654,,completed,
592,egfr < $nmbr$ . $nmbr$ ( vs egfr > $nmbr$ ),C3811844;C0017654,,completed,
592,egfr $nmbr$ to < $nmbr$ ml / min n ( % ),C3811844;C0017654,,inprogress,
592,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$,C3811844;C0017654,,inprogress,
592,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,inprogress,
592,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ’,C3811844;C0017654,,inprogress,
592,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m *,C3811844;C0017654,,inprogress,
592,egfr $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ( n = $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr n ( % ) normal ( egfr > $nmbr$ ml / min / em ^ ),C3811844;C0017654,,completed,
592,egfr s $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,completed,
592,egfr s $nmbr$ o ml / min / $nmbr$ . $nmbr$ m ^,C3811844;C0017654,,completed,
592,egfr using cg / mdrd formulae % of patients,C3811844;C0017654,,completed,
592,egfr via mdrd ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,egfr   < $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,egfr   ≥ $nmbr$   ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,completed,
592,estimated gfr ^,C0035078,;C1424601,completed,
592,estimated gfr at baseline ml • min $nmbr$,C3811844;C0017654,,inprogress,
592,estimated gfr mean ( sd ) mlvmin per $nmbr$ . $nmbr$ m ^ *,C0035078,;C1424601,completed,
592,estimated gfr ml / min,C3811844;C0017654,,inprogress,
592,estimated gfr — ml / min / $nmbr$ . $nmbr$ m ^ |,C3811844;C0017654,,inprogress,
592,estimated gfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) ^ |,C3811844;C0017654,,inprogress,
592,estimated gfr — ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) lipid baseline lipid profile,C3811844;C0017654,,inprogress,
592,estimated gfr ( ml / min / $nmbr$ . $nmbr$ m $nmbr$ ) mean ( sd ),C3811844;C0017654,,inprogress,
592,estimated gfr ml / min / $nmbr$ . $nmbr$ m $nmbr$   of body - surface area,C3811844;C0017654,,inprogress,
592,estimated gfr ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$ ( sd ) a,C3811844;C0017654,,inprogress,
592,estimated gfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) mean ( sd ),C3811844;C0017654,,inprogress,
592,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,estimated gfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ no . ( % ),C0035078,;C1424601,completed,
592,estimated gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ — no . ( % ),C0035078,;C1424601,completed,
592,estimated gfr < $nmbr$ ml min - $nmbr$ $nmbr$ . $nmbr$ m - $nmbr$ n ( % ) a,C3811844;C0017654,,inprogress,
592,estimated gfr — no . ( % ) ^ |,C0035078,;C1424601,completed,
592,estimated gfr — no . ( % ) $nmbr$,C0035078,;C1424601,completed,
592,estimated glomerular filtration rate,C3811844;C0017654,,completed,
592,estimated glomerular filtration rate - no . ( % ) : :,C3811844;C0017654,,completed,
592,estimated glomerular filtration rate — no . ( % ),C3811844;C0017654,,completed,
592,gfr as assessed by mdrd,C0035078,;C1424601,completed,
592,gfr ( mdrd ) ( ml / min / $nmbr$ - $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,gfr ( ml / min per $nmbr$ . $nmbr$ nr ),C3811844;C0017654,,inprogress,
592,gfr < $nmbr$,C0035078,;C1424601,completed,
592,gfr > $nmbr$,C0035078,;C1424601,completed,
592,gfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,gfr $nmbr$ - $nmbr$,C0035078,;C1424601,completed,
592,gfr $nmbr$ $nmbr$,C0035078,;C1424601,completed,
592,gmr,C0035078,;C1424601,completed,
592,mdrd egfr geometric mean ( cv % ) a b ml /,C3811844;C0017654,,completed,
592,mdrd egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,mdrd - egfr ( ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,mean ( s . d . ) egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,mean ( sd ) egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,mild reduction in egfr,C3811844;C0017654,,completed,
592,moderate impairment ( egfr $nmbr$ - $nmbr$ ),C3811844;C0017654,,completed,
592,moderate impairment ( egfr $nmbr$ - $nmbr$ ml / min / m ^ ),C3811844;C0017654,,completed,
592,moderate impairment ( egfr $nmbr$ – $nmbr$ ) n ( % ),C3811844;C0017654,,completed,
592,moderate / severe reduction in egfr,C3811844;C0017654,,completed,
592,> $nmbr$ egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,> $nmbr$ egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ a,C3811844;C0017654,,inprogress,
592,$nmbr$ — em,C3811844;C0017654,,completed,
592,normal ( egfr > $nmbr$ ),C3811844;C0017654,,completed,
592,normal egfr ( $nmbr$ < egfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,completed,
592,normal ( egfr ≥ $nmbr$ ) n ( % ),C3811844;C0017654,,completed,
592,normal or high egfr ( > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) at baseline to low egfr ( < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,normal or increased baseline gfr ( > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,normal or increased egfr,C3811844;C0017654,,completed,
592,outcome according to renal function level ( in ml / min ),C3811844;C0017654,,inprogress,
592,patients with egfr < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C3811844;C0017654,,inprogress,
592,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ at baseline,C3811844;C0017654,,inprogress,
592,patients with egfr > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n,C3811844;C0017654,,inprogress,
592,patients with egfr $nmbr$ > $nmbr$ to < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$ n,C3811844;C0017654,,inprogress,
592,renal function ( egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ ),C3811844;C0017654,,inprogress,
592,renal function ( egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$ according to mdrd ) n ( % ),C3811844;C0017654,,inprogress,
592,renal function ( ml / min ),C3811844;C0017654,,inprogress,
592,renal function < $nmbr$ egfr ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,renal impairment ( crcl < $nmbr$ ml / min ),C3811844;C0017654,,inprogress,
592,stage i ( gfr > $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) and stage v ( gfr < $nmbr$ ml / min per $nmbr$ . $nmbr$ m $nmbr$ ) were not considered because they included only $nmbr$ and $nmbr$ patient respectively . chf congestive,C3811844;C0017654,,inprogress,
592,stage $nmbr$ ckd egfr > $nmbr$ ml / ( n = $nmbr$ ),C3811844;C0017654,,completed,
592,stage $nmbr$ ckd egfr $nmbr$ to $nmbr$ ml / min ( n = $nmbr$ ),C3811844;C0017654,,inprogress,
592,stage $nmbr$ : < $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,stage $nmbr$ : > $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,stage $nmbr$ : $nmbr$ - $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C3811844;C0017654,,inprogress,
592,sustained decrease of > $nmbr$ % in egfr ®,C3811844;C0017654,,completed,
592,treatment by egfr stage,C3811844;C0017654,,completed,
596,diabetic eye disease,C0342245,,completed,
596,major diabetic eye disease n ( % ),C0342245,,completed,
599,western europe,,,completed,
599,western europe ( % ),,,completed,
599,western europe and lebanon,,,completed,
599,western europe and other,,,completed,
599,western europe australia new zealand,,,completed,
599,western europe australia new zealand and middle east,,,completed,
599,western europe australia new zealand middle east,,,completed,
599,western europe ( including south africa ),,,completed,
599,western europe ( n = $nmbr$ ),,,completed,
599,western europe ( n   = $nmbr$ $nmbr$ ),,,completed,
599,western europe plus other,,,completed,
601,central and eastern europe,C0239309,,completed,
601,eastern europe,C0239309,,completed,
601,eastern europe ( % ),C0239309,,completed,
601,eastern europe africa,C0239309,,completed,
601,eastern european,C0239309,,completed,
601,eastern europe and africa,C0239309,,completed,
601,eastern europe ( n = $nmbr$ ),C0239309,,completed,
601,eastern europe ( n   = $nmbr$ $nmbr$ ),C0239309,,completed,
615,baseline systolic bp,C0871470,,completed,
615,nonglycemic cardiovascular risk factors systolic blood pressure — mmhg,C0871470,,completed,
615,systolic blood pressure,C0871470,,completed,
615,systolic blood pressure ^,C0871470,,completed,
615,systolic blood pressure ( median $nmbr$ . $nmbr$ ),C0871470,,completed,
615,systolic blood pressure mmhg,C0871470,,completed,
615,systolic blood pressure ( mmhg ),C0871470,,completed,
615,systolic blood pressure mm hq,C0871470,,completed,
615,systolic blood pressure subgroups,C0871470,,completed,
615,systolic bp,C0871470,,completed,
615,systolic bp at baseline :,C0871470,,completed,
630,isolated pulmonary embolism,C0271650,,completed,
685,biguanide,C0005382,,completed,
685,biguanide ( metformin ),C0005382,,completed,
685,biguanides,C0005382,,completed,
685,biguanides ¶,C0005382,,completed,
685,biguanides ( metformin ),C0005382,,completed,
685,biguanide use at baseline,C0005382,,completed,
704,non - dihydropyridine ccbs,,,completed,
716,methotrexate treatment !,C0025677,,completed,
716,on - treatment,C0025677,,completed,
716,past treatment for paod,C0025677,,completed,
716,planned treatment duration n ( % ),C0025677,,completed,
716,previously taken methotrexate %,;C0039260,,completed,
716,rank based on treatment   =   placebo,C0025677,,completed,
716,treatment satisfaction,C0025677,,completed,
752,any sulfonylurea,C0038766,,completed,
752,duration of sulphonylurea use ( months ) mean ± s . d .,C0038766,,completed,
752,insulin + metformin + sulphonylureas,C0038766,,completed,
752,insulin + sulphonylureas,C0038766,,completed,
752,non - sulfonylurea secretagogues,C0038766,,completed,
752,on sulfonylurea,C0038766,,completed,
752,other sulfonylurea 一 no . ( % ),C0038766,,completed,
752,sulfonylurea,C0038766,,completed,
752,sulfonylureaa,C0038766,,completed,
752,sulfonylurea based,C0038766,,completed,
752,sulfonylurea derivatives,C0038766,,completed,
752,sulfonylurea — no . ( % ),C0038766,,completed,
752,sulfonylureas,C0038766,,completed,
752,sulfonylureasb,C0038766,,completed,
752,sulfonylurea use at baseline,C0038766,,completed,
752,sulphonylurea,C0038766,,completed,
752,sulphonylureas,C0038766,,completed,
775,dabigatran $nmbr$ vs . warfarin p ( inter ),C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
779,angiotensin ii receptor blocker,C0521942,,completed,
779,angiotensin ii receptor blockers,C0521942,,completed,
779,angiotensin il - receptor blocker,C0521942,,completed,
779,angiotensin ll - receptor antagonist — no . ( % ),C0521942,,completed,
779,angiotensin ll - receptor blocker,C0521942,,completed,
779,angiotensin receptive blocker,C0521942,,completed,
779,angiotensin receptor,C0521942,,completed,
779,angiotensin - receptor,C0521942,,completed,
779,angiotensin receptor blockers,C0521942,,completed,
780,fecal calprotectin — pg / g * *,,,completed,Faecal calprotectin (No CUI assigned)
780,median fecal calprotectin — mg / kg gi areas involved — no . ( % ),C0005902;C1879646,,completed,
803,fenofibrate ( n = $nmbr$ ),C0033228,,completed,
803,simvastatin $nmbr$ mg plus fenofibrate $nmbr$ mg ( n = $nmbr$ /,C0033228,,completed,
811,ace inhibitor,C0003015,,completed,
811,ace inhibitor %,C0003015,,completed,
811,ace inhibitor monotherapy,C0003015,,completed,
811,ace inhibitor n ( % ),C0003015,,completed,
811,ace inhibitor — no . ( % ),C0003015,,completed,
811,ace inhibitor or angiotensin ii receptor,C0003015,,completed,
811,ace inhibitor or angiotensin ii receptor blocker,C0521942,,completed,
811,ace inhibitor or angiotensin receptor blocker,C0521942,,completed,
811,ace inhibitor or angiotensin - receptor blocker — no . / total no . ( % ),C0003015,,completed,
811,ace inhibitor or arb use,C0003015,,completed,
811,ace inhibitors,C0003015,,completed,
811,ace - inhibitors,C0003015,,completed,
811,ace - inhibitors n ( % ),C0003015,,completed,
811,ace inhibitors or angiotensin - receptor blockers,C0521942,,completed,
811,ace inhibitors or angiotensin - receptor blockers ^,C0521942,,completed,
811,ace inhibitors or angiotensin receptor blockers,C0521942,,completed,
811,ace inhibitors / sartans,C0003015,,completed,
811,ace inhibitors through hospital discharge or day $nmbr$ — %,C0003015,,completed,
811,ace - inhibitor use,C0003015,,completed,
811,ace inhibitor use ( % ),C0003015,,completed,
811,angiotensin - converting - enzyme inhibitor,C0003015,,completed,
811,angiotensin - converting enzyme inhibitor,C0003015,,completed,
811,angiotensin - converting enzyme inhibitor / angiotensin receptor blocker,C0003015,,completed,
811,angiotensin - converting - enzyme inhibitor or angiotensin -,C0003015,,completed,
811,angiotensin - converting enzyme inhibitors,C0003015,,completed,
811,angiotensin - converting enzyme inhibitors ^,C0003015,,completed,
811,current use of an ace inhibitor,C0003015,,completed,
811,use of ace inhibitor,C0003015,,completed,
817,both iv vasodilator and inotrope,C0042402,,completed,
817,iv vasodilator,C0042402,,completed,
817,other vasodilator,C0042402,,completed,
817,other vasodilators §,C0042402,,completed,
817,vasodilator,C0042402,,completed,
817,vasodilator therapy,C0042402,,completed,
818,isolated igt,C0271650,,completed,
818,isolated impaired glucose tolerance — no .,C0271650,,completed,
820,any hba $nmbr$ c,,,completed,
820,baseline hba ^ c,,,completed,
820,baseline hba $nmbr$ c,,,completed,
820,baseline hba $nmbr$ c ^,,,completed,
820,baseline hba $nmbr$ c %,,,completed,
820,baseline hba $nmbr$ c ( % ),,,completed,
820,baseline hba $nmbr$ c concentration,,,completed,
820,baseline hba $nmbr$ c in $nmbr$ classes,,,completed,
820,baseline hba $nmbr$ c mean ( s . e . ),,,completed,
820,baseline hba $nmbr$ c n ( % ),,,completed,
820,baseline hba $nmbr$ c < $nmbr$ . $nmbr$ %,,,completed,
820,baseline hba $nmbr$ c > $nmbr$ . $nmbr$ %,,,completed,
820,change from baseline in hba $nmbr$ c ( % ),,,completed,
820,hba ( % ),,,completed,
820,hba „ ( % ),,,completed,
820,hba c ( % ),,,completed,
820,hba ] c ( mmol / mol ),,,completed,
820,hba % $nmbr$ c,,,completed,
820,hba $nmbr$ c,,,completed,
820,hba $nmbr$ c ( % ),,,completed,
820,hba $nmbr$ c %,,,completed,
820,hba $nmbr$ c % §,,,completed,
820,hba $nmbr$ c % *,,,completed,
820,hba $nmbr$ c ( % ),,,completed,
820,hba $nmbr$ c ( % ) *,,,completed,
820,hba $nmbr$ ca % ( mmol / mol ),,,completed,
820,hba $nmbr$ c at baseline,,,completed,
820,hba $nmbr$ c at baseline %,,,completed,
820,hba $nmbr$ c at baseline :,,,completed,
820,hba $nmbr$ c at $nmbr$ weeks *,,,completed,
820,hba $nmbr$ c at week $nmbr$,,,completed,
820,hba $nmbr$ c baseline mean hba $nmbr$ c % ( sd ),,,completed,
820,hba $nmbr$ c categories n ( % ),,,completed,
820,hba $nmbr$ c category,,,completed,
820,hba $nmbr$ c category n ( % ),,,completed,
820,hba $nmbr$ c ( change from baseline ),,,completed,
820,hba $nmbr$ c % d,,,completed,
820,hba $nmbr$ c distribution,,,completed,
820,hba $nmbr$ c distribution at baseline,,,completed,
820,hba $nmbr$ c distribution at baseline n ( % ),,,completed,
820,hba $nmbr$ c in patients with baseline hba $nmbr$ c < $nmbr$ % ( < $nmbr$ mmol / l ) % [ mmol / mol ] la n baseline ( sd ) adjusted mean change ( $nmbr$ % ci ) placebo - subtracted change ( se ),,,completed,
820,hba $nmbr$ c levels,,,completed,
820,hba $nmbr$ c % ( mean $nmbr$ sd ),,,completed,
820,hba $nmbr$ c % mean ( sd ),,,completed,
820,hba $nmbr$ c % mean ± sd,,,completed,
820,hba $nmbr$ c mean = sd %,,,completed,
820,hba $nmbr$ c mean ( sd ),,,completed,
820,hba $nmbr$ c mean ( sd ) %,,,completed,
820,hba $nmbr$ c ( % ) mean ( sd ),,,completed,
820,hba $nmbr$ c % mean ( sd ) b,,,completed,
820,hba $nmbr$ c mean ( sd ) % [ mmol / mol ],,,completed,
820,hba $nmbr$ c % ( mean ± sd ) [ range ],,,completed,
820,hba $nmbr$ c median ( sd ) %,,,completed,
820,% hba $nmbr$ c ( mmol / mol ),,,completed,
820,hba $nmbr$ c mmol / mol,,,completed,
820,hba $nmbr$ c ( mmol / mol ),,,completed,
820,hba $nmbr$ c mmol / mold,,,completed,
820,hba $nmbr$ c mmol / mole,,,completed,
820,hba $nmbr$ c n,,,completed,
820,hba $nmbr$ c ( n ),,,completed,
820,hba $nmbr$ c \n,,,completed,
820,hba $nmbr$ c % n ( % ) b,,,completed,
820,hba $nmbr$ c < = $nmbr$ %,,,completed,
820,hba $nmbr$ c < $nmbr$ %,,,completed,
820,hba $nmbr$ c > = $nmbr$ %,,,completed,
820,hba $nmbr$ c > $nmbr$ %,,,completed,
820,hba $nmbr$ c < $nmbr$ % level,,,completed,
820,hba $nmbr$ c > $nmbr$ % level,,,completed,
820,hba $nmbr$ c < $nmbr$ . $nmbr$ %,,,completed,
820,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ %,,,completed,
820,hba $nmbr$ c > $nmbr$ . $nmbr$ %,,,completed,
820,hba $nmbr$ c > $nmbr$ · $nmbr$ %,,,completed,
820,hba $nmbr$ c < $nmbr$ . $nmbr$,,,completed,
820,hba $nmbr$ c > $nmbr$ . $nmbr$,,,completed,
820,hba $nmbr$ c $nmbr$ - < = $nmbr$ %,,,completed,
820,hba $nmbr$ c $ $nmbr$ . $nmbr$ % ( $nmbr$ mmol / mol ),,,completed,
820,hba $nmbr$ c $nmbr$ . $nmbr$ – $nmbr$ . $nmbr$,,,completed,
820,hba $nmbr$ c $nmbr$ % - < $nmbr$ % ( n - $nmbr$ ),,,completed,
820,hba $nmbr$ c ≤ $nmbr$ . $nmbr$ % without gi adverse reactions,,,completed,
820,hba $nmbr$ c < $nmbr$ % ( n - $nmbr$ ),,,completed,
820,hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),,,completed,
820,hba $nmbr$ c > $nmbr$ % ( n $nmbr$ $nmbr$ ),,,completed,
820,hba $nmbr$ c $nmbr$ weeks,,,completed,
820,hba $nmbr$ c ( % patients < $nmbr$ . $nmbr$ % ),,,completed,
820,hba $nmbr$ c % ( range ),,,completed,
820,hba $nmbr$ c % ( sd ),,,completed,
820,hba $nmbr$ c ( sd ) %,,,completed,
820,hba $nmbr$ c strata,,,completed,
820,hba $nmbr$ c subgroups,,,completed,
820,hba $nmbr$ c   ( % ),,,completed,
820,hba $nmbr$ c   at randomization,,,completed,
820,hba $nmbr$ c   baseline ( % ),,,completed,
820,hba $nmbr$ c   ( mmol / mol ),,,completed,
820,mean hba $nmbr$ c %,,,completed,
820,mean hba $nmbr$ c ± s . d . %,,,completed,
820,mean ( s . d . ) baseline hba $nmbr$ c %,,,completed,
820,mean ± s . d . hba $nmbr$ c,,,completed,
820,mean ( sd ) hba $nmbr$ c level %,,,completed,
820,$nmbr$ % < hba $nmbr$ c < = $nmbr$ %,,,completed,
820,$nmbr$ % < hba $nmbr$ c < = $nmbr$ % ( n $nmbr$ $nmbr$ ),,,completed,
820,proportion ( $nmbr$ % ci ) adjusted for baseline hba $nmbr$ c %,,,completed,
820,qualifying hba $nmbr$ c ( % ),,,completed,
820,screening hba $nmbr$ c ( % ),,,completed,
820,subgroup analysis : change from baseline in hba $nmbr$ c at week $nmbr$ per baseline hba $nmbr$ c category,,,completed,
820,subpopulation analyses according to baseline hba $nmbr$ c,,,completed,
820,week $nmbr$ hba $nmbr$ c mean ( s . e . ),,,completed,
820,with highest hba $nmbr$ cc,,,completed,
821,baseline hdl - c,C0023822,,completed,
821,baseline hdl - c in $nmbr$ classes,C0023822,,completed,
821,baseline high - density lipoprotein cholesterol ( mg / dl ),C0008377,,completed,
821,baseline non - hdl - ca,C0023822,,completed,
821,hdl,C0023822,,completed,
821,hdl *,C0023822,,completed,
821,hdl - c,C0023822,,completed,
821,hdl - c at baseline .,C0023822,,completed,
821,hdl - cd,C0023822,,completed,
821,hdl choleslerol,C0023822,,completed,
821,- hdl cholesterol,C0008377,,completed,
821,hdl cholesterol,C0008377,,completed,
821,hdl - cholesterol,C0008377,,completed,
821,hdl cholesterol ^ :,C0008377,,completed,
821,hdl cholesterol §,C0008377,,completed,
821,hdl cholesterol *,C0008377,,completed,
821,hdl cholesterol level,C0008377,,completed,
821,hdl - cholesterol ( mg / dl ),C0008377,,completed,
821,hdl cholesterol mg / dl,C0008377,,completed,
821,hdl cholesterol ( mg / dl ),C0008377,,completed,
821,hdl cholesterol — mg / dl,C0008377,,completed,
821,hdl - cholesterol mmol / l,C0008377,,completed,
821,hdl - cholesterol ( mmol / l ),C0008377,,completed,
821,hdl cholesterol ( mmol / l ),C0008377,,completed,
821,hdl cholesterol mmol / l,C0008377,,completed,
821,hdl cholesterol mmol / l *,C0008377,,completed,
821,hdl cholesterol ( mmol / l ),C0008377,,completed,
821,hdl cholesterol ( mmol / l ) :,C0008377,,completed,
821,hdl - cholesterol mmol / le,C0008377,,completed,
821,hdl cholesterol ( mmol / l ) mean ( sd ),C0008377,,completed,
821,hdl cholesterol ( mmol / l ) ( median iqr ),C0008377,,completed,
821,hdl cholesterol mmol / l men mean ± sd,C0008377,,completed,
821,hdl cholesterol mmol / 冲,C0008377,,completed,
821,hdl cholesterol < $nmbr$ mg / dl *,C0008377,,completed,
821,hdl cholesterol < $nmbr$ - $nmbr$ mmol / l,C0008377,,completed,
821,hdl cholesterol > $nmbr$ - $nmbr$ mmol / l,C0008377,,completed,
821,hdl cholesterol ( sd ) mg / dl,C0008377,,completed,
821,hdl - c mmol / l,C0023822,,completed,
821,hdl - c ( mmol / l ),C0023822,,completed,
821,hdl - c mmol / l mean ( sd ),C0023822,,completed,
821,hdl - cy,C0023822,,completed,
821,hdl — female,C0023822,,completed,
821,hdl — male,C0023822,,completed,
821,hdl ( mmol / l ),C0023822,,completed,
821,hdl $nmbr$,C0023822,,completed,
821,hdl $nmbr$ - c,C0023822,,completed,
821,high - density lipoprotein cholesterol mean ( mg / dl ± sd ),C0008377,,completed,
821,high - density lipoprotein cholesterol median ( $nmbr$ th — $nmbr$ th percentiles ) mg / dl,C0008377,,completed,
821,high - density lipoprotein cholesterol mg / dl,C0008377,,completed,
821,high - density lipoprotein cholesterol — mg / dl,C0008377,,completed,
821,high density lipoprotein cholesterol mg / dl ^,C0008377,,completed,
821,high density lipoprotein cholesterol - mg / dl * *,C0008377,,completed,
821,high - density lipoprotein cholesterol mg / l,C0006560,,inprogress,
821,kdl cholesterol ( mmol / ),C0008377,,completed,
821,ldl - c : hdl - c,C0023822,,completed,
821,ldl - c / hdl - c,C0023822,,completed,
821,ldl - c / hdl - cx,C0023822,,completed,
821,> $nmbr$ . $nmbr$ hdl cholesterol level,C0008377,,completed,
821,non - hdl,C0023822,,completed,
821,non - hdl - c,C0023822,,completed,
821,non - hdl - c *,C0023822,,completed,
821,non - hdl - c / hdl - c,C0023822,,completed,
821,non - hdl choleslerol,C0023822,,completed,
821,non - hdl - c in $nmbr$ classes,C0023822,,completed,
821,non - hdl - c mean ( sd ),C0023822,,completed,
821,non - hdl - c mean ( sd ) rng / dl,C0023822,,completed,
821,non - hdl - c mmol / l,C0023822,,completed,
821,non - hdl - c ( mmol / l ),C0023822,,completed,
821,non - hdl - c ( mmol / l mean ),C0023822,,completed,
821,non - hdl - c mmol / l mean ( sd ),C0023822,,completed,
821,ratio of ldl to hdl,C0023822,,completed,
821,terol hdl - c high - density lipoprotein cholesterol,C0008377,,completed,
821,total - c : hdl - c,C0023822,,completed,
821,total c / hdl - c ratio * *,C0023822,,completed,
821,total cholesterol / hdl - c,C0023822,,completed,
821,totalhdl cholesterol ratio,C0008377,,completed,
824,hospitalization for heart failure within previous $nmbr$ mo — no . ( % ),C3898876,;C0026544,completed,
824,previous hospitalization for heart failure,C3898876,;C0026544,completed,
837,group d ( high risk more symptoms ) n ( % ),C4319571,,completed,
837,high cardiovascular risk n ( % ) ^,C4319571,,completed,
837,high cv risk,C4319571,,completed,
837,higher risk ( n = $nmbr$ ),C4319571,,completed,
837,high fracture risk stratum,C4319571,,completed,
837,high ( > $nmbr$ risk factor ),C4319571,,completed,
837,high risk,C4319571,,completed,
837,high - risk,C4319571,,completed,
837,high risk * %,C4319571,,completed,
837,high risk and fewer symptoms ( group c ),C4319571,,completed,
837,high - risk clinical features,C4319571,,completed,
837,high - risk criterion,C4319571,,completed,
837,high - risk cvd n ( % ),C4319571,,completed,
837,high risk for diabetes *,C4319571,,completed,
837,high risk ( - ics ),C4319571,,completed,
837,high risk ( ? ics ),C4319571,,completed,
837,high risk ( > $nmbr$ ),C4319571,,completed,
837,high risk ( $nmbr$ - $nmbr$ ),C4319571,,completed,
837,high risk ( n $nmbr$ $nmbr$ ),C4319571,,completed,
837,high risk ( receiving treatment for ) :,C4319571,,completed,
837,high risk ( ri ≥ $nmbr$ ),C4319571,,completed,
837,high risk without atherosclerotic vascular disease +,C4319571,,completed,
837,moderately high risk,C4319571,,completed,
837,moderately high risk without atherosclerotic vascular disease *,C4319571,,completed,
837,> $nmbr$ ( high risk ),C4319571,,completed,
837,$nmbr$ or $nmbr$ high cardiovascular risk categories,C4319571,,completed,
837,$nmbr$ or $nmbr$ high - risk categories,C4319571,,completed,
837,qualifying high - risk features — %,C4319571,,completed,
837,very high risk,C4319571,,completed,
838,high - school graduate,C0870649,,completed,
838,high - school graduate or ged,C0870649,,completed,
838,less than high school,C0870649,,completed,
842,diastolic blood pressure,C0428883,,completed,
842,diastolic blood pressure and lp ( a ),C0428883,,completed,
842,diastolic blood pressure mm hg,C0428883,,completed,
842,diastolic blood pressure ( mm hg ),C0428883,,completed,
842,diastolic blood pressure mm hg median ( range ),C0428883,,completed,
842,diastolic blood pressure ( mm hg ) medications,C0428883,,completed,
842,diastolic blood pressure mm hq,C0428883,,completed,
842,diastolic blood pressure subgroups,C0428883,,completed,
842,diastolic bp,C0428883,,completed,
842,diastolic bp mmhg,C0428883,,completed,
842,diastolic bp mm hg,C0428883,,completed,
842,diastolic bp ( mm hg ),C0428883,,completed,
842,diastolic bp ( mmhg ),C0428883,,completed,
842,diastolic bp ( mmhg ) *,C0428883,,completed,
842,diastolic bp mm   hg mean ( sd ),C0428883,,completed,
842,diastolic bp mm hg mean ( sd ),C0428883,,completed,
842,diastolic bp mmhg ( sd ),C0428883,,completed,
843,idiopathic,C0332240,,completed,
843,idiopathica,C0332240,,completed,
843,idiopathic / familial,C0332240,,completed,
844,diastolic,C0012000,,completed,
844,diastolic fmmhff ' ),C0012000,,completed,
844,diastolic total,C0012000,,completed,
844,diastolic treated at baseline,C0012000,,completed,
846,baseline killip class,C1881332,,completed,
846,killip class,C1881332,,completed,
846,killip class *,C1881332,,completed,
846,killip class at admission — no . / total no . ( % ),C1881332,,completed,
846,killip class > i %,C1881332,,completed,
846,killip class > ii ( % ),C1881332,,completed,
846,killip class i — no . ( % ),C1881332,,completed,
846,killip class ( interaction : p = $nmbr$ . $nmbr$ ),C1881332,,completed,
846,killip class iv at randomization,C1881332,,completed,
846,killip class lll - iv,C1881332,,completed,
846,killip class n ( % ),C1881332,,completed,
846,killip class n ( % ) i,C1881332,,completed,
846,killip class $nmbr$,C1881332,,completed,
846,killip class $nmbr$ / $nmbr$,C1881332,,completed,
846,killip class > $nmbr$ no . ( % ),C1881332,,completed,
846,killip class — no . ( % ) i,C1881332,,completed,
846,killip class — no . / total no . ( % ) i,C1881332,,completed,
846,< $nmbr$ baseline killip class,C1881332,,completed,
847,ii lisinopril i,C0065374,,completed,
847,i lisinopril ( n = $nmbr$ ),C0065374,,completed,
847,lisinopril,C0065374,,completed,
847,lisinopril ( n = $nmbr$ ),C0065374,,completed,
847,$nmbr$ lisinopril,C0065374,,completed,
848,blood eosinophil count — cells / mm ’,C0750879,,completed,
848,blood eosinophil count cells / mm $nmbr$ no .,C0750879,,completed,
848,blood eosinophil count ( $nmbr$ cells per l ),C0750879,,completed,
848,blood eosinophil count > $nmbr$ / mm $nmbr$ at screening — no . ( % ),C0750879,,completed,
848,eosinophil count,C0750879,,completed,
848,local eosinophil count,C0750879,,completed,
848,local eosinophil count [ cells / µ l ] median ( range ),C0750879,,completed,
848,local eosinophil count [ cells / ml ] median ( range ),C0750879,,completed,
848,median blood eosinophil count cells per pla,C0750879,,completed,
849,blood eosinophil,C0014467,,completed,
849,blood eosinophil count geometric mean ( sd loge scale ) cells / ll,C0014467,,completed,
849,blood eosinophil proportion ( % ),C0014467,,completed,
849,blood eosinophils cells / ml,C0014467,,completed,
849,blood eosinophils count,C0014467,,completed,
849,blood eosinophils mean ( range ) cells / mlb,C0014467,,completed,
849,calima japandhigh - dosage ics / laba and baseline blood eosinophils > $nmbr$ cells / ml ( n = $nmbr$ ) y,C0014467,,completed,
849,eosinophils,C0014467,,completed,
849,eosinophils < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils £ $nmbr$ % ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ^ ^ ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ^ ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( itt ) ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils < $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / l ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils > $nmbr$ $nmbr$ x $nmbr$ * $nmbr$ / $nmbr$ ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils < $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils > $nmbr$ . $nmbr$ x $nmbr$ * $nmbr$ ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils $nmbr$ . $nmbr$ x $nmbr$ ' ' $nmbr$ ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils < $nmbr$ % ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils > $nmbr$ % ( n = $nmbr$ ),C0014467,,completed,
849,eosinophils $nmbr$ % ( n - $nmbr$ ),C0014467,,completed,
849,eosinophils £ $nmbr$ % ( n = $nmbr$ ),C0014467,,completed,
849,geometric mean blood eosinophil count on loge scale — cells / ^ ljj,,,inprogress,
849,geometric mean blood eosinophil count ( sd on a loge scale ) — cells / mm $nmbr$,,,inprogress,
855,tadalafil,C1176316,,completed,
855,tadalafil $nmbr$ mg,C1176316,,completed,
855,tadalafil $nmbr$ mg mean change ( sd ),C1176316,,completed,
855,tadalafil $nmbr$ mg ( n = $nmbr$ ),C1176316,,completed,
855,tadalafil $nmbr$ mg n = $nmbr$,C1176316,,completed,
855,tadalafil $nmbr$ . $nmbr$ mg,C1176316,,completed,
855,tadalafil $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C1176316,,completed,
855,tadalafil $nmbr$ . $nmbr$ mg n = $nmbr$,C1176316,,completed,
856,anacetrapib $nmbr$ mg,C2604745,,completed,
856,anacetrapib $nmbr$ mg ( n = $nmbr$ ),C2604745,,completed,
856,anacetrapib $nmbr$ mg ( n - $nmbr$ ),C2604745,,completed,
856,anacetrapib ( n = $nmbr$ ),C2604745,,completed,
856,anacetrapib ( n = $nmbr$ $nmbr$ ),C2604745,,completed,
857,tofacitinib,C2930696,,completed,
857,tofacitinib $nmbr$ mg bid,C2930696,,completed,
857,tofacitinib $nmbr$ mg bid ( n = $nmbr$ ),C2930696,,completed,
857,tofacitinib $nmbr$ mg bid [ n = $nmbr$ |,C2930696,,completed,
857,tofacitinib $nmbr$ mg bid ( n   = $nmbr$ ),C2930696,,completed,
857,tofacitinib $nmbr$ mg ( n = $nmbr$ ),C2930696,,completed,
857,tofacitinib $nmbr$ mg two times a day,C2930696,,completed,
858,d $nmbr$ vs warfarin,C0043031,,completed,
858,d $nmbr$ vs warfarin rr ( $nmbr$ % ci p value ),C0043031,,completed,
858,edoxaban vs . warfarin,C0043031,,completed,
858,edoxaban warfarin,C0043031,,completed,
858,hr vs . warfarin ( $nmbr$ % ci ),C0043031,,completed,
858,ld edoxaban vs warfarin,C0043031,,completed,
858,low - dose edoxaban vs warfarin,C0043031,,completed,
858,median time in therapeutic range for warfarin recipients %,C0043031,,completed,
858,previous transient ischaemic attack / ischaemic stroke previous warfarin use,C0043031,,completed,
858,previous warfarin use no . ( % ),C0043031,,completed,
858,re - cover $nmbr$ warfarin,C0043031,,completed,
858,ttr ( warfarin arm only ),C0043031,,completed,
858,vs . warfarin,C0043031,,completed,
858,warf,C0043031,,completed,
858,warfarin,C0043031,,completed,
858,warfarin ( % ),C0043031,,completed,
858,warfarin at enrollment,C0043031,,completed,
858,warfarin group,C0043031,,completed,
858,warfarin group ( n = $nmbr$ ),C0043031,,completed,
858,warfarin naive,C0043031,,completed,
858,warfarin % ( n / n ),C0043031,,completed,
858,warfarin ( n = $nmbr$ ),C0043031,,completed,
858,warfarin n = $nmbr$,C0043031,,completed,
858,warfarin ( n - $nmbr$ $nmbr$ ),C0043031,,completed,
858,warfarin n = $nmbr$ n / n ( % ),C0043031,,completed,
858,warfarin ( n = $nmbr$ ) n ( % / y ),C0043031,,completed,
858,warfarin n / n rate ( % ),C0043031,,completed,
858,warfarin no . ( % ),C0043031,,completed,
858,warfarin ( s $nmbr$ % cl ),C0043031,,completed,
859,commercially available fondaparinux,C1098510,,completed,
859,fondaparinux,C1098510,,completed,
859,fondaparinux ( n = $nmbr$ ),C1098510,,completed,
859,fondaparinux ( n = $nmbr$ $nmbr$ ),C1098510,,completed,
859,fondaparinux — no . ( % ),C1098510,,completed,
859,heparin fondaparinux or brvalirudin use between - oex event,C1098510,,completed,
859,heparins and fondaparinux,C1098510,,completed,
859,total time of fondaparinux treatment before,C1098510,,completed,
860,nadroparin,C0206232,,completed,
860,nadroparin ( n = $nmbr$ ),C0206232,,completed,
860,nadroparin vs control,C0206232,,completed,
860,no nadroparin ( n = $nmbr$ ),C0206232,,completed,
862,enoxaparin,C0206460,,completed,
862,enoxaparin $nmbr$ mg ( n = $nmbr$ $nmbr$ ),C0206460,,completed,
862,enoxaparin ( n = $nmbr$ ),C0206460,,completed,
862,enoxaparin ( n = $nmbr$ $nmbr$ ),C0206460,,completed,
862,enoxaparin / vka,C0206460,,completed,
862,enoxaparin / vka n / n ( % ) $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0206460,,completed,
862,unfractionated heparin or enoxaparin plus glycoprotein iib / iiia inhibitors ( n = $nmbr$ ),C0206460,,completed,
863,additional heparin,C0019134,,completed,
863,bivalirudin - heparin plus gpi,C0019134,,completed,
863,heparin,C0019134,,completed,
863,heparin dose regimen,C0019134,,completed,
863,heparin only,C0019134,,completed,
863,heparin plus a gpi ( n = $nmbr$ ),C0019134,,completed,
863,heparin plus gpi ( n = $nmbr$ $nmbr$ ),C0019134,,completed,
863,initial heparin treatment duration,C0019134,,completed,
863,initial heparin treatment duration on or after randomization,C0019134,,completed,
863,neither uh or lmw heparin,C0019134,,completed,
863,> = $nmbr$ day s initial heparin treatment duration,C0019134,,completed,
863,> = $nmbr$ ^ initial heparin treatment duration,C0019134,,completed,
864,both unfractionated heparin and low - molecular - weight heparin,C0019134,,completed,
864,intravenous heparin,C0019134,,completed,
864,neither unfractionated heparin nor low - molecular - weight heparin,C0019134,,completed,
864,non - pci intravenous unfractionated heparin,C0019134,,completed,
864,unfractionated heparin,C0019134,,completed,
864,unfractionated heparin before randomisation,C0019134,,completed,
864,unfractionated heparin ( n = $nmbr$ ),C0019134,,completed,
864,unfractionated heparin ( n = $nmbr$ $nmbr$ ),C0019134,,completed,
864,unfractionated heparin — no . ( % ),C0019134,,completed,
864,unfractionated heparin within $nmbr$ hr before randomization — no . / total no . ( % ),C0019134,,completed,
865,american hispanic ( n   = $nmbr$ ),C0086409,,completed,
865,biack,C0086409,,completed,
865,biack hispanic,C0086409,,completed,
865,biack non - hispanic,C0086409,,completed,
865,black hispanic,C0086409,,completed,
865,black hispanic - n ( % ),C0086409,,completed,
865,black non - hispanic,C0086409,,completed,
865,ethnicity not hispanic / latino   n   ( % ),C0086409,,completed,
865,hispanic,C0086409,,completed,
865,hispanic ethnic group n ( % ),C0086409,,completed,
865,hispanic ethnic group — no . ( % ) f,C0086409,,completed,
865,hispanic ethnic group — no . { % ) ’ i ',C0086409,,completed,
865,hispanic ethnic group — no . ( % ) : t,C0086409,,completed,
865,hispanic ethnic group — no . / total no . ( % ) ‘ j ‘,C0086409,,completed,
865,hispanic n ( % ),C0086409,,completed,
865,hispanic ( n = $nmbr$ ),C0086409,,completed,
865,hispanic ( n = $nmbr$ l $nmbr$ ),C0086409,,completed,
865,hispanic — no . ( % ),C0086409,,completed,
865,hispanic / non - hispanic,C0086409,,completed,
865,hispanic or non - hispanic ethnic group — no . ( % ) f,C0086409,,completed,
865,non - hispanic,C0086409,,completed,
865,non - hispanic and latino,C0086409,,completed,
865,non - hispanic / latino,C0086409,,completed,
865,non - hispanic non - latino,C0086409,,completed,
865,non - hispanic or latino,C0086409,,completed,
865,not hispanic,C0086409,,completed,
865,not hispanic / latino,C0086409,,completed,
865,not hispanic / latino ( n = $nmbr$ $nmbr$ ),C0086409,,completed,
865,not hispanic or latino,C0086409,,completed,
865,not hispanic or latino ( n = $nmbr$ ),C0086409,,completed,
865,not hispanic or latino ( n — $nmbr$ ),C0086409,,completed,
865,white not of hispanic origin,C0086409,,completed,
866,baseline vitamin - d,C0042866,,completed,
866,daily dose of vitamin d ( iu / day ),C0042866,,completed,
866,$nmbr$ ( oh ) vitamin d ( ng / ml ),C0042866,,completed,
866,serum vitamin d ( nmol / l ),C0042866,,completed,
866,vitamin d §,C0042866,,completed,
867,other plain vitamin preparations,C0042890,,completed,
867,vitamins,C0042890,,completed,
868,previous use of vitamin k antagonist for > $nmbr$ days — no . ( % ),;C0043031,,completed,
868,vitamin k antagonist,;C0043031,,completed,
868,vitamin k antagonist ( e . g . warfarin / coumarol ),;C0043031,,completed,
868,vitamin k antagonist experiencedk ( n = $nmbr$ $nmbr$ ),;C0043031,,completed,
868,vitamin k antagonist experienced n ( % ),;C0043031,,completed,
868,vitamin k antagonist naive,;C0043031,,completed,
868,vitamin k antagonists,;C0043031,,completed,
869,i vitamin e,C0042874,,completed,
869,i vitamin e ( n = $nmbr$ ),C0042874,,completed,
869,$nmbr$ vitamin e,C0042874,,completed,
869,$nmbr$ vitamin e ( n = $nmbr$ $nmbr$ ),C0042874,,completed,
869,randomized to receive vitamin e,C0042874,,completed,
869,vitamin e,C0042874,,completed,
870,anti - histamines,C0019590,,completed,
870,histamine - $nmbr$ - receptor antagonist,C0019590,,completed,
871,niacin,C0027996,,completed,
871,niacini,C0027996,,completed,
871,niacin n ( % ),C0027996,,completed,
871,niacin ( n = $nmbr$ ),C0027996,,completed,
871,niacin + statin,C0027996,,completed,
872,all patients on maximally tolerated statin ± other llt,C0360714,,completed,
872,any statin,C0360714,,completed,
872,any statin versus no statin at randomization,C0360714,,completed,
872,any statin ( with / without llt ),C0360714,,completed,
872,a . overall and subgroups bv statin potency - -,C0360714,,completed,
872,baseiine statin,C0360714,,completed,
872,baseline statin use,C0360714,,completed,
872,extended - release niacin plus statin ( n = $nmbr$ ),C0027996,,completed,
872,eze + statin,C0360714,,completed,
872,eze + statin n = $nmbr$,C0360714,,completed,
872,high - dose statin pretreatment ( n = $nmbr$ ),C0360714,,completed,
872,history of statin use,C0360714,,completed,
872,llv wlalil $nmbr$ statin,C0360714,,completed,
872,ltt other than statin,C0360714,,completed,
872,moderate - intensity statin,C0360714,,completed,
872,moderate - intensity statin use,C0360714,,completed,
872,non high dose statin ( n = $nmbr$ $nmbr$ ),C0360714,,completed,
872,non - statin ( n = $nmbr$ ),C0360714,,completed,
872,no statin,C0360714,,completed,
872,no statin during admission,C0360714,,completed,
872,no statin ( + / - llt ),C0360714,,completed,
872,patients not receiving statin,C0360714,,completed,
872,patients receiving statin,C0360714,,completed,
872,peri - op statins : no ( n = $nmbr$ ),C0360714,,completed,
872,prevention ) n ( % ) patients on llt ( other than statin ) n ( % ),C0360714,,completed,
872,stalin,C0360714,,completed,
872,statin,C0360714,,completed,
872,statin ( % ),C0360714,,completed,
872,statin alone,C0360714,,completed,
872,statin during admission,C0360714,,completed,
872,statin + er niacin ( n = $nmbr$ ),C0360714,,completed,
872,statin intolerant *,C0360714,,completed,
872,statin medication,C0360714,,completed,
872,statin % ( n ),C0360714,,completed,
872,statin n ( % ),C0360714,,completed,
872,statin ( n = $nmbr$ ),C0360714,,completed,
872,statin ( n - $nmbr$ ),C0360714,,completed,
872,statin potency stratum n ( % ),C0360714,,completed,
872,statins,C0360714,,completed,
872,statin ( s ),C0360714,,completed,
872,statins n ( % ),C0360714,,completed,
872,statins no . ( % ),C0360714,,completed,
872,statins 一 no . ( % ),C0360714,,completed,
872,statin treatment,C0360714,,completed,
872,statin usage,C0360714,,completed,
872,statin use at baseline,C0360714,,completed,
872,statin use n ( % ),C0360714,,completed,
872,statin with niacin,C0360714,,completed,
872,statin with other llt,C0360714,,completed,
872,statin without other llt,C0360714,,completed,
872,treatment with statins,C0360714,,completed,
872,use of statin at any follow - up visit ( % ),C0360714,,completed,
872,use of statins,C0360714,,completed,
873,placebo + $nmbr$ mg / d of simvastatin,C0074554,,completed,
873,placebo / simvastatin,C0074554,,completed,
873,pooled simvastatin factorial studies,C0074554,,completed,
874,sildenafil ( n = $nmbr$ ),C0529793,,completed,
875,alcohol consumption,C0001948,,completed,
875,alcohol consumption !,C0001948,,completed,
875,alcohol consumption ( % ),C0001948,,completed,
875,alcohol consumption *,C0001948,,completed,
875,alcohol consumption at baseline,C0001948,,completed,
875,alcohol consumption n ( % ),C0001948,,completed,
875,alcohol consumption ( % ) < $nmbr$ drink / dav,C0001948,,completed,
875,alcohol consumption no . ( % ),C0001948,,completed,
875,alcohol consumption > once weekly,C0001948,,completed,
875,alcohol consumption ( yes ) ( n ),C0001948,,completed,
875,alcohol intake,C0001948,,completed,
875,alcohol intake ( + ) ( % ),C0001948,,completed,
875,alcohol intake ( a ),C0001948,,completed,
875,alcohol intake drinks / week,C0001948,,completed,
875,alcohol intake never / rarely,C0001948,,completed,
875,alcohol use,C0001948,,completed,
875,alcohol use ( % ),C0001948,,completed,
875,alcohol use n ( % ),C0001948,,completed,
875,alcohol use ( % > $nmbr$ / day ),C0001948,,completed,
875,alcohol use ( > $nmbr$ drink / wk ),C0001948,,completed,
875,alcohol % with > $nmbr$ drink / d,C0001948,,completed,
875,current alcohol use n ( % ),C0001948,,completed,
875,current drinker,C3241966,,completed,
875,current weekly alcohol use ( % ),C0001948,,completed,
875,drinking,C0001948,,completed,
875,drinking n ( % ),C0001948,,completed,
875,no alcohol consumption on average,C0001948,,completed,
875,regular alcohol consumption per week no . ( % ),C0001948,,completed,
877,treated with atenolol ( n = $nmbr$ ),C0004147,,completed,
881,migraine with aura,C0154723,,completed,
885,aiorvasiaiin,C0286651,,completed,
885,atorvastatin,C0286651,,completed,
885,atorvastatinb,C0286651,,completed,
885,atorvastatin dose,C0286651,,completed,
885,atorvastatin factorial study,C0286651,,completed,
885,atorvastatin monotherapy ( n = $nmbr$ * ),C0286651,,completed,
885,atorvastatin n ( % ),C0286651,,completed,
885,atorvastatin $nmbr$ mg,C0286651,,completed,
885,atorvastatin $nmbr$ mg + ezetimibe $nmbr$ mg ( n = $nmbr$ ),C0286651,,completed,
885,atorvastatin $nmbr$ mg ( n = $nmbr$ ),C0286651,,completed,
885,atorvastatin $nmbr$ mg ( n = $nmbr$ $nmbr$ ),C0286651,,completed,
885,atorvastatin ( n = $nmbr$ $nmbr$ ),C0286651,,completed,
885,atorvastatin { n = $nmbr$ $nmbr$ ),C0286651,,completed,
885,atv atorvastatin ldl - c low - density lipoprotein cholesterol . * p - values pertain to treatment - by - stratum interaction test for stratum or treatment - by - subgroup interaction test for subgroups . ' multiplicity adjustments were not applied to this predefined subgroup analysis of ldl - c goal attainment [ expressed as number of patients reaching ldl - c goal at week $nmbr$ / number of patients above goal at baseline ^ treatment stratum was defined by intake of atv $nmbr$ or $nmbr$ mg .,C0286651,,completed,
885,concomitant atorvastatin dose mg,C0286651,,completed,
885,dose of atorvastatin,C0286651,,completed,
885,z\tonastaiin,C0286651,,completed,
886,copd - rosuvastatin ( $nmbr$ pt ) n . ( % ),C0965129,,completed,
886,copd - rosuvastatin ( n = $nmbr$ ),C0965129,,completed,
886,crosuvastatin + fenofibric acid vs . rosuvastatin monotherapy .,C0965129,,completed,
886,dose of rosuvastatin,C0965129,,completed,
886,i rosuvastatin ( n = $nmbr$ ),C0965129,,completed,
886,$nmbr$ mg rosuvastatin $nmbr$ mg .,C0965129,,completed,
886,placebo / rosu vastatin,C0032042,,inprogress,
886,rosuva rosuvastatin sd standard deviation t $nmbr$ dm type $nmbr$ diabetes mellitus .,C0965129,,completed,
886,rosuvastatin,C0965129,,completed,
886,rosuvastatin +,C0965129,,completed,
886,rosuvastatin events / patients ( % ),C0965129,,completed,
886,rosuvastatin events / patients ( % ),C0965129,,completed,
886,rosuvastatin + fenofibric acid,C0965129,,completed,
886,rosuvastatin n ( % ),C0965129,,completed,
886,rosuvastatin $nmbr$ mg,C0965129,,completed,
886,rosuvastatin $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C0965129,,completed,
886,rosuvastatin ( n = $nmbr$ ),C0965129,,completed,
886,rosuvastatin n = $nmbr$,C0965129,,completed,
886,rosuvastatin ( n = $nmbr$ $nmbr$ ),C0965129,,completed,
886,rosuvastatin ( n = $nmbr$ . $nmbr$ ),C0965129,,completed,
886,rosuvastatin n ( rate ),C0965129,,completed,
886,rosuvastatin n ( rate ),C0965129,,completed,
886,rosuvastatin n ( rate ) *,C0965129,,completed,
886,rosuvastatin n ( rate ) $nmbr$,C0965129,,completed,
886,rosuvastatin of patients ( rate ),C0965129,,completed,
886,rosuvastatin   n   =   $nmbr$,C0965129,,completed,
887,ejection fraction,C2700378,,completed,
887,ejection fraction %,C2700378,,completed,
887,ejection fraction ( % ),C2700378,,completed,
887,ejection fraction *,C2700378,,completed,
887,ejection fraction based on local reading,C2700378,,completed,
887,ejection fraction category,C2700378,,completed,
887,ejection fraction group,C2700378,,completed,
887,ejection fraction : < $nmbr$ % ( n = $nmbr$ ),C2700378,,completed,
887,ejection fraction % nyha class n ( % ),C2700378,,completed,
887,ejection fraction percent ( sd ),C2700378,,completed,
887,fraction ( % ),C2700378,,completed,
887,method of assessing ejection fraction,C2700378,,completed,
887,section $nmbr$ a,C2700378,,completed,
887,section $nmbr$ b,C2700378,,completed,
887,section $nmbr$ c,C2700378,,completed,
889,exacerbation historyh n ( % ),C4086268,,completed,
889,exacerbations,C4086268,,completed,
889,exacerbations in the past $nmbr$ months n,C4086268,,completed,
889,hospitalized exacerbation rates,C4086268,,completed,
889,hospitalized for an exacerbation,C4086268,,completed,
889,$nmbr$ exacerbation,C4086268,,completed,
889,> $nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C4086268,,completed,
889,$nmbr$ exacerbation in prev $nmbr$ m ( n = $nmbr$ ),C4086268,,completed,
889,> $nmbr$ exacerbations,C4086268,,completed,
889,$ $nmbr$ exacerbations,C4086268,,completed,
889,$nmbr$ exacerbations,C4086268,,completed,
889,number of exacerbation in the previous $nmbr$ months n ( % ),C4086268,,completed,
889,number of exacerbations,C4086268,,completed,
889,number of exacerbations in last $nmbr$ months,C4086268,,completed,
889,number of exacerbations in previous $nmbr$ months,C4086268,,completed,
889,number of exacerbations in previous $nmbr$   months,C4086268,,completed,
889,number of exacerbations in the last $nmbr$ months,C4086268,,completed,
889,number of exacerbations in the last $nmbr$ months mean ± sd,C4086268,,completed,
889,number of exacerbations in the past $nmbr$ months,C4086268,,completed,
889,number of exacerbations $nmbr$ months before randomisation,C4086268,,completed,
889,number of patients with exacerbations in the previous $nmbr$ months n ( % ),C4086268,,completed,
889,patients having exacerbation,C4086268,,completed,
889,patients with > $nmbr$ exacerbation in previous $nmbr$ months,C4086268,,completed,
889,patients with > $nmbr$ exacerbations resulting in ed visit,C4086268,,completed,
889,p ) atients with > $nmbr$ exacerbations resulting in emergency department visit,C4086268,,completed,
889,patients with > $nmbr$ exacerbations resulting in emergency department visit,C4086268,,completed,
889,patients with > $nmbr$ exacerbations resulting in hospital admission,C4086268,,completed,
889,s $nmbr$ exacerbations,C4086268,,completed,
890,asthma exacerbations,C0349790,,completed,
890,mean number of clinically significant asthma exacerbations †,C0349790,,completed,
891,copd exacerbation : no,C0740304,,completed,
891,one or more copd exacerbations ( n / n [ % ] ),C0740304,,completed,
894,• ml without st - segment elevation,C3810814,,completed,
894,ml without st - segment elevation !,C3810814,,completed,
894,• ml with st - segment elevation,C3810814,,completed,
894,ml with st - segment elevation,C3810814,,completed,
894,non - st - elevation ml,C3810814,,completed,
894,non - st - segment elevation,C3810814,,completed,
894,non - st - segment elevation acs,C3810814,,completed,
894,non - st - segment elevation mi,C3810814,,completed,
894,st - segment elevation mi,C3810814,,completed,
895,amputation,C0002688,,completed,
895,amputations n ( % ),C0002688,,completed,
895,major amputations at week $nmbr$,C0002688,,completed,
895,prior amputation,C0002688,,completed,
897,antihypertensive antianginal and other cardiovascular medications,C0007220,,completed,
897,baseline cardiovascular medication,C0007220,,completed,
897,baseline cardiovascular medication c n ( % ),C0007220,,completed,
897,baseline cardiovascular medications n ( % ),C0007220,,completed,
897,baseline concomitant cardiovascular medications,C0007220,,completed,
897,cardiac medications at discharge %,C1319171,,completed,
897,cardiovascular medications,C0007220,,completed,
897,cardiovascular medications %,C0007220,,completed,
897,cardiovascular medication usage,C0007220,,completed,
898,medication effects,C1319171,,completed,
899,infarct localisation,C0021308;C0475264,,completed,
899,infarct localization,C0021308;C0475264,,completed,
899,infarct localization n ( % ),C0021308;C0475264,,completed,
902,age of completion of highest education years ( sd ),C0013658,,completed,
902,education,C0013658,,completed,
902,education ( % ),C0013658,,completed,
902,education *,C0013658,,completed,
902,education level,C0013658,,completed,
902,education mean ( sd ) y,C0013658,,completed,
902,education mean ( sd ) ya,C0013658,,completed,
902,education $nmbr$ to $nmbr$ y,C0013658,,completed,
902,education < $nmbr$ y,C0013658,,completed,
902,education > $nmbr$ y,C0013658,,completed,
902,education > $nmbr$ yr ( % ),C0013658,,completed,
902,education — no . ( % ),C0013658,,completed,
902,education y,C0013658,,completed,
902,education y mean ( sd ),C0013658,,completed,
902,education yrs mean ( sd ),C0013658,,completed,
902,years of education *,C0013658,,completed,
903,disease characteristics duration of psoriatic arthritis — yr,C0449238;C0872146,,completed,
903,disease duration,C0449238;C0872146,,completed,
903,disease duration : < baseline mean,C0449238;C0872146,,completed,
903,disease duration b $nmbr$ years ( n = $nmbr$ ),C0449238;C0872146,,completed,
903,disease duration mean [ sd ] years,C0449238;C0872146,,completed,
903,disease duration mean yr ( sd ),C0449238;C0872146,,completed,
903,disease duration > $nmbr$ years $nmbr$ [ % ] disease activity ‘ s,C0449238;C0872146,,completed,
903,disease duration y,C0449238;C0872146,,completed,
903,disease duration [ year ] mean ± sda,C0449238;C0872146,,completed,
903,disease duration year ( median ),C0449238;C0872146,,completed,
903,disease duration y mean ± sd,C0449238;C0872146,,completed,
903,disease duration ( y ) median ( m / n max ),C0449238;C0872146,,completed,
903,disease duration ( yr ),C0449238;C0872146,,completed,
903,disease duration ( yr ) mean ± sd,C0449238;C0872146,,completed,
903,duration of disease before baseline,C0449238;C0872146,,completed,
903,duration of disease median,C0449238;C0872146,,completed,
903,duration of disease n ( % ),C0449238;C0872146,,completed,
903,duration of disease since,C0449238;C0872146,,completed,
903,duration of disease y,C0449238;C0872146,,completed,
903,duration of disease ( y ) median ( min max },C0449238;C0872146,,completed,
903,duration of disease ( yr ),C0449238;C0872146,,completed,
903,duration of disease — yr,C0449238;C0872146,,completed,
903,duration of disease — yr ^ mean,C0449238;C0872146,,completed,
903,duration of disease — yr : t,C0449238;C0872146,,completed,
903,mean disease duration years,C0449238;C0872146,,completed,
903,mean disease duration y ( sd ),C0449238;C0872146,,completed,
903,mean ( sd ) disease duration years,C0449238;C0872146,,completed,
903,uc disease duration ( y ),C0449238;C0872146,,completed,
907,diabetes mellitus ( type $nmbr$ ) n ( % ),C0011849;C1320657,,completed,
907,diabetes mellitus ( type $nmbr$ or $nmbr$ ),C0011849;C1320657,,completed,
907,duration of type $nmbr$ diabetes,C0011849;C1320657,,completed,
907,duration of type $nmbr$ diabetes categories n ( % ),C0011849;C1320657,,completed,
907,duration of type $nmbr$ diabetes mellitus years,C0011849;C1320657,,completed,
907,duration of type $nmbr$ diabetes mellitus ( years ),C0011849;C1320657,,completed,
907,duration of type $nmbr$ diabetes years,C0011849;C1320657,,completed,
907,duration of type $nmbr$ diabetes ( years ),C0011849;C1320657,,completed,
907,known duration of type $nmbr$ diabetes,C0011849;C1320657,,completed,
907,known duration of type $nmbr$ diabetes ( years ),C0011849;C1320657,,completed,
907,no type $nmbr$ diabetes ( n = $nmbr$ $nmbr$ ),C0011849;C1320657,,completed,
907,progression to diabetes,C0598284,,inprogress,
907,time since diagnosis of type $nmbr$ diabetes mellitus,C0011849;C1320657,,completed,
907,time since diagnosis of type $nmbr$ diabetes - no . ( % ),C0011849;C1320657,,completed,
907,type $nmbr$ diabetes,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes *,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes history n ( % ),C0011849;C1320657,,completed,
907,type $nmbr$ diabetes meiiitus,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes mellitus,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes mellitus ’,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes mellitusa,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes mellitus n ( % ),C0011849;C1320657,,completed,
907,type $nmbr$ diabetes mellitus ' $nmbr$ ',C0011849;C1320657,,completed,
907,type $nmbr$ diabetes n ( % ),C0011849;C1320657,,completed,
907,type $nmbr$ diabetes . n ( % ),C0011849;C1320657,,completed,
907,type $nmbr$ diabetes n ( % ) d,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes ( n = $nmbr$ $nmbr$ ),C0011849;C1320657,,completed,
907,type $nmbr$ diabetes no . ( % ),C0011849;C1320657,,completed,
907,type $nmbr$ diabetes — no . ( % ),C0011849;C1320657,,completed,
907,type $nmbr$ diabetes — no . ( % ) §,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes — no . { % ) §,C0011849;C1320657,,completed,
907,type $nmbr$ diabetes 一 no . ( % ),C0011849;C1320657,,completed,
907,years since diagnosis of type $nmbr$ diabetes n ( % ),C0011849;C1320657,,completed,
909,all with diabetes ( n = $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,all without diabetes ( n = $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,amputation due to diabetes — no . ( % ),C0598284,,inprogress,
909,current cvd / diabetes n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,dabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes ^,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes | |,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes %,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes *,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes absent $nmbr$ ( $nmbr$ . $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes and currently on an oral hypoglycaemic agent orinsulin,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes and untreated hypertension,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes at randomization,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes classificationa,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes durationa < median,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration ( known ) % of patients,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration mean ± sd,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration subgroups,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration y,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration ( y ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration ycars “,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration years,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration ( years ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes duration years ( mean ± sd ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetesf,C0598284,,inprogress,
909,diabetes history mean ( sd ) years,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes melitus,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus %,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus :,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus !,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus duration ( sd ) y,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus duration y,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus duration y ( sd ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus § n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus [ n ( % ) ],C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus n / n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus n = $nmbr$,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus n = $nmbr$ $nmbr$,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus — no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus no . / total no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus — no . / total no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitust,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes mellitus 一 no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes * n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes ( n [ % ] ) *,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes $nmbr$,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes $nmbr$ ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes ( n = $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes ( n - $nmbr$ $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes — no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes no . ( % ) c,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes ( p = . $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes ( p = . o $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes ( p = . oo $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes present $nmbr$ ( $nmbr$ . $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes - related medication use   n   ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes t,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes treatment,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetes with target organ disease *,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diabetesz,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diagnosed diabetes ( n = $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,diagnosis of diabetes n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,drugs used in diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,drugs used in diabetes n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes by tertiles,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes mean ( sd ) y,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes median ( iqr ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes mellitus,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes mellitus median ( iqr ) y,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes mellitus y,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes mellitus y mean ( sd ) §,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes microvascular disease — no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes ( months ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes < $nmbr$ yrs,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes y,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes ( y ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes ( years ) mean ( sd ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes y mean ( sd ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes — yr ^,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,duration of diabetes yrs,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,high risk of diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,history of diabetes :,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,history of diabetes ( a ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,history of diabetes - n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,history of diabetes ( n = $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,history of diabetes requiring drugs,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,hx of diabetes n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,individuals with diabetes n = $nmbr$,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,individuals without diabetes n = $nmbr$ $nmbr$,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,individuals with t $nmbr$ dm ( scale diabetes ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,laboratory values in patients with history of diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,long ( i $nmbr$ years ) duration of diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,long ( > $nmbr$ years ) duration of diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,median duration of diabetes ( yr ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,mellitus,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,new diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,new diabetes — no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,new - onset diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,new - onset diabetes §,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,n o diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,no diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,no diabetes mellitus,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,no diabetes ( n = $nmbr$ $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,no diabetes ( n - $nmbr$ $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,no diabetes ( p = . $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,no diabetes ( p = . o $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,non - diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,other ( % ) diabetes ( interaction : p = $nmbr$ . $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,patients with diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,patients with diabetes mellitus,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,patients with diabetes mellitus ( n = $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,patients without diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,patients without diabetes mellitus ( n = $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,people with diabetes n = $nmbr$,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,people without diabetes n = $nmbr$,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,postbaseline new - onset diabetes - n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,reported diabetes mellitus,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,( scale diabetes ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,short ( < $nmbr$ years ) duration of diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,time since diagnosis of diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,time since diagnosis of diabetes n ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,time since diagnosis of diabetes — no . ( % ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,time since diagnosis of type $nmbr$ diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,undiagnosed diabetes mellitus,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,undiagnosed diabetes mellitus n = $nmbr$,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,undiagnosed diabetes ( n = $nmbr$ ),C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,with diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
909,without diabetes,C0011849,;C1704656;C3687832;C1705970;C4285062;C1079230;C0449450;C3250443;C0021966;C0221138;C0369718;C0441922;C0684224,completed,
910,baseline prediabetes,C0362046,;C0168634;C1334085;C1708411,completed,
910,ifg / prediabetes ^,C0362046,;C0168634;C1334085;C1708411,completed,
910,prediabetes %,C0362046,;C0168634;C1334085;C1708411,completed,
910,prediabetese,C0362046,;C0168634;C1334085;C1708411,completed,
910,pre – diabetes mellitus,C0362046,;C0168634;C1334085;C1708411,completed,
910,pre – diabetes mellitus n = $nmbr$,C0362046,;C0168634;C1334085;C1708411,completed,
910,prediabetes n ( % ),C0362046,;C0168634;C1334085;C1708411,completed,
910,prediabetes — no . ( % ) $nmbr$,C0362046,;C0168634;C1334085;C1708411,completed,
910,prediabeticb,C0362046,;C0168634;C1334085;C1708411,completed,
912,comorbid diseasesa diabetesb,C0011849,,completed,
912,diabetesc,C0011849,,completed,
912,diabetese,C0011849,,completed,
912,prior diabetes,C0011849,,completed,
912,prior gestational diabetes,C0011849,,completed,
912,prior or new diabetes,C0011849,,completed,
913,$nmbr$ - $nmbr$ ( very severe ),C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
913,severe or very severe,C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
913,severe or very severe smoking status,C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
913,very severe,C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
913,very severe ( itt ) ( n = $nmbr$ ),C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
913,very severe n z $nmbr$,C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
914,clinically evident vascular disease,C0042373,,completed,
914,patients with clinically evident vascular disease,C0042373,,completed,
914,patients without clinically evident vascular disease,C0042373,,completed,
918,jugular venous distension n ( % ),C0425687,,completed,
918,jugular venous distention > $nmbr$ cm,C0425687,,completed,
933,any established peripheral arterial disease,C0085096,,completed,
933,any peripheral arterial disease,C0085096,,completed,
933,cerebrovascular or peripheral arterial disease,C0085096,,completed,
933,cerebrovascular or peripheral arterial disease n ( % ),C0085096,,completed,
933,cerebrovascular or peripheral arterial disease   n   ( % ),C0085096,,completed,
933,peripheral arterial disease,C0085096,,completed,
933,peripheral arterial disease §,C0085096,,completed,
933,peripheral arterial disease n ( % ),C0085096,,completed,
933,peripheral arterial disease ( n = $nmbr$ $nmbr$ ),C0085096,,completed,
933,peripheral arterial disease — no . ( % ),C0085096,,completed,
933,peripheral arterial disease — no . ( % ) §,C0085096,,completed,
933,peripheral artery occlusive disease,C0085096,,completed,
933,peripheral artery occlusive disease ( stage $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ / $nmbr$ ),C0085096,,completed,
933,peripheral vascular disease,C0085096,,completed,
933,peripheral vascular disease n ( % ),C0085096,,completed,
933,prior peripheral arterial disease,C0085096,,completed,
933,qualifying peripheral arterial disease,C0085096,,completed,
937,history of impaired renal function,C1565489,,completed,
937,history of impaired renal function no . ( % ),C1565489,,completed,
937,impaired renal function §,C1565489,,completed,
937,impaired renal function †,C1565489,,completed,
937,level of renal impairment,C1565489,,completed,
937,level of renal impairment ',C1565489,,completed,
937,mild to moderate renal impairment *,C1565489,,completed,
937,moderate renal impairment,C1565489,,completed,
937,moderate renal impairment n ( % ) *,C1565489,,completed,
937,non - end - stage renal dysfunction,C1565489,,completed,
937,non - endstage renal dysfunction *,C1565489,,completed,
937,no renal dysfunction,C1565489,,completed,
937,renal dysfunction,C1565489,,completed,
937,renal failure,C0035078;C0011065,,completed,
937,renal impairment,C1565489,,completed,
937,renal impairment *,C1565489,,completed,
937,renal impairmentf,C2986535;C0022646,,completed,
937,renal impairment n ( % ),C1565489,,completed,
937,renal impairmentt,C2986535;C0022646,,completed,
937,renal insufficiency,C0035078;C0011065,,completed,
937,renal insufficiency *,C0035078;C0011065,,completed,
937,renal insufficiency / failure,C0035078;C0011065,,completed,
937,renal insufficiency $nmbr$,C0035078;C0011065,,completed,
937,renal insufficiency — no . ( % ),C0035078;C0011065,,completed,
937,renal insufficiency or failure,C0035078;C0011065,,completed,
937,severe renal impairment,C1565489,,completed,
938,primary renal endpoint,C2986535;C0022646,,completed,
938,primary renal endpoint or death,C2986535;C0022646,,completed,
939,death due to renal failure ®,C0035078;C0011065,,completed,
939,death due to renal failure or sustained esrd,C0035078;C0011065,,completed,
940,omalizumab,C0966225,,completed,
940,omalizumab ( lsm ),C0966225,,completed,
940,prior therapy with omalizumab : yes,C0966225,,completed,
952,acute increase in serum creatinine,C0600061;C0010294,,inprogress,
952,composite endpoint of doubling of serum creatinine esrd,C0600061;C0010294,,inprogress,
952,creatinine,C0010294,;C0205173;C0549183,completed,
952,creatinine mmol 八,C0010294,;C0205173;C0549183,completed,
952,creatinine ( µ mol / l ),C0010294,;C0205173;C0549183,completed,
952,creatinine ( ^ mol / l ) ( median iqr ),C0010294,;C0205173;C0549183,completed,
952,creatinine pmol / l,C0010294,;C0205173;C0549183,completed,
952,creatinine ( p mol / l ),C0010294,;C0205173;C0549183,completed,
952,creatinine ratio,C0010294,;C0205173;C0549183,completed,
952,creatinine ratio $nmbr$ - $nmbr$,C0010294,;C0205173;C0549183,completed,
952,doubling of creatinine,C0010294,;C0205173;C0549183,completed,
952,doubling of creatinine †,C0010294,;C0205173;C0549183,completed,
952,doubling of serum creatinine,C0600061;C0010294,,inprogress,
952,first serum creatinine,C0600061;C0010294,,inprogress,
952,increase in serum creatinine,C0600061;C0010294,,inprogress,
952,mean serum creatinine mg / dl,C0600061;C0010294,,inprogress,
952,plasma creatine mg / dl,C0023820,,completed,
952,preoperative serum creatinine > $nmbr$ pmol / l,C0600061;C0010294,,inprogress,
952,second serum creatinine,C0600061;C0010294,,inprogress,
952,serum creatinine,C0600061;C0010294,,inprogress,
952,serum creatinine concentration and randomization to losartan,C0126174,,completed,
952,serum creatinine ( gmol / ),C0600061;C0010294,,inprogress,
952,serum creatinine gmol / l |,C0600061;C0010294,,inprogress,
952,serum creatinine gmol / ' l mean ( sd ),C0600061;C0010294,,inprogress,
952,serum creatinine level,C0600061;C0010294,,inprogress,
952,serum creatinine limo $nmbr$ $nmbr$,C0600061;C0010294,,inprogress,
952,serum creatinine mean ( sd ) mg / dl,C0600061;C0010294,,inprogress,
952,serum creatinine mean ( sd ) mg / dl,C0600061;C0010294,,inprogress,
952,serum creatinine - mean ( sd n ),C0600061;C0010294,,inprogress,
952,serum creatinine mean ( sd ) pmol / l,C0600061;C0010294,,inprogress,
952,serum creatinine mg / dl,C0600061;C0010294,,inprogress,
952,serum creatinine . mg / dl,C0600061;C0010294,,inprogress,
952,serum creatinine ( mg / dl ),C0600061;C0010294,,inprogress,
952,serum creatinine — mg / dl,C0600061;C0010294,,inprogress,
952,serum creatinine — mg / dl | |,C0600061;C0010294,,inprogress,
952,serum creatinine — mg / dl §,C0600061;C0010294,,inprogress,
952,serum creatinine mg / dl mean ( sd ),C0600061;C0010294,,inprogress,
952,serum creatinine ( mmol / l ),C0600061;C0010294,,inprogress,
952,serum creatinine ^ mol / l,C0600061;C0010294,,inprogress,
952,serum creatinine > $nmbr$ mmol / l n ( % ),C0600061;C0010294,,inprogress,
952,serum creatinine ≥ $nmbr$ . $nmbr$ mg / dl,C0600061;C0010294,,inprogress,
952,serum creatinine > $nmbr$ pmol / l . n ( % ) |,C0600061;C0010294,,inprogress,
952,serum creatinine > $nmbr$ / xmol / l n ( % ) | |,C0600061;C0010294,,inprogress,
952,serum creatinine ( pmol / l ) mean ( sd ),C0600061;C0010294,,inprogress,
952,serum creatinine / xmol / l | |,C0600061;C0010294,,inprogress,
952,serum creatinine μ mol / l,C0600061;C0010294,,inprogress,
959,b - blockers n ( % ),C0001645,,completed,
959,beta - adrenergic blocker,C0001645,,completed,
959,betablocker,C0001645,,completed,
959,beta blocker,C0001645,,completed,
959,beta - blocker,C0001645,,completed,
959,beta - blocker %,C0001645,,completed,
959,beta - blocker !,C0001645,,completed,
959,beta blocker %,C0001645,,completed,
959,beta - blocker at enrollment,C0001645,,completed,
959,beta - blocker at last follow - up |,C0001645,,completed,
959,beta - blocker ( except sotalol ),C0001645,,completed,
959,beta - blocker n ( % ),C0001645,,completed,
959,beta blocker n ( % ),C0001645,,completed,
959,beta - blocker — no . / total no . ( % ),C0001645,,completed,
959,beta blockers,C0001645,,completed,
959,beta - blockers,C0001645,,completed,
959,beta - blockers ( % ),C0001645,,completed,
959,beta - blockers ( all ) n ( % ),C0001645,,completed,
959,beta - blockers n ( % ),C0001645,,completed,
959,beta - blockers through hospital discharge or day $nmbr$ — %,C0001645,,completed,
959,beta - blocker % target dose,C0001645,,completed,
959,beta - blocker use,C0001645,,completed,
959,beta blocker use,C0001645,,completed,
959,beta blocker use ( % ),C0001645,,completed,
959,betablocker use,C0001645,,completed,
959,beta - blocker use at baseline,C0001645,,completed,
959,beta - blocker use at randomization,C0001645,,completed,
959,beta blocker users,C0001645,,completed,
959,blocker,C0001645,,completed,
959,no betablocker use,C0001645,,completed,
959,peri - op beta - blockers : no ( n = $nmbr$ ),C0001645,,completed,
959,use of beta - blocker,C0001645,,completed,
959,use of beta - blockers,C0001645,,completed,
959,with beta blocker,C0001645,,completed,
959,without beta blocker,C0001645,,completed,
959,β blocker,C0001645,,completed,
959,β ‐ blocker,C0001645,,completed,
959,β blockers,C0001645,,completed,
961,a - blockers,C0001641,,completed,
961,alpha - blocker,C0001641,,completed,
961,alpha - blocker / other vasodilator,C0042402,,completed,
961,alpha blockers,C0001641,,completed,
961,alpha - blockers,C0001641,,completed,
961,alpha $nmbr$ blockers,C0001641,,completed,
961,no . previous alpha - blocker use,C0001641,,completed,
967,baseline - ckd - epi,C1561643,,completed,
967,change from baseline stage $nmbr$ ckd,C1561643,,completed,
967,chronic kidney disease,C1561643,,completed,
967,chronic kidney disease ( % ),C1561643,,completed,
967,chronic kidney disease †,C1561643,,completed,
967,chronic kidney disease n ( % ),C1561643,,completed,
967,chronic kidney disease no . ( % ) t,C1561643,,completed,
967,chronic renal disease,C1561643,,completed,
967,chronic renal disease — no . ( % ),C1561643,,completed,
967,chronic renal failure,C1561643,,completed,
967,chronic renal failure n ( % ),C1561643,,completed,
967,chronic renal insufficiency,C1561643,,completed,
967,chronic renal insufficiency %,C1561643,,completed,
967,ckd,C1561643,,completed,
967,ckd *,C1561643,,completed,
967,ckd at baseline,C1561643,,completed,
967,ckdc n ( % ),C1561643,,completed,
967,ckd n,C1561643,,completed,
967,ckd n ( % ) t,C1561643,,completed,
967,ckd prognosis by kdigo ' ',C1561643,,completed,
967,ckd rate ( # events ),C1561643,,completed,
967,cvd ckd,C1561643,,completed,
967,established renal disease ( egfr $nmbr$ - < $nmbr$ ml / min / $nmbr$ . $nmbr$ m ^ with any uacr mg / g or egfr > $nmbr$ - $nmbr$ ml / inin / l $nmbr$ m $nmbr$ with an uacr > $nmbr$ mg / g ) without previous maerovaseular and albuminuria disease,C0443211,,completed,
967,gfr ( ckd - epi ),C1561643,,completed,
967,moderate ckd,C1561643,,completed,
967,moderate ckd at randomization,C1561643,,completed,
967,no ckd,C1561643,,completed,
967,no ckd ( % ),C1561643,,completed,
967,no - ckd intensive ( n = $nmbr$ ),C1561643,,completed,
967,no ckd n,C1561643,,completed,
967,no ckd rate ( # events ),C1561643,,completed,
967,no - ckd standard ( n = $nmbr$ ),C1561643,,completed,
967,no moderate ckd,C1561643,,completed,
967,stage > $nmbr$ chronic kidney disease ( % ),C1561643,,completed,
967,with ckd intensive ( n = $nmbr$ ),C1561643,,completed,
967,with ckd ( $nmbr$ ),C1561643,,completed,
967,with ckd standard ( n = $nmbr$ ),C1561643,,completed,
967,without ckd ( $nmbr$ ),C1561643,,completed,
975,adiusted hazard ratio *,C2985465,,inprogress,
975,adjusted hazard ratio *,C2985465,,inprogress,
975,adjusted ⁎ hazard ratio ( $nmbr$ % ci ),C2985465,,inprogress,
975,adjusted hazard ratio ≠ ( $nmbr$ % ci ),C2985465,,inprogress,
975,adjusted hazard ratio ( $nmbr$ % ci ) †,C2985465,,inprogress,
975,adjusted hazard ratio § ( $nmbr$ % ci ),C2985465,,inprogress,
975,adjusted hazard ratio ‡ ( $nmbr$ % ci ),C2985465,,inprogress,
975,adjusted hazard ratio ( $nmbr$ % cl ) *,C2985465,,inprogress,
975,genotype - specific treatment effect hazard ratio ( $nmbr$ % ci ),C2985465,,inprogress,
975,hazard ratio,C2985465,,inprogress,
975,hazard ratio * ( and $nmbr$ % ci ),C2985465,,inprogress,
975,hazard ratio and $nmbr$ % confidence interval,C2985465,,inprogress,
975,hazard ratio for event ( $nmbr$ % ci ),C2985465,,inprogress,
975,hazard ratio $nmbr$,C2985465,,inprogress,
975,hazard ratio $nmbr$ ),C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % c,C2985465,,inprogress,
975,hazard . ratio . ( $nmbr$ % ci ) . . . . . . . . . .,C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % ci ) *,C2985465,,inprogress,
975,hazard ratio [ $nmbr$ % ci ],C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % ci ) for adjudicated type $nmbr$ diabetes,C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % ci ) - j -,C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % ci ) vs . placebo,C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % cl ),C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % cl ) *,C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % cl ],C2985465,,inprogress,
975,hazard ratio [ $nmbr$ % cl ],C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % cl ) nateglinide vs . placebo,C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % cl ) $nmbr$ . $nmbr$ ( $nmbr$ . $nmbr$ $nmbr$ . $nmbr$ ),C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % confi dence interval ),C1272706,,completed,
975,hazard ratio ( $nmbr$ % confidence interval ),C2985465,,inprogress,
975,hazard ratio ( $nmbr$ % confidence interval ) *,C2985465,,inprogress,
975,hazard ratio umec / vi vs . tio ( $nmbr$ % ci ),C2985465,,inprogress,
975,hazard ratio vs . placebo,C2985465,,inprogress,
975,hazard ratio with,C2985465,,inprogress,
975,hazard ratio with high ( $nmbr$ % cl ),C2985465,,inprogress,
975,hazard ratio with low ( $nmbr$ % cl ),C2985465,,inprogress,
975,selexipag vs placebo hazard ratio ( $nmbr$ % cl ),C2985465,,inprogress,
975,unadjusted hazard ratio ( $nmbr$ % ci ),C2985465,,inprogress,
975,unadjusted hazard ratio ( $nmbr$ % cl ),C2985465,,inprogress,
989,digoxin,C0012265,,completed,
989,digoxin ( % ),C0012265,,completed,
989,digoxin %,C0012265,,completed,
989,digoxin at enrollment,C0012265,,completed,
989,digoxin % ( n ),C0012265,,completed,
989,digoxin n ( % ),C0012265,,completed,
989,digoxin n ( % ),C0012265,,completed,
989,digoxin n = $nmbr$ ( $nmbr$ % ),C0012265,,completed,
989,digoxin or digitalis preparation,C0012265,,completed,
989,digoxin or digitalis preparations,C0012265,,completed,
989,digoxin scd no . ( % / y ),,,inprogress,
989,no digoxin n = $nmbr$ $nmbr$ ( $nmbr$ % ),C0012265,,completed,
989,no digoxin scd no . ( % / y ),C0012265,,completed,
989,previous digoxin use,C0012265,,completed,
989,previous digoxin use ( % ),C0012265,,completed,
989,previous use of digoxin,C0012265,,completed,
991,intravenous loop diuretics !,C0354100,,completed,
991,loop diuretic,C0354100,,completed,
991,loop diuretics,C0354100,,completed,
991,loop diuretic use,C0354100,,completed,
991,loop diureties,C0354100,,completed,
991,total intravenous loop diuretics mg,C0354100,,completed,
991,use of loop diuretics,C0354100,,completed,
991,use of loop diuretics n ( % ),C0354100,,completed,
993,any thiazide diuretic,,,completed,
993,diuretic thiazide,,,completed,
993,loop or thiazide diuretic,,,completed,
993,loop or thiazide diuretic ^,,,completed,
993,loop or thiazide diuretic : ! :,,,completed,
993,loop or thiazide diuretic #,,,completed,
993,thiazide diuretic,,,completed,
993,thiazide diuretic *,,,completed,
993,thiazide diuretics,,,completed,
1009,af or atrial flutter !,;C0004238,,completed,
1009,af or atrial flutter 卞,;C0004238,,completed,
1009,arial flutter or fibrillation,;C0004238,,completed,
1009,atrial fibrillation,;C0004238,,completed,
1009,atrial fibrillation %,;C0004238,,completed,
1009,atrial fibrillation !,;C0004238,,completed,
1009,atrial fibrillation ( % ),;C0004238,,completed,
1009,atrial fibrillation alone ),;C0004238,,completed,
1009,atrial fibrillation / atrial flutter %,;C0004238,,completed,
1009,atrial fibrillation / flutter,;C0004238,,completed,
1009,atrial fibrillation / flutter n ( % ),;C0004238,,completed,
1009,atrial fibrillation n ( % ),;C0004238,,completed,
1009,atrial fibrillation . no . ( % ),;C0004238,,completed,
1009,atrial fibrillation — no . ( % ),;C0004238,,completed,
1009,atrial fibrillation — no . / total no . ( % ),;C0004238,,completed,
1009,atrial fibrillation onset,;C0004238,,completed,
1009,atrial fibrillation or flutter,;C0004238,,completed,
1009,atrial fibrillation or flutter ( ecg ) §,;C0004238,,completed,
1009,atrial fibrillation or flutter — no . ( % ),;C0004238,,completed,
1009,atrial fibrillation pattern,;C0004238,,completed,
1009,atrial fibrillation type n ( % ),;C0004238,,completed,
1009,atrial fibrillation   n   ( % ),;C0004238,,completed,
1009,atrial flutter,;C0004238,,completed,
1009,atrial flutter / fibrillation,;C0004238,,completed,
1009,current atrial fibrillation or flutter on ecg,;C0004238,,completed,
1009,duration of last qualifying episode of atrial fibrillation > $nmbr$ days,;C0004238,,completed,
1009,ecg atrial fibrillation n ( % ),;C0004238,,completed,
1009,fibrillation / flutter ),;C0004238,,completed,
1009,first episode of atrial fibrillation ( vs . recurrent episode ) — no . ( % ) f,;C0004238,,completed,
1009,history of atrial fibrillation / flutter,;C0004238,,completed,
1009,history of atrial fibrillation / flutter ( % ),;C0004238,,completed,
1009,> $nmbr$ episodes of atrial fibrillation in previous $nmbr$ mo,;C0004238,,completed,
1009,no atrial fibrillation,;C0004238,,completed,
1009,rate of atrial fibrillation,;C0004238,,completed,
1009,type of atrial fibrillation,;C0004238,,completed,
1009,type of atrial fibrillation ( % ),;C0004238,,completed,
1009,type of atrial fibrillation n ( % ),;C0004238,,completed,
1009,type of atrial fibrillation - n ( % ),;C0004238,,completed,
1009,type of atrial fibrillation ( n = $nmbr$ $nmbr$ ),;C0004238,,completed,
1009,type of atrial fibrillation no . / total no . ( % ),;C0004238,,completed,
1009,type of atrial fibrillation — no . / total no . ( % ),;C0004238,,completed,
1023,nausea and / or vomiting adverse events,C0042963,,completed,
1023,vomiting,C0042963,,completed,
1027,low periostin subgroup ( $nmbr$ ng / ml ) ( n = $nmbr$ ),C3812270,,completed,
1027,periostin,C3812270,,completed,
1027,periostin ( ng / ml ),C3812270,,completed,
1028,apolipoproiein a $nmbr$ ( tng / $nmbr$ ),C0003591,,completed,
1028,apolipoproiein b ( mij / $nmbr$ ),C0003591,,completed,
1028,apolipoprotein,C0003591,,completed,
1028,apolipoprotein a,C0003591,,completed,
1028,apolipoprotein a - i,C0003591,,completed,
1028,apolipoprotein a - i *,C0003591,,completed,
1028,apolipoprotein a $nmbr$ ( g / l ),C0003591,,completed,
1028,apolipoprotein b,C0003591,,completed,
1028,apolipoprotein b ^,C0003591,,completed,
1028,apolipoprotein b tx difference vs pbo ls mean % change from baseline ( se ),C0003591,,completed,
1032,multivitamins,C0301532,;C1710701;C1705970,completed,
1032,multivitamin use,C0301532,;C1710701;C1705970,completed,
1032,multivitamin use ( current ),C0301532,;C1710701;C1705970,completed,
1032,multivitamin use yes,C0301532,;C1710701;C1705970,completed,
1037,male patients *,;C0150904,,completed,
1037,male patients n ( % ),;C0150904,,completed,
1038,a new vertebral fractures ( mfas ),C0080179,,completed,
1038,b pooled new and worsened vertebral fractures ( mfas ),C0080179,,completed,
1038,new or worsening vertebral fracture at $nmbr$ months,C0080179,,completed,
1038,new vertebral fracture at $nmbr$ months,C0080179,,completed,
1038,spinal fractures,C0040185,,completed,
1039,perianal gi tract,C0442158,,completed,
1039,perianal n ( % ),C0442158,,completed,
1039,perianal or anus,C0442158,,completed,
1041,female : ≥ $nmbr$ years postmenopausal,C0232970,,completed,
1041,female participants who are ≥ $nmbr$ years postmenopausal,C0232970,,completed,
1041,female : perimenopausal or < $nmbr$ years postmenopausal,C0232970,,completed,
1041,peri - or postmenopausal,C0232970,,completed,
1041,postmenopausal,C0232970,,completed,
1041,postmenopausal ( % ),C0232970,,completed,
1041,post - menopausal ( a ),C0232970,,completed,
1041,postmenopausal hormone use,C0232970,,completed,
1041,postmenopausal never or past hormone therapy use,C0232970,,completed,
1042,female : premenopausal,C0279752,,completed,
1042,menopausal status and hormone therapy use premenopausal,C0279752,,completed,
1042,premenopausal,C0279752,,completed,
1042,premenopausal %,C0279752,,completed,
1043,menopause and hrt,C0282402,,completed,
1043,menopause and ht,C0282402,,completed,
1043,poslmenopausal ht,C0282402,,completed,
1043,poslmenopausal no ht,C0282402,,completed,
1043,postmenopausal and current ht,C0282402,,completed,
1043,postmenopausal and no ht,C0282402,,completed,
1048,hypotension,C0020649,,completed,
1048,hypotension n ( % ),C0020649,,completed,
1048,orthostatic hypotension,C0020649,,completed,
1048,symptomatic hypotension,C0020649,,completed,
1048,symptomatic hypotension ( sbp < $nmbr$ mmhg ),C0020649,,completed,
1048,symptomatic hypotension with sbp < $nmbr$ mm   hg,C0020649,,completed,
1051,isolated systolic hypertension,C0745133,,completed,
1051,isolated systolic hypertension ^,C0745133,,completed,
1051,isolated systolic hypertension ⁎,C0745133,,completed,
1051,isolated systolic hypertension n ( ' % >,C0745133,,completed,
1051,isolated systolic hypertension n ( % ) “,C0745133,,completed,
1051,previously untreated isolated systolic hypertension,C0745133,,completed,
1053,alcohol,;C0001962,,completed,
1053,alcohol ^,;C0001962,,completed,
1053,alcohol abuse,;C0001962,,completed,
1053,alcohol < = $nmbr$ / wk,;C0001962,,completed,
1053,alcohol > $nmbr$ / wk,;C0001962,,completed,
1053,alcohol useb,;C0001962,,completed,
1053,alcohol usef n ( % ),;C0001962,,completed,
1053,current alcohol n ( % ),;C0001962,,completed,
1053,history of alcohol use,;C0001962,,completed,
1054,ileocolon,C0020885;C0009368,,completed,
1054,ileocolonic ( both ileum and colon ),C0020885;C0009368,,completed,
1054,ileum and colon,C0020885;C0009368,,completed,
1054,ileum and colon ' n ( % ),C0020885;C0009368,,completed,
1054,ileum and colon n ( % ),C0020885;C0009368,,completed,
1054,ileum or colon,C0020885;C0009368,,completed,
1054,lleocolon,C0020885;C0009368,,completed,
1055,atenoioi ( n = $nmbr$ ),C0004147,,completed,
1055,atenolol,C0004147,,completed,
1055,atenolol *,C0004147,,completed,
1055,atenolol ( « = $nmbr$ $nmbr$ ),C0004147,,completed,
1055,atenolol ( n = $nmbr$ ),C0004147,,completed,
1055,atenolol n = $nmbr$,C0004147,,completed,
1055,atenolol ( n = $nmbr$ $nmbr$ ),C0004147,,completed,
1055,atenolol n = $nmbr$ no . ( % ),C0004147,,completed,
1055,atenolol ( no . = $nmbr$ ),C0004147,,completed,
1066,vldl,C0023824;C0023826,,completed,
1066,vldl - c,C0023824;C0023826,,completed,
1066,vldl cholesterol,C0023824;C0023826,,completed,
1068,aldl cholesterol,C0008377,,completed,
1068,atrial fibrillation ldl cholesterol level,C0023824,,completed,
1068,baseline ldl cholesterol,C0023824,,completed,
1068,baseline ldl cholesterol ( derived ),C0023824,,completed,
1068,lcl,C0023824,,completed,
1068,ldl,C0023824;C0023826,,completed,
1068,ldl - c,C0023824;C0023826,,completed,
1068,ldl - c,C0023824,,completed,
1068,ldl - c : hdl - c ratio,C0023824,,completed,
1068,ldl - c / hdl - c ratio,C0023824,,completed,
1068,ldl - c / hdl - c ratio mean ( sd ),C0023824,,completed,
1068,ldl cholesicrol ( minol / l ),C0023824,,completed,
1068,ldl choleslerol,C0023824;C0023826,,completed,
1068,ldl cholesterohhdl cholesterol ratio,C0023824;C0023826,,completed,
1068,- ldl cholesterol,C0023824,,completed,
1068,ldl cholesterol,C0023824,,completed,
1068,ldl - cholesterol,C0023824,,completed,
1068,ldl - cholesterol (,C0023824,,completed,
1068,ldl cholesterol ^ :,C0023824,,completed,
1068,ldl cholesterol level,C0023824,,completed,
1068,ldl cholesterol mean,C0023824,,completed,
1068,ldl - cholesterol ( mmol / ),C0023824,,completed,
1068,ldl - cholesterol mmol / lf,C0023824,,completed,
1068,ldl cholesterolt,C0023824;C0023826,,completed,
1068,ldl - c ( measured ) *,;C0444706;C3541902,;C2699239;C0439230,inprogress,weeks_measured
1068,ldl - c ( measured ) mean ( sd ),;C0444706;C3541902,;C2699239;C0439230,inprogress,weeks_measured
1068,ldl - c > median,C0023824,,completed,
1068,ldl - c ( median iqr ) mg / dl,C0023824,,completed,
1068,ldl - c mmol / l ( mg / dl ),C0001924,,completed,
1068,ldl - csmedian,C0023824,,completed,
1068,ldl / hdl cholesterol ratio mean ( sd ) §,C0023824,,completed,
1068,ldl : hdl ratio,C0023824,,completed,
1068,ldl $nmbr$ - c,C0023824,,completed,
1068,ldl - to - hdl cholesterol ratio mean ( sd ),C0023824,,completed,
1068,low - density lipoprotein cholesterol %,C0023824,,completed,
1068,mean ( s . d . ) calculated ldl cholesterol,C0023824,,completed,
1068,mean ( s . d . ) measured ldl cholesterol,C0023824,,completed,
1068,ratio of ldl to hdl cholesterol,C0023824;C0023826,,completed,
1068,serum ldl cholesterol,C0023824;C0023826,,completed,
1068,visit $nmbr$ ldl cholesterol strata,C0023824,,completed,
1070,adcs - adl,C3641947,,completed,
1070,adcs - adl score *,C3641947,,completed,
1071,albumin g / dl,C0001924,,completed,
1071,albumin ( mg / dl ),C0001924,,completed,
1075,adas - cog,C3539026,,completed,
1075,adas - cog score *,C3539026,,completed,
1075,adas — cog score,C3539026,,completed,
1078,estimated odds ratio,C0028873,,completed,
1078,estimated response rate and odds ratio,C0028873,,completed,
1078,odds ratio,C0028873,,completed,
1080,knee,C0022742,,completed,
1080,knees ( n ),C0022742,,completed,
1083,eze / simva gender,C0079399,,completed,
1083,gendar,C0079399,,completed,
1083,gender,C0079399,,completed,
1083,gender %,C0079399,,completed,
1083,gender :,C0079399,,completed,
1083,gender female,C0079399,,completed,
1083,gender female n ( % ),C0079399,,completed,
1083,gender ( m / f ) ( % ),C0079399,,completed,
1083,gender n ( % ),C0079399,,completed,
1083,gender n ( % ],C0079399,,completed,
1083,gender - n ( % ),C0079399,,completed,
1083,gender [ n ( % ) ],C0079399,,completed,
1083,gender n ( % ),C0079399,,completed,
1083,gender no . ( % ),C0079399,,completed,
1083,gender % of patients,C0079399,,completed,
1083,gender   n   ( % ),C0079399,,completed,
1083,gertder,C0079399,,completed,
1083,> $nmbr$ n ( % ) gender n ( % ),C0079399,,completed,
1084,gene,C0017337,,completed,
1084,gene / chr / snp,C0017337,,completed,
1087,undetermined etiology,C0478157,,completed,
1087,undetermined etiology n ( % ),C0478157,,completed,
1088,life - threatening,C2826244,,completed,
1088,life - threatening bleed,C2826244,,completed,
1088,life - threatening bleeding disabling stroke and death,C2826244,,completed,
1089,risk of bleeding,C3251812,,completed,
1089,specific risk of bleeding ^,C3251812,,completed,
1091,major st depression or t - wave inversion,C0520887,,completed,
1091,st - depression and t - wave inversion,C0520887,,completed,
1091,st - segment depression or t - wave inversion on ecg,C0520887,,completed,
1093,acute infection without septic shock,C3714514,,completed,
1093,infected n ( % ) a,C3714514,,completed,
1093,infections,C3714514,,completed,
1093,infections and infestations,C3714514,,completed,
1094,inadequate response or intolerance to > $nmbr$ anti - tnfdrug,C1744706;C0666743,,completed,
1094,patients with previous intolerance of infliximab,C1744706;C0666743,,completed,
1094,patients with previous loss of response to and intolerance of infliximab *,C1744706;C0666743,,completed,
1094,previous intolerance of infliximab n ( % ) *,C1744706;C0666743,,completed,
1095,nintedanib ( n = $nmbr$ ),C2930789,,completed,
1095,nintedanib ( n   =   $nmbr$ ),C2930789,,completed,
1096,intermediate,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1096,intermediate - acting,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1096,intermediate / long - acting + fast - acting,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1096,intermediate ( $nmbr$ ) %,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1096,intermediate ( $nmbr$ - $nmbr$ ),C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1096,intermediate ( $nmbr$ ) ( n = $nmbr$ $nmbr$ $nmbr$ % ),C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1096,long - acting intermediate / long - acting + fast - acting,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1097,interval between clinical evaluation and initiation of treatment — no . ( % ),C1272706,,completed,
1097,interval between clinical evaluation and initiation oftreatment — no . ( % ),C1272706,,completed,
1097,interval from onset of symptoms,C1272706,,completed,
1097,interval from symptom onset to qualifying ecg obtained in the er — hr,C1272706,,completed,
1102,respiratory rate breaths / min,C0231832,,completed,
1102,respiratory rate ( breaths / min ),C0231832,,completed,
1104,pulmonary rales,C0034642,,completed,
1104,pulmonary rales n ( % ),C0034642,,completed,
1104,rales,C0034642,,completed,
1104,rales ( % ),C0034642,,completed,
1104,rales n ( % ),C0034642,,completed,
1105,baseline heart rate,C0018810,,completed,
1105,baseline heart rate ( beats / min ),C0018810,,completed,
1105,heart rate,C0018810,,completed,
1105,heart rate beats per min,C0018810,,completed,
1105,heart rate ( beats per min ),C0018810,,completed,
1105,heart rate beats per minute,C0018810,,completed,
1105,heart rate ( beats per minute ),C0018810,,completed,
1105,heart rate ( b . p . m . ),C0018810,,completed,
1105,heart rate ( bpm ),C0018810,,completed,
1105,heart rate ( bpm ) *,C0018810,,completed,
1105,heart rate — bpm,C0018810,,completed,
1105,heart rate ( bpm $nmbr$ ) * * *,C0018810,,completed,
1105,preoperative heart rate ( beats per minute ),C0018810,,completed,
1106,incidence rate,C1708485,,completed,
1106,incidence rate *,C1708485,,completed,
1106,incidence rate ( n ),C1708485,,completed,
1106,incidence rate ( n ) a,C1708485,,completed,
1106,incidence rate ( per $nmbr$ person - yr ),C1708485,,completed,
1106,$nmbr$ - y incidence rate ( se ) per $nmbr$ participants,C1708485,,completed,
1106,no . ( % ) with event [ incidence rate per $nmbr$ patient - y ],C1708485,,completed,
1106,number and % of participants with events and incidence rate per $nmbr$ person - year,C1708485,,completed,
1107,nonblack race — no . ( % ) f,;C0034510,,completed,
1107,nonblack race — no . ( % ) - j -,;C0034510,,completed,
1107,other race,;C0034510,,completed,
1107,other race n ( % ),;C0034510,,completed,
1107,race,;C0034510,,completed,
1107,race %,;C0034510,,completed,
1107,race :,;C0034510,,completed,
1107,race ( % ),;C0034510,,completed,
1107,race ( % ) ) ',;C0034510,,completed,
1107,race ( % ) $,;C0034510,,completed,
1107,race ( % ) *,;C0034510,,completed,
1107,race §,;C0034510,,completed,
1107,race *,;C0034510,,completed,
1107,race asian n ( % ),;C0034510,,completed,
1107,racec n ( % ),;C0034510,,completed,
1107,race / ethnicity,;C0034510,,completed,
1107,race / ethnicity %,;C0034510,,completed,
1107,race / ethnicity chinese,;C0034510,,completed,
1107,race / ethnicity zz ( % ),;C0034510,,completed,
1107,race * ’ n ( % ),;C0034510,,completed,
1107,race n ( % ),;C0034510,,completed,
1107,race n ( % ) :,;C0034510,,completed,
1107,race n ( % ) ’,;C0034510,,completed,
1107,race n ( % ) *,;C0034510,,completed,
1107,race n ( % ) +,;C0034510,,completed,
1107,race n ( % ],;C0034510,,completed,
1107,race - n ( % ),;C0034510,,completed,
1107,race n ( % ),;C0034510,,completed,
1107,race n ( % ) a,;C0034510,,completed,
1107,race n ( % ) b,;C0034510,,completed,
1107,race $nmbr$,;C0034510,,completed,
1107,race no . ( % ),;C0034510,,completed,
1107,race no . ( % ) *,;C0034510,,completed,
1107,race - no . ( % ),;C0034510,,completed,
1107,race — no . ( % ),;C0034510,,completed,
1107,race — no . ( % ) |,;C0034510,,completed,
1107,race — no . ( % ) ' (,;C0034510,,completed,
1107,race no . ( % ) b,;C0034510,,completed,
1107,race no . ( % ) c,;C0034510,,completed,
1107,race — no . ( % ) : c,;C0034510,,completed,
1107,race — no . ( % ) f,;C0034510,,completed,
1107,race — no . { % ) - i -,;C0034510,,completed,
1107,race — no . { % ) ' i ',;C0034510,,completed,
1107,race nonwhite,;C0034510,,completed,
1107,race : non - white,;C0034510,,completed,
1107,race ( non - white ) ( % ),;C0034510,,completed,
1107,race - non - white ( n = $nmbr$ $nmbr$ ),;C0034510,,completed,
1107,race nonwhitet,;C0034510,,completed,
1107,race — no . ( % ) : t,;C0034510,,completed,
1107,race no . / total ( % ),;C0034510,,completed,
1107,race — no . / total no . ( % ) f,;C0034510,,completed,
1107,race — no . ( % ) 卞,;C0034510,,completed,
1107,race n ( % ) t,;C0034510,,completed,
1107,race n ( % ) white,;C0034510,,completed,
1107,race n ( % ) y,;C0034510,,completed,
1107,race % of patients,;C0034510,,completed,
1107,race or ethnic background — no . ( % ) f,;C0034510,,completed,
1107,race or ethnic group no . ( % ),;C0034510,,completed,
1107,race or ethnic group — no . ( % ) : t,;C0034510,,completed,
1107,race ( p = o - $nmbr$ ),;C0034510,,completed,
1107,$ race was determined by the investigator during the patient ' s interview .,;C0034510,,completed,
1107,race white,;C0034510,,completed,
1107,race % white,;C0034510,,completed,
1107,race white ( % ),;C0034510,,completed,
1107,race : white,;C0034510,,completed,
1107,race ( % ) white,;C0034510,,completed,
1107,race ( % white ),;C0034510,,completed,
1107,race white n ( % ),;C0034510,,completed,
1107,race ( white n [ % ] ),;C0034510,,completed,
1107,race - white ( n = $nmbr$ $nmbr$ ),;C0034510,,completed,
1107,race white   n   ( % ),;C0034510,,completed,
1107,race zz ( % ),;C0034510,,completed,
1107,race   n   ( % ),;C0034510,,completed,
1107,white race — no . { % ) t,;C0034510,,completed,
1110,anthropometric characteristics,C1521970,,completed,
1110,baseline characteristic,C1521970,,completed,
1110,baseline feature,C1521970,,completed,
1110,characteristic,C1521970,,completed,
1110,characteristic ^,C1521970,,completed,
1110,characteristic *,C1521970,,completed,
1110,characteristic †,C1521970,,completed,
1110,characteristic ( a ),C1521970,,completed,
1110,characteristic at baseline,C1521970,,completed,
1110,characteristic no . ( % ),C1521970,,completed,
1110,characteristics,C1521970,,completed,
1110,characteristics *,C1521970,,completed,
1110,characteristics of pulmonary embolism at inclusion,C1521970,,completed,
1110,demographic characteristic,C1521970,,completed,
1110,e ( characteristic n,C1521970,,completed,
1110,feature,C1521970,,completed,
1110,medical characteristics,C1521970,,completed,
1110,patient characteristic,C1521970,,completed,
1112,stratification factors,C1514984,,completed,
1113,tibia fracture,C0040185,,completed,
1114,hip fracture,C0019557,,completed,
1114,hip fracture + > $nmbr$,C0019557,,completed,
1114,hip fracture only,C0019557,,completed,
1114,pelvic fractures,C0019557,,completed,
1115,humerus fracture,;C0020162,,completed,
1116,baseline disease and quality - of - life scores,C0034380,,completed,
1116,disease and quality - of - life scores,C0034380,,completed,
1116,disease and quality - of - life scores mean ( sd ),C0034380,,completed,
1116,ipss qol,C0034380,,completed,
1116,ipss qol ( ls,C0034380,,completed,
1116,mean ipss qol ( sd ),C0034380,,completed,
1116,qol,C0034380,,completed,
1116,qol due to urinary symptoms,C0034380,,completed,
1116,quality of life,C0034380,,completed,
1117,pulse beats / min,C0232117,,completed,
1117,pulse — beats / min,C0232117,,completed,
1117,pulse ( beats / min ) cholesterol ( mmol / l ),C0232117,,completed,
1117,sitting pulse bpma,C0232117,,completed,
1118,mean pulse pressure mmhg ( s . d . ) “,C0949236,,completed,
1118,pulse pressure,C0949236,,completed,
1118,pulse pressure ( mm hg ),C0949236,,completed,
1118,pulse pressure ( mmhg ),C0949236,,completed,
1122,combined efficacy and safety endpoint,C1707887;C2349179,,completed,
1122,efficacy,C1707887;C2349179,,completed,
1122,efficacy and safety : net adverse clinical events *,C1707887;C2349179,,completed,
1122,efficacy endpoint,C1707887;C2349179,,completed,
1122,efficacy end points,C1707887;C2349179,,completed,
1122,efficacy endpoints *,C1707887;C2349179,,completed,
1122,efficacy variable,C1707887;C2349179,,completed,
1122,efficacy   n   ( % ) a,C1707887;C2349179,,completed,
1122,overall efficacy,C1707887;C2349179,,completed,
1122,peripheral limb vascular efficacy,C1707887;C2349179,,completed,
1122,primary / key efficacy endpoint,C1707887;C2349179,,completed,
1129,ecg,C1623258,,completed,
1129,ecg abnormality ( resting ) %,C1623258,,completed,
1129,electrocardiogram,C1623258,,completed,
1129,electrocardiograph results no . ( % ),C1623258,,completed,
1129,electrocardiography,C1623258,,completed,
1130,etoricoxib,C0972314,,completed,
1130,etoricoxib dose,C0972314,,completed,
1130,etoricoxib $nmbr$ mg n = $nmbr$ n ( % ),C0972314,,completed,
1130,etoricoxib $nmbr$ mg n = $nmbr$ n ( % ),C0972314,,completed,
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . . n . . . ( . % . . ) . . . . . . . . . . .,C0972314,,completed,
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . . n . . ( . % . . ) . . . . . . . . . . .,C0972314,,completed,
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . . n . . ( . % . . ) . . . . . . . . . . . .,C0972314,,completed,
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . n . . . ( . % . . ) . . . . . . . . . . . .,C0972314,,completed,
1130,etoricoxib $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . n . . . ( . % . . ) . . . . . . . . . . . . .,C0972314,,completed,
1130,etoricoxib ( n = $nmbr$ ),C0972314,,completed,
1130,etoricoxib ( n = $nmbr$ $nmbr$ ),C0972314,,completed,
1130,etoricoxib ( n = $nmbr$ $nmbr$ ),C0972314,,completed,
1131,absolute time spent “ on ” without troublesome dyskinesia h / day,C0013384,,completed,
1131,absolute time spent “ on ” with troublesome dyskinesia h / day,C0013384,,completed,
1131,“ on ” without troublesome dyskinesia,C0013384,,completed,
1131,“ on ” with troublesome dyskinesia,C0013384,,completed,
1136,additional endpoints,C2349179,,completed,
1136,combined end point,C2349179,,completed,
1136,combined end points,C2349179,,completed,
1136,endpoint,C2349179,,completed,
1136,end point,C2349179,,completed,
1136,endpoint *,C2349179,,completed,
1136,endpointc,C2349179,,completed,
1136,endpoint rate,C2349179,,completed,
1136,endpoints,C2349179,,completed,
1136,end points,C2349179,,completed,
1136,end - point ( sd ),C2349179,,completed,
1136,main accord endpoint,C2349179,,completed,
1136,mean change in radiographic end points,C2349179,,completed,
1136,other end points,C2349179,,completed,
1136,other prespecified end points,C2349179,,completed,
1136,patients with end point,C2349179,,completed,
1138,joint swelling,C0152031,,completed,
1138,joint swelling effusion or both on clinical examination,C0152031,,completed,
1138,joint swelling effusion or both on clinical examination — no . ( % ),C0152031,,completed,
1138,tender and swollen joints — mean no . : :,C0152031,,completed,
1139,mean ( sd ) tender joint count *,C0451530,,completed,
1139,number of tender joints ( $nmbr$ assessed ),C0449813;C0234234,,completed,
1139,number of tender joints ( $nmbr$ - $nmbr$ ),C0449813;C0234234,,completed,
1139,number of tender joints ( $nmbr$ - $nmbr$ ) mean ( sd ),C0449813;C0234234,,completed,
1139,tender joint count,C0451530,,completed,
1139,tender joint count ( $nmbr$ joints ),C0451530,,completed,
1139,tender joint count ( $nmbr$ joints ) mean ( sd ),C0451530,,completed,
1139,tender joint count ( $nmbr$ joints ) mean ( sd ) ’,C0451530,,completed,
1139,tender joint count ( $nmbr$ ) mean ( sd ),C0451530,,completed,
1139,tender joint count ( $nmbr$ - $nmbr$ ),C0451530,,completed,
1139,tender joint count ( $nmbr$ - $nmbr$ joints ),C0451530,,completed,
1139,tender joint count ( $nmbr$ – $nmbr$ joints ) mean ( sd ),C0451530,,completed,
1139,tender joint count ( $nmbr$ - $nmbr$ per tender joint ),C0451530,,completed,
1139,tender joint count ( n / $nmbr$ ),C0451530,,completed,
1139,tender joint count of $nmbr$,C0451530,,completed,
1139,tender - joint count ( of $nmbr$ joints ),C0451530,,completed,
1139,tender joint count of $nmbr$ joints,C0451530,,completed,
1139,tender - joint count of $nmbr$ joints examined,C0451530,,completed,
1139,tender joint count ( range $nmbr$ - $nmbr$ joints ),C0451530,,completed,
1139,tender joints ( $nmbr$ - joint count ) mean ± sd,C0451530,,completed,
1139,tjc ( / $nmbr$ joints ),C0022417,,completed,
1139,tjc ( $nmbr$ joints ),C0022417,,completed,
1139,tjc ( $nmbr$ joints ) mean ( sd ),C0022417,,completed,
1140,mean ( sd ) swollen joint count *,;C0451521,,completed,
1140,sjc ( / $nmbr$ joints ),C0022417,,completed,
1140,sjc ( $nmbr$ joints ),C0022417,,completed,
1140,sjc ( $nmbr$ joints ) mean ( sd ),C0022417,,completed,
1140,swollen joint count,;C0451521,,completed,
1140,swollen joint count ( $nmbr$ joints ),;C0451521,,completed,
1140,swollen joint count ( $nmbr$ joints ) mean ( sd ),;C0451521,,completed,
1140,swollen joint count ( $nmbr$ joints ) mean ( sd ) ’,;C0451521,,completed,
1140,swollen joint count ( $nmbr$ ) mean ( sd ),;C0451521,,completed,
1140,swollen joint count ( $nmbr$ - $nmbr$ ),;C0451521,,completed,
1140,swollen joint count ( $nmbr$ - $nmbr$ joints ),;C0451521,,completed,
1140,swollen joint count ( $nmbr$ – $nmbr$ joints ) mean ( sd ),;C0451521,,completed,
1140,swollen joint count ( $nmbr$ — $nmbr$ per swollen joint ),;C0451521,,completed,
1140,swollen joint count ( $nmbr$ - $nmbr$ possible joints ),;C0451521,,completed,
1140,swollen joint count ( n / $nmbr$ ),;C0451521,,completed,
1140,swollen joint count of $nmbr$,;C0451521,,completed,
1140,swollen - joint count ( of $nmbr$ joints ),;C0451521,,completed,
1140,swollen joint count of $nmbr$ joints,;C0451521,,completed,
1140,swollen - joint count ( of $nmbr$ joints assessed ) — no .,;C0451521,,completed,
1140,swollen - joint count of $nmbr$ joints examined,;C0451521,,completed,
1140,swollen joint count ( range $nmbr$ - $nmbr$ joints ),;C0451521,,completed,
1140,swollen joints ( $nmbr$ - joint count ) mean ± sd,;C0451521,,completed,
1140,swollen joints > $nmbr$ n ( % ),C0152031,,completed,
1142,fibrinogen,C0016006,,completed,
1142,fibrinogen g / l,C0016006,,completed,
1142,fibrinogen ( pmol / l ) c,C0016006,,completed,
1143,fibrinolysis ( n = $nmbr$ ),C0016017,,completed,
1143,fibrinolysist,C0016017,,completed,
1144,data missing,C1705492,,completed,
1144,data missing or no drug given,C1705492,,completed,
1144,missing,C1705492,,completed,
1144,missing *,C1705492,,completed,
1144,missing hb at yr $nmbr$,C1705492,,completed,
1144,missing n ( % ) a,C1705492,,completed,
1144,other / missing,C1705492,,completed,
1144,unknown / missing,C1705492,,completed,
1144,unknown or missing,C1705492,,completed,
1145,missing data,C4684714,,completed,
1145,missing data — no . / total no . ( % ),C4684714,,completed,
1145,other or missing data,C4684714,,completed,
1146,physical activity ( hours walking / wk ),C0080331,,completed,
1146,some walking,C0080331,,completed,
1146,walking,C0080331,,completed,
1147,history of smoking,C1519384,,completed,
1147,smoking history,C1519384,,completed,
1147,smoking history ( ever ),C1519384,,completed,
1147,smoking history n ( % ),C1519384,,completed,
1147,smoking history — no . ( % ),C1519384,,completed,
1147,smoking history r ( % ),C1519384,,completed,
1147,smoking history   n   ( % ),C1519384,,completed,
1148,coping,C0009967,,completed,
1150,muscle spasms,C0037763,,completed,
1150,muscle twitching,C0037763,,completed,
1153,glucagon - like peptide - $nmbr$ agonist,C0014361;C2987634,;C1422069;C1425391;C1539338,completed,
1153,glucagon - like peptide - $nmbr$ receptor agonist,C0014361;C2987634,;C1422069;C1425391;C1539338,completed,
1154,c - peptide,C0006558,,completed,
1154,c peptide nmol / l * ',C0006558,,completed,
1154,c - peptide tx difference vs pbo median change from baseline ( se ) $nmbr$,C0006558,,completed,
1154,fasting c - peptide ( nmol / l ) c,C0006558,,completed,
1155,glimepiride,C0061323,,completed,
1155,placebo + glimepiride,C0061323,,completed,
1156,meglitinide,;C0065880,,completed,
1156,meglitinides ( glinides ),;C0065880,,completed,
1157,glinide,C2266929,,completed,
1157,glinide 一 no . ( % ),C2266929,,completed,
1159,budesonide - budesonide / formoterol,C1276807,,completed,
1159,budesonide - formoterol $nmbr$ ^ g + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C1276807,,completed,
1159,budesonide - formoterol $nmbr$ + $nmbr$ . $nmbr$ ^ g ( n = $nmbr$ ),C1276807,,completed,
1159,budesonide - formoterol ( n = $nmbr$ ),C1276807,,completed,
1160,budesonide,C0054201,,completed,
1160,budesonide mmx $nmbr$ mg ( n = $nmbr$ ),C0054201,,completed,
1160,budesonide n ( % ),C0054201,,completed,
1160,budesonide $nmbr$ ^ g ( n = $nmbr$ ),C0054201,,completed,
1160,budesonide ( n = $nmbr$ ),C0054201,,completed,
1160,budesonide — no . ( % ),C0054201,,completed,
1160,budesonide ( symptom days a week ),C0054201,,completed,
1160,budesonide { symptom days a week ),C0054201,,completed,
1160,bumetanide,C0054201,,completed,
1161,glucosamine,C0017718,,completed,
1161,glucosamine + chondroitin sulfate ( n = $nmbr$ ),C0017718,,completed,
1161,glucosamine ( n = $nmbr$ ),C0017718,,completed,
1162,furosemide,C0016860,,completed,
1162,furosemide equivalent mg / kg,C0016860,,completed,
1164,highly sensitive,C0332324,,completed,
1164,highly sensitive responder ( n = $nmbr$ ),C0332324,,completed,
1164,highly sensitive responders ( n = $nmbr$ ),C0332324,,completed,
1164,hypersensitivity n ( % ),C0332324,,completed,
1164,sensitive,C0332324,,completed,
1164,sensitive responder ( n = $nmbr$ ),C0332324,,completed,
1164,sensitive responders ( n = $nmbr$ ),C0332324,,completed,
1165,ezetimibe,C1142985,,completed,
1165,ezetimibe n ( % ),C1142985,,completed,
1167,extensive,C0205231,,completed,
1167,extensive n ( % ),C0205231,,completed,
1167,non - extensive,C0205231,,completed,
1168,normotensive ( n = $nmbr$ ),C2712122,,completed,
1169,elective procedure,C0747973,,completed,
1169,elective surgery,C0747973,,completed,
1171,adamantane derivatives,C3653470,,completed,
1172,aliskiren,C1120110,,completed,
1172,aliskiren dm = $nmbr$ non - dm = $nmbr$,C1120110,,completed,
1172,aliskiren ( dm - vs . dm + ),C1120110,,completed,
1172,aliskiren ( n = $nmbr$ ),C1120110,,completed,
1172,aliskiren / valsartan ( n = $nmbr$ ),C1120110,,completed,
1172,enalapril + aliskiren dm = $nmbr$ non - dm = $nmbr$,C1120110,,completed,
1176,baseline glycated hemoglobin ( % ),,,completed,
1176,glycated haemoglobin %,,,completed,
1176,glycated haemoglobin ( % ),,,completed,
1176,glycated hemoglobin,,,completed,
1176,glycated hemoglobin | |,,,completed,
1176,glycated hemoglobin %,,,completed,
1176,glycated hemoglobin - % ’,,,completed,
1176,glycated hemoglobin ( % ),,,completed,
1176,glycated hemoglobin — %,,,completed,
1176,glycated hemoglobin — % -,,,completed,
1176,glycated hemoglobin % mean ( sd ),,,completed,
1176,glycated hemoglobin < median,,,completed,
1176,glycated hemoglobin median ( iqr ),,,completed,
1176,glycated hemoglobin standardized level — %,,,completed,
1176,glycosylated hemoglobin %,,,completed,
1176,glyeated haemoglobin,C0019046,,completed,
1176,mean glycated hemoglobin reduction during characteristic follow - up ( $nmbr$ % ci ) percent,,,completed,
1176,patients with glycated hemoglobin > $nmbr$ . $nmbr$ % and > $nmbr$ episode ofdiabetic ketoacidosis *,,,completed,
1177,baseline hemoglobin aj ^ values,C0019046,,completed,
1177,haemoglobin ( g / l ),C0019046,,completed,
1177,haemoglobin mg / dl,C0019046,,completed,
1177,haemoglobin ( mg / dl ),C0019046,,completed,
1177,hemoglobin,C0019046,,completed,
1177,hemoglobin aj ^ ( % ),C0019046,,completed,
1177,hemoglobin category,C0019046,,completed,
1177,hemoglobin g / l,C0019046,,completed,
1177,hemoglobin ( g / l ),C0019046,,completed,
1177,hemoglobin mg / dl,C0019046,,completed,
1180,ertugliflozin,C4079805,,completed,
1180,ertugliflozin $nmbr$ mg,C4079805,,completed,
1180,ertugliflozin $nmbr$   mg,C4079805,,completed,
1180,ertugliflozin $nmbr$   mg ( n   =   $nmbr$ ),C4079805,,completed,
1180,ertugliflozin $nmbr$ mg ( n = $nmbr$ ),C4079805,,completed,
1180,ertugliflozin $nmbr$ mg ( n   =   $nmbr$ ),C4079805,,completed,
1180,ertugliflozin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C4079805,,completed,
1180,ertugliflozin $nmbr$ mg vs placebo / giimepiride,C4079805,,completed,
1180,ertugliflozin $nmbr$ mg vs placebo / glimepiride,C4079805,,completed,
1180,ertugliflozin $nmbr$ mg vs placebo / glinepiride,C4079805,,completed,
1180,ertugliflozin $nmbr$ mg vs placebo / glirneplride,C4079805,,completed,
1181,canagiiflozin,C2974540,,completed,
1181,canagliflozin,C2974540,,completed,
1181,canagliflozin dose,C2974540,,completed,
1181,canagliflozin ( n = $nmbr$ ),C2974540,,completed,
1182,empagliflozin,C3490348,,completed,
1182,empagliflozin $nmbr$ mg,C3490348,,completed,
1182,empagliflozin $nmbr$ mg / day ( n = $nmbr$ ),C3490348,,completed,
1182,empagliflozin $nmbr$ mg ( n = $nmbr$ ),C3490348,,completed,
1182,empagliflozin ( n = $nmbr$ ),C3490348,,completed,
1182,empagliflozin ( n   =   $nmbr$ ),C3490348,,completed,
1182,empagliflozin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C3490348,,completed,
1182,empagliflozin n with event / n,C3490348,,completed,
1182,empagllflozin,C3490348,,completed,
1182,empagllflozln,C3490348,,completed,
1182,$nmbr$ mg empagliflozin,C3490348,,completed,
1183,allogliptin,C1958126,,completed,
1183,alogliptin,C1958126,,completed,
1183,alogliptin n ( % ),C1958126,,completed,
1183,alogliptin ( n = $nmbr$ ),C1958126,,completed,
1183,with alogliptin $nmbr$ mg,C1958126,,completed,
1183,with alogliptin $nmbr$ mg ( n $nmbr$ $nmbr$ ),C1958126,,completed,
1183,with alogliptin $nmbr$ . $nmbr$ mg,C1958126,,completed,
1183,with alogliptin $nmbr$ . $nmbr$ mg ( n $nmbr$ $nmbr$ ),C1958126,,completed,
1184,canagliflozin $nmbr$ mg vs sitagliptin $nmbr$ mg,C1565750,,completed,
1184,sitagliptin,C1565750,,completed,
1184,sitagliptin $nmbr$,C1565750,,completed,
1184,sitagliptin $nmbr$ mg n = $nmbr$,C1565750,,completed,
1184,sitagliptin $nmbr$ $nmbr$ . $nmbr$ 士 $nmbr$ . $nmbr$ $nmbr$ - h postprandial plasma glucose ( ppg ) ( mmol / l ),C1565750,,completed,
1184,sitagliptin ( n = $nmbr$ ),C1565750,,completed,
1184,sitagliptin n = $nmbr$,C1565750,,completed,
1184,sitagliptin no . / total no .,C1565750,,completed,
1184,sitagliptin ± oad,C1565750,,completed,
1185,comparator - linagliptin,C2746078,,completed,
1185,incidence rate difference linagliptin - placebo ( $nmbr$ % cl ),C2746078,,completed,
1185,linagliptin,C2746078,,completed,
1185,linagliptin ( n = $nmbr$ ),C2746078,,completed,
1185,linagliptin ( n = $nmbr$ ) ',C2746078,,completed,
1185,linagliptin ( n z $nmbr$ ),C2746078,,completed,
1185,linagliptin patients with events / total patients,C2746078,,completed,
1185,placebo - linagliptin,C2746078,,completed,
1186,baseline parameter,C0549193,,completed,
1186,efficacy parameter,C0549193,,completed,
1186,$nmbr$ parameter,C0549193,,completed,
1186,parameter,C0549193,,completed,
1186,parameter at baseline,C0549193,,completed,
1186,parameter mean ± s . d .,C0549193,,completed,
1186,parameter ( mg / dl ),C0549193,,completed,
1186,parameter n ( % ),C0549193,,completed,
1186,parameter % ( $nmbr$ % ci ),C0549193,,completed,
1186,parameter / variable,C0549193,,completed,
1189,intravenous ( n = $nmbr$ ),C0348016,,completed,
1189,intravenous study drug administered — no . ( % ),C0348016,,completed,
1190,abatacept,C1619966,,completed,
1190,abatacept ‡,C1619966,,completed,
1190,abatacept monotherapy ( n = $nmbr$ ),C1619966,,completed,
1190,abatacept ~ $nmbr$ mg / kg ( n = $nmbr$ ),C1619966,,completed,
1190,abatacept $nmbr$ mg / kg ( n = $nmbr$ ),C1619966,,completed,
1190,abatacept $nmbr$ / — $nmbr$ mg / kg ( n = $nmbr$ ),C1619966,,completed,
1190,abatacept $nmbr$ / $nmbr$ ( n = $nmbr$ ),C1619966,,completed,
1190,abatacept ( n = $nmbr$ * ),C1619966,,completed,
1190,abatacept / open - label abatacept,C1619966,,completed,
1190,abatacept plus mtx ( n = $nmbr$ ),C1619966,,completed,
1190,placebo - abatacept $nmbr$ / $nmbr$ - abatacept $nmbr$ / $nmbr$,C1619966,,completed,
1190,placebo / open - label abatacept,C1619966,,completed,
1191,antiplatelet agent,,,completed,
1191,antiplatelet agent n ( % ),,,completed,
1191,antiplatelet agents,,,completed,
1191,antiplatelet agents ( % ),,,completed,
1191,antiplatelet drug,,,completed,
1191,antiplatelet drugs,,,completed,
1191,antiplateletsa,,,completed,
1191,antiplatelets agents,,,completed,
1191,antiplatelets any,,,completed,
1191,asa or antiplatelet agent,,,completed,
1191,aspirin or other antiplatelet agent,C0456525,,completed,
1191,aspirin or other antiplatelet agents,C0456525,,completed,
1191,aspirin or other antiplatelet drug,,,completed,
1191,aspirin orother antiplatelet drug,,,completed,
1191,aspirin / other antiplatelet agents n ( % ),C0456525,,completed,
1191,> $nmbr$ . $nmbr$ mg / liter antiplatelet agents,,,completed,
1191,other antiplatelet,C0456525,,completed,
1191,other anti - platelet agents,C0456525,,completed,
1191,other antiplatelet agents,C0456525,,completed,
1191,other antiplatelet agents n ( % ),C0456525,,completed,
1191,other antiplatelet agent 一 no . ( % ),,,completed,
1191,previous chronic use of antiplatelet drugs,,,completed,
1191,previous use of antiplatelet drugs,,,completed,
1191,use of antiplatelet agents ^,,,completed,
1191,use of antiplatelet agents n ( % ),,,completed,
1191,use of antiplatelet agents — no . / total no . ( % ),,,completed,
1192,platelet $nmbr$ / l,C0456525,,completed,
1194,sample size,C0242618,,completed,
1194,sample size n,C0242618,,completed,
1194,sample size ( n ),C0242618,,completed,
1194,sample size n ( % ) by treatment,C0242618,,completed,
1195,mod / sev exacerbation rate,C4086268;C1521828;C0439793,,completed,
1195,mod / sev exacerbation rates,C4086268;C1521828;C0439793,,completed,
1196,left atrial anteroposterior diameter — mm,C0225860,,completed,
1196,left atrial diameter,C0225860,,completed,
1196,left atrial diameter mm ( sd ),C0225860,,completed,
1196,left atrial diameter : < $nmbr$ mm ( n = $nmbr$ ),C0225860,,completed,
1197,baseline spirometry,;C0037981,,completed,
1197,spirometric values at baseline,;C0037981,,completed,
1197,spirometry,;C0037981,,completed,
1198,primary safety outcome -,C0036043,,completed,
1198,safety %,C0036043,,completed,
1198,safety : non - cabg - related bleeding,C0036043,,completed,
1198,safety variable,C0036043,,completed,
1198,safety   n   ( % ) b,C0036043,,completed,
1199,diet,C0012155,,completed,
1199,diet alone,C0012155,,completed,
1199,diet and exercise,C0012155,,completed,
1199,diet diet + pravastatin,C0012155,,completed,
1199,diet group,C0012155,,completed,
1199,diet group ( n = $nmbr$ ),C0012155,,completed,
1199,diet - i - pravastatin ( n = $nmbr$ ),C0012155,,completed,
1199,diet $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155,,completed,
1199,diet ( n = $nmbr$ ),C0012155,,completed,
1199,diet ( n 二 $nmbr$ ),C0012155,,completed,
1199,diet only,C0012155,,completed,
1199,diet plus pravastatin group ( n = $nmbr$ ),C0012155,,completed,
1199,diet + pravastatin,C0012155,,completed,
1199,diet + pravastatin group,C0012155,,completed,
1199,diet + pravastatin $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),C0012155,,completed,
1199,diet + pravastatin ( n = $nmbr$ ),C0012155,,completed,
1199,hr is < $nmbr$ if pravastatin is better than diet alone,C0012155,,completed,
1199,none or diet,C0012155,,completed,
1204,any dynamic st - segment shift,C0429029,,completed,
1205,randomization to placebo or telmisartan,C0248719,,completed,
1205,telmisartan,C0248719,,completed,
1205,telmisartan group ( n = $nmbr$ ),C0248719,,completed,
1205,telmisartan ( n = $nmbr$ ),C0248719,,completed,
1205,telmisartan ( n = $nmbr$ $nmbr$ ),C0248719,,completed,
1206,hazard ratio ( $nmbr$ % cl ) valsartan vs . placebo,C0216784,,completed,
1206,valsartan,C0216784,,completed,
1206,valsartan / hctz,C0216784,,completed,
1206,valsartan / hctz n / n ( % ),C0216784,,completed,
1206,valsartan / hctz ( n = $nmbr$ ),C0216784,,completed,
1206,valsartan n ( % ),C0216784,,completed,
1206,valsartan n / n ( % ),C0216784,,completed,
1206,valsartan n / n,C0216784,,completed,
1206,valsartan ( n = $nmbr$ ),C0216784,,completed,
1207,adjusted $nmbr$ risk reduction losartan vs placebo ( $nmbr$ % cl ),C0126174,,completed,
1207,losartan,C0126174,,completed,
1207,losartan n / n ( % ),C0126174,,completed,
1207,losartan ( n = $nmbr$ ),C0126174,,completed,
1207,losartan n = $nmbr$,C0126174,,completed,
1207,losartan ( n = $nmbr$ $nmbr$ ),C0126174,,completed,
1207,losartan + placebo,C0126174,,completed,
1207,losartan plus placebo ( n = $nmbr$ ),C0126174,,completed,
1207,p ( losartan versus placebo ),C0126174,,completed,
1208,candesartan,,,completed,
1208,candesartan group ( n = $nmbr$ ),,,completed,
1208,candesartan $nmbr$ / $nmbr$,,,completed,
1208,other - candesartan,,,completed,
1209,irbesartan,C0288171,,completed,
1209,irbesartan ( n = $nmbr$ ),C0288171,,completed,
1210,affected body - surface area > $nmbr$ % — no . { % ),C0005902;C1879646,,completed,
1211,distal forearm,C0016536,,completed,
1211,forearm,C0016536,,completed,
1211,forearm fracture,C0016536,,completed,
1212,cvd / mi / stroke / urgent coronary revascularization,C0877341;C3272275,,completed,
1212,• urgent coronaiy revascularization > $nmbr$ days,C0581603,,completed,
1212,urgent coronary revascularization,C0877341;C3272275,,completed,
1212,urgent revascularisation due to unstable angina,C0581603,,completed,
1212,urgent revascularizati on,C0877341;C3272275,,completed,
1212,with rehospitalization urgent coronary revascularization,C0877341;C3272275,,completed,
1212,with revascularisation,C0581603,,completed,
1213,any peripheral revascularization,C0581603,,completed,
1213,any revascularization,C0581603,,completed,
1213,arterial revascularization,C0581603,,completed,
1213,$nmbr$ days urgent revascularization,C0581603,,completed,
1213,no prior revascularization ( n = $nmbr$ $nmbr$ ),C0581603,,completed,
1213,no revascularisation,C0581603,,completed,
1213,peripheral arterial revascularization,C0581603,,completed,
1213,prior revascularization,C0581603,,completed,
1213,prior revascularization ( % ),C0581603,,completed,
1213,prior revascularization ( n = $nmbr$ $nmbr$ ),C0581603,,completed,
1213,revascularisation n ( % ),C0581603,,completed,
1213,revascularization,C0581603,,completed,
1213,revascularization during index hospitalization %,C0581603,,completed,
1213,revascularization in $nmbr$ days,C0581603,,completed,
1214,microvascular complicationsb,C0443258;C0009566,,completed,
1214,microvascular complications n ( % ) ’,C0443258;C0009566,,completed,
1214,patients with microvascular complications n ( % ),C0443258;C0009566,,completed,
1216,lacunar,C0333559;C0241970,,completed,
1216,lacunar infarction n ( % ),C0333559;C0241970,,completed,
1217,ventricular tachyarrhythmias,C3827656,,completed,
1217,ventricular tachycardia or fibrillation,C3827656,,completed,
1218,endovascular,C0524425,,completed,
1218,endovascular — no . ( % ),C0524425,,completed,
1219,doxazosin,C0114873,,completed,
1219,doxazosin group,C0114873,,completed,
1220,edoxaban,C2975435,,completed,
1220,edoxaban ( n = $nmbr$ ),C2975435,,completed,
1220,edoxaban n = $nmbr$,C2975435,,completed,
1220,edoxaban n = $nmbr$ n / n ( % ),C2975435,,completed,
1220,edoxaban n / n rate ( % ),C2975435,,completed,
1220,higher dose edoxaban regimen,C2975435,,completed,
1220,hr with edoxaban ( $nmbr$ % ci ),C2975435,,completed,
1221,plasma lipoproteins mmol / l,C0023820,,completed,
1222,fluvastatin $nmbr$ mg,C0082608,,completed,
1222,fluvastatin ( n = $nmbr$ ),C0082608,,completed,
1223,placebo tolvaptan ( $nmbr$ mg ) ( n $nmbr$ $nmbr$ ) ( n $nmbr$ $nmbr$ ),C1176308,,completed,
1223,tolvaptan,C1176308,,completed,
1223,tolvaptan ( n = $nmbr$ ),C1176308,,completed,
1224,apixaban,C1831808,,completed,
1224,apixaban dose ( or matching placebo ),C1831808,,completed,
1224,apixaban ( n = $nmbr$ ),C1831808,,completed,
1224,apixaban vs . placebo,C1831808,,completed,
1225,low - dose rivaroxaban + aspirin group,C1739768,,completed,
1225,low - dose rivaroxaban + aspirin ( n / n ),C1739768,,completed,
1225,low - dose rivaroxaban plus aspirin ( n = $nmbr$ ),C1739768,,completed,
1225,rivaroxaban,C1739768,,completed,
1225,rivaroxaban +,C1739768,,completed,
1225,rivaroxaban + aspirin,C1739768,,completed,
1225,rivaroxaban $nmbr$ mg,C1739768,,completed,
1225,rivaroxaban ( n = $nmbr$ ),C1739768,,completed,
1225,rivaroxaban ( n   = $nmbr$ ),C1739768,,completed,
1225,rivaroxaban plus,C1739768,,completed,
1225,rivaroxaban plus aspirin ( $nmbr$ % cl ),C1739768,,completed,
1225,rivaroxaban plus aspirin ( n = $nmbr$ ),C1739768,,completed,
1225,rivaroxaban plus aspirin ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C1739768,,completed,
1226,paroxysmal nocturnal dyspnea,C1956415,,completed,
1226,pnd,C1956415,,completed,
1227,cangrelor dyspnoea vs no dyspnoea *,C0013404,,completed,
1227,clopidogrel dyspnoea vs no dyspnoea *,C0013404,,completed,
1227,dyspnea,C0013404,,completed,
1227,dyspnea % ( frequent / continuous ),C0013404,,completed,
1227,dyspnea frequent / continuous,C0013404,,completed,
1227,dyspnea t,C0013404,,completed,
1227,dyspnoea ( n = $nmbr$ ),C0013404,,completed,
1227,mmrc dyspnea scale n ( % ),C0013404,,completed,
1227,mmrc dyspnea scale score : t : t,C0013404,,completed,
1227,no dyspnoea ( n = $nmbr$ ),C0013404,,completed,
1227,with dyspnoea,C0013404,,completed,
1227,without dyspnoea,C0013404,,completed,
1228,dipyridamole,C0012582,,completed,
1228,dipyridamole alone,C0012582,,completed,
1229,dihydropyridine,,,completed,
1232,pctindopnl - indapamide ( n = $nmbr$ ),C1273169,,completed,
1232,perindopril - indapamide,C1273169,,completed,
1233,abi,C1328319,,completed,
1233,abi < $nmbr$ . $nmbr$,C1328319,,completed,
1233,abi > $nmbr$ . $nmbr$,C1328319,,completed,
1233,abi # $nmbr$ . $nmbr$,C1328319,,completed,
1233,ankle / brachial index,C1328319,,completed,
1233,ankle - brachial index < $nmbr$ . $nmbr$,C1328319,,completed,
1233,ankle - brachial index £ $nmbr$ . $nmbr$,C1328319,,completed,
1233,ankle - brachial index < $nmbr$ . $nmbr$ — no . ( % ),C1328319,,completed,
1233,baseline abi affected limb,C1328319,,completed,
1233,cad and abi < $nmbr$ - $nmbr$ §,C1328319,,completed,
1236,fatty acid composition,C0015684,,completed,
1241,any blood product transfusion,C0005841,,completed,
1241,any blood transfusion,C0005841,,completed,
1241,blood transfusion,C0005841,,completed,
1241,transfusion,C0005841,,completed,
1241,transfusion ≥ $nmbr$ units rbcs or whole blood,C0005841,,completed,
1241,transfusions,C0005841,,completed,
1243,anterior,C0205094,,completed,
1243,nonanterior,C0205094,,completed,
1246,in hospital ticagrelor,C1999375;C1510665,,completed,
1246,in - hospital ticagrelor ( n = $nmbr$ ),C1999375;C1510665,,completed,
1246,prehospital ticagrelor ( n = $nmbr$ ),C1999375;C1510665,,completed,
1246,ticagrelor in ‐ hosp ( n = $nmbr$ ),C1999375;C1510665,,completed,
1247,cangrelor,C1121991,,completed,
1247,cangrelor %,C1121991,,completed,
1247,cangrelor clopidogrel no . of events / total no . ( % ),C1121991,,completed,
1247,cangrelor n / n ( % ),C1121991,,completed,
1247,cangrelor ( n = $nmbr$ ),C1121991,,completed,
1247,cangrelor ( n = $nmbr$ ) n / n ( % ),C1121991,,completed,
1248,bmi $nmbr$ – $nmbr$ overweight,C0497406,,completed,
1248,lisinopril vs chlorthalidone overweight,C0497406,,completed,
1248,$nmbr$ - $nmbr$ - $nmbr$ overweight,C0497406,,completed,
1248,$nmbr$ - $nmbr$ . $nmbr$ : overweight,C0497406,,completed,
1248,overweight,C0497406,,completed,
1248,overweight ( bmi = $nmbr$ - $nmbr$ . $nmbr$ ),C0497406,,completed,
1248,overweight ( bmi £ $nmbr$ to < $nmbr$ ),C0497406,,completed,
1248,overweight ( $nmbr$ to < $nmbr$ kg / m $nmbr$ ),C0497406,,completed,
1249,baseline height ( cm ),C0489786,,completed,
1249,height cm,C0489786,,completed,
1249,height cm *,C0489786,,completed,
1249,height ' cm,C0489786,,completed,
1249,height ( cm ),C0489786,,completed,
1249,height — cm,C0489786,,completed,
1249,height cm mean ( sd ),C0489786,,completed,
1249,height cm ( mean ± s . d . ),C0489786,,completed,
1249,height ( cm ) ( mean ± sd ),C0489786,,completed,
1249,height ( cm ) mean ( sd ) a,C0489786,,completed,
1249,height ( cm ) mean ( s . e . ),C0489786,,completed,
1249,height inches,C0489786,,completed,
1249,height loss,C0489786,,completed,
1249,height loss ( cm ),C0489786,,completed,
1249,height mean ( sd ) cm,C0489786,,completed,
1250,body weight,C0005910,,completed,
1250,body weight %,C0005910,,completed,
1250,body weight *,C0005910,,completed,
1250,body weighta kg,;C0005890,,completed,height
1250,body weight at randomization,;C0005890,,completed,height
1250,body weight at randonization { ixrs ),C0005910,,completed,
1250,body weight index ( kg / m $nmbr$ ),C0005910,,completed,
1250,body weight ( kg ) mean ( s . d . ),C0005910,,completed,
1250,body weight ( kg ) mean ( sd ),C0005910,,completed,
1250,body weight mean ± sd kg,C0005910,,completed,
1250,body weight reduction > $nmbr$ %,C0005910,,completed,
1250,body weiqht,;C0005890,,completed,height
1250,healthy weight,C0005910,,completed,
1250,male sex — no . ( % ) weight — no . ( % ),C0005910,,completed,
1250,> $nmbr$ kg body weight at randomization,;C0005890,,completed,height
1250,> $nmbr$ ( n % ) weight kg,C0005910,,completed,
1250,no body weight at randomization ( ixrs ),;C0005890,,completed,height
1250,per body weight u / kg,C0005910,,completed,
1250,weight,C0005910,,completed,
1250,weight ^,C0005910,,completed,
1250,weight ab %,C0005910,,completed,
1250,weight category,C0005910,,completed,
1250,weight group no . ( % ),C0005910,,completed,
1250,weight in kg median ( iqr ),C0005910,,completed,
1250,w eight ( k g ),;C0005890,,completed,height
1250,weight ( kg ) *,C0005910,,completed,
1250,weight ( kg ) bmi ( kg / m $nmbr$ ),C0005910,,completed,
1250,weight — kg cardiovascular history — no . ( % ),C0005910,,completed,
1250,weight kg duration of pah n ( % ),C0005910,,completed,
1250,weight — kg ( median ),C0005910,,completed,
1250,weight - kg median ( iqr ),C0005910,,completed,
1250,weight ( kg ) median ( iqr ),C0005910,,completed,
1250,weight ( kg } median ( min max },C0005910,,completed,
1250,weight ( kg ) median ( m / n max ),C0005910,,completed,
1250,weight kg median ( range ),C0005910,,completed,
1250,weight kg $nmbr$,C0005910,,completed,
1250,weight lbs,C0005910,,completed,
1250,weight mean ( sd ) kgb,C0005910,,completed,
1250,weight mean ( sd ) lbs .,C0005910,,completed,
1250,weight median ( interquartile range ) kg,C0005910,,completed,
1250,weight median ( iqr ) kg,C0005910,,completed,
1250,weight ( median [ iqr ] ) kg,C0005910,,completed,
1250,weight < $nmbr$,C0005910,,completed,
1250,weight $nmbr$ +,C0005910,,completed,
1250,weight < $nmbr$ kg,C0005910,,completed,
1250,weight > $nmbr$ kg,C0005910,,completed,
1250,weight # $nmbr$ kg,C0005910,,completed,
1250,weight $nmbr$ - $nmbr$,C0005910,,completed,
1250,weight < $nmbr$ . $nmbr$ kg n,C0005910,,completed,
1250,weight $ $nmbr$ . $nmbr$ kg n,C0005910,,completed,
1250,weight $ $nmbr$ . $nmbr$ kg < $nmbr$ . $nmbr$ kg n,C0005910,,completed,
1250,weight — no . ( % ),C0005910,,completed,
1250,weight of < $nmbr$ kg n ( % ),C0005910,,completed,
1250,weight ( range ) ( kg ),C0005910,,completed,
1250,yes ( % ) weight [ kg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0005910,,completed,
1251,body height ( cm ),;C0005890,,completed,height
1254,ipf,;C1800706,,completed,Idiopathic something testing
1254,time since ipf diagnosisa mean years ( sd ),;C1800706,,completed,Idiopathic something testing
1262,average maximum cimt ( mm ),;C1524031;C0806909,,completed,
1262,average maximum common and bifurcation cimt ( mm ),;C1524031;C0806909,,completed,
1262,average of maximum common carotid cimt ( mm ),;C1524031;C0806909,,completed,
1262,average of maximum far wall cimt ( mm ),;C1524031;C0806909,,completed,
1262,carotid imt,,,completed,carotid intima medial thickness
1262,imt ( mm ),,,completed,carotid intima medial thickness
1262,maximum cimt a med an,;C1524031;C0806909,,completed,
1262,mean of maximum cimt mean ( sd ) mm,;C1524031;C0806909,,completed,
1268,years since last gout flare,C0018099;C1517741;C1517205,,completed,
1272,history of lvh on echocardiogram,C0149721,,completed,
1272,lvh,C0149721,,completed,
1272,lvh by echocardiogram,C0149721,,completed,
1272,lvh by echocardiography,C0149721,,completed,
1272,lvh by minnesota code,C0149721,,completed,
1272,lvh by minnesota code no . ( % ),C0149721,,completed,
1272,lvh ( from echocardiogram ),C0149721,,completed,
1272,lvh - n = $nmbr$,C0149721,,completed,
1272,lvh + n = $nmbr$,C0149721,,completed,
1273,baseline lvef,C0018801;C0428772,,completed,
1273,baseline lvef %,C0018801;C0428772,,completed,
1273,continuous lvef $nmbr$ treatment interaction,C0018801;C0428772,,completed,
1273,heart failure lvef < $nmbr$ % or both,C0018801;C0428772,,completed,
1273,heart failure or lvef < $nmbr$ % associated with index acs event,C0018801;C0428772,,completed,
1273,hf or lvef < $nmbr$ % associated with index event,C0018801;C0428772,,completed,
1273,history of hf or lvef b $nmbr$ % with index event no . ( % ),C0018801;C0428772,,completed,
1273,left ventricular ejection fraction,C0018801;C0428772,,completed,
1273,left ventricular ejection fraction %,C0018801;C0428772,,completed,
1273,left ventricular ejection fraction % *,C0018801;C0428772,,completed,
1273,left ventricular ejection fraction ( % ),C0018801;C0428772,,completed,
1273,left ventricular ejection fraction — %,C0018801;C0428772,,completed,
1273,left ventricular ejection fraction — % §,C0018801;C0428772,,completed,
1273,left ventricular ejection fraction % af history,C0018801;C0428772,,completed,
1273,left ventricular ejection fraction median ( iqr ) %,C0018801;C0428772,,completed,
1273,left ventricular ejection fraction < $nmbr$ %,C0018801;C0428772,,completed,
1273,left ventricular ejection fraction — no . / total no . ( % ),C0018801;C0428772,,completed,
1273,lvef,C0018801;C0428772,,completed,
1273,lvef %,C0018801;C0428772,,completed,
1273,lvef ( % ),C0018801;C0428772,,completed,
1273,lvef ( % ) mean ± sd,C0018801;C0428772,,completed,
1273,lvef ( mean ± sd ),C0018801;C0428772,,completed,
1273,lvef < $nmbr$ %,C0018801;C0428772,,completed,
1273,lvef > $nmbr$ %,C0018801;C0428772,,completed,
1273,lvef < $nmbr$ . $nmbr$,C0018801;C0428772,,completed,
1273,lvef ^ $nmbr$ . $nmbr$ and nyha class ii iii at baseline,C0018801;C0428772,,completed,
1273,lvef < $nmbr$ % n = $nmbr$ $nmbr$ ) “,C0018801;C0428772,,completed,
1273,lvef ≤ $nmbr$ % n   =   $nmbr$   $nmbr$ a,C0018801;C0428772,,completed,
1273,lvef ≤ $nmbr$ % n   =   $nmbr$   $nmbr$ ) a,C0018801;C0428772,,completed,
1273,lvef ( u ),C0018801;C0428772,,completed,
1273,lvef within $nmbr$ months %,C0018801;C0428772,,completed,
1273,mean lvef,C0018801;C0428772,,completed,
1273,nyha ll / lll patients with lvef < $nmbr$ . $nmbr$ at baseline,C0018801;C0428772,,completed,
1273,white race — no . ( % ) y left ventricular ejection fraction — %,C0018801;C0428772,,completed,
1276,female / male ( % ),C0086582,,completed,male gender
1276,gender male,C0086582,,completed,male gender
1276,gender male,C0086582,,completed,male gender
1276,gender male ( % ),C0086582,,completed,male gender
1276,gender male / female,C0086582,,completed,male gender
1276,gender ( % ) male / female,C0086582,,completed,male gender
1276,gender ( male / female ) ( number ),C0086582,,completed,male gender
1276,gender male n ( % ),C0086582,,completed,male gender
1276,gender - male n ( % ),C0086582,,completed,male gender
1276,gender ( male ) n ( % ),C0086582,,completed,male gender
1276,gender : male   n   ( % ),C0086582,,completed,male gender
1276,gender n ( % ) male,C0086582,,completed,male gender
1276,gender n [ % ] male,C0086582,,completed,male gender
1276,genital mycotic infections male $nmbr$,C0086582,,completed,male gender
1276,male,C0086582,,completed,male gender
1276,male %,C0086582,,completed,male gender
1276,male ( % ),C0086582,,completed,male gender
1276,male / female,C0086582,,completed,male gender
1276,male / female %,C0086582,,completed,male gender
1276,male gender,C0086582,,completed,male gender
1276,male gender ( % ),C0086582,,completed,male gender
1276,male gender n ( % ),C0086582,,completed,male gender
1276,male gender   n   ( % ),C0086582,,completed,male gender
1276,male n,C0086582,,completed,male gender
1276,male % ( n ),C0086582,,completed,male gender
1276,male n ( % ),C0086582,,completed,male gender
1276,male * n ( % ),C0086582,,completed,male gender
1276,male n / n ( % ),C0086582,,completed,male gender
1276,male ( n = $nmbr$ ),C0086582,,completed,male gender
1276,male ( n - $nmbr$ ),C0086582,,completed,male gender
1276,male ( n = $nmbr$ $nmbr$ ),C0086582,,completed,male gender
1276,male no ( % ),C0086582,,completed,male gender
1276,male - no . ( % ),C0086582,,completed,male gender
1276,male nyha class,C0086582,,completed,male gender
1276,male ( n z $nmbr$ ),C0086582,,completed,male gender
1276,male ( n   = $nmbr$ $nmbr$ ),C0086582,,completed,male gender
1276,males,C0086582,,completed,male gender
1276,males %,C0086582,,completed,male gender
1276,males ( % ),C0086582,,completed,male gender
1276,male sex,C0086582,,completed,male gender
1276,male sex ^,C0086582,,completed,male gender
1276,male sex ( % ),C0086582,,completed,male gender
1276,male sex %,C0086582,,completed,male gender
1276,male sex ( % ),C0086582,,completed,male gender
1276,male sex — %,C0086582,,completed,male gender
1276,male sex n ( % ),C0086582,,completed,male gender
1276,male sex n [ % ],C0086582,,completed,male gender
1276,male sex no . ( % ),C0086582,,completed,male gender
1276,male sex \ no . ( % ),C0086582,,completed,male gender
1276,male sex — no . ( % ),C0086582,,completed,male gender
1276,male sex — no . { % ),C0086582,,completed,male gender
1276,male sex — no . ( % ) f,C0086582,,completed,male gender
1276,male sex — no . ( % ) medical history — no . / total no . ( % ),C0086582,,completed,male gender
1276,male sex — no . ( % ) race — no . ( % ) ) :,C0086582,,completed,male gender
1276,male sex no . / total no . ( % ),C0086582,,completed,male gender
1276,male sex — no . / total no . ( % ),C0086582,,completed,male gender
1276,male sex 一 no . ( % ),C0086582,,completed,male gender
1276,males ( itt ) ( n = $nmbr$ ),C0086582,,completed,male gender
1276,males n ( % ),C0086582,,completed,male gender
1276,males [ n ( % ) ],C0086582,,completed,male gender
1276,males < $nmbr$,C0086582,,completed,male gender
1276,males > $nmbr$,C0086582,,completed,male gender
1276,males < $nmbr$ . $nmbr$,C0086582,,completed,male gender
1276,males > $nmbr$ . $nmbr$,C0086582,,completed,male gender
1276,males ( n = $nmbr$ ),C0086582,,completed,male gender
1276,male   n   ( % ),C0086582,,completed,male gender
1276,overall male : female,C0086582,,completed,male gender
1276,sexa male,C0086582,,completed,male gender
1276,sex male,C0086582,,completed,male gender
1276,sex % male,C0086582,,completed,male gender
1276,sex : male,C0086582,,completed,male gender
1276,sex ( male % ),C0086582,,completed,male gender
1276,sex ( male ),C0086582,,completed,male gender
1276,sex ( male ) %,C0086582,,completed,male gender
1276,sex male / female %,C0086582,,completed,male gender
1276,sex ( male / female ),C0086582,,completed,male gender
1276,sex ( male / female ) ( n ),C0086582,,completed,male gender
1276,sex male n ( % ),C0086582,,completed,male gender
1276,sex ( male ) n ( % ),C0086582,,completed,male gender
1276,sex : male ( n = $nmbr$ ),C0086582,,completed,male gender
1276,sex male no . ( % ),C0086582,,completed,male gender
1276,sex ( male ) - no . ( % ),C0086582,,completed,male gender
1276,sex n ( % ) male,C0086582,,completed,male gender
1276,years male gender n ( % ),C0086582,,completed,male gender
1277,female,C0086287,,completed,
1277,female %,C0086287,,completed,
1277,female ( % ),C0086287,,completed,
1277,femaleb,C0086287,,completed,
1277,female eze / simva ( „ = $nmbr$ },C0086287,,completed,
1277,female eze / simva ( n = $nmbr$ ),C0086287,,completed,
1277,female gender,C0086287,,completed,
1277,female gender ( % ),C0086287,,completed,
1277,female gender n ( % ),C0086287,,completed,
1277,female n ( % ),C0086287,,completed,
1277,female - n ( % ),C0086287,,completed,
1277,female n ( % ),C0086287,,completed,
1277,female ( n = lll $nmbr$ ),C0086287,,completed,
1277,female $nmbr$,C0086287,,completed,
1277,female ( n = $nmbr$ ),C0086287,,completed,
1277,female ( n — $nmbr$ ),C0086287,,completed,
1277,female ( n = $nmbr$ $nmbr$ ),C0086287,,completed,
1277,female no . ( % ),C0086287,,completed,
1277,female no ( % ),C0086287,,completed,
1277,female — no . ( % ),C0086287,,completed,
1277,female ( n z $nmbr$ ),C0086287,,completed,
1277,female ( n   = $nmbr$ $nmbr$ ),C0086287,,completed,
1277,females,C0086287,,completed,
1277,females %,C0086287,,completed,
1277,femalesex,C0086287,,completed,
1277,female sex,C0086287,,completed,
1277,female sex %,C0086287,,completed,
1277,female sex ( % ),C0086287,,completed,
1277,female sex — %,C0086287,,completed,
1277,female sex n ( % ),C0086287,,completed,
1277,female sex no . ( % ),C0086287,,completed,
1277,female sex — no . ( % ),C0086287,,completed,
1277,female sex — no . { % ),C0086287,,completed,
1277,female sex no . / total ( % ),C0086287,,completed,
1277,females ( itt ) ( n = $nmbr$ ),C0086287,,completed,
1277,females n ( % ),C0086287,,completed,
1277,females < $nmbr$,C0086287,,completed,
1277,females > $nmbr$,C0086287,,completed,
1277,females < $nmbr$ . $nmbr$,C0086287,,completed,
1277,females > $nmbr$ . $nmbr$,C0086287,,completed,
1277,females ( n = $nmbr$ ),C0086287,,completed,
1277,females only,C0086287,,completed,
1277,gender ( female : male % ),C0086287,,completed,
1277,number of ( % ) females,C0086287,,completed,
1277,number of females n ( % ),C0086287,,completed,
1277,sex female,C0086287,,completed,
1277,sex % female,C0086287,,completed,
1277,sex female %,C0086287,,completed,
1277,sex : female,C0086287,,completed,
1277,sex ( female ),C0086287,,completed,
1277,sex female n ( % ),C0086287,,completed,
1277,sex female   n   ( % ),C0086287,,completed,
1278,cardiac disease,C0018799,,completed,
1278,cardiac disorder,C0018799,,completed,
1278,cardiac disorder n ( % ) §,C0018799,,completed,
1278,cardiac disorders ( soc ),C0018799,,completed,
1278,no apparent heart disease,C0018799,,completed,
1278,no cardiac disease,C0018799,,completed,
1278,patients with cardiac disorders n ( % ) §,C0018799,,completed,
1278,patients with cardiac disorders n ( % ) c,C0018799,,completed,
1281,saba,,,completed,
1281,saba §,,,completed,
1281,sabae,,,completed,
1281,saba ( inhaled ) c   n ( % ),,,completed,
1282,any sae,C1519255,,completed,
1282,because of sae,C1519255,,completed,
1282,drug - related saes,C1519255,,completed,
1282,due to drug - relateda sae,C1519255,,completed,
1282,due to sae,C1519255,,completed,
1282,≥ $nmbr$ sae,C1519255,,completed,
1282,saes,C1519255,,completed,
1284,abaloparatide - sc n ( % ),C4042342,,completed,
1284,abl - sc mean,C4042342,,completed,
1284,abl - sc n / n,C4042342,,completed,
1285,evolocumab + soc ( n = $nmbr$ ),C3529352,,completed,
1288,any infarct,C0021308,,completed,
1288,any relevant infarct,C0021308,,completed,
1288,atherothrombotic infarction n ( % ),C0021308,,completed,
1288,infarct size,C0021308,,completed,
1288,infarct territory ( % ),C0021308,,completed,
1288,no infarct visible,C0021308,,completed,
1288,prior infarction,C0021308,,completed,
1288,vertebrobasilar infarct,C0021308,,completed,
1289,upper respiratory tract infection,;C0041912,,completed,
1289,upper respiratory tract infection $nmbr$ ( $nmbr$ . $nmbr$ ),;C0041912,,completed,
1289,upper respiratory tract inflammation,;C0041912,,completed,
1290,cataract,;C0086543,,completed,
1290,cataract removal,;C0086543,,completed,
1290,total cataract,;C0086543,,completed,
1290,total cataract extraction,;C0086543,,completed,
1292,baseline hematocrit median ( iqr ),C0518014,,completed,
1292,hematocrit %,C0518014,,completed,
1293,acq - $nmbr$ score,C2919686,,completed,
1293,acq - $nmbr$ score ' ! ',C2919686,,completed,
1293,acq - $nmbr$ score *,C2919686,,completed,
1293,acq $nmbr$ score,C2919686,,completed,
1293,acq $nmbr$ score mean ( sd ),C2919686,,completed,
1293,acq - $nmbr$ score mean ( sd ) e,C2919686,,completed,
1293,acq - $nmbr$ scoret,C2919686,,completed,
1293,acq - $nmbr$ score 本,C2919686,,completed,
1293,acq score mean,C2919686,,completed,
1293,( sd ) l / min acq - $nmbr$ score mean ( sd ),C2919686,,completed,
1293,uncontrolled : acq - $nmbr$ > $nmbr$ . $nmbr$,C2919686,,completed,
1295,history of a transient ischaemic attack,C0455536,,completed,
1297,estimated number of pack - years,C1277691,,completed,
1297,nicotine pack - years,C1277691,,completed,
1297,number of pack years,C1277691,,completed,
1297,number of pack - years,C1277691,,completed,
1297,pack years,C1277691,,completed,
1297,pack - years smoked,C1277691,,completed,
1297,smoking consumption pack - years,C1277691,,completed,
1297,smoking history pack - years,C1277691,,completed,
1297,smoking history ( pack - years ),C1277691,,completed,
1297,smoking history ( pack - years ) ∗,C1277691,,completed,
1301,canada or united states,C0006823;C0041703,,completed,
1301,united states canada,C0006823;C0041703,,completed,
1309,white hispanic,C1533021,,completed,
1309,white hispanic - n ( % ),C1533021,,completed,
1312,all - causa mortality,C0026565,,completed,
1312,mortality,C0026565,,completed,
1312,mortality outcomes,C0026565,,completed,
1312,non - cardiovascular mortality,C0026565,,completed,
1312,non - cvd mortality,C0026565,,completed,
1312,or morbidity and mortality,C0026565,,completed,
1312,overall mortality,C0026565,,completed,
1312,shfm annual mortality,C0026565,,completed,
1313,abdominal obesity,C0311277,,completed,
1313,abdominal obesity *,C0311277,,completed,
1313,obesityj,C0311277,,completed,
1314,any electrocardiographic abnormality — no . ( % ),C0522055,,completed,
1314,ecg abnormality at entry,C0522055,,completed,
1315,absolute reversibility in fev $nmbr$ ml *,C0449261;C0231999,,completed,
1315,airflow reversibility — no . ( % ) |,C0449261;C0231999,,completed,
1315,airway reversibility %,C0449261;C0231999,,completed,
1315,airway reversibility mean %,C0449261;C0231999,,completed,
1315,albuterol reversibility %,C0449261;C0231999,,completed,
1315,bronchial reversibility %,C0449261;C0231999,,completed,
1315,% bronchial reversibility ( sd ),C0449261;C0231999,,completed,
1315,fev $nmbr$ % reversibility,C0449261;C0231999,,completed,
1315,fev $nmbr$ reversibility % *,C0449261;C0231999,,completed,
1315,fev $nmbr$ reversibility % b,C0449261;C0231999,,completed,
1315,fev $nmbr$ % reversibility ( sd ),C0449261;C0231999,,completed,
1315,mean reversibility ( % ),C0449261;C0231999,,completed,
1315,mean ( sd ) postbronchodilator fev $nmbr$ reversibility %,C0449261;C0231999,,completed,
1315,mean ( sd ) % reversibility fev $nmbr$ at,C0449261;C0231999,,completed,
1315,post - bronchodilator fev i reversibility % b,C0449261;C0231999,,completed,
1315,post - bronchodilator fev $nmbr$ reversibility %,C0449261;C0231999,,completed,
1315,postbronchodilator fev $nmbr$ reversibility %,C0449261;C0231999,,completed,
1315,post - bronchodilator fev $nmbr$ reversibility % a,C0449261;C0231999,,completed,
1315,post - bronchodilator fev reversibility,C0449261;C0231999,,completed,
1315,reversibility ( anticholinergic ) % mean ( sd ) $,C0449261;C0231999,,completed,
1315,reversibility ( b $nmbr$ - agonist ) % mean ( sd ) $nmbr$,C0449261;C0231999,,completed,
1315,% reversibility in fev ^ at,C0449261;C0231999,,completed,
1315,reversibility of fev $nmbr$ ( % ),C0449261;C0231999,,completed,
1315,reversibility ( % predicted fev $nmbr$ ) *,C0449261;C0231999,,completed,
1315,reversibility to salbutamolc d mean ( sd ),C0449261;C0231999,,completed,
1315,saba reversibility,C0449261;C0231999,,completed,
1315,screening absolute reversibility fev $nmbr$ ml,C0449261;C0231999,,completed,
1315,screening % reversibility fev $nmbr$,C0449261;C0231999,,completed,
1317,eligibility risk factors,C0013893;C0035648,,completed,
1317,eligibility risk factors :,C0013893;C0035648,,completed,
1317,eligibility risk factors !,C0013893;C0035648,,completed,
1317,eligibility risk factors /,C0013893;C0035648,,completed,
1317,eligibility risk factors ’ ),C0013893;C0035648,,completed,
1317,eligibility risk factorsa,C0013893;C0035648,,completed,
1317,* eligibility risk factors n ( % ) *,C0013893;C0035648,,completed,
1317,eligibility risk factors — n ( % ) :,C0013893;C0035648,,completed,
1317,eligibility risk factors no . ( % ) t,C0013893;C0035648,,completed,
1317,eligibility risk factors % t ascvo,C0013893;C0035648,,completed,
1318,seropositivity,C0521143,,completed,
1318,seropositivity status n,C0521143,,completed,
1323,all women,C0043210,;C3541888;C1720467,completed,
1323,fpci vs . ppci in women,C0043210,;C3541888;C1720467,completed,
1323,gender women n % ),C0043210,;C3541888;C1720467,completed,
1323,gmi ( women ),C0043210,;C3541888;C1720467,completed,
1323,< $nmbr$ ( men ) / < $nmbr$ ( women ),C0043210,;C3541888;C1720467,completed,
1323,£ $nmbr$ ( men ) / £ $nmbr$ ( women ),C0043210,;C3541888;C1720467,completed,
1323,$nmbr$ - $nmbr$ ( women ),C0043210,;C3541888;C1720467,completed,
1323,no . women,C0043210,;C3541888;C1720467,completed,
1323,woman,C0043210,;C3541888;C1720467,completed,
1323,women,C0043210,;C3541888;C1720467,completed,
1323,women %,C0043210,;C3541888;C1720467,completed,
1323,women ( % ),C0043210,;C3541888;C1720467,completed,
1323,women / men %,C0043210,;C3541888;C1720467,completed,
1323,women / men [ % ],C0043210,;C3541888;C1720467,completed,
1323,women n ( % ),C0043210,;C3541888;C1720467,completed,
1323,women n ( % ) *,C0043210,;C3541888;C1720467,completed,
1323,women ( n ( % ) ),C0043210,;C3541888;C1720467,completed,
1323,women ( n = $nmbr$ ),C0043210,;C3541888;C1720467,completed,
1323,women ( n = $nmbr$ ) events,C0043210,;C3541888;C1720467,completed,
1323,women ( n = $nmbr$ ) n / n ( % ),C0043210,;C3541888;C1720467,completed,
1323,women no . ( % ),C0043210,;C3541888;C1720467,completed,
1323,women - no . ( % ),C0043210,;C3541888;C1720467,completed,
1323,women — no . ( % ),C0043210,;C3541888;C1720467,completed,
1323,( women only ),C0043210,;C3541888;C1720467,completed,
1323,womens,C0043210,;C3541888;C1720467,completed,
1323,women t,C0043210,;C3541888;C1720467,completed,
1324,diclofenac,C0012091,,completed,
1324,diclofenac $nmbr$ mg n = $nmbr$ n ( % ),C0012091,,completed,
1324,diclofenac $nmbr$ mg ( n = $nmbr$ ) n ( % ),C0012091,,completed,
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . . n . . ( . % . . ) . . . . . . . . . . .,C0012091,,completed,
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . . n . . ( . % . . ) . . . . . . . . . . . .,C0012091,,completed,
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . n . . . ( . % . . ) . . . . . . . . . . . . . . . . .,C0012091,,completed,
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ ) . . n . . ( . % . . ) . . . . . . . . . . .,C0012091,,completed,
1324,diclofenac $nmbr$ mg ( n $nmbr$ $nmbr$ ) . n . . . ( . % . . ) . . . . . . . . . . .,C0012091,,completed,
1324,diclofenac ( n = $nmbr$ ),C0012091,,completed,
1324,diclofenac ( n = $nmbr$ $nmbr$ ),C0012091,,completed,
1324,diclofenac ( n = $nmbr$ $nmbr$ ),C0012091,,completed,
1327,supplemental oxygen,C4534306,,completed,
1327,supplementary oxygen,C4534306,,completed,
1327,use of supplemental oxygen n ( % ),C4534306,,completed,
1328,bosentan,C0252643,,completed,
1328,bosentan ( n = $nmbr$ ),C0252643,,completed,
1328,bosentan use :,C0252643,,completed,
1328,concomitant use of bosentan n ( % ),C0252643,,completed,
1329,caucasian,C0043157,,completed,
1329,caucasian %,C0043157,,completed,
1329,caucasian ( % ),C0043157,,completed,
1329,caucasiana ( % ),C0043157,,completed,
1329,caucasian ethnicity,C0043157,,completed,
1329,caucasian eze / simva,C0043157,,completed,
1329,caucasian eze / simva ( „ = $nmbr$ },C0043157,,completed,
1329,caucasian eze / simva ( n = $nmbr$ ),C0043157,,completed,
1329,caucasian n ( % ),C0043157,,completed,
1329,caucasian n ( % ) *,C0043157,,completed,
1329,caucasian $nmbr$,C0043157,,completed,
1329,caucasian n = $nmbr$ $nmbr$,C0043157,,completed,
1329,caucasian race,C0043157,,completed,
1329,caucasian race ( % ),C0043157,,completed,
1329,caucasians,C0043157,,completed,
1329,caucasian simva ( „ = $nmbr$ },C0043157,,completed,
1329,caucasian simva ( n = $nmbr$ ),C0043157,,completed,
1329,caucasians ( n = $nmbr$ ),C0043157,,completed,
1329,causaslan,C0043157,,completed,
1329,noncaucasian,C0043157,,completed,
1329,non - caucasian,C0043157,,completed,
1329,non - caucasian eze / simva,C0043157,,completed,
1329,non - caucasian eze / simva ( „ = $nmbr$ },C0043157,,completed,
1329,non - caucasian eze / simva ( n = $nmbr$ ),C0043157,,completed,
1329,non - caucasian simva,C0043157,,completed,
1329,non - caucasian simva ( „ = $nmbr$ },C0043157,,completed,
1329,non - caucasian simva ( n = $nmbr$ ),C0043157,,completed,
1329,race % caucasian,C0043157,,completed,
1329,white / caucasian,C0043157,,completed,
1329,white or caucasian n ( % ),C0043157,,completed,
1331,hawaiian / pacific,C0337920;C0242191,,completed,
1331,hawaiian / pacific islander,C0337920;C0242191,,completed,
1331,hawaiian pacific islander,C0337920;C0242191,,completed,
1331,native hawaiian or,C0337920;C0242191,,completed,
1331,native hawaiian or other pacific,C0337920;C0242191,,completed,
1331,native hawaiian or other pacific islander,C0337920;C0242191,,completed,
1331,native hawaiian / other,C0337920;C0242191,,completed,
1331,native hawaiian / pacific islander,C0337920;C0242191,,completed,
1332,taiwan,;C0039260,,completed,
1334,patients taking mtx n ( % ),C0025677,,completed,
1334,patients taking mtx no . ( % ),C0025677,,completed,
1336,patient - reported outcome measures,C4277735,,completed,
1336,patient - reported outcomes,C4277735,,completed,
1337,back pain,C0004604,,completed,
1337,question $nmbr$ ( neck / back / hip pain ),C0004604,,completed,
1337,total back pain mean ( sd ),C0004604,,completed,
1337,total back pain score ( $nmbr$ – $nmbr$   mm scale ) mean   ±   sd,C0004604,,completed,
1338,eq - $nmbr$ d - $nmbr$   l no pain or discomfortc,C0030193,,completed,
1338,eq - $nmbr$ d - $nmbr$   l no pain or discomfortf,C0030193,,completed,
1338,ontario and mcmaster universities osteoarthritis index ( womac ) can range from $nmbr$ to $nmbr$ for the pain subscale $nmbr$ to $nmbr$ for the stiffness,C0030193,,completed,
1338,pain,C0030193,,completed,
1338,pain subscale,C0030193,,completed,
1338,patient assessment of pain ( $nmbr$ - $nmbr$ mm ) mean ( sd ),C0030193,,completed,
1338,patient ' s assessment of pain,C0030193,,completed,
1338,patient ' s assessment of pain !,C0030193,,completed,
1340,$nmbr$ % decrease in womac pain score,;C0030198,,completed,
1340,scores for global and pain assessments §,;C0030198,,completed,
1340,womac pain score,;C0030198,,completed,
1341,ileum,C0020885,,completed,
1341,ileum only,C0020885,,completed,
1341,ileum only n ( % ),C0020885,,completed,
1342,left main coronary artery,C1261082,,completed,
1342,left main coronary artery n ( % ),C1261082,,completed,
1343,lmwh,C3536766,,completed,
1343,lmwh within $nmbr$ days before randomization — no . / total no . ( % ),C3536766,,completed,
1343,low - molecular - weight heparin,C3536766,,completed,
1343,low molecular weight heparin,C3536766,,completed,
1343,low - molecular - weight heparin — no . ( % ),C3536766,,completed,
1343,low - molecular - weight heparin only,C3536766,,completed,
1343,low - molecular weight heparin or intravenous unfractionated heparin,C3536766,,completed,
1343,low molecular weight ( lmw ) heparin before randomisation,C3536766,,completed,
1345,baseline metformin,C0025598,,completed,
1345,merformin,C0025598,,completed,
1345,metformin,C0025598,,completed,
1345,metformin monotherapy,C0025598,,completed,
1345,metformin n ( % ),C0025598,,completed,
1345,metformin ( n = $nmbr$ ),C0025598,,completed,
1345,metformin ( n $nmbr$ $nmbr$ ),C0025598,,completed,
1345,metformin — no . ( % ),C0025598,,completed,
1345,metformin open - label *,C0025598,,completed,
1345,metformin ± other oral anti - dm drugs,C0025598,,completed,
1345,metformin ? pioglitazone,C0025598,,completed,
1345,metformin • pioglitazone,C0025598,,completed,
1345,metformin use,C0025598,,completed,
1345,metformin use n ( % ),C0025598,,completed,
1345,metformin 一 no . ( % ),C0025598,,completed,
1345,no metformin,C0025598,,completed,
1345,no metformin use,C0025598,,completed,
1345,on metformin ir or metformin xr $nmbr$   mg / d,C0025598,,completed,
1345,overall cohort ( post hoc analysis excluding metformin users ),C0025598,,completed,
1345,plus metformin,C0025598,,completed,
1345,previous metformin use %,C0025598,,completed,
1346,tamsulosin,C0257343,,completed,
1346,tamsulosin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C0257343,,completed,
1346,tamsulosin $nmbr$ . $nmbr$ mg vs . $nmbr$ . $nmbr$ mg,C0257343,,completed,
1346,tamsulosin $nmbr$ . $nmbr$ mg vs . placebo,C0257343,,completed,
1346,tamsulosin ( n = $nmbr$ ),C0257343,,completed,
1346,tamsulosin ( w = $nmbr$ ) $nmbr$ / $nmbr$,C0257343,,completed,
1346,without tamsulosin,C0257343,,completed,
1346,with tamsulosin,C0257343,,completed,
1347,albumin measurements ^ ^,C0201838,,completed,
1347,baseline microalbumin : < $nmbr$,C0201838,,completed,
1348,any glucocorticoid *,C0017710,,completed,
1348,baseline corticosteroidst ( mean dose : $nmbr$ . $nmbr$ mg / day ) n ( % ),,,inprogress,
1348,glucocorticoid,C0017710,,completed,
1348,glucocorticoid ],C0017710,,completed,
1348,glucocorticoids,C0017710,,completed,
1348,glucocorticoids *,C0017710,,completed,
1348,glucocorticoids at baseline,C0017710,,completed,
1348,glucocorticoids only,C0017710,,completed,
1348,good tried previous glucocorticoid,C0205170,,completed,
1348,good tried previous glucocorticoid + laba,C0205170,,completed,
1348,ics dose of stable maintenance treatment ( μ g ) ∗ †,C2930789,,completed,
1348,no glucocorticoids at baseline,C0017710,,completed,
1348,oral glucocorticoid use,C0017710,,completed,
1348,oral glucocorticoid use at baseline — no . ( % ) : t,C0017710,,completed,
1348,postoperative glucocorticoid use,C0017710,,completed,
1348,postoperative glucocorticoid use post - randomisation characteristic * *,C0017710,,completed,
1348,postoperative nsaid or glucocorticoid use,C0017710,,completed,
1348,postoperative nsaid or glucocorticoid use post - randomisation characteristic * *,C0017710,,completed,
1348,steroid use at baseline ( mg / day ),,,inprogress,
1348,systemic glucocorticoid use at randomisation,C0017710,,completed,
1348,systemic glucocorticoid use at randomization n ( % ),C0017710,,completed,
1348,use of oral glucocorticoids,C0017710,,completed,
1349,blood glucose,C0005802,,completed,
1349,blood glucose lowering treatment,C0005802,,completed,
1349,blood glucose - lowering treatments n ( % ),C0005802,,completed,
1349,glycemic characteristics,C0005802,,completed,
1349,glycemic variability mmol / lc,C0005802,,completed,
1350,glyburide,C0017628,,completed,
1350,glyburide dose duringthe study ( mg ),C0017628,,completed,
1350,glyburide ( n = $nmbr$ ),C0017628,,completed,
1351,glycemic indexes,C1136206,,completed,
1354,basdai ⁎ ⁎,C1998004,,completed,
1354,basdai $nmbr$ %,C1998004,,completed,
1354,basdai $nmbr$ n ( % ),C1998004,,completed,
1354,basdai responses at week $nmbr$,C1998004,,completed,
1354,baseline basdai,C1998004,,completed,
1354,total basdai mean ( sd ),C1998004,,completed,
1354,total basdai score mean ( sd ),C1998004,,completed,
1355,mean ( sd ) sdai *,C3871128,,completed,
1355,sdai,C3871128,,completed,
1355,sdai mean ( sd ),C3871128,,completed,
1355,sdai < $nmbr$ . $nmbr$ *,C3871128,,completed,
1355,sdai ( $nmbr$ - $nmbr$ ),C3871128,,completed,
1355,sdai < $nmbr$ t,C3871128,,completed,
1356,duration of osteoarthritis symptoms — yr,C0029408,,completed,
1356,less severe oa symptoms at baseline,C0029408,,completed,
1356,oa,C0029408,,completed,
1356,osteoarthritis,C0029408,,completed,
1356,severe oa symptoms at baselined,C0029408,,completed,
1357,organic,C0747055,,completed,
1358,facial psoriasis n ( % ),C0033860,,completed,
1358,patients without psoriasis ( n = $nmbr$ ),C0033860,,completed,
1358,patients with psoriasis ( n = $nmbr$ ),C0033860,,completed,
1358,psoriasis,C0033860,,completed,
1358,psoriasis characteristics,C0033860,,completed,
1358,psoriasis covering > $nmbr$ % bsa n ( % ) §,C0033860,,completed,
1358,psoriasis ( n =,C0033860,,completed,
1358,psoriasis > $nmbr$ % of bsa,C0033860,,completed,
1358,without psoriasis ( n = $nmbr$ ),C0033860,,completed,
1358,without psoriasis ( n = $nmbr$ $nmbr$ ),C0033860,,completed,
1358,without psoriasis ( zi = $nmbr$ ),C0033860,,completed,
1358,without psoriasis ( zi = $nmbr$ $nmbr$ ),C0033860,,completed,
1358,with psoriasis ( n = $nmbr$ ),C0033860,,completed,
1358,with psoriasis ( zi = $nmbr$ ),C0033860,,completed,
1360,aicd ( % ),C0972395,,completed,
1360,icd,C0972395,,completed,
1360,icd %,C0972395,,completed,
1360,icd n ( % ),C0972395,,completed,
1360,icd vs . placebo,C0972395,,completed,
1360,pacemaker or icd,C0972395,,completed,
1360,relative risk comparing icd therapy and placebo,C0972395,,completed,
1360,relative risk ( $nmbr$ % cl ) comparing icd therapy and placebo using a linear interaction term in the model ( shfmxicd ) *,C0972395,,completed,
1361,combined ischaemic heart disease and / or cerebrovascular disorder *,C0010054;C0151744,,completed,
1361,ihd,C0010054;C0151744,,completed,
1361,ischaemic heart disease,C0010054;C0151744,,completed,
1361,ischaemic heart disease n ( % ),C0010054;C0151744,,completed,
1361,ischaemic heart disease or cerebrovascular disorder n ( % ),C0010054;C0151744,,completed,
1361,ischemic heart disease,C0010054;C0151744,,completed,
1361,ischemic heart disease ( % ),C0010054;C0151744,,completed,
1361,ischemic heart disease %,C0010054;C0151744,,completed,
1361,ischemic heart disease ( % ),C0010054;C0151744,,completed,
1361,ischemic heart disease *,C0010054;C0151744,,completed,
1361,ischemic heart disease indicator no ( n = $nmbr$ l ),C0010054;C0151744,,completed,
1361,ischemic heart disease n ( % ),C0010054;C0151744,,completed,
1361,ischemic heart disease no . ( % ),C0010054;C0151744,,completed,
1361,isehemie heart disease,C0018799,,completed,
1361,myocardial ischaemia,C0010054;C0151744,,completed,
1361,previous ischemic heart disease — no . ( % ),C0010054;C0151744,,completed,
1362,itch nrs,C0033774;C4050142,,completed,
1362,itch nrs $nmbr$ - $nmbr$ ( a ' = $nmbr$ ),C0033774;C4050142,,completed,
1362,itch nrs $nmbr$ - $nmbr$ ( at = $nmbr$ ),C0033774;C4050142,,completed,
1362,itch nrs $nmbr$ - $nmbr$ ( . \ ' = $nmbr$ ),C0033774;C4050142,,completed,
1362,itch nrs $nmbr$ - $nmbr$ ( v = $nmbr$ ),C0033774;C4050142,,completed,
1362,itch nrs $nmbr$ ( v = $nmbr$ ),C0033774;C4050142,,completed,
1364,arterial hypertension,C0020538,,completed,
1364,arterial hypertension *,C0020538,,completed,
1364,arterial hypertension n ( % ),C0020538,,completed,
1364,arterial hypertension no . ( % ),C0020538,,completed,
1364,arterial hypertension — no . ( % ),C0020538,,completed,
1364,duration of hypertension ( months ),C0020538,,completed,
1364,duration of hypertension n ( % ),C0020538,,completed,
1364,duration of hypertension y,C0020538,,completed,
1364,duration of hypertension ( years ),C0020538,,completed,
1364,grade of hypertension,C0020538,,completed,
1364,hvpertension,C0020538,,completed,
1364,hyperlension,C0020538,,completed,
1364,hypertension,C0020538,,completed,
1364,hyper - tension,C0020538,,completed,
1364,hypertension ^,C0020538,,completed,
1364,hypertension ( % ),C0020538,,completed,
1364,hypertension %,C0020538,,completed,
1364,hypertension !,C0020538,,completed,
1364,hypertension ( % ),C0020538,,completed,
1364,hypertension §,C0020538,,completed,
1364,hypertension *,C0020538,,completed,
1364,hypertension history,C0020538,,completed,
1364,hypertension * n ( % ),C0020538,,completed,
1364,hypertension n ( % ),C0020538,,completed,
1364,hypertension n ( % ),C0020538,,completed,
1364,hypertension $nmbr$ ( % ),C0020538,,completed,
1364,hypertension ( > $nmbr$ / $nmbr$ mm hg or taking,C0020538,,completed,
1364,hypertension n / n ( % ),C0020538,,completed,
1364,hypertension — no . ( % ),C0020538,,completed,
1364,hypertension — no . ( % ) |,C0020538,,completed,
1364,hypertension : no ( n = $nmbr$ ),C0020538,,completed,
1364,hypertension — no . / total no . ( % ),C0020538,,completed,
1364,hypertension no . / total no . ( % ) medications in use at baseline no . / total no . ( % ),C0020538,,completed,
1364,hypertension n ( % ) yes,C0020538,,completed,
1364,hypertension ( n 二 $nmbr$ ),C0020538,,completed,
1364,hypertension serum lipid values,C0020538,,completed,
1364,hypertension ( % ) : t,C0020538,,completed,
1364,hypertension treated,C0020538,,completed,
1364,hypertension / yes,C0020538,,completed,
1364,hypertension § yes,C0020538,,completed,
1364,hypertension   n   ( % ),C0020538,,completed,
1364,hypertension 一 no . ( % ),C0020538,,completed,
1364,hypertension 本,C0020538,,completed,
1364,hypertensive,C2712122,,completed,
1364,hypertensive n ( % ),C2712122,,completed,
1364,( including hypertension ),C0020538,,completed,
1364,isoiated systoiic hypertension *,C0020538,,completed,
1364,medical history of hypertension,C0020538,,completed,
1364,no hypertension,C0020538,,completed,
1364,no hypertension ( n = $nmbr$ ),C0020538,,completed,
1364,participant - reported hypertension — no . { % ),C0020538,,completed,
1364,patient - reported hypertension — no . { % ),C0020538,,completed,
1364,previous hypertension,C0020538,,completed,
1364,reported hypertension *,C0020538,,completed,
1364,systemic arterial hypertension n ( % ),C0020538,,completed,
1364,systemic hypertension,C0020538,,completed,
1364,treated for hypertension %,C0020538,,completed,
1364,treated hypertension :,C0020538,,completed,
1365,elevated blood pressure,C0020538,,completed,
1365,high blood pressure,C0020538,,completed,
1365,htn,C0020538,,completed,
1365,no htn,C0020538,,completed,
1365,no prior htn ( n = $nmbr$ $nmbr$ ),C0020538,,completed,
1365,no resistant htn n = $nmbr$ $nmbr$,C0020538,,completed,
1365,prior htn ( n = $nmbr$ $nmbr$ ),C0020538,,completed,
1365,prior hypertension,C0020538,,completed,
1365,prior hypertension yes,C0020538,,completed,
1365,resistant htn n = $nmbr$,C0020538,,completed,
1365,resistant htn : placebo n = $nmbr$,C0020538,,completed,
1365,resistant htn : spiro n = $nmbr$,C0020538,,completed,
1366,aspirin,C0004057,,completed,
1366,aspirin ( % ),C0004057,,completed,
1366,aspirin alone,C0004057,,completed,
1366,aspirin alone ( n / n ),C0004057,,completed,
1366,aspirin alone ( n = $nmbr$ ),C0004057,,completed,
1366,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$,C0004057,,completed,
1366,aspirin alone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,C0004057,,completed,
1366,aspirin and other antiplatelet,C0004057,,completed,
1366,aspirin and ppi,C0004057,,completed,
1366,aspirin / antiplatelet,C0004057,,completed,
1366,aspirin but no ppi,C0004057,,completed,
1366,aspirin - erdp clopidogrel no . of patients / total no .,C0004057,,completed,
1366,aspirin - erdp ( n = $nmbr$ $nmbr$ ),C0004057,,completed,
1366,aspirin n ( % ),C0004057,,completed,
1366,aspirin ( n % ),C0004057,,completed,
1366,aspirin ( n = $nmbr$ $nmbr$ ),C0004057,,completed,
1366,aspirin ( n = $nmbr$ $nmbr$ ),C0004057,,completed,
1366,aspirin ( n = $nmbr$ ) no . of participants with events ( % ),C0004057,,completed,
1366,aspirin no . ( % ),C0004057,,completed,
1366,aspirin or thienopyridines ( % ),C0004057,,completed,
1366,aspirin plus placebo ( n = $nmbr$ ),C0032042,,inprogress,
1366,initial aspirin — no . ( % ),C0004057,,completed,
1366,long - term aspirin,C0004057,,completed,
1366,$nmbr$ aspirin ( n = $nmbr$ $nmbr$ ),C0004057,,completed,
1366,no aspirin,C0004057,,completed,
1366,spirono ( n = $nmbr$ ),C0004057,,completed,
1366,with aspirin ( n = $nmbr$ $nmbr$ ),C0004057,,completed,
1366,without aspirin ( n = $nmbr$ $nmbr$ ),C0004057,,completed,
1369,asian,C0078988,,completed,
1369,asian *,C0078988,,completed,
1369,asian n ( % ),C0078988,,completed,
1369,asian ( $nmbr$ . $nmbr$ % ),C0078988,,completed,
1369,asian ( n = $nmbr$ ),C0078988,,completed,
1369,asian ( n — $nmbr$ ),C0078988,,completed,
1369,asian ( n = $nmbr$ $nmbr$ ),C0078988,,completed,
1369,asian ( n   = $nmbr$ ),C0078988,,completed,
1369,asians ( n = $nmbr$ ),C0078988,,completed,
1369,aslan,C0078988,,completed,
1369,black or asian,C0078988,,completed,
1369,east asian,C0078988,,completed,
1369,non - asian,C0078988,,completed,
1369,non - asian ( n = $nmbr$ $nmbr$ ),C0078988,,completed,
1369,non - east asian §,C0078988,,completed,
1369,non - east asianf,C0078988,,completed,
1369,other asian,C0078988,,completed,
1369,p - value for east asian versus non - east asian *,C0078988,,completed,
1371,hyperkalemia ‡   ( potassium ≥ $nmbr$ . $nmbr$ mmol / l ),C0032821,,completed,
1371,potassium,C0032821,,completed,
1371,potassium mean ( sd ) meq / l,C0032821,,completed,
1371,potassium meq / dl mean,C0032821,,completed,
1371,potassium meq / l,C0032821,,completed,
1371,potassium ( meq / l ),C0032821,,completed,
1371,potassium ( meql ) mean + sd available for $nmbr$ patients,C0032821,,completed,
1371,potassium ( mg / dl ),C0032821,,completed,
1371,potassium — mg / dl,C0032821,,completed,
1371,potassium mmol / l,C0032821,,completed,
1371,potassium ( mmol / l ),C0032821,,completed,
1371,potassium — mmol / liter,C0032821,,completed,
1371,potassium - sparing at enrollment,C0032821,,completed,
1371,potassium supplement,C0032821,,completed,
1372,formoterol tiotropium n = $nmbr$ non - tiotropium n = $nmbr$,C0213771,,completed,
1372,lama ( tiotropium ) b   n ( % ),C0213771,,completed,
1372,non - tiotropium,C0213771,,completed,
1372,patients using concurrent tiotropium,C0213771,,completed,
1372,tiotropium,C0213771,,completed,
1372,tiotropiumc,C0213771,,completed,
1372,tiotropium group ( n = $nmbr$ ),C0213771,,completed,
1372,tiotropium $nmbr$ meg ( n = $nmbr$ ),C0213771,,completed,
1372,tiotropium $nmbr$ m g,C0213771,,completed,
1372,tiotropium $nmbr$ . $nmbr$ pg,C0213771,,completed,
1372,tiotropium $nmbr$ . $nmbr$ μ g ( n   = $nmbr$ ),C0213771,,completed,
1372,tiotropium $nmbr$ . $nmbr$   μ g ( n   =   $nmbr$ ),C0213771,,completed,
1372,tiotropium $nmbr$ pg,C0213771,,completed,
1372,tiotropium $nmbr$   μ g ( n   =   $nmbr$ ),C0213771,,completed,
1372,tiotropium ( n = $nmbr$ ),C0213771,,completed,
1372,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ ),C0213771,,completed,
1372,( tiotropium n = $nmbr$ non - tiotropium n = $nmbr$ $nmbr$,C0213771,,completed,
1372,tiotropium ( n z $nmbr$ ),C0213771,,completed,
1372,tiotropium ( nz $nmbr$ ),C0213771,,completed,
1372,tiotropium + placeb ( n [ $nmbr$ ),C0213771,,completed,
1372,tiotropium vs . salmeterol,C0213771,,completed,
1372,versus tiotropium $nmbr$ . $nmbr$ pg,C0213771,,completed,
1372,versus tiotropium $nmbr$ pg,C0213771,,completed,
1372,with tiotropium,C0213771,,completed,
1373,calcium ( mmol / l ),C0006675,,completed,
1373,calcium mmol $nmbr$ $nmbr$,C0006675,,completed,
1373,dense calcium,C0006675,,completed,
1373,dense calcium mm ’,C0006675,,completed,
1373,serum albumin - adjusted calcium ( mg / dl ),C0006675,,completed,
1374,non - calcium antagonist strategy ( ncas ) ( events / n ),C1518422;C0679199;C0006684,,completed,
1374,non - calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C1518422;C0679199;C0006684,,completed,
1375,belgium,C0004950,,completed,
1376,median ( minimum – maximum ) focal seizure frequency / $nmbr$   days at baseline,;C1524031;C0806909,,completed,
1376,minimum maximum,;C1524031;C0806909,,completed,
1376,minimum - maximum,;C1524031;C0806909,,completed,
1376,minimum : maximum,;C1524031;C0806909,,completed,
1376,minimum / maximum,;C1524031;C0806909,,completed,
1376,minimum — maximum,;C1524031;C0806909,,completed,
1376,minimum — maxim um,;C1524031;C0806909,,completed,
1378,sodium,C0037473,,completed,
1378,sodium meq / l,C0037473,,completed,
1379,serum sodium meq / l,C0523891,,completed,
1379,serum sodium . meq / l,C0523891,,completed,
1379,serum sodium — meq / liter,C0523891,,completed,
1380,daily exercise ( % ),C0015259,,completed,
1380,exercise,C0015259,,completed,
1380,exercise ( % ),C0015259,,completed,
1380,exercise at least weekly ( a ),C0015259,,completed,
1380,exercise n ( % ),C0015259,,completed,
1380,exercise > once weekly,C0015259,,completed,
1380,exercise > once weekly ?,C0015259,,completed,
1380,exercise status,C0015259,,completed,
1380,exercise times per week ( minimum,C0015259,,completed,
1380,physical activity §,C0015259,,completed,
1380,physical activity kcal / wk,C0015259,,completed,
1380,physical activity kcal / wk *,C0015259,,completed,
1380,physical activity kcal / wk < $nmbr$,C0015259,,completed,
1380,some physical activity,C0015259,,completed,
1380,walk for exercise,C0015259,,completed,
1380,walk for exercise ( % ),C0015259,,completed,
1380,with higher classes indicating greater limitations on physical activity owing to,C0015259,,completed,
1381,saudi arabia,C0036243,,completed,
1382,asia,C0003980,,completed,
1382,asia #,C0003980,,completed,
1382,asia and pacific islands,C0003980,,completed,
1382,asia ( n = $nmbr$ ),C0003980,,completed,
1382,asia ( n = $nmbr$ $nmbr$ ),C0003980,,completed,
1382,asia pacific,C0003980,,completed,
1382,asia - pacific,C0003980,,completed,
1382,asia / pacific,C0003980,,completed,
1382,asia / pacific ( % ),C0003980,,completed,
1382,asia pacific and other,C0003980,,completed,
1382,asia pacific and other,C0003980,,completed,
1382,asia - pacific and south africa,C0003980,,completed,
1382,asia pacific and south africa,C0003980,,completed,
1382,asia - pacific hr ( $nmbr$ % cl ),C0003980,,completed,
1382,asia pacific ( n = $nmbr$ ),C0003980,,completed,
1382,asia pacific or other,C0003980,,completed,
1382,asia / pacific / other,C0003980,,completed,
1382,asia - pacific region and south africa,C0003980,,completed,
1382,east asia,C0003980,,completed,
1382,geo graphic region : asia,C0003980,,completed,
1382,region asia / paafic,C0003980,,completed,
1382,residence in asia n ( % ),C0003980,,completed,
1384,cyclosporin,C0010594,,completed,
1384,cyclosporine ( n = $nmbr$ ),C0010594,,completed,
1385,abrupt vessel closure,C0005847;C1521802;C1276802,,completed,
1385,threatened abrupt vessel closure,C0005847;C1521802;C1276802,,completed,
1388,any cough,C0010200,,completed,
1388,cough,C0010200,,completed,
1388,cough ( investigator reported ),C0010200,,completed,
1388,cough n ( % ),C0010200,,completed,
1388,rs - cough & sputumc,C0010200,,completed,
1390,duration of hypercholesterolaemia mean ± sd ( year ),,,completed,
1390,elevated cholesterol,,,completed,
1390,hvpercholesterolemia,C0342882,,completed,
1390,hypercholesterolaemia,,,completed,
1390,hypercholesterolaemia ( % ),,,completed,
1390,hypercholesterolemia,,,completed,
1390,hypercholesterolemia ( % ),,,completed,
1390,hypercholesterolemia *,,,completed,
1390,hypercholesterolemia n ( % ),,,completed,
1390,hypercholesterolemia ( > $nmbr$ mg / dl ),,,completed,
1390,hypercholesterolemia no . ( % ),,,completed,
1390,hypercholesterolemia — no . ( % ),,,completed,
1390,hypercholesterolemia — no . ( % ) *,,,completed,
1390,hypercholesterolemia 一 no . ( % ),,,completed,
1390,hypertension — no . ( % ) hypercholesterolemia — no . ( % ),,,completed,
1390,reported high cholesterol ' !,,,completed,
1391,heterozygous familial hypercholesterolemia,C0342882,,completed,
1391,heterozygous familial hypercholesterolemia †,C0342882,,completed,
1393,cholecystectomy ( n = $nmbr$ ),C0162522,,completed,
1393,laparoscopic cholecystectomy,C0162522,,completed,
1394,cluster seizures,C0036572,,completed,
1394,convulsion,C0036572,,completed,
1394,seizure types reported during baselinee,C0036572,,completed,
1394,seizure worry,C0036572,,completed,
1394,time from end of fit years ( meanisd ),C0036572,,completed,
1397,anti - tnf ir,,,completed,
1397,anti - tnf - ir patients,,,completed,
1397,bdmard - ir,,,completed,
1397,dmard - biologic ir,,,completed,
1397,dmard - ir,,,completed,
1397,dmard - ir / anti - tnf - ir,,,completed,
1397,homa - ir,,,completed,
1397,homa - ir ( % ) b,,,completed,
1397,homa - ir index,,,completed,
1397,homa - ir index — median ( iqr ),,,completed,
1397,homa - ir mean ( sd ) ( mu / l $ mmol / l ) b,,,completed,
1397,homa - ir ( mu / l ^ mmol / l ),,,completed,
1397,homa - ir score,,,completed,
1397,mtx ir,,,completed,
1397,mtx - ir,,,completed,
1397,tnfi - ir,,,completed,
1397,tnf - ir,,,completed,
1401,nonwhite,C0034510;C1518422;C0043157,,completed,
1401,non white,C0043157,,completed,
1401,non - white,C0043157,,completed,
1401,non - white race,C0043157,,completed,
1401,nonwhite race,C0034510;C1518422;C0043157,,completed,
1401,nonwhite race !,C0034510;C1518422;C0043157,,completed,
1401,non - white raceb,C0043157,,completed,
1401,nonwhite race — no . ( % ) ejection fraction,C0034510;C1518422;C0043157,,completed,
1401,race % nonwhite,C0034510;C1518422;C0043157,,completed,
1401,race non - white,C0043157,,completed,
1401,race - nonwhite,C0034510;C1518422;C0043157,,completed,
1401,race - non - white,C0043157,,completed,
1402,asian / black / white / hispanic / other ( % ) clinical parameters,C0043157,,completed,
1402,non - hispanic white,C0043157,,completed,
1402,race no . ( % ) white,C0043157,,completed,
1402,race while,C0034510;C1518422;C0043157,,completed,
1402,race_white %,C0043157,,completed,
1402,white,C0043157,,completed,
1402,w hite,C0043157,,completed,
1402,white %,C0043157,,completed,
1402,whiteb,C0043157,,completed,
1402,white : black : other,C0043157,,completed,
1402,white mtx ( n ),C0043157,,completed,
1402,white n ( % ),C0043157,,completed,
1402,white ( $nmbr$ . $nmbr$ % ),C0043157,,completed,
1402,white n / n ( % ),C0043157,,completed,
1402,white ( n = $nmbr$ ),C0043157,,completed,
1402,white ( n — $nmbr$ ),C0043157,,completed,
1402,white ( n = $nmbr$ $nmbr$ ),C0043157,,completed,
1402,white no . ( % ),C0043157,,completed,
1402,white non - hispanic,C0043157,,completed,
1402,white non - hispanic,C0043157,,completed,
1402,white non - hispanic - n ( % ),C0043157,,completed,
1402,white ( n   = $nmbr$ $nmbr$ ),C0043157,,completed,
1402,white / other,C0043157,,completed,
1402,white race %,C0043157,,completed,
1402,white race n ( % ),C0043157,,completed,
1402,white race — no . ( % ) :,C0043157,,completed,
1402,white race — no . { % ) $,C0043157,,completed,
1402,white race — no . ( % ) f,C0043157,,completed,
1402,white race — no . { % ) - i -,C0043157,,completed,
1402,white race — no . { % ) ' i ',C0043157,,completed,
1402,white race — no . ( % ) : t,C0043157,,completed,
1402,white race — no . / total no . ( % ) $,C0043157,,completed,
1402,white race — no . / total no . ( % ) f,C0043157,,completed,
1403,hydroxychloroquine,C0020336,,completed,
1403,hydroxychloroquine treatment §,C0020336,,completed,
1403,no methotrexate hydroxychloroquine or sulfasalazine treatment,C0020336,,completed,
1404,chondroitin sulfate,;C0008466,,completed,
1404,chondroitin sulfate ( n = $nmbr$ ),;C0008466,,completed,
1404,glucosamine + chondroitin sulfate,;C0008466,,completed,
1405,in the spironolactone group and $nmbr$ patients in the placebo group .,C0037982,,completed,
1405,mra ( spironolactone or eplerenone ),C0037982,,completed,
1405,outcomes by treatment ( spironolactone vs placebo ),C0037982,,completed,
1405,spironolactone,C0037982,,completed,
1405,spironolactone n ( % ),C0037982,,completed,
1405,spironolactone ( n = $nmbr$ ),C0037982,,completed,
1405,values were reported for $nmbr$ patients in the spironolactone group and $nmbr$,C0037982,,completed,
1406,certolizumab pegol ( n = $nmbr$ ),C1872109,,completed,
1406,czp baseline,C1872109,,completed,
1406,czp combined arms ( n = $nmbr$ ),C1872109,,completed,
1406,week $nmbr$ czp dose combined,C1872109,,completed,
1406,week $nmbr$ czp dose combined ( n   =   $nmbr$ ),C1872109,,completed,
1408,concomitant methotrexate n ( % ),C0025677,,completed,
1408,concomitant mtx —,C0025677,,completed,
1408,concomitant mtx use n ( % ),C0025677,,completed,
1408,concomitant use of mtx to week $nmbr$,C0025677,,completed,
1408,csdmard otherthan methotrexate,C0025677,,completed,
1408,csdmards + mtx ( n = $nmbr$ ),C0025677,,completed,
1408,etn + mtx ( n = $nmbr$ ),C0025677,,completed,
1408,etn $nmbr$ mg + mtx n = $nmbr$,C0025677,,completed,
1408,hcq + mtx ( n = $nmbr$ ),C0025677,,completed,
1408,lef + mtx ( n = $nmbr$ ),C0025677,,completed,
1408,methotrexate,C0025677,,completed,
1408,methotrexate dose on day $nmbr$ — mg per wl < $nmbr$,,,inprogress,
1408,methotrexate plus other csdmardfl,C0025677,,completed,
1408,methotrexate user,C0025677,,completed,
1408,mtx,C0025677,,completed,
1408,mtx at baseline,C0025677,,completed,
1408,mtx at baseline n ( % ),C0025677,,completed,
1408,mtx ( n ),C0025677,,completed,
1408,mtx naive or free,C0025677,,completed,
1408,mtx ( n = $nmbr$ ),C0025677,,completed,
1408,mtx n = $nmbr$,C0025677,,completed,
1408,mtx + non - mtx,C0025677,,completed,
1408,mtx only,C0025677,,completed,
1408,mtx + other csdmards,C0025677,,completed,
1408,mtx + other csomards,C0025677,,completed,
1408,mtx + othetcsdmards,C0025677,,completed,
1408,mtx plus infliximab,C0025677,,completed,
1408,mtx use at baseline,C0025677,,completed,
1408,mtx use at randomization n ( % ),C0025677,,completed,
1408,$nmbr$ non - mtx,C0025677,,completed,
1408,no mtx at baseline,C0025677,,completed,
1408,no mtx use at baseline,C0025677,,completed,
1408,other ^,C0025677,,completed,
1408,pbo + mtx,C0025677,,completed,
1408,pbo + mtx ^ mtx,C0025677,,completed,
1408,pbo + mtx n = $nmbr$,C0025677,,completed,
1408,pbo + mtx to mtx,C0025677,,completed,
1408,ssz + mtx ( n = $nmbr$ ),C0025677,,completed,
1409,body - mass index ! waist - to - hip ratio,C0205682,,completed,
1409,waist - hip ratio,C0205682,,completed,
1409,waist : hip ratio,C0205682,,completed,
1409,waist - to - hip female,C0205682,,completed,
1409,waist - to - hip ratio,C0205682,,completed,
1412,atopic,C0392707,,completed,
1412,atopic at baseline : yes,C0392707,,completed,
1412,atopy ( n = $nmbr$ $nmbr$ ),C0392707,,completed,
1412,atopy ( specific ige ) c n ( % ),C0392707,,completed,
1412,dermatitis atopic,C0392707,,completed,
1412,met atopy and ige $nmbr$ - $nmbr$ ku / l criteria ( n = $nmbr$ ),C0392707,,completed,
1412,no atopy ( n = $nmbr$ ),C0392707,,completed,
1413,mean ± sd waist circumference cm,C0455829,,completed,
1413,waist circumference,C0455829,,completed,
1413,waist circumference .,C0455829,,completed,
1413,waist circumference cm,C0455829,,completed,
1413,waist circumference ( cm ),C0455829,,completed,
1413,waist circumference ( cm ),C0455829,,completed,
1413,waist circumference — cm,C0455829,,completed,
1413,waist circumference — cmj,C0455829,,completed,
1413,waist circumference cm mean ( sd ),C0455829,,completed,
1413,waist circumference cm mean ( sd ),C0455829,,completed,
1413,waist circumference ( cm ) : mean ± sd,C0455829,,completed,
1413,waist circumference cm ( sd ),C0455829,,completed,
1413,waist circumference mean ( sd ) cm,C0455829,,completed,
1413,waist circumference mean ( sd ) in,C0455829,,completed,
1413,waist circumference s $nmbr$ ( men ) or > $nmbr$ cm ( women ),C0455829,,completed,
1414,left circumflex,C0226037,,completed,
1414,left circumflex artery,C0226037,,completed,
1414,left circumflex artery n ( % ),C0226037,,completed,
1414,left circumflex coronary artery,C0226037,,completed,
1414,left circumflex n ( % ),C0226037,,completed,
1416,current medication n ( % ),C0746467,,completed,
1416,current medication — no . ( % ),C0746467,,completed,
1420,current cigarette smoker,C3241966,,completed,
1420,current cigarette smoker n ( % ),C3241966,,completed,
1420,current cigarette smoker or within past year,C3241966,,completed,
1420,current / past smoker,C3241966,,completed,
1420,current smoker,C3241966,,completed,
1420,current smoker %,C3241966,,completed,
1420,current smoker »,C3241966,,completed,
1420,current smoker ( % ),C3241966,,completed,
1420,current smoker at baseline   n   ( % ),C3241966,,completed,
1420,current smoker at screeninga n ( % ),C3241966,,completed,
1420,current smoker at screening n ( % ),C3241966,,completed,
1420,current smoker : ex - smoker ( % ),C3241966,,completed,
1420,current smoker n ( % ),C3241966,,completed,
1420,current smoker n ( % },C3241966,,completed,
1420,current smoker n [ % ],C3241966,,completed,
1420,current smoker ( > $nmbr$ cigarettes / day ) — no . ( % ),C3241966,,completed,
1420,current smoker n / n ( % ),C3241966,,completed,
1420,current smoker ( n = $nmbr$ ),C3241966,,completed,
1420,current smoker ( n = $nmbr$ $nmbr$ ),C3241966,,completed,
1420,current smoker ( n = $nmbr$ $nmbr$ ) former smoker ( n = $nmbr$ $nmbr$ ),C3241966,,completed,
1420,current smoker — no . { % ),C3241966,,completed,
1420,current smoker n ( % of patients ),C3241966,,completed,
1420,current smoker ( n z $nmbr$ ),C3241966,,completed,
1420,current smokers,C3241966,,completed,
1420,current smokers %,C3241966,,completed,
1420,current smokers ( % ),C3241966,,completed,
1420,current smokers *,C3241966,,completed,
1420,current smokers ( itt ) ( n = $nmbr$ ),C3241966,,completed,
1420,current smokers n ( % ),C3241966,,completed,
1420,current smokers n ( % ) medicai history n ( % ),C3241966,,completed,
1420,current smokers ( n = $nmbr$ ),C3241966,,completed,
1420,current smokers   n   ( % ),C3241966,,completed,
1420,current tobacco smoker,C3241966,,completed,
1420,current tobacco smoker ( % ) qualifying event ( % ),C3241966,,completed,
1420,ex - / current smoker,C3241966,,completed,
1420,former or current smokers ( % ),C3241966,,completed,
1420,> $nmbr$ . $nmbr$ bpm current smoker,C3241966,,completed,
1420,smoking : current smoker,C3241966,,completed,
1420,smoking history : current smoker,C3241966,,completed,
1420,smoking status current smoker ( n = $nmbr$ ),C3241966,,completed,
1423,by cause of death,C0007465,,completed,
1423,cause of death unknown,C0007465,,completed,
1423,• death from any cause,C0007465,,completed,
1423,death from any cause,C0007465,,completed,
1424,any immunosuppressive agent,C0021081,,completed,
1424,both adalimumab groups ( n = $nmbr$ ) baseline immunosuppressant use,C0021081,,completed,
1424,concomitant immunosuppressive and / or prior anti - tnf use,C0021081,,completed,
1424,corticosteroids and immunosuppressants only,C0021081,,completed,
1424,glucocorticoids and immunosuppressants,C0021081,,completed,
1424,glucocorticoids combined with immunosuppressive agents,C0021081,,completed,
1424,glucocorticoids plus immunosuppressive agents,C0021081,,completed,
1424,immunosuppressant ^,C0021081,,completed,
1424,immunosuppressant ^ ^,C0021081,,completed,
1424,immunosuppressants,C0021081,,completed,
1424,immunosuppressants only,C0021081,,completed,
1424,immunosuppressants onlyff,C0021081,,completed,
1424,immunosuppressant use %,C0021081,,completed,
1424,immunosuppressive agents only,C0021081,,completed,
1424,immunosuppressive use n ( % ),C0021081,,completed,
1424,neither glucocorticoids nor immunosuppressive agents,C0021081,,completed,
1424,no baseline immunosuppressant use,C0021081,,completed,
1424,no concomitant immunosuppressive and / or prior anti - tnf use,C0021081,,completed,
1424,no glucocorticoids or immunosuppressants,C0021081,,completed,
1425,immunomodulators,C1527392,,completed,
1425,immunomodulatory agents,C1527392,,completed,
1426,transient monocular blindness,C0149793,,completed,
1435,positive for rheumatoid factor — no . ( % ) : t,C0035448,,completed,
1435,% rf +,C0035448,,completed,
1435,rf and acpa positive n ( % ),C0035448,,completed,
1435,rf ( iu / ml ),C0035448,,completed,
1435,rf ( mg / dl ),C0035448,,completed,
1435,rf ( mg / dl per unit ),C0035448,,completed,
1435,rf negative and acpa positive n ( % ),C0035448,,completed,
1435,rf positive,C0035448,,completed,
1435,rf % positive,C0035448,,completed,
1435,rf positive %,C0035448,,completed,
1435,rf positive and acpa negative n ( % ),C0035448,,completed,
1435,rf positive n ( % ),C0035448,,completed,
1435,rf - positive > $nmbr$ iu / ml %,C0035448,,completed,
1435,rf positive ( > $nmbr$ iu / ml ) n ( % ),C0035448,,completed,
1435,rf positive no . ( % ),C0035448,,completed,
1435,rf positive — number ( % ),C0035448,,completed,
1435,rheumatoid factor !,C0035448,,completed,
1435,rheumatoid factor - positive,C0035448,,completed,
1435,seropositive ( rf + ve and / or acpa + ve ) subgroup,C0035448,,completed,
1438,time to rx,;C0040223,,completed,time to treatment
1441,rectum and sigmoid colon only,C0034896;C0227391,,completed,
1445,post - procedure,C3272301,,completed,
1446,history of paroxysmal af,C0235480,,completed,
1446,history of paroxysmal atrial fibrillation n ( % ),C0235480,,completed,
1446,paroxysmal af,C0235480,,completed,
1446,paroxysmal atrial fibrillation — no . ( % ),C0235480,,completed,
1447,proximal,C0205107,,completed,
1447,proximal - mainleft,C0205107,,completed,
1448,vorapaxar,C2974521,,completed,
1448,vorapaxar event rate ( n = $nmbr$ ) %,C2974521,,completed,
1448,vorapaxar group ( n = $nmbr$ ),C2974521,,completed,
1448,vorapaxar $nmbr$ - y,C2974521,,completed,
1448,vorapaxar ( n = $nmbr$ ),C2974521,,completed,
1448,vorapaxar n = $nmbr$,C2974521,,completed,
1448,vorapaxar ( n = $nmbr$ ) n ( % ),C2974521,,completed,
1448,vorapaxar ( n = $nmbr$ $nmbr$ ),C2974521,,completed,
1448,vorapaxar ( n = $nmbr$ . $nmbr$ ),C2974521,,completed,
1448,vorapaxar ( n = $nmbr$ $nmbr$ ),C2974521,,completed,
1448,vorapaxar no . ( $nmbr$ - y km % ),C2974521,,completed,
1448,vorapaxar placebo,C2974521,,completed,
1449,varespladib,C2713485,,completed,
1449,varespladib ( n = $nmbr$ ),C2713485,,completed,
1450,use of verapamil or quinidine,C0042523,,completed,
1450,verapamil ( n % ),C0042523,,completed,
1450,verapamil sr,C0042523,,completed,
1450,verapamil - sr ( « = $nmbr$ $nmbr$ ),C0042523,,completed,
1450,verapamil sr n = $nmbr$,C0042523,,completed,
1450,verapamil sr n = $nmbr$ no . ( % ),C0042523,,completed,
1450,verapamil sr ( no . = $nmbr$ ),C0042523,,completed,
1450,verapamil - sr strategy,C0042523,,completed,
1450,verapamil sr strategy ( n = $nmbr$ $nmbr$ ),C0042523,,completed,
1451,or ulcerations ® n ( % ),C0041582,,completed,
1451,ulcer,C0041582,,completed,
1451,ulcer n ( % ) a,C0041582,,completed,
1451,ulcers / gangrene,C0041582,,completed,
1452,alleles,,,completed,
1455,biomarker levels,C0005516,,completed,
1456,gall bladder adverse event ( n = $nmbr$ ),C0877248;C0016976,,completed,
1458,hd edoxaban vs warfarin,C0043031;C2975435,,completed,
1461,latin,;C0023122,,completed,
1461,latin america,;C0023122,,completed,
1461,latin america hr ( $nmbr$ % cl ),;C0023122,,completed,
1461,latin american,;C0023122,,completed,
1461,latin america ( n = $nmbr$ ),;C0023122,,completed,
1461,latin ameriea,;C0023122,,completed,
1461,region latin american,;C0023122,,completed,
1462,mexican,;C0023122,,completed,
1462,mexico,C0025885,,completed,
1462,mexico central / south america,C0025885,,completed,
1463,geographic region - north america,C0028405,,completed,
1463,latin and north america,C0028405,,completed,
1463,n america,C0028405,,completed,
1463,north america,C0028405,,completed,
1463,north america ( % ),C0028405,,completed,
1463,north america *,C0028405,,completed,
1463,north america ( n = $nmbr$ ),C0028405,,completed,
1463,north america n z $nmbr$,C0028405,,completed,
1463,north america / oceania,C0028405,,completed,
1463,north america ( plus america and new zealand ),C0028405,,completed,
1463,region north america,C0028405,,completed,
1463,region - north america,C0028405,,completed,
1463,region north america,C0028405,,completed,
1463,sonti amenca,C0028405,,completed,
1465,adherence > $nmbr$ %,C2364172,,completed,
1465,medication adherence,C2364172,,completed,
1467,cumulative incidence lyear,C0021149,,completed,
1467,cumulative incidence $nmbr$ years,C0021149,,completed,
1467,event incidence / n,C0021149,,completed,
1467,event / patients in group ( incidence / $nmbr$ person - year ),C0021149,,completed,
1467,incidence ^,C0021149,,completed,
1467,incidence %,C0021149,,completed,
1467,incidence *,C0021149,,completed,
1467,incidencea,C0021149,,completed,
1467,incidence of each outcome,C0021149,,completed,
1467,incidence ° / o ( $nmbr$ / $nmbr$ cl ),C0021149,,completed,
1467,$nmbr$ - year cumulative incidence % ( ci ),C0021149,,completed,
1469,at clinic diastolic pressure < $nmbr$ mm hg,C0005823,,completed,
1469,at clinic diastolic pressure > $nmbr$ mm hg,C0005823,,completed,
1469,at clinic systolic pressure < $nmbr$ mm hg,C0005823,,completed,
1469,at clinic systolic pressure > $nmbr$ mm hg,C0005823,,completed,
1469,at home diastolic pressure < $nmbr$ mm hg,C0005823,,completed,
1469,at home diastolic pressure > $nmbr$ mm hg,C0005823,,completed,
1469,at home systolic pressure < $nmbr$ mm hg,C0005823,,completed,
1469,at home systolic pressure > $nmbr$ mm hg,C0005823,,completed,
1469,baseline diastolic blood pressure mean ( sd ) mm hg,C0005823,,completed,
1469,baseline diastolic blood pressure ( mm hg ),C0005823,,completed,
1469,baseline mm hg,C0005823,,completed,
1469,baseline mssbp / msdbp mm hg,C0005823,,completed,
1469,baseline sbp ( mm hg ),C0005823,,completed,
1469,baseline sedbp mean ( sd ) mm hg §,C0005823,,completed,
1469,baseline sitting sbp $nmbr$ mm hg,C0005823,,completed,
1469,baseline systolic blood pressure mean ( sd ) mm hg,C0005823,,completed,
1469,baseline systolic blood pressure ( mm hg ),C0005823,,completed,
1469,bl mean ( mmhg ),C0005823,,completed,
1469,blood pressure in mm hg mean ( sd ),C0005823,,completed,
1469,blood pressure mean ( sd ) mm hg,C0005823,,completed,
1469,blood pressure mean ± sd mm hg,C0005823,,completed,
1469,blood pressure mean ( sd ) mm hg systolic,C0005823,,completed,
1469,blood pressure mean ( sd ) [ range ] mm hg,C0005823,,completed,
1469,blood pressure mm hg mean ( sd ),C0005823,,completed,
1469,blood pressure mmhg mean ( sd ),C0005823,,completed,
1469,blood pressure ( mm hg ) systolic,C0005823,,completed,
1469,blood pressure : systolic / diastolic ( mm hg ) ( mean sd ),C0005823,,completed,
1469,blood pressure systolic mm hg,C0005823,,completed,
1469,change from baseline mmhg,C0005823,,completed,
1469,change in bp mm hg,C0005823,,completed,
1469,daytime mean dbp ( abpm ) at week $nmbr$ mmhg,C0005823,,completed,
1469,diastolic blood pressurea mmhg,C0005823,,completed,
1469,diastolic blood pressure mmhg,C0005823,,completed,
1469,diastolic blood pressure ( mm hg ),C0005823,,completed,
1469,diastolic blood pressure mm   hg,C0005823,,completed,
1469,diastolic blood pressure mm hg ^,C0005823,,completed,
1469,diastolic blood pressure - mmhg,C0005823,,completed,
1469,diastolic blood pressure ( mm hg ) :,C0005823,,completed,
1469,diastolic blood pressure ( mmhg ),C0005823,,completed,
1469,diastolic blood pressure — mm hg,C0005823,,completed,
1469,diastolic blood pressure mm hg mean ( sd ),C0005823,,completed,
1469,diastolic blood pressure mm hg mean ± sd,C0005823,,completed,
1469,diastolic blood pressure mmhg mean ( sd ),C0005823,,completed,
1469,diastolic blood pressure ( mm hg ) mean ( sd ),C0005823,,completed,
1469,diastolic blood pressure mmhg mean ( sd ),C0005823,,completed,
1469,diastolic blood pressure mm hg ( sd ),C0005823,,completed,
1469,diastolic blood pressure > $nmbr$ mm hg,C0005823,,completed,
1469,diastolic mean ( sd ) mm hg,C0005823,,completed,
1469,diastolic — mean ( sd ) ( mm hg ),C0005823,,completed,
1469,diastolic ( mm hg ),C0005823,,completed,
1469,diastolic ( mmhg ),C0005823,,completed,
1469,diastolic — mm hg,C0005823,,completed,
1469,diastolic pressure mm hg,C0005823,,completed,
1469,map ( mmhg ),C0005823,,completed,
1469,mean blood pressure mm hg,C0005823,,completed,
1469,mean bp ( mmhg ),C0005823,,completed,
1469,mean diastolic blood pressure mm hg,C0005823,,completed,
1469,mean diastolic blood pressure ( sd ) mm hg,C0005823,,completed,
1469,mean — mm hg,C0005823,,completed,
1469,mean pulmonary artery pressure mm hg,C0005823,,completed,
1469,mean ( s . d . ) diastolic blood pressure mm hg,C0005823,,completed,
1469,mean ± sd msdbp mm hg,C0005823,,completed,
1469,mean sd mssbp mm hg,C0005823,,completed,
1469,mean ( s . d . ) systolic blood pressure mm hg,C0005823,,completed,
1469,mean systolic blood pressure mm hg,C0005823,,completed,
1469,mean systolic blood pressure mm hg ( sd ),C0005823,,completed,
1469,mean systolic blood pressure ( sd ) mm hg,C0005823,,completed,
1469,mean systolic bp mmhg mean = sd,C0005823,,completed,
1469,mm hg,C0005823,,completed,
1469,msdbp mm hg,C0005823,,completed,
1469,msdbp ( mm hg ),C0005823,,completed,
1469,mssbp mm hg,C0005823,,completed,
1469,mssbp ( mm hg ),C0005823,,completed,
1469,mssbp < $nmbr$ mmhg,C0005823,,completed,
1469,n ( % ) blood pressure - mean ( sd ) mm hg,C0005823,,completed,
1469,nighttime mean dbp ( abpm ) at week $nmbr$ mmhg,C0005823,,completed,
1469,$nmbr$ l $nmbr$ mmhg,C0005823,,completed,
1469,nob systolic blood pressure ( mm hg ),C0005823,,completed,
1469,^ numbers do not always sum to group totals due to missing information for some variables . fbody mass index was calculated as weight in kilograms divided by the square of height in meters . ^ hypertension was defined as a self - reported systolic blood pressure > $nmbr$ mm hg a diastolic blood pressure > $nmbr$ mm hg or physician - diagnosed hypertension . § hyperlipidemia was defined as a self - reported total cholesterol > $nmbr$ mg / dl ( $nmbr$ . $nmbr$ mmol / l ) or physician - diagnosed high cholesterol . | | diabetes was defined by self - report .,C0005823,,completed,
1469,receiving antihypertensive treatment n ( % ) blood pressure mm hg mean ( sd ),C0005823,,completed,
1469,sbp mm hg,C0005823,,completed,
1469,sbp mm   hg,C0005823,,completed,
1469,sbp < $nmbr$ mm hg,C0005823,,completed,
1469,sbp > $nmbr$ mm hg,C0005823,,completed,
1469,sitting blood pressure — mmhg,C0005823,,completed,
1469,sitting diastolic blood pressure ( mm hg ),C0005823,,completed,
1469,sitting systolic blood pressure ( mm hg ),C0005823,,completed,
1469,sl $nmbr$ mm hg,C0005823,,completed,
1469,s $nmbr$ mmhg,C0005823,,completed,
1469,systolic blood pressurea mm hg,C0005823,,completed,
1469,systolic blood pressure mean ( sd ) mm hg,C0005823,,completed,
1469,systolic blood pressure ( mm hg ),C0005823,,completed,
1469,systolic blood pressure mm hg,C0005823,,completed,
1469,systolic blood pressure mm   hg,C0005823,,completed,
1469,systolic blood pressure mm hg ^,C0005823,,completed,
1469,systolic blood pressure mmhg *,C0005823,,completed,
1469,systolic blood pressure - mmhg,C0005823,,completed,
1469,systolic blood pressure ( mm hg ),C0005823,,completed,
1469,systolic blood pressure — mmhg,C0005823,,completed,
1469,systolic blood pressure — mm hg,C0005823,,completed,
1469,systolic blood pressure [ mmhg ] ( interaction : p = $nmbr$ . $nmbr$ ),C0005823,,completed,
1469,systolic blood pressure mm hg mean ( sd ),C0005823,,completed,
1469,systolic blood pressure mm hg mean ± sd,C0005823,,completed,
1469,systolic blood pressure mmhg mean ( sd ),C0005823,,completed,
1469,systolic blood pressure ( mm hg ) mean ( sd ),C0005823,,completed,
1469,systolic blood pressure ( mmhg ) mean ± sd,C0005823,,completed,
1469,systolic blood pressure mmhg mean ( sd ),C0005823,,completed,
1469,systolic blood pressure mm hg < $nmbr$,C0005823,,completed,
1469,systolic blood pressure mm hg ( sd ),C0005823,,completed,
1469,systolic blood pressure > $nmbr$ mm hg,C0005823,,completed,
1469,systolic blood pressure < $nmbr$ mm hg and diastolic,C0005823,,completed,
1469,systolic blood pressure < $nmbr$ mm hg and diastolic blood pressure < $nmbr$ mm hg,C0005823,,completed,
1469,systolic blood pressure > $nmbr$ mm hg n ( % ),C0005823,,completed,
1469,systolic blood pressure > $nmbr$ mm hg — no . ( % ),C0005823,,completed,
1469,systolic blood pressure > $nmbr$ mm hg or diastolic,C0005823,,completed,
1469,systolic blood pressure > $nmbr$ mm hg or diastolic blood pressure > $nmbr$ mm hg,C0005823,,completed,
1469,systolic bp mmhg,C0005823,,completed,
1469,systolic bp mm hg,C0005823,,completed,
1469,systolic bp ( mm hg ),C0005823,,completed,
1469,systolic bp ( mmhg ),C0005823,,completed,
1469,systolic bp ( mmhg ) *,C0005823,,completed,
1469,systolic bp mm hg ( mean ) nyha class,C0005823,,completed,
1469,systolic bp mm   hg mean ( sd ),C0005823,,completed,
1469,systolic bp mm hg mean ( sd ),C0005823,,completed,
1469,systolic bp mmhg mean ( sd ),C0005823,,completed,
1469,systolic bp mmhg mean ± sd,C0005823,,completed,
1469,systolic bp mmhg ( sd ),C0005823,,completed,
1469,systolic — mean ( sd ) ( mm hg ),C0005823,,completed,
1469,systolic ( mm hg ),C0005823,,completed,
1469,systolic ( mmhg ),C0005823,,completed,
1469,systolic — mm hg,C0005823,,completed,
1469,systolic pressure mm hg,C0005823,,completed,
1469,systolic pressure — mm hg,C0005823,,completed,
1469,systolic pulmonary arterial pressure mean ( sd ) mm hg,C0005823,,completed,
1469,treated at baseline mm hg : sbp mean ( sd ),C0005823,,completed,
1469,untreated at baseline mean ( sd ) mm hg,C0005823,,completed,
1469,untreated at baseline mm hg : sbp mean ( sd ),C0005823,,completed,
1469,visit $nmbr$ sbp mm hg,C0005823,,completed,
1493,family history ^,C0241889,,completed,
1493,family history n ( % ),C0241889,,completed,
1493,family history of cancera,C0241889,,completed,
1493,family history of cancerf,C0241889,,completed,
1493,family history of chd ( n = $nmbr$ $nmbr$ ),C0241889,,completed,
1493,family history of premature,C0241889,,completed,
1493,family history of premature chd,C0241889,,completed,
1493,family history of premature chd * *,C0241889,,completed,
1493,family history of premature chdj,C0241889,,completed,
1493,family history of venous thromboembolism ( % ),C0241889,,completed,
1493,family history of vte,C0241889,,completed,
1493,history of cancer,C0241889,,completed,
1493,history of pvd,C0241889,,completed,
1493,history of pvd n ( % ),C0241889,,completed,
1493,history of pvd no . ( % ),C0241889,,completed,
1493,no family history of chd ( n = $nmbr$ $nmbr$ ),C0241889,,completed,
1493,no history of cancer,C0241889,,completed,
1493,no history of migraine,C0241889,,completed,
1495,hypertrophy n ( % ),,,completed,
1496,history of lvh on electrocardiogram,C1623258,,completed,
1496,hypertension and left ventricular hypertrophy,C0149721,,completed,
1496,hypertrophy per ecg ( n = $nmbr$ $nmbr$ ),,,completed,
1496,left ventricular hypertrophy,C0149721,,completed,
1496,left ventricular hypertrophy ( % ),C0149721,,completed,
1496,left ventricular hypertrophy * *,C0149721,,completed,
1496,left ventricular hypertrophy n ( % ),C0149721,,completed,
1496,left ventricular hypertrophy — no . ( % ),C0149721,,completed,
1496,left ventricular hypertrophy on echo,C0149721,,completed,
1496,lelt ventricular hypertrophy *,C0149721,,completed,
1496,lvh by electrocardiogram,C1623258,,completed,
1496,lvh by electrocardiogram n ( % ),C1623258,,completed,
1496,lvh ( from electrocardiogram ),C1623258,,completed,
1496,lv hypertrophy n ( % ),C0149721,,completed,
1499,chylomicron cholesterol,C0008731,,completed,
1499,chylomicron triglycerides,C0008731,,completed,
1501,cholesterol,C0008377,,completed,
1501,cholesterol ( % ),C0008377,,completed,
1501,cholesterol mmol / l,C0008377,,completed,
1501,cholesterol ( mmol / l ),C0008377,,completed,
1501,cholesterol — mmol / liter,C0008377,,completed,
1501,cholesterol ( . $nmbr$ . $nmbr$ mmol / l ) n ( % ),C0008377,,completed,
1501,hba $nmbr$ c — % cholesterol — mmol / l,C0008377,,completed,
1504,baseline total cholesterol,C0543421,,completed,
1504,cholesterol mg / dl total,C0543421,,completed,
1504,median total cholesterol mmol / l,C0543421,,completed,
1504,total cholesterohhdl cholesterol ratio,C0543421,,completed,
1504,total cholesterol,C0543421,,completed,
1504,total cholesterol ^,C0543421,,completed,
1504,total cholesterol %,C0543421,,completed,
1504,total cholesterol *,C0543421,,completed,
1504,total cholesterol mean ( sd ),C0543421,,completed,
1504,total cholesterol mean ( sd ) mg / dl,C0543421,,completed,
1504,total cholesterol mg / dl,C0543421,,completed,
1504,total cholesterol mg / dl ^,C0543421,,completed,
1504,total cholesterol mg / dl ^,C0543421,,completed,
1504,total cholesterol - mg / dl * *,C0543421,,completed,
1504,total cholesterol ( mg / dl ),C0543421,,completed,
1504,total cholesterol — mg / dl,C0543421,,completed,
1504,total cholesterol mg / dl mean ( sd ),C0543421,,completed,
1504,total cholesterol ( mg / dl ) mean + sd available for $nmbr$ patients,C0543421,,completed,
1504,total cholesterol mmol / l,C0543421,,completed,
1504,total cholesterol ( mmol / l ),C0543421,,completed,
1504,total cholesterol ( mmol / l ) :,C0543421,,completed,
1504,total cholesterol mmol / l mean ( sd ),C0543421,,completed,
1504,total cholesterol ( mmol / l ) mean ( sd ),C0543421,,completed,
1504,total cholesterol mmol / l ( sd ),C0543421,,completed,
1504,total cholesterol mmol / l 本,C0543421,,completed,
1504,total cholesterol ( mmo $nmbr$ / $nmbr$ ),C0543421,,completed,
1504,total cholesterol > $nmbr$ mg / dl,C0543421,,completed,
1504,total cholesterol $nmbr$ < $nmbr$ mg / dl,C0543421,,completed,
1504,total cholesterol $nmbr$ > $nmbr$ mg / dl,C0543421,,completed,
1504,total cholesterol ( sd ) mg / dl,C0543421,,completed,
1508,formoterol $nmbr$ gg bid,C0060657;C0073992,,inprogress,
1508,formoterol $nmbr$ gg ( n = $nmbr$ ),C0060657;C0073992,,inprogress,
1508,formoterol $nmbr$   μ g ( n   =   $nmbr$ ),C0060657;C0073992,,inprogress,
1508,laba ',,,inprogress,
1508,laba alone,,,inprogress,
1508,labd alone,,,inprogress,
1508,previous labd alone,,,inprogress,
1508,salmeterol,C0060657;C0073992,,inprogress,
1508,salmeterol $nmbr$ gg bid,C0060657;C0073992,,inprogress,
1508,salmeterol ( n = $nmbr$ ),C0060657;C0073992,,inprogress,
1508,salmeterol ( n [ $nmbr$ ),C0060657;C0073992,,inprogress,
1508,treated with laba %,C0004147,,completed,
1509,indacaterol - glycopyrronium group ( n = $nmbr$ ),C3814772;C1722260,,completed,
1509,indacaterol / glycopyrronium $nmbr$ / $nmbr$   μ g o . d .,C3814772;C1722260,,completed,
1524,both ptca and cabg,C2936173;C0010055,,completed,
1524,cabg or ptca ( % ),C2936173;C0010055,,completed,
1524,cabg or ptca / pci,C2936173;C0010055,,completed,
1524,percutaneous coronary intervention or coronary artery bypass graft surgery n ( % ),C0010055,,completed,
1524,prior ptca or cabg,C2936173;C0010055,,completed,
1524,ptca / cabg,C2936173;C0010055,,completed,
1524,ptca or pci,C2936173;C0010055,,completed,
1532,baseline renal function ( eclcr ),C0232804,,completed,
1532,deterioration in renal function ( investigator reported ),C0232804,,completed,
1532,renal function,C0232804,,completed,
1532,renal function *,C0232804,,completed,
1532,renal functiona,C2986535;C0022646,,completed,
1532,renal functionb,C2986535;C0022646,,completed,
1532,renal function bn ( % ),C0232804,,completed,
1532,renal functionc n ( % ),C2986535;C0022646,,completed,
1532,renal function : creatinine clearance,C0232804,,completed,
1532,renal function ( egfr ) according to mdrd n ( % ),C0232804,,completed,
1532,renal function : ! : n ( % ),C0232804,,completed,
1536,erectile dysfunction,C0242350,;C0221138;C0277785;C0542341;C0700205;C1705273;C3887505,completed,
1547,carotid,C0007272,,completed,
1547,carotid artery diseaset,C0007272,,completed,
1547,carotid artery — no . ( % ),C0007272,,completed,
1547,carotid infarct,C0007272,,completed,
1547,carotid revascularization,C0007272,,completed,
1547,> $nmbr$ % stenosis of coronary carotid or lower extremity arteries,C0007272,,completed,
1547,ultrasound carotid arteries,C0007272,,completed,
1566,liraglutide,C1456408,,completed,
1566,liraglutide n ( % ),C1456408,,completed,
1566,liraglutide ( « = $nmbr$ ),C1456408,,completed,
1566,liraglutide $nmbr$ . $nmbr$ mg,C1456408,,completed,
1566,liraglutide $nmbr$ . $nmbr$ mg / day ( n = $nmbr$ ),C1456408,,completed,
1566,liraglutide $nmbr$ . $nmbr$ mg ls means ( n ),C1456408,,completed,
1566,liraglutide $nmbr$ - $nmbr$ mg mean ( n ),C1456408,,completed,
1566,liraglutide $nmbr$ . $nmbr$ mg mean ( n ),C1456408,,completed,
1566,liraglutide $nmbr$ - $nmbr$ mg ( n = $nmbr$ ),C1456408,,completed,
1566,liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$,C1456408,,completed,
1566,liraglutide $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C1456408,,completed,
1566,liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$,C1456408,,completed,
1566,liraglutide $nmbr$ . $nmbr$ mg n = $nmbr$ $nmbr$,C1456408,,completed,
1566,liraglutide ( $nmbr$ . $nmbr$ mg ) ± oad,C1456408,,completed,
1566,liraglutide ( n = $nmbr$ ),C1456408,,completed,
1566,liraglutide ( n = $nmbr$ $nmbr$ ),C1456408,,completed,
1566,n ( % ) liraglutide $nmbr$ placebo,C1456408,,completed,
1575,prostate volume ( cm $nmbr$ ),C1441416,,completed,
1575,prostate volume ( ml ),C1441416,,completed,
1579,antihypertensive,;C0003364,,completed,
1579,anti - hypertensive,;C0003364,,completed,
1579,antihypertensive agents,;C0003364,,completed,
1579,antihypertensive agents *,;C0003364,,completed,
1579,antihypertensive agents n ( % ),;C0003364,,completed,
1579,antihypertensive agents ( n per patient ),;C0003364,,completed,
1579,antihypertensive agent use,;C0003364,,completed,
1579,antihypertensive drug %,;C0003364,,completed,
1579,antihypertensive drugs,;C0003364,,completed,
1579,antihypertensive medication,;C0003364,,completed,
1579,antihypertensive medication ),;C0003364,,completed,
1579,antihypertensive medication $nmbr$ ',;C0003364,,completed,
1579,antihypertensive medication or,;C0003364,,completed,
1579,antihypertensive medication use n ( % ),;C0003364,,completed,
1579,antihypertensives,;C0003364,,completed,
1579,anti - hypertensives,;C0003364,,completed,
1579,antihypertensives ' *,;C0003364,,completed,
1579,antihypertensives n ( % ),;C0003364,,completed,
1579,antihypertensive treatment,;C0003364,,completed,
1579,anti - hypertensive treatment history n ( % ),C2712122,,completed,
1579,antihypertensive treatment n ( % ),;C0003364,,completed,
1579,antihypertensive treatments,;C0003364,,completed,
1579,antihypertensive use,;C0003364,,completed,
1579,any anti - hypertensive agent,;C0003364,,completed,
1579,any antihypertensive agent,;C0003364,,completed,
1579,any antihypertensive drug,;C0003364,,completed,
1579,baseline anti - hypertensive usea,;C0003364,,completed,
1579,hypertension ( bp > $nmbr$ / $nmbr$ mmhg or using antihypertensive medication ),;C0003364,,completed,
1579,mean number of antihypertensive medications at $nmbr$ year   *,;C0003364,,completed,
1579,medications antihypertensive drugs,;C0003364,,completed,
1579,$nmbr$ antihypertensive medication,;C0003364,,completed,
1579,> $nmbr$ antihypertensive medications,;C0003364,,completed,
1579,number of antihypertensive medications at study entry,;C0003364,,completed,
1579,number of antihypertensive medications n ( % ),;C0003364,,completed,
1579,on antihypertensive medication at baseline n ( % ) ‡,;C0003364,,completed,
1579,on antihypertensive treatment n ( % ),;C0003364,,completed,
1579,one antihypertensive medication,;C0003364,,completed,
1579,or taking antihypertensive medication,;C0003364,,completed,
1579,other antihypertensive,;C0003364,,completed,
1579,other anti - hypertensive,;C0003364,,completed,
1579,other antihypertensive agents,;C0003364,,completed,
1579,other antihypertensive drug,;C0003364,,completed,
1579,other antihypertensive medications,;C0003364,,completed,
1579,other anti - hypertensives,;C0003364,,completed,
1579,other blood - pressure drug,;C0003364,,completed,
1579,other blood pressure - lowering drugs,;C0003364,,completed,
1579,patients on antihypertensive medications n ( % ) | |,;C0003364,,completed,
1579,previous antihypertensive treatment,;C0003364,,completed,
1579,previous antihypertensive treatment — no . ( % ),;C0003364,,completed,
1579,prior antihypertensive medication n ( % ),;C0003364,,completed,
1579,taking antihypertensive medication at baseline no . ( % ) e,;C0003364,,completed,
1579,type of antihypertensive medication use among patients using antihypertensive medications n ( % ),;C0003364,,completed,
1579,types of antihypertensive medications at $nmbr$ year   †,;C0003364,,completed,
1579,use of anti - hypertensive agents n ( % ) *,C2712122,,completed,
1579,use of antihypertensive drugs,;C0003364,,completed,
1611,hepatic disorders,C0023895,,completed,
1611,liver disorder,C0023895,,completed,
1631,components of primary composite end point — secondary end points,C0205199,,completed,
1631,composite,C0205199,,completed,
1631,( composite endpoint ),C0205199,,completed,
1631,composite endpoint,C0205199,,completed,
1631,composite endpoint ( a $nmbr$ c < $nmbr$ . $nmbr$ % bp,C0205199,,completed,
1631,composite microvascular end point *,C0205199,,completed,
1631,composite ocular end point ^,C0205199,,completed,
1631,composite of doubling of serum creatinine end - stage kidney disease or death from renal causes,C0205199,,completed,
1631,composite vascular endpoint,C0205199,,completed,
1631,cromoglicate,C0205199,,completed,
1631,disease - progression composite outcome !,C0205199,,completed,
1631,primary composite end point,C0205199,,completed,
1631,primary composite end point ‡,C0205199,,completed,
1631,primary composite endpoint ‡,C0205199,,completed,
1631,renal composite *,C0205199,,completed,
1661,cardiac catheterisation or pci for index event,C0018795,;C4049621,completed,
1661,history of pci / ptca,C2936173;C0010055,,completed,
1661,index percutaneous coronary intervention,C1532338,,completed,
1661,pci - hospital,C0019994,;C4049621,completed,
1661,percutaneous coronary intervention,C1532338,,completed,
1661,percutaneous coronary intervention §,C1532338,,completed,
1661,percutaneous coronary intervention done *,C1532338,,completed,
1661,percutaneous coronary intervention n ( % ),C1532338,,completed,
1661,percutaneous coronary intervention n ( % ),C1532338,,completed,
1661,percutaneous coronary revascularization,C1532338,,completed,
1661,percutaneous transluminal coronary angioplasty,C2936173;C0010055,,completed,
1661,previous percutaneous coronary intervention,C1532338,,completed,
1661,previous percutaneous coronary intervention %,C1532338,,completed,
1661,previous ptca,C2936173;C0010055,,completed,
1661,prior percutaneous coronary intervention,C1532338,,completed,
1661,prior percutaneous coronary intervention n ( % ),C1532338,,completed,
1661,prior percutaneous coronary intervention — no . ( % ),C1532338,,completed,
1661,prior percutaneous coronary intervention — no . / total no . ( % ),C1532338,,completed,
1661,ptca,C2936173;C0010055,,completed,
1684,total bilirubin mg / dl,;C0005437,,completed,
1684,total bilirubin > $nmbr$ x uln $nmbr$,;C0005437,,completed,
1691,aminosalicylate,C0368663,,completed,
1691,aminosalicylates,C0368663,,completed,
1691,aminosalicylates * *,C0368663,,completed,
1691,aminosalicylates n,C0368663,,completed,
1691,concomitant aminosalicylates n [ % ] concomitant corticosteroids n [ % ] mayo score mean [ sd ],C0368663,,completed,
1691,$nmbr$ - aminosalicylates | | | |,C0368663,,completed,
1691,$nmbr$ - aminosalicylates {,C0368663,,completed,
1691,$nmbr$ - aminosalicylates ’ i i ‘,C0368663,,completed,
1691,no aminosalicylates n,C0368663,,completed,
1691,oral aminosalicylates,C0368663,,completed,
1698,arteriosclerosis,C0004153,,completed,
1698,atherosclerosis,C0004153,,completed,
1698,atherosclerosis ^ n ( % ),C0004153,,completed,
1698,atherosclerotic cardiovascular disease,C0004153,,completed,
1698,atherosclerotic cardiovascular disease *,C0004153,,completed,
1698,atherosclerotic vascular disease n ( % ) §,C0004153,,completed,
1698,atherosclerotic vascular disease — no .,C0004153,,completed,
1698,established ascvd,C0443211,,completed,
1698,established ascvd or > $nmbr$ cv risk factors,C0443211,,completed,
1698,established atherosclerotic,C0443211,,completed,
1698,established atherosclerotic cardiovascular disease,C0004153,,completed,
1698,established atherosclerotic cardiovascular disease — no . { % ),C0004153,,completed,
1698,established atherosclerotic cv disease §,C0007222,,completed,
1698,established atherosclerotic disease n ( % ),C0443211,,completed,
1698,high risk with atherosclerotic vascular disease *,C0004153,,completed,
1698,large - artery atherosclerosis,C0004153,,completed,
1698,> $nmbr$ cv risk factors ^ or established atherosclerotic cv disease,C0007222,,completed,
1698,> $nmbr$ cv risk factors 咐 or established atherosclerotic cv disease,C0443211,,completed,
1698,qualifying atherosclerosis,C0004153,,completed,
1698,qualifying type of atherosclerosis n ( % ),C0004153,,completed,
1698,qualifying type of atherosclerosis — no . ( % ),C0004153,,completed,
1698,risk factors for atherosclerosis,C0004153,,completed,
1721,balloon angioplasty,C0002996,,completed,
1721,balloon angioplasty — no . ( % ),C0002996,,completed,
1721,balloon angioplasty plus abciximab,C0002996,,completed,
1721,previous balloon angioplasty,C0002996,,completed,
1721,previous balloon angioplasty n ( % ),C0002996,,completed,
1722,angioplasty,C0162577,,completed,
1722,cabg or angioplasty,C0162577,,completed,
1722,peripheral angioplasty,C0162577,,completed,
1722,post - fibrinolysis angioplasty ( n = $nmbr$ ),C0016017,,completed,
1722,previous angioplasty n ( % ),C0162577,,completed,
1722,previous coronary angioplasty n ( % ),C2144990,,completed,
1722,prior angioplasty,C0162577,,completed,
1734,baseline body mass index,C1305855,,completed,
1734,bmi ( $nmbr$ . $nmbr$ $nmbr$ . $nmbr$ ),C1305855,,completed,
1734,body - mass index,C1305855,,completed,
1734,body - mass index ^,C1305855,,completed,
1734,body - mass index ^ :,C1305855,,completed,
1734,body - mass index !,C1305855,,completed,
1734,body - mass index - ! ',C1305855,,completed,
1734,body - mass index : ! :,C1305855,,completed,
1734,body - mass index ”,C1305855,,completed,
1734,body - mass index ),C1305855,,completed,
1734,body - mass index ) -,C1305855,,completed,
1734,body - mass index ) ',C1305855,,completed,
1734,body - mass index §,C1305855,,completed,
1734,body - mass index $,C1305855,,completed,
1734,body - mass index *,C1305855,,completed,
1734,body mass index,C1305855,,completed,
1734,body mass index ^,C1305855,,completed,
1734,body mass index %,C1305855,,completed,
1734,body mass index :,C1305855,,completed,
1734,body mass index *,C1305855,,completed,
1734,body mass index +,C1305855,,completed,
1734,body mass index blood pressure — mmhg,C1305855,,completed,
1734,body mass index ( bmi ) kg / m $nmbr$,C1305855,,completed,
1734,body - mass index categories — no . ( % ) : c,C1305855,,completed,
1734,body mass index category no . ( % ) l,C1305855,,completed,
1734,body mass index group ( kg / m $nmbr$ ) ≥ $nmbr$ kg / m $nmbr$ — no . ( % ),C1305855,,completed,
1734,body - mass index ( kg / cm $nmbr$ ),C1305855,,completed,
1734,body - mass index ( kg / m - ),C1305855,,completed,
1734,body - mass index ( kg / m ' ),C1305855,,completed,
1734,body mass index kg / m ^,C1305855,,completed,
1734,body mass index kg / m ’,C1305855,,completed,
1734,body mass index ( kg / m ^ ) ^,C1305855,,completed,
1734,body mass index ( kg / m ’ ) ^,C1305855,,completed,
1734,body mass index ( kg / m “ ) ^,C1305855,,completed,
1734,body mass index ( kg / m ),C1305855,,completed,
1734,body mass index kg / m ^ ( meanisd ),C1305855,,completed,
1734,body mass index kg / m ^ mean ( sd ),C1305855,,completed,
1734,body - mass index ( kg / m $nmbr$ ),C1305855,,completed,
1734,body - mass index ( kg / m $nmbr$ ) *,C1305855,,completed,
1734,body - mass index \ kg / m $nmbr$,C1305855,,completed,
1734,body mass index * kg / m $nmbr$,C1305855,,completed,
1734,body mass index kg / m $nmbr$,C1305855,,completed,
1734,body mass index ( kg / m $nmbr$ ),C1305855,,completed,
1734,body mass index ( kg / m $nmbr$ ) * ',C1305855,,completed,
1734,body mass index ( kgm _ $nmbr$ ),C1305855,,completed,
1734,body mass index ( kg / m $nmbr$ ) baseline systolic blood,C1305855,,completed,
1734,body - mass index ( kg / m $nmbr$ ) mean ( sd ),C1305855,,completed,
1734,body - mass index ( kg / m $nmbr$ ) ( mean sd ),C1305855,,completed,
1734,body mass index kg / m $nmbr$ mean ( sd ),C1305855,,completed,
1734,body mass index kg / m $nmbr$ mean ( sd ) §,C1305855,,completed,
1734,body mass index kg / m $nmbr$ mean + sd,C1305855,,completed,
1734,body mass index kg / m $nmbr$ mean ± sd,C1305855,,completed,
1734,body mass index kg / m $nmbr$ ( mean ± sd ),C1305855,,completed,
1734,body mass index ( kg / m $nmbr$ ) - mean ± sd,C1305855,,completed,
1734,body mass index [ kg / m $nmbr$ ] mean ± sd,C1305855,,completed,
1734,body mass index ( kg / m $nmbr$ ) mean ( sd ) c,C1305855,,completed,
1734,body - mass index - kg / m $nmbr$ median ( iqr ),C1305855,,completed,
1734,body mass index kg / m $nmbr$ median ( q $nmbr$ q $nmbr$ ),C1305855,,completed,
1734,body mass index kg / m $nmbr$ ( sd ),C1305855,,completed,
1734,body - mass index ( kg / m $nmbr$ ) t,C1305855,,completed,
1734,body mass index - kg / m $nmbr$ t,C1305855,,completed,
1734,body mass index kg / m $nmbr$   ( sd ),C1305855,,completed,
1734,body - mass index ( kg / m   $nmbr$ ),C1305855,,completed,
1734,body mass index kg / rn \ mean ( sd ),C1305855,,completed,
1734,body - mass index kq / nrn,C1305855,,completed,
1734,body mass index mean kg / m $nmbr$ ( sd ),C1305855,,completed,
1734,body mass index mean kg / m ^ ( sd ),C1305855,,completed,
1734,body - mass index mean ( sd ),C1305855,,completed,
1734,body mass index mean ( sd ),C1305855,,completed,
1734,body mass index - mean ( sd ),C1305855,,completed,
1734,body mass index / mean ( sd ),C1305855,,completed,
1734,body mass index mean ( sd ) d,C1305855,,completed,
1734,body mass index mean + sd ( kg / m ),C1305855,,completed,
1734,body mass index mean ( sd ) kg / m $nmbr$,C1305855,,completed,
1734,body mass index mean ( sd ) ( kg m ) $nmbr$ ),C1305855,,completed,
1734,body mass index mean ( sd ) kg / m $nmbr$,C1305855,,completed,
1734,body mass index mean ± sd ( kg / m $nmbr$ ),C1305855,,completed,
1734,body mass index mean ( sd ) [ range ] a,C1305855,,completed,
1734,body mass index mean ( sd ) t,C1305855,,completed,
1734,body mass index median ( $nmbr$ th — $nmbr$ th percentiles ) kg / m $nmbr$,C1305855,,completed,
1734,body - mass index > $nmbr$,C1305855,,completed,
1734,body mass index $nmbr$,C1305855,,completed,
1734,body mass index > $nmbr$ kg / m n ( % ),C1305855,,completed,
1734,body - mass index > $nmbr$ n ( % ),C1305855,,completed,
1734,body mass index > $nmbr$ n ( % ),C1305855,,completed,
1734,body mass index > $nmbr$ — no . ( % ) f,C1305855,,completed,
1734,body mass index > $nmbr$ t,C1305855,,completed,
1734,body - mass index — no . ( % ) $,C1305855,,completed,
1734,body - mass index — no . ( % ) : i :,C1305855,,completed,
1734,body mass index subgroups,C1305855,,completed,
1734,• j . the body - mass index is the weight in kilograms divided by the square of the,C1305855,,completed,
1734,mean body - mass index kg / m $nmbr$,C1305855,,completed,
1734,mean body mass index kg / m $nmbr$,C1305855,,completed,
1734,mean body mass index ( kg / m $nmbr$ ),C1305855,,completed,
1734,mean body mass index ( kg / m $nmbr$ ) *,C1305855,,completed,
1734,mean body - mass index kg / m $nmbr$ ( sd ) *,C1305855,,completed,
1734,mean body - mass index kg / m $nmbr$   ( sd ) *,C1305855,,completed,
1734,mean body - mass index ( = sd ) kg / m $nmbr$,C1305855,,completed,
1734,mean body mass index ( sd ) kg / m $nmbr$,C1305855,,completed,
1734,mean ( sd ) body mass index kg / m $nmbr$,C1305855,,completed,
1734,median body mass index kg / m $nmbr$ ( iqr ),C1305855,,completed,
1734,median body mass index kg / m $nmbr$ ( range ),C1305855,,completed,
1744,oral antihyperglycaemic n ( % ),C0359086,,completed,
1744,oral hypoglycemic,C0359086,,completed,
1744,oral hypoglycemic agent,C0359086,,completed,
1744,oral hypoglycemic agents,C0359086,,completed,
1744,oral hypoglycemic agentsj,C0359086,,completed,
1744,oral hypoglycemic drug,C0359086,,completed,
1744,oral hypoglycemics,C0359086,,completed,
1744,oral hypoglycemics hormone replacement,C0359086,,completed,
1744,other oral hypoglycemic drug ( s ),C0359086,,completed,
1747,oral anticoagulant,C0354604,,completed,
1747,oral anticoagulant agent,C0354604,,completed,
1747,oral anticoagulant drugs,C0354604,,completed,
1747,oral anticoagulant drugs n ( % ),C0354604,,completed,
1747,oral anticoagulant n ( % ),C0354604,,completed,
1747,oral anticoagulant n ( % ),C0354604,,completed,
1747,oral anticoagulant — no . / total no . ( % ),C0354604,,completed,
1747,oral anticoagulants,C0354604,,completed,
1748,total stent length,C0038257;C1444754,,completed,
1748,total stent length mm,C0038257;C1444754,,completed,
1748,total stent length - mm,C0038257;C1444754,,completed,
1748,total stent length ( mm ) mean ± sd,C0038257;C1444754,,completed,
1749,less than $nmbr$,C0439092,,completed,
1749,less than $nmbr$ %,C0439092,,completed,
1749,less than $nmbr$ kg / m $nmbr$,C0439092,,completed,
1749,less than $nmbr$ ml / min / $nmbr$ . $nmbr$ m $nmbr$,C0439092,,completed,
1749,less than $nmbr$ mm hg,C0439092,,completed,
1749,less than $nmbr$ . $nmbr$ %,C0439092,,completed,
1756,fibrinolytic agent — no . ( % ) : t,C0016018,,completed,
1757,amiodarone,,,completed,
1757,amiodarone n ( % ),,,completed,
1757,amiodarone ( n % ),,,completed,
1757,amiodarone ( n = $nmbr$ ),,,completed,
1757,amiodarone ote at baseline,,,completed,
1757,amiodarone use at baseline,,,completed,
1757,amiodarone vs . placebo,,,completed,
1757,amiodarone vs . placebo no . hazard ratio ( $nmbr$ . $nmbr$ % cl ),,,completed,
1757,no amiodarone,,,completed,
1757,peri - op amiodarone : no ( n = $nmbr$ ),,,completed,
1758,aldosterone antagonist,C0002007,;C0034678;C0525678;C1514727,completed,
1758,aldosterone antagonists,C0002007,;C0034678;C0525678;C1514727,completed,
1758,aldosterone antagonists ( e . g . spironolactone ),C0002007,;C0034678;C0525678;C1514727,completed,
1758,aldosterone inhibitor,C0002007,;C0034678;C0525678;C1514727,completed,
1758,ras - aldosterone inhibitor ^,C0002007,;C0034678;C0525678;C1514727,completed,
1761,p value for heterogeneity （ rosiglitazone versus glyburide ）,C0289313,,completed,
1761,rosiglitazone,C0289313,,completed,
1761,rosiglitazone ( n = $nmbr$ ),C0289313,,completed,
1761,rosiglitazone versus glyburide,C0289313,,completed,
1761,rosiglitazone versus metformin,C0289313,,completed,
1761,rotigotine ( n = $nmbr$ ),C0289313,,completed,
1761,rotigotine n = $nmbr$,C0289313,,completed,
1762,stroke of undetermined cause,C0478157,,completed,
1769,baseline lipoprotein ( a ) ( nmol / l ) median ( iqr ),C0065058,,completed,
1769,change in lp ( a ),C0065058,,completed,
1769,lipoprotein ( a ) median ( qi q $nmbr$ ) nmol / l,C0065058,,completed,
1769,lipoprotein ( a ) median ( ql q $nmbr$ ) nmol / l,C0065058,,completed,
1769,lipoprotein ( a ) ( mg / dl ),C0065058,,completed,
1769,lipoprotein ( a ) ( nmol / l ),C0065058,,completed,
1769,lp ( a ) §,C0065058,,completed,
1769,lp ( a ) ( pmol / l ),C0065058,,completed,
1769,lp ( a ) ( week $nmbr$ ),C0065058,,completed,
1769,lp ( a ) ( μ mol / l ),C0065058,,completed,
1770,baseline dyslipidemia,C0242339,,completed,
1770,dyslipidaemia,C0242339,,completed,
1770,dyslipidaemia and hypertension n ( % ),C0242339,,completed,
1770,dyslipidaemia including hypercholesterol — no . ( % ),C0242339,,completed,
1770,dyslipidaemiaj,C0242339,,completed,
1770,dyslipidaemia n ( % ),C0242339,,completed,
1770,dyslipidaemia — no . ( % ),C0242339,,completed,
1770,dyslipidaemiat,C0242339,,completed,
1770,dyslipidaemia 本,C0242339,,completed,
1770,dyslipidemia,C0242339,,completed,
1770,dyslipidemia n ( % ),C0242339,,completed,
1770,dyslipidemia $nmbr$,C0242339,,completed,
1770,dyslipidemia — no . ( % ),C0242339,,completed,
1770,dyslipidemia — no . ( % ) |,C0242339,,completed,
1770,dyslipidemia — no . { % ),C0242339,,completed,
1772,baseline lipid profile mg / dl mean ( sd ),C0023779,,completed,
1772,baseline lipids mg / dl,C0023779,,completed,
1772,drinking n ( % ) lipid values mmol / l,C0023779,,completed,
1772,lipid,C0023779,,completed,
1772,lipid concentrations,C0023779,,completed,
1772,lipid concentrations total cholesterol ( mmol / l ),C0023779,,completed,
1772,lipid - lowerinq druq,C0023779,,completed,
1772,lipid modifiers,C0023779,,completed,
1772,lipid profile,C0023779,,completed,
1772,lipids,C0023779,,completed,
1772,lipids — mg / dl,C0023779,,completed,
1772,lipid values,C0023779,,completed,
1772,lipid values mean ( sd ),C0023779,,completed,
1772,lipid values mmol / l,C0023779,,completed,
1772,mean lipid values mg / dl,C0023779,,completed,
1772,metabolic syndrome $nmbr$ baseline lipids mg / dl,C0023779,,completed,
1772,other lipid - modifying drug use at study entry n ( % ),C0023779,,completed,
1772,select lipids and lipoproteins,C0023779,,completed,
1773,any lipid - lowering agent,C0086440,,completed,
1773,any lipid - lowering agent use,C0086440,,completed,
1773,fibrate or other lipid - lowering agent,C0086440,,completed,
1773,lipid disorder,C0086440,,completed,
1773,lipid - lowering agent,C0086440,,completed,
1773,lipid - lowering agent §,C0086440,,completed,
1773,lipid lowering agent n ( % ),C0086440,,completed,
1773,lipid - lowering agents,C0086440,,completed,
1773,lipid - lowering agents ( % ),C0086440,,completed,
1773,lipid lowering agents,C0086440,,completed,
1773,lipid - lowering drug,C0086440,,completed,
1773,lipid - lowering drug * *,C0086440,,completed,
1773,lipid - lowering drugs,C0086440,,completed,
1773,lipid lowering drugs,C0086440,,completed,
1773,lipid - lowering drugs n ( % ),C0086440,,completed,
1773,non - smokers receiving lipid lowering drugs ( $nmbr$ blockers and either an ace inhibitor or angiotension receptor blocker,C0086440,,completed,
1773,non - smokers receiving lipid - lowering drugs p blockers,C0086440,,completed,
1773,non - smokers receiving lipid - lowering drugs p blockers and either an ace inhibitor or angiotension receptor blocker,C0086440,,completed,
1773,other lipid lowering drugs,C0086440,,completed,
1773,revascularisation + antiplatelets + lipid - lowering agents + p blockers,C0086440,,completed,
1773,revascularisation but no antiplatelets lipid - lowering agents or p blockers,C0086440,,completed,
1773,with lipid - lowering agents,C0086440,,completed,
1773,without lipid - lowering agents,C0086440,,completed,
1774,any other lipid ‐ lowering therapy n ( % ),C0585943;C0086440,,completed,
1774,background lipid - lowering therapy,C0585943;C0086440,,completed,
1774,concomitant lipid - lowering therapy ( any ),C0585943;C0086440,,completed,
1774,concomitant lipid - lowering therapy n ( % ),C0585943;C0086440,,completed,
1774,hyperlipidaemia therapy use n ( % ) * no lipid - lowering agent therapy,C0585943;C0086440,,completed,
1774,lipc,C0585943;C0086440,,completed,
1774,lipid ‐ lowering therapies n ( % ),C0585943;C0086440,,completed,
1774,lipid - lowering therapy,C0585943;C0086440,,completed,
1774,lipid lowering therapy,C0585943;C0086440,,completed,
1774,lipid - lowering therapy - no . ( % ),C0585943;C0086440,,completed,
1774,lipid - lowering therapy — no . ( % ),C0585943;C0086440,,completed,
1774,statin and / or other lipid - lowering agent therapy,C0585943;C0086440,,completed,
1774,use of concomitant lipid - lowering therapy - no . ( % ),C0585943;C0086440,,completed,
1788,gliclazide ( modified release ) 一 no . ( % ) ^,C0017631,,completed,
1789,apremilast,C1678805,,completed,
1790,any cardiovascular disease,C0007222,,completed,
1790,any cardiovascular disease history n ( % ),C0007222,,completed,
1790,baseline cardiovascular disease,C0007222,,completed,
1790,cardiovascular disease,C0007222,,completed,
1790,cardiovascular disease *,C0007222,,completed,
1790,cardiovascular disease history,C0007222,,completed,
1790,cardiovascular disease history ‡,C0007222,,completed,
1790,cardiovascular disease history n ( % ) *,C0007222,,completed,
1790,cardiovascular disease n ( % ),C0007222,,completed,
1790,cardiovascular disease ( n = $nmbr$ ),C0007222,,completed,
1790,cardiovascular disorder,C0007222,,completed,
1790,cardiovascular disorder n ( % ),C0007222,,completed,
1790,cvd,C0007222,,completed,
1790,cv disease,C0007222,,completed,
1790,cvd total,C0007222,,completed,
1790,cvd without miatroke,C0007222,,completed,
1790,cvd without ml / stroke,C0007222,,completed,
1790,cvd without ml ^ troke,C0007222,,completed,
1790,established cardiovascular disease,C0007222,,completed,
1790,lisinopril cvd total,C0007222,,completed,
1790,$nmbr$ - $nmbr$ cv disease ( n = $nmbr$ $nmbr$ ),C0007222,,completed,
1790,$nmbr$ - $nmbr$ with cv disease ( n = $nmbr$ ),C0007222,,completed,
1790,no cardiovascular disease ( n = $nmbr$ ),C0007222,,completed,
1790,no cardiovascular disorder $nmbr$ ',C0007222,,completed,
1790,no cvd,C0007222,,completed,
1790,no prior cvd,C0007222,,completed,
1790,n ( % ) patients with risk faetors for cv disease aged > $nmbr$,C0007222,,completed,
1790,patients with established cv disease aged > $nmbr$ years .,C0007222,,completed,
1790,patients with no prior cvd ( primary,C0007222,,completed,
1790,prior cardiovascular disease,C0007222,,completed,
1790,prior cvd,C0007222,,completed,
1791,< $nmbr$ beds,C0004916,,completed,
1791,> $nmbr$ beds,C0004916,,completed,
1792,rivaroxaban $nmbr$ . $nmbr$ mg bid + aspirin $nmbr$ mg od,C1739768;C0004057,,completed,
1792,riva roxa ban n / n { % ) $nmbr$ ( $nmbr$ . $nmbr$ ),C1553379,,completed,
1799,health - related quality of life,C4279947,,completed,
1799,hrqol,C4279947,,completed,
1806,baseline eosinophil < $nmbr$ cells / pl,C0014467;C0007584,,completed,
1806,baseline eosinophil $nmbr$ cells / pl,C0014467;C0007584,,completed,
1806,biomarker high ( periostin > $nmbr$ ng / ml or blood eosinophils > $nmbr$ cells per pl ) t,C0014467;C0007584,,completed,
1806,( cells per pl ) t,C0014467;C0007584,,completed,
1806,eos count ( cells / pl ),C0014467;C0007584,,completed,
1806,eosinophil counf cells pl ',C0014467;C0007584,,completed,
1806,eosinophil count ( cells per pl ),C0014467;C0007584,,completed,
1806,eosinophil count ( cells / pl ) median ( range ) c,C0014467;C0007584,,completed,
1806,local eosinophil count ( cells per pl ) t,C0014467;C0007584,,completed,
1806,median blood eosinophil count ( cells per pl ) t,C0014467;C0007584,,completed,
1809,angiographic extent of disease,C0449279,,completed,
1809,extent of disease,C0449279,,completed,
1809,extent of disease %,C0449279,,completed,
1809,extent of disease n ( % ),C0449279,,completed,
1809,extent of disease — no . / total no . ( % ) § ^ |,C0449279,,completed,
1810,number of events,C4330837,,completed,
1810,number of events ( annualised rate [ % ] ),C4330837,,completed,
1810,number of events event per $nmbr$ person - years,C4330837,,completed,
1810,numbers of events ( % ) :,C4330837,,completed,
1815,calima japan ( n = $nmbr$ ),C0022341,,completed,
1815,japan,C0022341,,completed,
1815,japan and south korea,C0022341,,completed,
1815,japanese,,,completed,
1815,japanese subgroup ( n = $nmbr$ ),,,completed,
1815,japanese subpopulation,,,completed,
1815,japan n = $nmbr$,C0022341,,completed,
1815,no . japanese,,,completed,
1815,not - japan,C0022341,,completed,
1815,not - japan n = $nmbr$ $nmbr$,C0022341,,completed,
1816,caffeine,C0006644,;C1710701,completed,
1816,caffeine consumption *,C0006644,;C1710701,completed,
1816,caffeine consumption ( yes ) ( n ),C0006644,;C1710701,completed,
1816,caffeine user,C0006644,;C1710701,completed,
1816,caffeine user n ( % ),C0006644,;C1710701,completed,
1816,caffeine users n ( % ),C0006644,;C1710701,completed,
1818,colorectal cancer,C1527249,,completed,
1818,non - colorectal cancer,C1527249,,completed,
1819,active cancer,C0006826,,completed,
1819,active cancer at any timeb,C0006826,,completed,
1819,active cancer at baseline,C0006826,,completed,
1819,active cancer at randomisation,C0006826,,completed,
1819,active cancer at randomization,C0006826,,completed,
1819,active cancer at randomization n ( % ),C0006826,,completed,
1819,active cancer — no . ( % ),C0006826,,completed,
1819,active or previous cancer,C0006826,,completed,
1819,ac tve cancer,C0006826,,completed,
1819,all cancer,C0006826,,completed,
1819,cancer,C0006826,,completed,
1819,cancer §,C0006826,,completed,
1819,cancer *,C0006826,,completed,
1819,cancer * *,C0006826,,completed,
1819,cancer fatal and nonfatal,C0006826,,completed,
1819,cancer medications,C0006826,,completed,
1819,cancer n ( % ),C0006826,,completed,
1819,cancer ( n = $nmbr$ ),C0006826,,completed,
1819,cancer — no . ( % ),C0006826,,completed,
1819,medical history : cancer,C0006826,,completed,
1819,no active cancer,C0006826,,completed,
1819,no adk / e cancer,C0006826,,completed,
1819,no prior cancer,C0006826,,completed,
1819,previous cancer,C0006826,,completed,
1819,previous cancer n ( % ),C0006826,,completed,
1819,previous cancer — no . ( % ),C0006826,,completed,
1819,prior cancer,C0006826,,completed,
1828,esrd or $nmbr$ % decline in gfr,C0035078,;C1424601,completed,
1828,esrd or $nmbr$ % dedine in gfr,C0035078,;C1424601,completed,
1835,* plus – minus values are means ± sd . percentages may not total $nmbr$ because of rounding . the body - mass index is the weight in kilograms divided by the square of the height in meters . to convert the values for creatinine to micromoles per liter multiply by $nmbr$ . $nmbr$ . ace denotes angiotensin - converting enzyme cabg coronary - artery bypass grafting nt - probnp n - terminal pro - b – type natriuretic peptide nyha new york heart association and pci percutaneous coro - nary intervention . † race was reported by the investigators . ‡ one patient in nyha class i was mistakenly included in the placebo group . § this category includes any angina - like symptoms at any time in the past with no confirmation of diagnosis of coro - nary heart disease required . ¶ possible scores range from $nmbr$ to $nmbr$ with lower scores indicating a better quality of life . ∥ anemia was defined by world health organization criteria as a hemoglobin level of less than $nmbr$ g per deciliter in men and less than $nmbr$ g per deciliter in women . * * nt - probnp levels are influenced by a variety of factors including age sex body - mass index and renal function . no clinically useful normal range has been established . † † some patients were taking both loop and thiazide diuretics .,C0032042,,inprogress,
1836,severe or very severe copd,C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
1836,very severe copd,C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
1836,very severe gold $nmbr$,C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
1836,very severe ( gold $nmbr$ ),C3641272,;C0018026;C1304897;C1412502;C4050419;C4050465;C4050466,completed,
1837,ticlopidin,C0070166,,completed,
1837,ticlopidine,C0070166,,completed,
1837,ticlopidine after completion of study drug,C0070166,,completed,
1837,ticlopidine ( n = $nmbr$ ),C0070166,,completed,
1838,chronic sinusitis + nasal polypsd n ( % ),C0006277,,completed,
1838,sinusitis,C0006277,,completed,
1839,synovitis,C0006277,,completed,
1840,atorvastatin $nmbr$ mg and simvastatin $nmbr$ - $nmbr$ mg ( zi = $nmbr$ ),C0074554,,completed,
1840,exetimibe / simvastatin,C0074554,,completed,
1840,patients on atorvastatin rosuvastatin or simvastatin at,C0074554,,completed,
1840,pooled eze / simva,C1709595;C1524024,,completed,
1840,pooled simva,C1709595;C1524024,,completed,
1840,simvastatin,C0074554,,completed,
1840,simvastatin monotherapy ( n = $nmbr$ $nmbr$ * ),C0074554,,completed,
1840,simvastatin n ( % ),C0074554,,completed,
1840,simvastatin $nmbr$ mg,C0074554,,completed,
1840,simvastatin $nmbr$ mg ( n = $nmbr$ ),C0074554,,completed,
1840,simvastatin $nmbr$ mg ( n = $nmbr$ ) *,C0074554,,completed,
1840,simvastatin $nmbr$ mg ( n = $nmbr$ $nmbr$ ),C0074554,,completed,
1840,simvastatin ( $nmbr$ / $nmbr$ mg / d ),,,inprogress,
1840,simvastatin ( $nmbr$ / $nmbr$ mg / d ) ( n = $nmbr$ ),,,inprogress,
1840,simvastatin ( n = $nmbr$ ),C0074554,,completed,
1840,simvastatin ( n = $nmbr$ $nmbr$ ),C0074554,,completed,
1840,simvastatin ( n = $nmbr$ . $nmbr$ ),C0074554,,completed,
1841,pravastatin sodium,C0523891,,completed,
1842,all men,,,inprogress,
1842,chd + cerebrovascular disease men $nmbr$ / $nmbr$ ( $nmbr$ . $nmbr$ ),,,inprogress,
1842,chd men,,,inprogress,
1842,men,,,inprogress,
1842,men %,,,inprogress,
1842,men ( % ),,,inprogress,
1842,men n ( % ),,,inprogress,
1842,men n ( % ) *,,,inprogress,
1842,men ( n % ),,,inprogress,
1842,men ( n [ % ] ),,,inprogress,
1842,men < $nmbr$ cm,,,inprogress,
1842,men > $nmbr$ cm,,,inprogress,
1842,men : < $nmbr$ mg / dl ( < $nmbr$ . $nmbr$ mmol / l ),,,inprogress,
1842,men ( n = $nmbr$ ),,,inprogress,
1842,men ( n = $nmbr$ $nmbr$ ),,,inprogress,
1842,men ( n = $nmbr$ ) n / n ( % ),,,inprogress,
1842,men ( n = $nmbr$ vs $nmbr$ ),,,inprogress,
1842,men no . ( % ),,,inprogress,
1842,men ( n 二 $nmbr$ ),,,inprogress,
1842,men total ( n = $nmbr$ ),,,inprogress,
1842,men total ( n 二 $nmbr$ ),,,inprogress,
1842,men with ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,,,inprogress,
1842,men without ed ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,,,inprogress,
1842,men : women ( % ),,,inprogress,
1842,men / women,,,inprogress,
1842,men   n   ( % ),,,inprogress,
1842,no . men,,,inprogress,
1842,sex men ( % ),,,inprogress,
1844,ibuprofen,C0027396,,completed,
1848,duration of rheumatoid arthritis ( years ),C0003862,,completed,
1848,duration of rheumatoid arthritis — yr,C0003862,,completed,
1848,rheumatoid arthritis,C0003862,,completed,
1851,serious adverse events,C1320716,,completed,
1852,apo a - i,C0003593,,completed,
1852,apoa - i,C0003593,,completed,
1852,apo a - i mg / dl,C0003593,,completed,
1852,apo a - i ( mg / dl ) *,C0003593,,completed,
1852,apo a - l ( g / l ),C0003593,,completed,
1854,dipeptidyl peptidase - $nmbr$ inhibitor,C0003015,,completed,
1854,dipeptidyl peptidase $nmbr$ inhibitor,C0003015,,completed,
1854,dipeptidyl peptidase $nmbr$ inhibitors,C0003015,,completed,
1862,ezetimibe $nmbr$ mg + statin ( n = $nmbr$ $nmbr$ ),C1142985,,completed,
1862,statin and / or ezetimibe,C1142985,,completed,
1862,statin + ezetimibe,C1142985,,completed,
1862,statin + ezetimibe n ( % ),C1142985,,completed,
1862,statin + ezetimibe ( n = $nmbr$ . $nmbr$ ),C1142985,,completed,
1862,statin + ezetimibe { n = $nmbr$ $nmbr$ ),C1142985,,completed,
1862,statin or ezetimibe,C1142985,,completed,
1862,statins / ezetimibe,C1142985,,completed,
1862,statin with ezetimibe,C1142985,,completed,
1863,dates of recruitment,C0449279,,completed,
1864,asia ( excluding japan ),C0022341,,completed,
1865,pancreatic cancer,C0006826,,completed,
1866,prostate cancer,C0006826,,completed,
1870,number of lesions n ( % ) a,C4330837,,completed,
1870,number of treated lesions,C4330837,,completed,
1870,number of treated lesions ( per patient ),C4330837,,completed,
1875,indacaterol group ( n = $nmbr$ ),C3814772;C1722260,,completed,
1875,indacaterol $nmbr$ ug ( n = $nmbr$ ),C3814772;C1722260,,completed,
1875,indacaterol $nmbr$ ug versus indacaterol $nmbr$ ug,C3814772;C1722260,,completed,
1875,indacaterol $nmbr$ ug versus placebo,C3814772;C1722260,,completed,
1875,indacaterol n = $nmbr$,C3814772;C1722260,,completed,
1875,indacaterol + tiotropium ( n [ $nmbr$ ),C3814772;C1722260,,completed,
1876,reteplase,C0017631,,completed,
1877,roflumilast ( n = $nmbr$ $nmbr$ ),C1678805,,completed,
1878,number of arterial beds involved,C0004916,,completed,
1882,right ventricular dysfunction n / n ( % ) j,C0242350,;C0221138;C0277785;C0542341;C0700205;C1705273;C3887505,completed,
1882,right ventricular dysfunction — no . / total no . ( % ) §,C0242350,;C0221138;C0277785;C0542341;C0700205;C1705273;C3887505,completed,
1884,calcium aniagonisi,C1518422;C0679199;C0006684,,completed,
1884,calcium antagonist,C1518422;C0679199;C0006684,,completed,
1884,calcium antagonist — no . ( % ),C1518422;C0679199;C0006684,,completed,
1884,calcium antagonists,C1518422;C0679199;C0006684,,completed,
1884,calcium antagonists n ( % ),C1518422;C0679199;C0006684,,completed,
1884,calcium antagonist strategy ( cas ) ( events / n ),C1518422;C0679199;C0006684,,completed,
1884,calcium antagonist strategy ( n = $nmbr$ $nmbr$ ),C1518422;C0679199;C0006684,,completed,
1884,calcium channelantagonist,C0006675,,completed,
1884,calcium - channel antagonists,C1518422;C0679199;C0006684,,completed,
1884,calcium channel antagonists n ( % ),C1518422;C0679199;C0006684,,completed,
1884,calcium - channel blockerf,C0004950,,completed,
1884,calcium - channel blockersubgroup,C0004950,,completed,
1884,calcium - channel inhibitor,C0004950,,completed,
1886,paroxysmal,C0235480,,completed,
1886,paroxysmal !,C0235480,,completed,
1886,paroxysmal n ( % ),C0235480,,completed,
1886,paroxysmal ( n % ),C0235480,,completed,
1887,iop mm hg,C0005823,,completed,
1888,^ $nmbr$ mm hg,C0005823,,completed,
1888,< $nmbr$ mmhg,C0005823,,completed,
1888,< $nmbr$ mm hg,C0005823,,completed,
1888,> = $nmbr$ mmhg,C0005823,,completed,
1888,> $nmbr$ mmhg,C0005823,,completed,
1888,> $nmbr$ mm hg,C0005823,,completed,
1888,$nmbr$ mmhg,C0005823,,completed,
1888,$nmbr$ mm hg,C0005823,,completed,
1888,< $nmbr$ mm hg heart rate,C0005823,,completed,
1888,< $nmbr$ mm hg — no . ( % ),C0005823,,completed,
1888,> $nmbr$ mm hg — no . ( % ),C0005823,,completed,
1888,< $nmbr$ / < $nmbr$ mm hg,C0005823,,completed,
1888,< $nmbr$ / $nmbr$ mm hg,C0005823,,completed,
1888,< $nmbr$ / $nmbr$ mm hg +,C0005823,,completed,
1888,< $nmbr$ . $nmbr$ mm hg,C0005823,,completed,
1888,> = $nmbr$ - < $nmbr$ mmhg,C0005823,,completed,
1888,> $nmbr$ - < $nmbr$ mmhg,C0005823,,completed,
1888,> $nmbr$ / > $nmbr$ mm hg,C0005823,,completed,
1888,> $nmbr$ . $nmbr$ mm hg,C0005823,,completed,
1888,< $nmbr$ . $nmbr$ mm hg diastolic blood pressure,C0005823,,completed,
1888,$nmbr$ - $nmbr$ / $nmbr$ - $nmbr$ mm hg,C0005823,,completed,
1888,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mmhg,C0005823,,completed,
1888,$nmbr$ . $nmbr$ to < $nmbr$ . $nmbr$ mm hg,C0005823,,completed,
1888,$nmbr$ o - i $nmbr$ mm hg,C0005823,,completed,
1888,> $nmbr$ to < $nmbr$ mm hg,C0005823,,completed,
1888,$nmbr$ to < $nmbr$ mmhg,C0005823,,completed,
1888,$nmbr$ to < $nmbr$ mm hg,C0005823,,completed,
1888,$nmbr$ to $nmbr$ mm hg,C0005823,,completed,
1888,$nmbr$ to < $nmbr$ mm hg — no . { % ),C0005823,,completed,
1889,apasp ( per mmhg ),C0005823,,completed,
1905,pollen exposure,C0949236,,completed,
1906,pollent < $nmbr$,C0949236,,completed,
1906,pollent s $nmbr$,C0949236,,completed,
1921,oral contraceptives,C0354604,,completed,
1921,oral medications,C0354604,,completed,
1922,laa length,C0038257;C1444754,,completed,
1923,dronedarone,,,completed,
1923,dronedarone ( n = $nmbr$ ),,,completed,
1923,dronedarone ( n = $nmbr$ ) $nmbr$ . $nmbr$ ± $nmbr$ . $nmbr$,,,completed,
1924,dose / weight ( iu / kg ),C0005910,,completed,
1925,electrophysiological study — no . ( % ) weight — ibj,C0005910,,completed,
1926,^ - blocker,C0001641,,completed,
1926,$nmbr$ blocker,C0001641,,completed,
1926,p - blocker use,C0001641,,completed,
1926,preoperative p - blocker use yes,C0001641,,completed,
1926,preoperative use p - blocker,C0001641,,completed,
1926,prior a - blocker use,C0001641,,completed,
1927,isolated upper gastrointestinal disease behavior n ( % ),C0271650,,completed,
1928,hbau %,,,completed,
1928,patients with possible new dm at randomization ( hba $nmbr$ c > $nmbr$ . $nmbr$ - $nmbr$ % ),,,completed,
1928,pen - label empagliflozin $nmbr$ mg ( baseline hba $nmbr$ c > $nmbr$ % ),,,completed,
1930,losartan + lisinopril,C0065374,,completed,
1930,losartan plus lisinopril ( n = $nmbr$ ),C0065374,,completed,
1933,dalteparin ( n = $nmbr$ ),C0206232,,completed,
1934,semuloparin ( n = $nmbr$ ),C0206460,,completed,
1935,unfractionated,C0019134,,completed,
1936,vitamin c,;C0043031,,completed,
1937,rivastigmine,C0019590,,completed,
1937,rivastigmine ( n = $nmbr$ ),C0019590,,completed,
1938,solifenacin ( n = $nmbr$ ),C0529793,,completed,
1939,patients treated with losartan ( n = $nmbr$ ),C0004147,,completed,
1939,table $nmbr$ . characteristics of patients treated with losartan and atenolol *,C0004147,,completed,
1939,treated with losartan ( n = $nmbr$ ),C0004147,,completed,
1940,epilepsy with grand mal seizures on awakening,C0154723,,completed,
1943,scarring on renal biopsy,C0194804,,completed,
1944,st elevation,C3810814,,completed,
1944,st - elevation mi,C3810814,,completed,
1944,st - segment elevation,C3810814,,completed,
1944,st segment elevation,C3810814,,completed,
1945,time from randomization to pci ( st - elevation mi ) min,C3810814,,completed,
1946,medications at discharge,C1319171,,completed,
1947,symptomatic localization - related,C0021308;C0475264,,completed,
1949,venous insufficiency,C0425687,,completed,
1950,acute rheumatic disorders,C0023895,,completed,
1951,renal,C2986535;C0022646,,completed,
1951,renal events,C2986535;C0022646,,completed,
1951,renal parameters,C2986535;C0022646,,completed,
1952,framingham risk score,C0035647,,completed,
1952,framingham risk score ( % ),C0035647,,completed,
1952,framingham risk score *,C0035647,,completed,
1952,framingham risk score arbitrary units,C0035647,,completed,
1953,vascular risk score |,C0035647,,completed,
1953,vascular risk score *,C0035647,,completed,
1953,vascular risk score — no . { % ) ^,C0035647,,completed,
1954,timi risk score category — no . ( % ),C0035647,,completed,
1954,timi risk score > $nmbr$ n ( % ),C0035647,,completed,
1954,timi risk score $nmbr$ - $nmbr$,C0035647,,completed,
1954,timi risk score n / n ( % ),C0035647,,completed,
1954,timi risk score — no . / total no . ( % ) : c,C0035647,,completed,
1954,timi risk scoret,C0035647,,completed,
1957,acholesterol ( % ),,,completed,
1965,chloroquine,C0020336,,completed,
1970,femaie,;C0150904,,completed,
1970,female patients ^,;C0150904,,completed,
1970,female patients n ( % ),;C0150904,,completed,
1970,female sex n ( % of patients ),;C0150904,,completed,
1970,male vs . female,C0086582;C0086287,,inprogress,
1970,women ( n = $nmbr$ vs $nmbr$ ),C0086582;C0086287,,inprogress,
1971,all of the colon,C0020885;C0009368,,completed,
1971,colon,C0020885;C0009368,,completed,
1971,colon only,C0020885;C0009368,,completed,
1971,colon only ' n ( % ),C0020885;C0009368,,completed,
1971,colon only n ( % ),C0020885;C0009368,,completed,
1971,colon or rectum,C0020885;C0009368,,completed,
1972,carvedilol,C0004147,,completed,
1972,carvedilol % ( n ),C0004147,,completed,
1976,adl,C3641947,,completed,
1976,adl subscale ( range $nmbr$ - $nmbr$ ) *,C3641947,,completed,
1977,fpg mmol / l ( mg / dl ),C0001924,,completed,
1977,hdl - c mmol / l ( mg / dl ),C0001924,,completed,
1977,tg mmol / l [ mg / dl ],C0001924,,completed,
1979,below - knee popliteal,C0022742,,completed,
1979,below - knee popliteal crural,C0022742,,completed,
1980,tender,C0449813;C0234234,,completed,
1981,symmetric t - wave inversions,C0520887,,completed,
1981,symmetric t wave inversions,C0520887,,completed,
1981,t - wave inversion,C0520887,,completed,
1981,t wave inversion,C0520887,,completed,
1983,injection - site reaction n ( % ),C3714514,,completed,
1983,potential injection site reactions,C3714514,,completed,
1984,intolerance,C1744706;C0666743,,completed,
1984,intolerance ',C1744706;C0666743,,completed,
1984,intolerance ®,C1744706;C0666743,,completed,
1985,maintenance dose,C2930789,,completed,
1986,inter . p - value,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1986,inter p - value,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1986,p for inter - act,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1986,p inter,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1986,p - inter,C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1986,p ( inter ),C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1986,p ( inter - action ),C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1986,p value ( inter ),C0205103,;C0015663;C1550465;C2827755;C3889971;C0079613;C1704930;C1869853;C3890007;C4048375,completed,
1999,statin intolerance $nmbr$ n ( % ),C1744706;C0666743,,completed,
2013,ramus,C0034642,,completed,
2014,female n ( % ) race n ( % ),;C0034510,,completed,
2014,female race / ethnicity,;C0034510,,completed,
2014,female race white,;C0034510,,completed,
2014,female sex — no . ( % ) race — no . ( % ) f,;C0034510,,completed,
2014,female sex n ( % ) race n ( % ),;C0034510,,completed,
2015,characteristic age,C1521970,,completed,
2015,characteristic age — yr,C1521970,,completed,
2016,infarct characteristics,C1521970,,completed,
2017,surgical technique post - randomisation characteristic * *,C1521970,,completed,
2018,angiographic characteristics no . ( % ),C1521970,,completed,
2018,angiographic features,C1521970,,completed,
2019,factor v leiden ( % ),C1514984,,completed,
2019,factor v leiden or prothrombin mutation,C1514984,,completed,
2020,stratification factor : menopausal status n ( % ),C1514984,,completed,
2021,factor xa inhibitor,C1514984,,completed,
2022,predictive factor,C1514984,,completed,
2023,clinical vertebral fractures,C0040185,,completed,
2023,number of prevalent vertebral fractures,C0040185,,completed,
2023,prevalent vertebral fracture,C0040185,,completed,
2023,prevalent vertebral fracture n ( % ),C0040185,,completed,
2023,prevalent vertebral fracture status,C0040185,,completed,
2023,vertebral fracture,C0040185,,completed,
2023,vertebral fracture and / or t score - $nmbr$ . $nmbr$,C0040185,,completed,
2023,vertebral fracture and / or t score s - $nmbr$ . $nmbr$,C0040185,,completed,
2024,ankle fracture,C0040185,,completed,
2024,clavicle fracture,C0040185,,completed,
2024,fibula fracture,C0040185,,completed,
2025,patella fracture,C0040185,,completed,
2026,bone fracture,;C0020162,,completed,
2026,bone fracture due to fall,;C0020162,,completed,
2026,c clinical fractures ( fas ),;C0020162,,completed,
2026,clinical fracture,;C0020162,,completed,
2026,d non - vertebral fragility fractures ( fas ),;C0020162,,completed,
2026,e major non - vertebral fragility fractures ( fas ),;C0020162,,completed,
2026,fracture,;C0020162,,completed,
2026,fracture history,;C0020162,,completed,
2026,fracture history n ( % ),;C0020162,,completed,
2026,fracture history ( predefined ) n ( % ),;C0020162,,completed,
2026,fractures,;C0020162,,completed,
2026,hip + other nonvertebral fractures,;C0020162,,completed,
2026,no fracture history,;C0020162,,completed,
2026,nonvertebral fracture,;C0020162,,completed,
2026,nonvertebral fractures,;C0020162,,completed,
2026,prior clinical fracture ( since age $nmbr$ ),;C0020162,,completed,
2026,prior nonvertebral fracture,;C0020162,,completed,
2026,prior nonvertebral fracture at age > $nmbr$ years,;C0020162,,completed,
2027,femur fracture,;C0020162,,completed,
2027,foot fracture,;C0020162,,completed,
2027,hand fracture,;C0020162,,completed,
2028,radius fracture,;C0020162,,completed,
2028,skull and facial bone fractures,;C0020162,,completed,
2028,thoracic cage fractures,;C0020162,,completed,
2029,wrist fracture,;C0020162,,completed,
2033,celecoxib,C0972314,,completed,
2033,celecoxib ( n = $nmbr$ ),C0972314,,completed,
2034,rofecoxib,C0972314,,completed,
2034,valdecoxib,C0972314,,completed,
2038,bleeding end points,C2349179,,completed,
2039,all randomized coronary end point,C2349179,,completed,
2039,coronary endpoint,C2349179,,completed,
2039,coronary end point,C2349179,,completed,
2040,bypass surgery,C0010055,,completed,
2040,hungary,C0010055,,completed,
2040,lower - limb angioplasty or bypass surgery,C0010055,,completed,
2040,previous bypass surgery n ( % ),C0010055,,completed,
2040,prior surgery : no,C0010055,,completed,
2042,morning peak expiratory flow — liters / min,C0009967,,completed,
2043,morning,C0009967,,completed,
2044,nsclc,C0037763,,completed,
2045,eduglinozin $nmbr$ mg vs placebo / glimepiride,C0061323,,completed,
2045,ertuglrflozin $nmbr$ mg vs placebo / glimepiride,C0061323,,completed,
2046,glipizide,C0061323,,completed,
2046,glipizide ( n = $nmbr$ ),C0061323,,completed,
2047,nateglinide and repaglinide,;C0065880,,completed,
2047,nateglinide n / n,;C0065880,,completed,
2047,nateglinide ( n = $nmbr$ ),;C0065880,,completed,
2048,flecainide,C2266929,,completed,
2049,lacosamide,C0017718,,completed,
2050,torsemide,C0016860,,completed,
2063,extensive colitis,C0205231,,completed,
2063,extensive colitis n,C0205231,,completed,
2063,extensive colitis or pancolitis,C0205231,,completed,
2063,extensive colitisy,C0205231,,completed,
2063,no extensive colitis n,C0205231,,completed,
2064,elective peripheral revascularization,C0747973,,completed,
2065,sulphonamides urea derivatives,C3653470,,completed,
2066,dapaglifloiin n *,C4079805,,completed,
2066,dapagliflozin,C4079805,,completed,
2066,dapagliflozin n *,C4079805,,completed,
2066,dapagliflozin $nmbr$ mg + insulin ( n = $nmbr$ ),C4079805,,completed,
2066,dapagliflozin $nmbr$ mg + insulin ( n   = $nmbr$ ),C4079805,,completed,
2066,dapagliflozin ( n = $nmbr$ ),C4079805,,completed,
2066,dapagliflozint,C4079805,,completed,
2067,sotagliflozin,C4079805,,completed,
2067,sotagliflozin $nmbr$ mg ( n = $nmbr$ ),C4079805,,completed,
2067,sotagliflozin ( n = $nmbr$ ),C4079805,,completed,
2068,vildagliptin,C1958126,,completed,
2068,vildagliptin $nmbr$ mg bid,C1958126,,completed,
2068,vildagliptin $nmbr$ mg bid n = $nmbr$,C1958126,,completed,
2068,vildagliptin $nmbr$ mg daily,C1958126,,completed,
2068,vildagliptin $nmbr$ mg daily + glimepiride,C1958126,,completed,
2068,vildagliptin $nmbr$ mg qd,C1958126,,completed,
2068,vildagliptin $nmbr$ mg qd n = $nmbr$,C1958126,,completed,
2068,vildagliptin ( n = $nmbr$ ),C1958126,,completed,
2069,saxagiiptin,C1958126,,completed,
2069,saxagliptin,C1958126,,completed,
2069,saxagliptin ( % ),C1958126,,completed,
2069,saxagliptin $nmbr$ mg,C1958126,,completed,
2069,saxagliptin $nmbr$ mg ( n = $nmbr$ $nmbr$ ),C1958126,,completed,
2069,saxagliptin $nmbr$ mg ( n z $nmbr$ ),C1958126,,completed,
2069,saxagliptin $nmbr$ . $nmbr$ mg,C1958126,,completed,
2069,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$ ),C1958126,,completed,
2069,saxagliptin $nmbr$ . $nmbr$ mg ( n = $nmbr$ $nmbr$ ),C1958126,,completed,
2069,saxagliptin $nmbr$ . $nmbr$ mg ( n z $nmbr$ ),C1958126,,completed,
2069,saxagliptin ( n = $nmbr$ ),C1958126,,completed,
2069,saxagliptin ( n = $nmbr$ $nmbr$ ),C1958126,,completed,
2070,intravenous anticoagulant during hospitalisation *,C0348016,,completed,
2070,intravenous anticoagulant during hospitalization,C0348016,,completed,
2071,intravenous vasoactive drugs % y,C0348016,,completed,
2071,intravenous vasodilators ( % ),C0348016,,completed,
2072,intravenous dobutamine,C0348016,,completed,
2074,hemoglobin a ( % ),,,completed,
2080,effect size ^,C0242618,,completed,
2080,effect size !,C0242618,,completed,
2081,diabetes type ii n ( % ),C4086268;C1521828;C0439793,,completed,
2081,type ii diabetes,C4086268;C1521828;C0439793,,completed,
2082,degree of stenosis % of diameter,C0225860,,completed,
2084,sacubitril / valsartan,C0216784,,completed,
2084,sacubitril / valsartan ( n = $nmbr$ ),C0216784,,completed,
2085,amlodipine and valsartan,C0216784,,completed,
2086,adjusted hr losartan vs atenolol *,C0126174,,completed,
2086,atenolol - losartan,C0126174,,completed,
2087,olmesartan along with diuretic ( n - $nmbr$ ),C0288171,,completed,
2087,olmesartan ( n = $nmbr$ ),C0288171,,completed,
2088,colonic area involved,C0005902;C1879646,,completed,
2088,intestinal area involved n ( % ) $,C0005902;C1879646,,completed,
2088,intestinal area involved — no . ( % ),C0005902;C1879646,,completed,
2088,involved intestinal area n ( % ),C0005902;C1879646,,completed,
2089,korea,C0016536,,completed,
2089,korean,C0016536,,completed,
2090,rv and pulmonary vascular,C0524425,,completed,
2091,low - dose edoxaban,C2975435,,completed,
2091,low - dose edoxaban ( n = $nmbr$ ),C2975435,,completed,
2091,lower dose edoxaban regimen,C2975435,,completed,
2095,thromboaspiration,C0015684,,completed,
2097,p value ( cangrelor versus clopidogrel in men ),C1121991,,completed,
2097,p value ( cangrelor versus clopidogrel in women ),C1121991,,completed,
2098,l eft anterior descending,C0205094,,completed,
2098,left anterior descending,C0205094,,completed,
2098,left anterior descending artery,C0205094,,completed,
2098,left anterior descending artery n ( % ),C0205094,,completed,
2098,l eft anterior descending coronary artery,C0205094,,completed,
2098,left anterior descending coronary artery,C0205094,,completed,
2098,left anterior descending n ( % ),C0205094,,completed,
2101,at least $nmbr$ flare,C0018099;C1517741;C1517205,,completed,
2101,at least $nmbr$ severe flare,C0018099;C1517741;C1517205,,completed,
2109,caleitonin ng / l males mean ± sd,C0086582,,completed,male gender
2109,[ cm ( female ) / cm ( male ) ],C0086582,,completed,male gender
2109,[ cm { female ) / cm { male ) ],C0086582,,completed,male gender
2110,eze,C0086287,,completed,
2110,eze / simva ( „ = $nmbr$ },C0086287,,completed,
2111,caleitonin ng / l females mean ± sd,C0086287,,completed,
2144,myocardiai infarction,C0021308,,completed,
2144,nonfatai myocardiai infarction,C0021308,,completed,
2144,nonfatal myocardiail infarction,C0021308,,completed,
2145,q wave in the infarct territory at baseline * %,C0021308,,completed,
2145,q waves in the infarct territory at baseline * %,C0021308,,completed,
2153,laaca,C0006823;C0041703,,completed,
2153,saaca,C0006823;C0041703,,completed,
2156,canada,C0006823;C0041703,,completed,
2157,cardiovascuiar mortaiity,C0026565,,completed,
2157,cardiovascular mortality,C0026565,,completed,
2157,cardiovascular mortality mi or revascularization,C0026565,,completed,
2157,cardiovascular mortality or mi,C0026565,,completed,
2157,cardiovascular mortality ( per $nmbr$ person - years ),C0026565,,completed,
2157,cvd mortality,C0026565,,completed,
2158,vitality,C0026565,,completed,
2159,nationality,C0522055,,completed,
2160,reversibility,C0449261;C0231999,,completed,
2160,% reversibility,C0449261;C0231999,,completed,
2160,reversibility %,C0449261;C0231999,,completed,
2160,reversibility ’ ' %,C0449261;C0231999,,completed,
2160,reversibility ( % ),C0449261;C0231999,,completed,
2160,reversibility *,C0449261;C0231999,,completed,
2160,reversibility %,C0449261;C0231999,,completed,
2160,reversibility — %,C0449261;C0231999,,completed,
2160,reversibility [ % ] median ( range ),C0449261;C0231999,,completed,
2160,reversibility ( % ) median ( range ) c,C0449261;C0231999,,completed,
2160,reversibility : < $nmbr$ %,C0449261;C0231999,,completed,
2160,reversibility : > $nmbr$ %,C0449261;C0231999,,completed,
2160,reversibility < $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261;C0231999,,completed,
2160,reversibility > $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261;C0231999,,completed,
2160,reversibility : > $nmbr$ - < $nmbr$ %,C0449261;C0231999,,completed,
2160,reversibility < $nmbr$ % ( n = $nmbr$ ),C0449261;C0231999,,completed,
2160,reversibility > $nmbr$ % ( n = $nmbr$ ),C0449261;C0231999,,completed,
2160,reversibility s $nmbr$ % ( itt ) ( n = $nmbr$ ),C0449261;C0231999,,completed,
2160,reversibility stratum *,C0449261;C0231999,,completed,
2160,reversibility ( % ) t,C0449261;C0231999,,completed,
2160,reversibility to,C0449261;C0231999,,completed,
2161,eligibility strata,C0013893;C0035648,,completed,
2161,eligibility stratum,C0013893;C0035648,,completed,
2166,levosimendan ( n   = $nmbr$ ),C0252643,,completed,
2167,taking statins n ( % ) a,C0025677,,completed,
2168,neck pain,C0004604,,completed,
2169,time from onset of pain to randomization — hr,C0030193,,completed,
2169,time from onset of pain to randomization median ( iqr ) h,C0030193,,completed,
2170,spain,;C0030198,,completed,
2170,spain ( n = $nmbr$ ),;C0030198,,completed,
2171,oropharyngeal pain,;C0030198,,completed,
2172,upper abdominal pain,;C0030198,,completed,
2173,shoulder pain,;C0030198,,completed,
2174,glycemic status,C1136206,,completed,
2174,glycemic status f,C1136206,,completed,
2175,mean selena - sledai score ± sd,C3871128,,completed,
2175,selena - sledai mean score ( sd ),C3871128,,completed,
2175,selena - sledai > $nmbr$ %,C3871128,,completed,
2176,psoriatic arthritis,C0747055,,completed,
2176,psoriatic arthritis %,C0747055,,completed,
2176,psoriatic arthritis pain ],C0747055,,completed,
2176,psoriatic arthropathy,C0747055,,completed,
2176,time from psoriatic arthritis diagnosis [ a ] years,C0747055,,completed,
2177,bsa > $nmbr$ % n ( % ) t,C0033860,,completed,
2177,dlqi ( patients with £ $nmbr$ % bsa psoriasis ),C0033860,,completed,
2177,£ $nmbr$ % bsa psoriasis no . ( % ),C0033860,,completed,
2177,patients with > $nmbr$ % bsa psoriasis skin involvement n ( % ),C0033860,,completed,
2177,patients with psoriasis ( bsa ≥   $nmbr$ % ),C0033860,,completed,
2177,patients with psoriasis > $nmbr$ % of body surface area,C0033860,,completed,
2177,psoriasis affecting > $nmbr$ % of body - surface,C0033860,,completed,
2177,psoriasis body surface area > $nmbr$ %,C0033860,,completed,
2177,psoriasis bsa > $nmbr$ % n ( % ),C0033860,,completed,
2178,scalp psoriasis n ( % ),C0033860,,completed,
2181,previous exposure to biologic systemic psoriasis therapyb ( yes ) n ( % ),C0033860,,completed,
2181,previous exposure to non - biologic systemic psoriasis therapyb ( yes ) n ( % ),C0033860,,completed,
2181,previous exposure to systemic psoriasis therapyb ( yes ) n ( % ),C0033860,,completed,
2182,poor tried previous glucocorticoid + laba,C2700379,,completed,
2182,poor tried previous glucocorticoid / non - laba,C2700379,,completed,
2182,use of inhaled glucocorticoids at baseline,C0017710,,completed,
2187,calcium supplements,C0006675,,completed,
2187,taking calcium supplements at baseline n ( % ),C0006675,,completed,
2194,carotid endarterectomy,C0007272,,completed,
2200,calcium channel,C0004950,,completed,
2201,maximum,;C1524031;C0806909,,completed,
2202,minimum,;C1524031;C0806909,,completed,
2203,( minimum - maximum ) focal seizure fre - quency / $nmbr$ days at baseline,;C1524031;C0806909,,completed,
2206,sodium - glucose cotransporter $nmbr$ inhibitor,C0037473,,completed,
2207,pacific,C0003980,,completed,
2211,pfo closure,C0005847;C1521802;C1276802,,completed,
2211,pfo closure group ( n = $nmbr$ ),C0005847;C1521802;C1276802,,completed,
2212,closure,C0005847;C1521802;C1276802,,completed,
2215,while,C0034510;C1518422;C0043157,,completed,
2216,chondroitin,;C0008466,,completed,
2217,czp + mtx,C1872109,,completed,
2217,czp + mtx ^ mtx,C1872109,,completed,
2217,czp + mtx n = $nmbr$,C1872109,,completed,
2217,czp + mtx to mtx,C1872109,,completed,
2218,circumflex,C0226037,,completed,
2230,nausea,C0007465,,completed,
2237,rectum,C0034896;C0227391,,completed,
2240,other diagnostic procedure *,C3272301,,completed,
2241,pre - procedure,C3272301,,completed,
2242,proximal gastrointestinal tract,C0205107,,completed,
2242,proximal gi tract,C0205107,,completed,
2242,proximal to the splenic flexure,C0205107,,completed,
2243,pyrexia,C0205107,,completed,
2244,diltiazem or verapamil,C0042523,,completed,
2245,irregular or ulcerated ica p ) laque : [ :,C0041582,,completed,
2245,irregular or ulcerated ica plaquef,C0041582,,completed,
2246,allergic disease by historyb n ( % ),,,completed,
2246,ongoing atopic or allergic condition — no . { % ),,,completed,
2247,elevated biomarkers and st - segment changes,C0005516,,completed,
2248,sle markers n ( % ),C0005516,,completed,
2250,hd ( n = $nmbr$ ),C0043031;C2975435,,completed,
2252,linagliptin / metformin,C0025598,,completed,
2253,metformin + sulphonylureas,C0038766,,completed,
2254,native american,;C0023122,,completed,
2254,native american / alaskan,;C0023122,,completed,
2254,native american or alaska native,;C0023122,,completed,
2254,native american or alaskan native,;C0023122,,completed,
2255,indian ( american ) or alaskan native,;C0023122,,completed,
2256,american,;C0023122,,completed,
2257,hispanic american,;C0023122,,completed,
2257,hispanic / latin american,;C0023122,,completed,
2258,america,C0028405,,completed,
2289,pramlintide,C1456408,,completed,
2295,tocilizumab,C0966225,,completed,
2295,tocilizumab ( n = $nmbr$ ),C0966225,,completed,
2312,diureties,C0354100,,completed,
2313,mean baseline ibdq score ( sd ) § crp concentration mg / l,C0006560,,inprogress,
2314,upadacitinib $nmbr$ mg ( n = l $nmbr$ ),C0006560,,inprogress,
2316,vasoprotectives,,,completed,Faecal calprotectin (No CUI assigned)
2317,glucose test,C1272092,,inprogress,
2319,leflunomide ( mean dose : $nmbr$ . $nmbr$ mg / day ),,,inprogress,
2320,levodopa dose mean ± sd mg / day,,,inprogress,
2321,rasagiline $nmbr$ mg / day,,,inprogress,
2332,empagliflozin pooled ( n = $nmbr$ ),C1709595;C1524024,,completed,
2332,pooled empagliflozin ( n = $nmbr$ ),C1709595;C1524024,,completed,
2333,pooled secukinumab,C1709595;C1524024,,completed,
2333,secukinumab pooled †   ( n   = $nmbr$ ),C1709595;C1524024,,completed,
2334,emergent / urgent surgery,C0920424,,completed,
2334,urgent surgery,C0920424,,completed,
2335,major surgery,C0920424,,completed,
2336,minor surgery,C0920424,,completed,
2337,other cardiac surgery n ( % ),C0920424,,completed,
2338,undergoing major vascular surgery,C0920424,,completed,
2350,magnetic resonance angiography,,,inprogress,mra
2352,most frequent aesa,C0242428,,completed,
2352,most frequent non - infectious teaesb,C0242428,,completed,
2352,most frequent serious teaes,C0242428,,completed,
2353,most frequent infections,C0242428,,completed,
2354,mostly dissatisfied,C0242428,,completed,
2355,timi flow grade $nmbr$ of mi culprit vessel post ‐ pci,C0856742,,completed,
2361,community hospital,C0019994,;C4049621,completed,
2361,community hospital ( % ),C0019994,;C4049621,completed,
2361,community hospital n ( % ),C0019994,;C4049621,completed,
2363,combination therapy * *,C0870128,,completed,
2363,combination therapy n = $nmbr$,C0870128,,completed,
2363,combination therapy ( n = $nmbr$ ),C0870128,,completed,
2365,presence of dactylitis,C1959609;C0150312,,completed,
2365,presence of dactylitis n ( % ),C1959609;C0150312,,completed,
2366,presence of angioedema at baseline,C1959609;C0150312,,completed,
2367,presence of enthesitis,C1959609;C0150312,,completed,
2367,presence of enthesitis n ( % ),C1959609;C0150312,,completed,
2368,baseline presence of nasal polyps,C1959609;C0150312,,completed,
2369,history / presence of tophi,C1959609;C0150312,,completed,
2369,presence of tophi,C1959609;C0150312,,completed,
2369,presence of tophi n ( % ),C1959609;C0150312,,completed,
2370,pregnancy,C1959609;C0150312,,completed,
2371,presence of honeycombing $nmbr$ n ( % ),C1959609;C0150312,,completed,
2383,pre - dose,C3714541;C0439565,,completed,
2383,study medication pre - dose,C3714541;C0439565,,completed,
2384,prednisone,C3714541,,completed,
2384,prednisone use %,C3714541,,completed,
2400,deathsb,C1861172,,completed,
2401,sudden death,C1836407,,completed,
2402,headache,C2960025,,completed,
2403,health habits,C2960025,,completed,
